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Abstract
Wounds research for patient benefit: a 5-year programme
of research
Nicky Cullum,1* Hannah Buckley,2 Jo Dumville,1 Jill Hall,2
Karen Lamb,3 Mary Madden,2 Richard Morley,2 Susan O’Meara,2
Pedro Saramago Goncalves,4 Marta Soares4 and Nikki Stubbs3
1School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK
2Department of Health Sciences, University of York, York, UK
3Leeds Community Healthcare NHS Trust, Leeds, UK
4Centre for Health Economics, University of York, York, UK
*Corresponding author nicky.cullum@manchester.ac.uk
Background: Complex wounds are those that heal by secondary intention and include lower-limb ulcers,
pressure ulcers and some surgical wounds. The care of people with complex wounds is costly, with care
mainly being delivered by community nurses. There is a lack of current, high-quality data regarding the
numbers and types of people affected, care received and outcomes achieved.
Objectives: To (1) assess how high-quality data about complex wounds can be captured effectively for
use in both service planning and research while ensuring integration with current clinical data collection
systems and minimal impact on staff time; (2) investigate whether or not a clinical register of people with
complex wounds could give valid estimates of treatment effects, thus reducing dependence on large-scale
randomised controlled trials (RCTs); (3) identify the most important research questions and outcomes for
people with complex wounds from the perspectives of patients, carers and health-care professionals;
(4) evaluate the potential contributions to decision-making of individual patient data meta-analysis and
mixed treatment comparison meta-analysis; and (5) complete and update systematic reviews in topic areas
of high priority.
Methods: To meet objectives 1 and 2 we conducted a prevalence survey and developed and piloted a
longitudinal disease register. A consultative, deliberative method and in-depth interviews were undertaken
to address objective 3. To address objectives 4 and 5 we conducted systematic reviews including mixed
treatment comparison meta-analysis.
Results: From the prevalence survey we estimated the point prevalence of all complex wounds to be
1.47 per 1000 people (95% confidence interval 1.38 to 1.56 per 1000 people). Pressure ulcers and venous
leg ulcers were the most common type of complex wound. A total of 195 people with a complex wound
were recruited to a complex wounds register pilot. We established the feasibility of correctly identifying,
extracting and transferring routine NHS data into the register; however, participant recruitment, data
collection and tracking individual wounds in people with multiple wounds were challenging. Most patients
and health professionals regarded healing of the wound as the primary treatment goal. Patients were
greatly troubled by the social consequences of having a complex wound. Complex wounds are frequently
a consequence of, and are themselves, a long-term condition but treatment is usually focused on healing
the wound. Consultative, deliberative research agenda setting on pressure ulcer prevention and treatment
with patients, carers and clinicians yielded 960 treatment uncertainties and a top 12 list of research
priorities. Of 167 RCTs of complex wound treatments in a systematic review of study quality, 41% did not
specify a primary outcome and the overall quality of the conduct and reporting of the research was poor.
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Mixed-treatment comparison meta-analysis in areas of high priority identified that matrix hydrocolloid
dressings had the highest probability (70%) of being the most effective dressing for diabetic foot ulcers,
whereas a hyaluronan fleece dressing had the highest probability (35%) of being the most effective
dressing for venous ulcers; however, the quality of this evidence was low and uncertainty is high.
Conclusions: Complex wounds are common and costly with a poor evidence base for many frequent
clinical decisions. There is little routine clinical data collection in community nursing. A prospective complex
wounds register has the potential to both assist clinical decision-making and provide important research
evidence but would be challenging to implement without investment in information technology in NHS
community services. Future work should focus on developing insights into typical wound healing
trajectories, identifying factors that are prognostic for healing and assessing the cost-effectiveness of
selected wound treatments.
Funding: The National Institute for Health Research Programme Grants for Applied Research programme.
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Plain English summary
Complex wounds are open wounds that heal from the base up and include leg ulcers, pressure ulcersand foot ulcers. Such complex wounds often affect older people. Care for people with complex
wounds is typically delivered by community nurses, often in patients’ own homes. Complex wounds are
very costly for the NHS and have a big impact on patients and their families. In the UK no routine data are
collected about complex wound care so we know little about how common the different types of wounds
are, which treatments are commonly used and what happens to patients over time. Research on complex
wounds tends to be of poor quality and at the start of this work we did not know if existing research
reflected patient and carer priorities in terms of the questions they had about complex wounds. The overall
aim of the programme was to use research to optimise the quality of care and outcomes for people with,
or at risk of, complex wounds.
Key findings
l Approximately 1.5 people per 1000 have a complex wound; pressure ulcers and venous leg ulcers
are the most common types and patients are greatly troubled by the social consequences of
complex wounds.
l It was not possible to implement a comprehensive, prospective complex wounds register, partly
because usable clinical data were not routinely collected in community nursing services in the UK.
If such a register could be implemented it could be useful in informing wound care services and help to
answer important research questions.
l Most patients and health professionals regarded healing of the wound as the primary treatment goal.
l We worked with patients, clinicians and carers to develop a top 12 list of research priorities for the
prevention and treatment of pressure ulcers.
l Research on which treatments are most effective at healing complex wounds was largely inadequate
and several strategies for improving the research were identified.
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Scientific summary
Background
Complex wounds are those that heal by secondary intention, that is, they are open wounds that heal
from the base upwards. Typically, complex wounds are a consequence of acute or long-term conditions
including diabetes, vascular disease and neurological conditions. The most common types of complex
wounds are ulcers of the lower limb and pressure ulcers. Community nurses deliver most of the care for
people with complex wounds and there is no routine clinical data collection. The cost of delivering care
for people with complex wounds has not been accurately estimated but will be high. Community
prescribing costs alone for wound dressings were £184M in 2012; however, staff time and hospitalisation
are the greatest cost elements. The high cost of wound care and large patient and family impact of
complex wounds are served by a weak evidence base and low-quality research. The overall aim of the
programme was to undertake research that would optimise the quality of care and outcomes for people
with, or at risk of, complex wounds.
The objectives for each workstream were as follows:
l workstream 1 – undertake a high-quality point prevalence survey and care audit of people with
complex wounds; pilot a prospective complex wounds register suitable for both health care and
research to assess how high-quality data about complex wounds can be captured effectively for use in
both service planning and research while ensuring integration with current clinical data collection
systems and minimal impact on staff time and investigate whether or not a clinical register of people
with complex wounds could give valid estimates of treatment effects, thus reducing dependence on
large-scale randomised controlled trials (RCTs).
l workstream 2 – explore people’s experiences of complex wound care; identify which outcomes matter
most to people with complex wounds, their carers and health-care professionals and compare these
with those reported in wounds research; derive a prioritised list of research questions in the area of
pressure ulcer prevention and treatment.
l workstream 3 – in collaboration with NHS colleagues, identify areas of high decision uncertainty and
summarise the best available evidence in those areas using appropriate systematic review methods;
evaluate the potential contributions of individual patient data meta-analysis and mixed treatment
comparison meta-analysis.
Workstream 1
Objectives
Our objectives were to undertake a high-quality point prevalence survey and care audit of complex
wounds and pilot a prospective complex wounds register suitable for both health care and research.
Methods
We undertook a systematic review of complex wounds prevalence studies and a point prevalence survey
and audit of people receiving care for a complex wound in Leeds. We designed and piloted a new
complex wounds register.
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Results
There were no previous high-quality prevalence surveys that focused on people with all kinds of complex
wounds and most previous studies were weak in terms of design and reporting. Our own prevalence
survey in Leeds estimated the point prevalence of all complex wounds to be 1.47 per 1000 people
[95% confidence interval (CI) 1.38 to 1.56 per 1000 people]. The point prevalence of complex wounds in
former or current injecting drug users was 5.64 per 1000 people (95% CI 3.97 to 7.99 per 1000 people).
Pressure ulcers and venous leg ulcers were the most common type of complex wound.
A total of 195 people with a complex wound were recruited to a complex wounds register pilot by the
Leeds Community Wound Prevention and Management Service and community nurses (a 26% consent
rate). We established the feasibility of correctly identifying, extracting and transferring routine NHS data
into the register; however, participant recruitment, data collection and tracking individual wounds in
people with multiple wounds were challenging. Staff feedback highlighted the need for further
developments to facilitate routine data collection along with consideration of new information technology
(IT) and devices. A possible method of electronic data collection, that is, smart pens, had severe limitations
as a data collection tool in the context of community wound management.
Conclusions
A complex wounds register that serves both clinical care and research would be valuable. Such a register
proved impossible to implement comprehensively. Challenges included an absence of existing electronic
data collection tools, lack of routine clinical data collection in the community nursing service, limited IT
infrastructure, a requirement for individual participant consent and the difficulty of accurately tracking
multiple wounds on the same patient.
Workstream 2
Objectives
Our objectives were to explore the experiences of people with complex wounds, their carers and health
professionals, identify which outcomes matter most to them, compare these with the outcomes reported
in wounds research and derive a prioritised list of research questions in the area of pressure ulcer
prevention and treatment.
Methods
We undertook semistructured interviews with people affected by complex wounds, carers and health
professionals regarding their experiences of complex wound care and desirable treatment outcomes; a
systematic review of the design and conduct of RCTs of complex wound treatments; and a consultative
and deliberative research agenda setting involving patients, carers and clinicians in the area of pressure
ulcer prevention and treatment.
Results
Most patients and health professionals viewed healing of the complex wound as the primary treatment
goal. Patients were greatly troubled by the socially inhibiting consequences of their complex wound, but
wound care services did not focus on the psychological or social impacts. The treatment model was geared
to healing, not ‘living with’ a long-term condition with potentially negative consequences. In total,
167 RCTs of complex wound treatments were analysed, of which 69 (41%) did not specify a primary
outcome; only 40 (24%) had complete healing as the primary outcome, 47 (28%) used a surrogate
measure of wound healing and 11 (7%) reported only outcomes unrelated to healing. A total of
960 treatment uncertainties were elicited and a top 12 list of research priorities was developed by patients,
carers and health professionals.
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Conclusions
There is a mismatch between the nature and quality of RCTs in complex wounds and the kind of research
evidence desired by patients, carers and clinicians. It was possible to work with patients, carers and health
professionals to identify and prioritise for research the uncertainties in pressure ulcer prevention and
treatment. Community nursing management of people with complex wounds may be improved by
adopting an approach aimed at helping patients live with a long-term condition.
Workstream 3
Objectives
Our objectives were to identify, in collaboration with NHS colleagues, areas of high decision uncertainty in
complex wound management and summarise the best available evidence in those areas and to evaluate
the potential contributions to decision-making of evidence synthesis using individual patient data and
mixed-treatment comparisons.
Methods
Stakeholder consultation was carried out to identify decision uncertainties; a scoping review of the
evidence for silver-containing wound dressings for treating venous leg ulcers was performed; Cochrane
methods of systematic review were applied to 11 complex wound topics; and mixed-treatment comparison
meta-analyses of dressings for diabetic foot ulcers and venous leg ulcers were carried out.
Results
Techniques involving facilitated face-to-face contact with health professionals performed best in generating
clinical uncertainties as topics for evidence synthesis. Research-based information regarding the relative
effectiveness of different wound dressings for different wound types had high priority. There was no
evidence that silver dressings were more effective than non-antimicrobial dressings for healing venous
ulcers; however, the limited availability of time-to-healing data in the existing trials hugely reduced the
potential value of meta-analysis using individual patient data. A series of Cochrane reviews in prioritised
topics identified several wound treatments that may be more effective than others in different wound types
but the quality of the evidence was low and much uncertainty remains. The matrix hydrocolloid dressing
was associated with the highest probability (70%) of being the best dressing for diabetic foot ulcers,
whereas a hyaluronan fleece dressing had the highest probability (35%) of being the best dressing for
venous ulcers; however, in both cases there was high uncertainty and the quality of the evidence was poor.
Conclusions
A range of approaches to evidence synthesis was applied to complex wound treatments across a broad
range of topics that had been prioritised by health-care professionals. This approach identified some
treatments associated with the highest probability of effectiveness.
Overall conclusions
We estimated a point prevalence of approximately 1.5 cases of complex wounds per 1000 population;
20% of these wounds were pressure ulcers, 28% were leg ulcers of various aetiologies and 14% were
foot ulcers. Most people with complex wounds were aged > 70 years and they often had other conditions,
incontinence and immobility. The planning and delivery of good-quality care for people with complex
wounds is hampered by an absence of good research evidence in terms of both basic epidemiological data
(e.g. prognostic information to facilitate realistic treatment goals and expectations) and evidence about
which treatments are effective and for whom. Most complex wounds are the manifestation of underlying
systemic disease; however, treatment is typically focused on trying to find the magic dressing that will heal
the wound. There is much scope for considering (and evaluating) more psychological approaches to
helping people live with their complex wound.
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Most patients with complex wounds are managed in the community by nurses (patients received an
average of two to three visits or consultations per week, each lasting nearly half an hour). Clinical practice,
as measured in the prevalence survey, generally compared well with current evidence-based guidelines;
areas for further implementation of best practice included hosiery and pentoxifylline for the treatment
of venous leg ulcers. There was little routine collection of clinical data in the community nursing service
and a lack of IT infrastructure. Current information systems are not geared towards supporting clinical
decisions, communicating between clinicians or collection of data for research. Although it is possible to
adapt and improve the collection of routine data to improve its suitability for clinical care and research,
comprehensive implementation of a complex wounds register is not currently possible.
Clinical decision-making and commissioning are themselves not served well by the evidence base in wound
care; our analysis of the quality of RCTs of complex wound treatments showed that 41% of trials did not
specify a primary outcome and most had a very short duration of follow-up and were at high risk of bias
(because of poor trial design and conduct) or the risk of bias was unclear (because of poor reporting).
The James Lind Alliance Pressure Ulcer Partnership (JLAPUP), involving extended consultation and
collaboration with patients, carers and clinicians, yielded a diverse top 12 list of research priorities about
pressure ulcer prevention and management. It was difficult to engage the population of people most
affected by pressure ulcers in this process (the frail elderly with comorbidities).
In undertaking mixed-treatment comparison meta-analysis to identify the dressings for venous leg ulcers
and diabetic foot ulcers that were most likely to be best for healing, we were struck by the importance of
incorporating an assessment of the quality of the evidence in the process. We developed and implemented
the iGRADE tool as a first attempt to do this. These evidence syntheses concluded that matrix hydrocolloid
dressings had the highest probability (70%) of being the most effective dressing for diabetic foot ulcers,
whereas a hyaluronan fleece dressing had the highest probability (35%) of being the most effective dressing
for venous ulcers; however, in both cases the quality of the evidence was low and uncertainty was high.
Recommendations for future research
The JLAPUP prioritised a further 12 genuine uncertainties that can be taken forward by the research
community. These were, in reducing order of priority:
1. How effective is repositioning in the prevention of pressure ulcers?
2. How effective at preventing pressure ulcers is involving patients, family and lay carers in patient care?
3. Does the education of health and social care staff on prevention lead to a reduction in the incidence
of pressure ulcers and, if so, which are the most effective education programmes (at the organisational
and health/social care level)?
4. What is the relative effectiveness of the different types of pressure-relieving beds, mattresses, overlays,
heel protectors and cushions (including cushions for electric and self-propelling wheelchairs) in
preventing pressure ulcers?
5. What impact do different service models have on the incidence of pressure ulcers, including staffing
levels, continuity of care (an ongoing relationship with the same staff members) and the current
organisation of nursing care in hospitals?
6. What are the best service models (and are they sufficiently accessible) to ensure that patients with
pressure ulcers receive the best treatment outcomes (including whether or not getting people with
pressure ulcers and their carers more involved in their own pressure ulcer management improves ulcer
healing and, if so, the most effective models of engagement)?
7. For wheelchair users sitting on a pressure ulcer, how effective is bed rest in promoting pressure
ulcer healing?
8. How effective are wound dressings in the promotion of pressure ulcer healing?
9. Does regular turning of patients in bed promote healing of pressure ulcers?
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
10. Does improving diet (eating) and hydration (drinking) promote pressure ulcer healing?
11. How effective are surgical operations to close pressure ulcers?
12. How effective are topical skincare products and skincare regimens at preventing pressure ulcers?
Other research areas emerging from this work include (in no particular order):
l The importance of prognostic research for common types of complex wound (pressure ulcers, leg
ulcers, foot ulcers, etc.). This research would begin with systematic reviews of the current evidence and
then move to targeted primary research including prognostic modelling. Such research would inform
patient and clinical expectations, shared decision-making and assessment of the cost-effectiveness of
treatments as well as the planning of new RCTs. Such data could be collected within a complex
wounds register that served both clinical practice and research although support for data collection
would have to be properly costed.
l Mixed treatment comparison meta-analysis, using individual patient data when available, of trials of
silver-containing dressings for venous ulcers to further explore if there is an incremental effect of silver
on wound outcomes.
l The relative cost-effectiveness of negative pressure wound therapy compared with usual care for the
treatment of foot wounds in people with diabetes.
l The relative cost-effectiveness of 0.5% chlorhexidine compared with povidone iodine in alcohol for
preoperative skin antisepsis in clean surgery.
l The cost-effectiveness of ibuprofen-containing dressings for reducing pain in people with painful
skin ulcers.
l The cost-effectiveness of different dressings for healing after toenail surgery.
l The cost-effectiveness of alternative postoperative strategies for managing pilonidal sinus.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Background
A wound is an interruption to skin integrity caused by physical trauma or disease. Everybody experiences
wounds and most wounds heal uneventfully; however, a significant minority of people have wounds that
are very slow to heal or which do not heal at all. These more complex wounds, which are mainly managed
by community nurses, were the focus of this programme of research.
The most common types of chronic wound are leg ulcers (mainly caused by venous and/or arterial disease),
pressure ulcers (caused by unrelieved pressure as a result of immobility) and diabetic foot ulcers (caused by
vascular and neurological complications of diabetes).1 Less common chronic wounds include surgical
wounds that have broken down. The term ‘chronic wound’ implies a wound of long duration; however,
from a clinical perspective, it is often clear that a wound is complex and likely to be longstanding at a fairly
early stage. For this reason we have used the term ‘complex wound’ (rather than ‘chronic wound’)
throughout this programme of research. We define ‘complex wounds’ as wounds that have superficial,
partial or full-thickness skin loss and that are healing by secondary intention.
Wounds healing by secondary intention are those that are left open to granulate and heal from the bottom
up (as opposed to those whose edges are brought together and closed by sutures, glue or clips). Reliable
estimates of the prevalence and incidence of complex wounds are rare. When we began this research
programme it had been reported that up to 32% of hospital inpatients and 7% of community-based
patients in the UK have a pressure ulcer at any point in time;2 that approximately 0.05% of people at any
time were thought to have open leg ulcers;3 and that foot ulcers were thought to affect 2.0–3.0% of people
with diabetes per year.4,5 One of the aims of the work was to derive better local estimates of prevalence.
A motivating factor for our research was the relative lack of contemporary, high-quality data about how
many people are affected by complex wounds, the amount of NHS resource consumed in wound
management, the nature of the care that people receive and the outcomes achieved and how these
outcomes are experienced. Clearly such intelligence is crucial from a research perspective to both
determine the need for future research and prioritise research questions. Just as importantly, better-quality
intelligence is needed by the NHS so that access to the right services can be ensured, staff training needs
identified and addressed and the delivery of effective (and cost-effective) management implemented.
This basic information is also needed to populate cost-effectiveness modelling that is currently being
undertaken to establish the cost-effectiveness of treatments currently being used or for value of
information analyses to inform future research. For example, we had already encountered a requirement
for formal elicitation methods in the absence of published data on the costs, healing and complication
rates of severe pressure ulcers and the frequency with which specific treatments are used in the UK.6,7
Most people with complex wounds are managed in the community by nurses along with referral to
specialist services such as tissue viability, various surgical specialties (e.g. vascular, plastics), dermatology
and podiatry as required. Because the care of people with complex wounds is community based and
delivered by nurses, there is little or no collection and analysis of routine clinical data, hence our collective
lack of basic intelligence. We do know that wound management is costly, although accurate cost data are
also hard to find. The NHS (England) expenditure on wound dressing prescribing increased by 21%
between 2004 and 2012 (Figure 1), with > 9 million wound dressing items prescribed in the community
(England) during 2012 at a cost of £184M.8 Importantly, however, the main cost drivers of complex
wounds are not the dressings themselves but staff time and hospitalisation costs. Added to these there are
clearly personal financial costs for patients and their families (because of an inability to work) as well as
non-financial impacts on quality of life. Data on the impact of complex wounds on patients were
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beginning to accumulate in 2008 when we began this work. We had already shown that pressure ulcers
had a measurable (negative) impact on quality of life when people with pressure ulcers were compared
with others matched for age and comorbidities.9 Research had also given some insights into the negative
impact on patients of leg10,11 and foot12 ulceration.
The evidence base for complex wound care
It is surprising that, given the evidence for complex wounds being common and costly and having
important negative impacts on quality of life, the evidence base for underpinning prevention and
treatment decisions is very poor. In 2005, the National Institute for Health and Care Excellence (NICE)13
published guidelines on the management of pressure ulcers in primary and secondary care. This guideline
contained 39 recommendations of which 38 were graded D (evidence extrapolated from observational
studies and formal consensus) and one was graded C (directly relevant evidence from observational studies
or evidence extrapolated from systematic reviews of observational studies).14 The Scottish Intercollegiate
Guidelines Network (SIGN)15 guideline of 2010 on chronic venous leg ulcer management contained
19 recommendations of which five were graded A, three were graded B, four were graded C and seven
were graded D.14 The NICE16 guideline on foot care in type 2 diabetes included a section devoted to
foot ulcer management consisting of 11 recommendations of which three were graded B, one was
graded C and seven were graded D.14 The evidence to support high-quality clinical decision-making is
therefore weak.
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Our vision in designing a programme of research in complex wounds was to initiate a step change in
research, but a calculated one underpinned by good information. Motivated by a belief that most of the
existing research had been driven by the needs of the pharmaceutical industry and not patient or service
priorities and that the NHS intelligence on the nature, treatment and costs of complex wounds and
outcomes for people with complex wounds was poor, we set out to improve the collection and analysis of
routine data on complex wounds in community nursing practice. We wanted to accurately determine the
number of people with complex wounds in Leeds and the nature of their wounds, care and treatments.
A further aim was to gain a patient perspective on future research priorities including the nature of the
treatment outcomes that matter most to patients.
Local context
The sine qua non of research funded by the National Institute for Health Research (NIHR) is that it must be
relevant for (and when possible embedded in) the NHS.17 This programme of research grew out of a
longstanding research collaboration with the Leeds Tissue Viability Service (now the Leeds Community
Wound Prevention and Management Service). This collaboration has resulted in NIHR- and Medical
Research Council-funded wounds research and particularly randomised controlled trials (RCTs), with Leeds
always being one of the most successful recruiting centres.18–21 An implicit aim of this research programme
was therefore to capitalise on this track record and explore how it could be used to promote much wider
collection of data and research involvement of staff beyond those working in the specialist service. An
overarching principle was also to ensure that the research that we carry out is of value nationally as well as
locally. In several ways, Leeds provides an ideal research laboratory for wounds research: it has a large and
diverse population of approximately 751,000, 20% of its population live in some of the most deprived
areas of the country22 and there are urban, suburban and rural communities. The population of Leeds is
ethnically diverse with approximately 17% of residents from black and minority ethnic groups.23
Aims and objectives of the programme
This programme of research commenced in 2008 and had the overarching aim of optimising the quality of
care and outcomes for people with, or at risk of, complex wounds.
Our objectives were to:
1. assess how high-quality data about complex wounds can be captured effectively for use in both service
planning and research while ensuring integration with current clinical data collection systems and
minimal impact on staff time
2. investigate whether or not a clinical register of people with complex wounds could give valid estimates
of treatment effects, thus reducing dependence on large-scale RCTs
3. identify the most important research questions and outcomes for people with complex wounds from
the perspectives of patients, carers and health-care professionals
4. evaluate the potential contributions to decision-making of individual patient data (IPD) meta-analysis
and mixed-treatment comparison meta-analysis
5. complete and update Cochrane systematic reviews in topic areas of high priority.
These objectives were refined slightly over the 5-year programme of research in response to research
findings and local priorities.
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Structure of this report
Chapters 2–4 present the findings of the component workstreams and their substudies. These workstreams
are constructed around focused, coherent themes rather than particular methodologies and they vary in the
volume of work in each:
l Chapter 2 outlines the work that relates to objectives 1 and 2 and explores the extent to which it is
possible for the NHS to routinely collect high-quality data about people with complex wounds and use
these data for research and service delivery
l Chapter 3 explores service user and service provider perspectives on research in wound care and
examines them against the current ‘research evidence terrain’ (objective 3)
l Chapter 4 outlines the theme of work that ran throughout the research programme, aiming to provide
up-to-date summaries of research evidence in areas of uncertainty prioritised by the NHS (objectives 4
and 5).
Each of these chapters includes a brief introduction to the context of the workstream, relevant previous
literature, the methods used, the main findings and the key implications.
l Chapter 5 draws together the overall conclusions and outlines the particular contributions to
knowledge that this research has made.
INTRODUCTION
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Chapter 2 Data capture and epidemiology
(workstream 1)
Abstract
Background
The specific objectives for this workstream were to undertake a high-quality point prevalence survey and
care audit of complex wounds and pilot a prospective complex wounds register suitable for both health
care and research.
Methods
We undertook a systematic review of complex wounds prevalence studies and a point prevalence survey
and audit of people receiving care for a complex wound in Leeds and designed and piloted a new complex
wounds register.
Results
There were no previous high-quality prevalence surveys focused on people with all types of complex
wound and most previous studies were weak in terms of design and reporting. Our own point prevalence
survey estimated a point prevalence of any complex wound of 1.47 per 1000 people [95% confidence
interval (CI) 1.38 to 1.56 per 1000 people]. The point prevalence of complex wounds in injecting drug
users was 5.64 per 1000 people (95% CI 3.97 to 7.99 per 1000 people). Pressure ulcers and venous leg
ulcers were the most common types of complex wound. A total of 195 people with a complex wound
were recruited to a complex wounds register pilot by the Leeds Tissue Viability Service and district nurses
(26% consent rate). We established the feasibility of correctly identifying and extracting routine NHS data
and transferring it into the register; however, comprehensive participant recruitment (which required
individual patient consent) and the tracking of individual wounds in people with multiple wounds were
challenging and analyses were limited by the lack of available data. Staff feedback highlighted the need
for further developments to facilitate routine data collection along with the need to consider a more
efficient recruitment process and new information technology (IT) and devices. Smart pens had severe
limitations as data collection tools in the context of community wound management.
Conclusions
A complex wounds register that serves both clinical care and research would be valuable. Such a register
proved impossible to implement comprehensively. Challenges included an absence of existing electronic
routine clinical data collection in the community nursing service, limited IT infrastructure, a requirement for
individual participant consent and the difficulty of accurately tracking multiple wounds in the same patient.
Background
Surprisingly little is known about the number, nature and care of people with complex wounds in the UK,
nor about outcomes. High-quality epidemiological data are vital in helping health-care providers understand
the extent of the condition, the characteristics of patients and how to best plan health-care services. When
we began this research programme no comprehensive survey of people with complex wounds in Leeds had
been undertaken and there was no reliable information regarding the number of people affected or the
nature of the care that they were receiving (including setting). Although our original objective was to
establish prospective data capture about people with complex wounds and their care and outcomes, it was
anticipated that a preliminary cross-sectional survey in advance of this would enable us to better plan for
prospective data collection and inform priorities across other workstreams.
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There are real advantages to prospective data collection. A live register of complex wounds would allow
monitoring of trends in treatments and outcomes, enable rapid identification of likely patient numbers
(and potential participants) for studies, aid research prioritisation and facilitate research implementation.
However, we regarded it as premature to commit large resources to the establishment of a complex
wounds register without first exploring if it would be feasible to establish and maintain one. A successful
register based in community nursing would need careful design to ensure that data collection was feasible
within typical work patterns and met both clinical and research needs. It was also important to assess the
resources required to ensure the sustainability of a wounds register.
Workstream 1 consisted of two parts (Figure 2). The first part focused on cross-sectional data collection
and the second part focused on prospective data collection.
Review of complex wound prevalence studies
Background
As part of developing our plans for a cross-sectional survey to estimate the prevalence of complex wounds
in a large UK city, we reviewed all cross-sectional studies that had estimated the prevalence of people with
complex wounds in community settings.
We were particularly interested in the measures taken in the prevalence studies to ensure the accuracy of
the numerator (the number of complex wounds) and the quality of the denominator (the population
identified as being at risk) as they are both crucial factors in estimating prevalence. Measures to help
ensure the accuracy of the numerator include the diagnostic criterion (or wound definition) used for the
inclusion of cases plus the validation process for identified cases and establishing underlying pathology
(to identify case subtypes). The quality of the denominator data is also extremely important in calculating
estimates of prevalence. Ideally, it should be a geographically defined population, preferably using
population statistics that are contemporaneous with the study itself.
• Review of complex wound prevalence studies
• Complex wounds prevalence study and audit of care
Cross-sectional
data collection
• Review of current UK disease/condition registries
• Pilot data collection methods (smart pen)
• Pilot register data collectionProspective
data collection
FIGURE 2 Overview of workstream 1.
DATA CAPTURE AND EPIDEMIOLOGY (WORKSTREAM 1)
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Objectives
This review was undertaken to answer the following questions:
i. What types of complex wound have been the focus of prevalence surveys?
ii. What diagnostic criteria have been used in complex wound surveys?
iii. What data items have been collected in prevalence surveys of complex wounds in
community settings?
iv. What methods have been used to collect and validate prevalence data (i.e. choice of denominator,
sampling strategies, case validation and validation of underlying pathology)?
v. What was the quality of the denominator data used in prevalence calculations?
vi. Has the ‘capture–recapture’ technique been used in any community prevalence studies in complex
wound care to estimate prevalence in hard-to-reach groups, for example injecting drug users?
vii. Have quality-of-life data been assessed in community prevalence studies in complex wound care?
viii. What are the current estimates of prevalence of complex wounds in community-dwelling persons?
Methods
A systematic review of the literature was undertaken. Cross-sectional studies were included if they
estimated the prevalence of people with complex wounds in community-dwelling populations or whole
geographical populations.
A cross-sectional study was defined as ‘a study that examines the relationship between diseases (or other
health-related characteristics) and other variables of interest as they exist in a defined population at one
particular time’.24
We included studies of people with complex wounds such as leg ulcers, pressure ulcers and diabetic and
non-diabetic foot ulcers plus any other types of complex wounds not included in the above (e.g. surgical
wounds healing by secondary intention). Studies conducted solely in non-community settings and single
institutions such as hospitals and nursing homes were excluded.
Search strategy
Using OvidSP, an electronic search in MEDLINE (1950 to March Week 2 2009 and updated to
March Week 3 2012) was undertaken as follows:
1. exp Skin Ulcer/
2. exp Leg Ulcer/
3. exp Pressure Ulcer/
4. exp Foot Ulcer/
5. exp Diabetic Foot/
6. (skin ulcer$or foot ulcer$or diabetic foot or diabetic feet or leg ulcer$or varicose ulcer$or venous ulcer
$or stasis ulcer$or arterial ulcer$or neuropathic ulcer$).tw.
7. ((ischaemic or ischaemic) adj (wound$or ulcer$)).tw.
8. (bed sore$or pressure sore$or pressure ulcer$or decubitus ulcer$).tw.
9. (chronic adj (wound$or ulcer$)).tw.
10. or/1–9
11. exp Epidemiology/
12. exp Prevalence/
13. (prevalence or audit or survey).tw.
14. 11 or 13 or 12
15. 10 and 14
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Relevant data items were identified a priori by one author (JH) and extracted from the included studies by
the same author. Extracted data items included:
l country and setting
l types of wounds and definitions
l prevalence estimates
l denominator information
l sampling strategies
l method of data collection
l method of case validation and establishing aetiology
l range of variables for which data were collected
l quality-of-life data
l use of the capture–recapture technique.
Quality assessment of included studies was conducted independently by two reviewers using a recently
published 22-item checklist.25 Agreement between reviewers was also assessed and a third reviewer
arbitrated final decisions when required.
A narrative report was written in answer to each of the review questions outlined.
Results
Results of the search and description of the included studies
The electronic search produced 1834 references of which 76 were deemed potentially relevant; the full
papers were retrieved for these references. Based on assessment of the full papers, 48 individual studies
(in 56 published papers) were included in the review (Table 1).3,26–80
The studies were predominantly conducted in Europe and industrialised countries (23 in the UK and
Ireland and 10 in Sweden) and were published between 1977 and 2009. Most were studies of the general
population and 13 were conducted in subgroups of the population, most frequently the elderly and
specific groups with conditions such as diabetes, rheumatoid arthritis or spinal injury.
Quality assessment
All included studies had a number of flaws (either minor or major) and instances of poor reporting. Overall,
the mean number of flaws and poorly reported items per study was 13.9, ranging from 7 to 20. Instances
of poor reporting accounted for the majority of these (mean 9.4, range 5–13). Studies had an average of
2.9 minor flaws (range 1–5) and 1.5 major flaws (range 0–3). The most frequently poorly reported and/or
flawed items included:
l the role of funding organisations
l conflict-of-interest declarations
l sampling issues
l assessment of sampling bias
l whether or not sampling bias was addressed in the analysis
l exclusion rates from analysis
l reliability of the estimates
l reporting of type of prevalence
l precision of estimates and prevalence in the total sample (crude or adjusted).
Items tending to have fewer instances of poor reporting and flaws included information about the funding
of the study, aims of the studies, study design, sampling method, response rate, the source for measuring
prevalence and issues around definitions of outcomes.
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Agreement between reviewers for each study was variable. The average agreement for studies (based on
the 22 items in the checklist) was 14.9 (67.7%) but agreement ranged between 9 and 22. Items that tended
to have higher levels of agreement between reviewers related to funding, conflicts of interest, ethics,
sampling frame, assessment of sampling bias and whether or not it was addressed in analysis, reliability of
estimates and precision of estimates. Items that tended to have lower levels of agreement between
reviewers included the aims of the studies, study design, sampling methods, source to measure prevalence,
aspects of definitions of prevalence, measurement of prevalence and reporting of type of prevalence.
Types of complex wounds
Few studies (n= 7)26–35 attempted to measure the prevalence of all wounds or all complex wounds; most
focused on people with leg ulcers (n= 15)3,36–52 or leg and foot ulcers (n= 10).53–64 However, it was not
always possible to determine from reports of leg ulcer studies if people with ulcers confined to the foot
were excluded. A total of 16 studies investigated either (people with) foot ulcers (diabetic foot ulcers
n= 6,65–70 non-diabetic foot ulcers n= 271,72) or pressure ulcers (n= 8).73–80
Diagnostic criteria
Twenty-one out of 48 studies (46%) reported a diagnostic criterion or definition for the type of wound
eligible for inclusion (Table 2). Definitions varied but tended to include a general description of the wound,
its location, its duration and the underlying pathology. General descriptions that were used included ulcer,
wound, chronic ulcer or wound, open wound or sore, defect in the dermis, break in the skin, full-thickness
skin break or defect, localised area of necrosis, destruction of skin and deeper soft tissues, and reference
to ulcer staging (e.g. Wagner stages for foot ulcers81).
The anatomical location of leg ulcers was most commonly referred to as ‘below the knee’ or ‘lower leg’.
Foot ulcers were referred to as ‘below ankle’ or ‘below malleoli’ and pressure ulcers as in an ‘area of
bony prominence’. The presence of the wound for ‘≥ 6 weeks’ was the most commonly used diagnostic
criterion relating to duration, although presence for ‘≥ 4 weeks’ and ‘> 14 days’ were also used. The
underlying pathology was rarely defined but included altered blood flow, immobile individuals and the
result of pressure, shear or friction.
Data items
The level of detail provided about the data items collected in the included studies varied but in the main
was brief (this may be explained in part by journal specifications on word limits). For example, it was widely
reported that ‘demographic’ data were collected but no further details were provided in many cases.
The data items collected are shown in Table 3. The ‘core’ or most frequently collected data items were
patient demographics and medical history (including comorbidities), current wound assessment
(including vascular assessment) and details of prevention strategies/equipment. There was more variation
in the collection of other data items depending on the wound type being studied. For example, studies
examining pressure ulcers were more likely to collect information on continence, whereas studies assessing
ulcers in people with diabetes and rheumatoid arthritis were more likely to report laboratory tests such as
creatinine, glucose and rheumatoid arthritis serology.
Methods used to collect and validate prevalence data
Sampling strategies
Most studies were surveys of health-care professionals who were asked to complete a questionnaire for
each patient they encountered with an eligible wound. Of those employing a sampling strategy, a random
sample was identified from the population of interest, whether that was patients with a particular condition
(e.g. diabetes65), health-care professionals71 or the wider public/population (e.g. from census data45).
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TABLE 2 Complex wound definitions
Wound type Definitions (when provided)
All complex wounds/all
wounds
Chronic wounds: leg, foot and pressure ulcers and other wounds that had not healed during
the previous 6 weeks.27 Leg ulcer: ulcers between the knee and malleoli.27 Foot ulcer: ulcers
below the malleoli27
Leg ulcer Chronic ulceration of the leg defined as a defect in the dermis at a site below the knee,
persistent for ≥ 1 month41
Chronic leg ulcer: an ulcer below the knee that had been open for ≥ 6 weeks42
Chronic leg ulcer: an ulcer distal to the knee that does not heal within 6 weeks47
Leg ulcer: an open wound on the leg that had not healed within the last 4 weeks3
Leg ulcer: an open sore anywhere below the knee48
Leg ulcer: an open wound on the leg49
Leg and foot ulcer Leg ulcers are situated on the lower legs or feet and are usually caused by altered blood flow53
Open sore below the knee anywhere on the leg or foot that takes > 6 weeks to heal55
An open sore on the skin of the lower leg, ankle region or the dorsum of the foot, excluding
only those clearly caused by pressure necrosis of the heel or bony high points, to neoplasia or
severe arterial disease with digital ischaemia44
Leg ulcer: chronic ulcers below the knee. Foot ulcer: ulcers below the ankle that do not involve
higher structures57
Chronic ulceration: an open wound below the knee (including foot ulcers) that did not heal or
was supposed to heal within a 6-week period after onset of ulceration60
Leg ulcer: any wound below the knee (including the foot) that did not heal within a 6-week
period after onset of ulceration, regardless of the cause of the ulcer61
Leg ulcer: any break in the skin on the lower leg (below the knee) or on the foot, that had been
present for > 6 weeks. Healed leg ulcer: a wound that had been resurfaced with epithelium and
looked pink, dry and smooth51
Lower limb ulceration: an open wound below the knee including both foot ulcers and leg
ulcers. Pressure ulcers were excluded64
Diabetic foot ulcer Foot ulcer: a full-thickness skin break to at least Wagner stage 1, occurring distal to the
malleoli65
Foot ulcer: according to Wagner classification and associated pathogens66
Foot ulcer: according to Wagner scale, stages 1 and 269
Non-diabetic foot ulcer Ulcer: an open wound on the foot below the ankle71
Foot ulcer: a full-thickness skin defect occurring in isolation on or below the midline of the
malleoli and requiring > 14 days to heal72
Pressure ulcer Pressure ulcer: any lesion caused by unrelieved pressure resulting in damage to underlying
tissue, usually found over bony prominences78
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TABLE 3 Data items collected in prevalence studies of complex wounds
Data category Category content (when provided)
Demographics Age, sex, ethnicity, geographical location, height, weight, body mass index
Medical history and comorbidities Especially vascular history and surgery, smoking status, neurological disorders
(stroke, multiple sclerosis, spinal cord injury), rheumatoid arthritis, kidney failure,
diabetes, hepatic cirrhosis, nutrition disorders (cachexia, obesity) and cancer
Vascular assessment Pulses, Doppler, ABPI, presence of oedema, varicose veins and skin condition
Neurological assessment Vibration and temperature perception, reflexes
Previous ulcers If yes, date of previous ulcer, number of episodes, site, type, treatment method,
time to heal
Current ulcer(s) Assessment: recurrent or primary ulcer, number, location (drawing or list of
anatomical locations), duration, size/measurement, aetiology, wound bed
characteristics, exudate, odour, pain, surrounding skin, cellulitis, haemorrhage,
staging/grading, self-treatment, suspicion or presence of infection, wound
swabbing, MRSA status, systemic infection, lymphangitis, osteomyelitis
Measurement by photographs or drawings
Staging/grading: Wagner scale81 (foot ulcers), Torrance82 and NPUAP83
(pressure ulcer), Shea classification84
Risk score: Waterlow85 and Norton et al.86 (pressure ulcer), Braden scale,87
Maelor score88
Treatment: cleansing agent used, dressing used, desired dressings but
unavailable, use of compression, use of skincare preparation
Setting and frequency of treatment, time taken to travel and treat
Use of miscellaneous items/services, additional procedures
Inpatient days attributable to the wound/whether wound was main reason for
admission or delayed discharge (acute care settings)
Referrals: specialist nurse, general practitioner, vascular surgeon, dermatologist,
diabetologist, other
Use of prevention strategies/equipment Compression stockings, seat cushion, mattress, repositioning, inspection
Laboratory tests Urea, creatinine, glucose, rheumatoid arthritis serology
Mobility/disability Paralysis, use of artificial limbs, callipers and wheelchairs
Continence Faecal and urinary incontinence
Workforce Source of referral, care provider details (profession and grade), level of education
and training (Doppler, compression bandages, wound care, prevention of
recurrence, wound care course)
Quality of life Nottingham Health Profile, SF-36
Social situation/support Employment status, living alone, marital status
Footwear Shoe fitting, orthotic use
Patient concordance Reasons for non-concordance
ABPI, ankle–brachial pressure index; MRSA, meticillin-resistant Staphylococcus aureus; NPUAP, National Pressure Ulcer
Advisory Panel; SF-36, Short Form questionnaire-36 items.
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Method of data collection
The method of data collection was not reported in 21 of the studies. When information was provided, the
most widely used method was paper-based questionnaires (including postal questionnaires; n= 16). Other
methods of data collection included interviews (including telephone interviews with patients), electronic or
web-based online questionnaires and questionnaires for which the method was unspecified.
Case validation
Fifteen studies3,26,36,37,41,42,45,53,55,57,58,60–62,72–74 undertook some method of case validation for positive reports
of ulcers. The majority of these undertook clinical examination of either all people identified as having
a wound or a random sample or convenience sample (e.g. those in hospital but not those in the
community). One study cross-referenced self-reported wounds with community nursing services.45 One
study attempted to identify false negatives, conducting a clinical examination of a random sample of
patients not reported as having a wound.47
Validation of underlying pathology in cases
The majority of studies did not describe or report validation of the underlying wound pathology.
Six studies39,40,56,59,63,71 accepted the differential diagnosis reported by the care provider.
Eight studies3,37,41,42,48,54,60,62 reported that the ankle–brachial pressure index (ABPI) had been measured
to determine whether or not there was any ischaemia. Venous competence was assessed in fewer
studies: vein status was assessed using ultrasound in one study;41 venous refilling was assessed by
photoplethysmography in two studies;37,41 and popliteal reflux was assessed in a single study using
Rheo Dopplex II and duplex scanning.3
Denominator data
Over half of the studies (n= 27) used a defined geographical population (or representative sample of
that population) for the denominator.3,26–28,31,32,36–44,48–51,53,54,56–63,73,74 The choice of denominator for the
remainder of the studies included the total current caseload29,30,64,69,75–78,82 of health-care professionals
or the provider organisation, the sample surveyed (not clear if these were representative samples of
geographical populations)45–47,55,62,65–68,70 and respondents to the survey.72,79 Of the studies that used a
defined geographical population, just over half (n= 15) reported that the source of the information was
census data or some type of official national statistics. The source of information was not stated in the
other 12 studies that used a geographical population. Fifteen of the 27 studies that used a geographical
population also gave an indication of how contemporary the denominator was in relation to the date
that the study was undertaken (they ranged from the same year to up to 6 years preceding the study).
Twelve studies did not provide any information on the contemporaneous nature of the denominator.
Capture–recapture technique
The technique of capture–recapture was employed in one of the included studies, although not for a
‘hard-to-reach’ group.50 Walker et al.50 conducted a population-based, cross-sectional study in New
Zealand in 1998 in which people with leg ulcers were identified by both health-care professionals and
self-notification. The team used both traditional and capture–recapture methods to estimate the
cumulative incidence and prevalence of leg ulcers. Their results indicated that actual leg ulcer prevalence
was six to eight times higher than that observed in the traditional method, although in this study the
prevalence estimate derived from traditional reporting methods was much lower than expected
(even taking account of differences in methods, etc.).
Quality-of-life data
Two studies52,89 compared quality of life data from individuals with leg ulcers with data from matched
control subjects.
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Jull et al.52 (a publication describing the Walker et al.51 2002 study population) compared Short Form
questionnaire-36 items (SF-36) scores of people with leg ulcers with those of a control group randomly
selected from the electoral roll using a stratified sampling process and population norms. Cases reported
significantly lower mean SF-36 scores than the control group (and the population norms), with an impact
similar to that of conditions such as diabetes and arthritis (as reported in the Medical Outcomes Study90).
Using cases from their 2004 study of the prevalence of leg ulceration in a south-west London population,3
Moffatt et al.89 matched these cases with control subjects from six general practice age/sex registers within
the same catchment area. The authors reported that cases had a significantly worse quality of life status
than control subjects for all domains on the Nottingham Health Profile.
Current estimates of the prevalence of complex wounds
Estimates of the prevalence of all chronic/complex wounds for individual studies are provided in Table 4
(in which cases are people not wounds). Prevalence estimates varied by wound type. Table 5 reports the
range of prevalence estimates for people affected by each wound type.
Tables 6–9 summarise the point prevalence estimates from studies in the following wound categories:
leg ulcers, leg and foot ulcers, diabetic foot ulcers and pressure ulcers. Data were taken directly from
published studies with no pooling or weighting. Cases are people rather than wounds.
TABLE 4 Prevalence estimates for all chronic/complex woundsa
Study Prevalence of chronic (complex) wounds (%)
Rodrigues 200630 1.40
Gupta 200426 0.45
Lindholm 199927 0.24
a Excludes studies that included acute wounds.28,29,31,32
TABLE 5 Range of estimates of prevalence by wound category
Wound category
Prevalence estimate (%)
Minimum Maximum
All complex wounds 0.24 1.4
Leg ulcers 0.039 0.48
Leg and foot ulcers 0.1 12.8
Diabetic foot ulcers 1.3 5.9
Non-diabetic foot ulcers 0.02 3.39
Pressure ulcers 0.056 23
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TABLE 7 Prevalence estimates for leg and foot ulcers
Study Prevalence estimate (%)
Wong 200564 12.8
Nelzén 199662 2.00a
Andersson 199353 1.02
Dale 198355 0.80
Nelzén 199662 0.63
Andersson 198454 0.32
Nelzén 1991,60 199461 0.31
Öien 200063 0.19
Harrison 2001,57 Lorimer 200358 0.18
Ebbeskog 199656 0.12
Lindholm 199259 0.12
a Includes healed ulcers.
TABLE 6 Prevalence estimates for leg ulcers
Study Prevalence estimate (%)
Marklund 200047 8.40a
Johnson 199545 0.48
Forssgren 200842 0.24
Lees 199246 0.19
Cornwall 198641 0.18
Callam 198538 0.15
Pina 200549 0.14
Clarke-Moloney 200639 0.13
O’Brien 200048 0.12
Baker 1991,36 199437 0.11
Clarke-Moloney 200840 0.11
Franks 199743 0.10
Freak 199544 0.11
Moffatt 20043 0.05
Walker 2002,50,51 Jull 200452 0.04
a Includes healed ulcers.
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Discussion
The existing literature on complex wound prevalence had three main shortcomings. First, there were very
few estimates of the prevalence of complex wounds per se, with studies tending to focus on the prevalence
of specific types of wounds. More than half of the studies identified (25/48) surveyed people for leg or leg
and foot ulcers in isolation; three studies surveyed people with any ‘chronic’ wound (definitions varied);
and a further four surveyed people with any kind of wound, including acute wounds. There was no
estimate of the impact or demand on services (such as community nursing) of caring for people with any
kind of complex wound and surveys focusing on particular wound subgroups are usually reliant on accurate
differential diagnosis (few studies had evidence of this). A survey that includes people with any chronic or
complex wound is more forgiving in terms of diagnostic accuracy (people may be misclassified as to type of
wound but are less likely to be misclassified as to whether or not they have a complex wound).
Second, no study had estimated the prevalence of complex wounds in hard-to-reach groups, for example
injecting drug users (although one study28 had included them there was no specific denominator for this
subgroup). By contrast, our research programme was, in part, borne out of a strong local perception that
chronic skin ulceration in injecting drug users was a growing and difficult issue. This review of previous
studies underlined the fact that no data on the prevalence or incidence of skin ulcers in injecting drug
users existed.
TABLE 8 Prevalence estimates for diabetic foot ulcers
Study Prevalence estimate (%)
Al-Mahroos 200766 5.9
Kumar 199467 5.3
Reid 200668 4.7
Tseng 200370 2.9
De Sonnaville 199769 1.8
Abbott 200565 1.3
TABLE 9 Prevalence estimates for pressure ulcers
Study Prevalence estimate (%)
Raghaven 200379 23.2
Pieper 199929 8.1
Meehan 199978 6.8
Bergquist 199975 6.0
Inman 199877 4.9
Hallett 199676 4.4
Torrance 199980 3.0
Barbenel 197773 0.09
Barbenel 198074 0.09
Vowden 200933 0.07
McDermott-Scales 200928 0.056
Srinisvasah 200731 0.05
Lindholm 199927 0.04
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Third, the pre-existing literature was characterised by huge variability in study design and wound
definitions plus common deficiencies in the design and reporting of studies. These issues were likely to
affect the validity of the prevalence estimates and make interpretation of the findings extremely difficult.
Complex wounds prevalence survey
Background
High-quality data on complex wounds are important in helping health-care providers plan sufficient and
adequate services for the people affected by this condition. This prevalence survey looking at people with
complex wounds in Leeds was motivated by a need to (1) estimate the numbers of people with a complex
wound in Leeds and the characteristics of the people affected, their wounds and their care and (2) inform
plans for a prospective register of people with complex wounds. It was essential that the survey and the
register overcame common deficiencies of design covered in the previous section of this report, including
focusing on poorly specified subgroups of people with complex wounds74,91 and wide variations and/or
lack of clarity regarding wound definitions.31,32,72 Our aim was to ensure that this survey overcame some of
the weaknesses in the existing literature.
Objectives
The overall aim of this research was to investigate the number, nature and care of complex wounds in the
geographical population of the city of Leeds, UK.
The specific objectives were to:
l estimate the overall point prevalence of complex wounds in Leeds
l estimate the point prevalence of different wound types, namely diabetic foot ulcer, non-diabetic foot
ulcer, venous leg ulcer, arterial leg ulcer, arterial/venous leg ulcer, pressure ulcer, dehisced surgical
wound, pilonidal sinus, pilonidal abscess, traumatic wound, other surgical wound, fungating
carcinoma, burn and any other types of complex wound identified
l estimate the point prevalence of complex wounds in intravenous drug users
l determine the characteristics of people with complex wounds
l describe who manages the care of people with complex wounds
l describe current wound management received by people for different types of complex wound.
Methods
Study design
A multiservice, cross-sectional survey was undertaken to identify the number, nature and care of complex
wounds across the city. The survey was conducted in the following areas: community and primary care
services, mental health services, acute services and independent care providers such as nursing homes
and hospices.
Study population
The study population consisted of residents of the city of Leeds (population 751,48722).
Inclusion criterion
People were included in the survey if they had at least one complex wound identified during the data
collection period (28 February 2011 to 13 March 2011). A complex wound was defined as one that
involves superficial, partial or full-thickness skin loss and is healing by secondary intention.
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Identification of health-care providers
All those managing the care of complex wounds within the city of Leeds were identified. The services included:
l community and primary care services (Leeds Community Healthcare NHS Trust and Leeds Primary Care
Trust), which covered the tissue viability service, district nursing, practice nurses, children’s nursing
services, podiatry, intermediate care team, intermediate care ward, community rehabilitation ward, no
fixed abode team and nursing services provided in prisons
l mental health and learning disability services (Leeds Partnerships NHS Foundation Trust); this included a
range of community-based and inpatient services)
l acute services (Leeds Teaching Hospitals NHS Trust), which included inpatient and outpatient wards
and departments
l independent organisations including nursing homes, hospices and private hospitals.
A data co-ordinator post was established and appointed to at the beginning of the research programme,
hosted within the Leeds Community Healthcare NHS Trust. Preparations with health-care providers in
Leeds began up to 12 months in advance to optimise participation by establishing an esprit de corps and
collaborative relationships. The data co-ordinator identified and engaged with health-care providers
and professionals in the months leading up to the survey to introduce, explain and encourage their
participation. Educational sessions were provided for health-care professionals prior to the survey to
familiarise them with the data capture form and survey procedures. The sessions linked into existing events
such as professional or team meetings and scheduled NHS training events within the city. The survey was
also publicised and promoted in articles included in city-wide NHS newsletters and bulletins. In the days
immediately prior to data collection all care providers were contacted by either e-mail or telephone to
remind them about the survey. Finally, project team members were available during the 2-week survey
to answer queries and provide further information on how to complete the data capture form.
Data capture form
After deliberation and consultation it became obvious that, because of the working arrangements of
community nurses, we required a paper-based survey (see Appendix 1) accompanied by guidance notes
regarding completion. It was also apparent that individual patient consent would be a huge barrier to the
collection of a comprehensive data set. Having taken advice from the National Information Governance
Board, we designed a data capture form that collected anonymised information about patients and their
wounds from their care providers. The questionnaire was designed to be completed by the health
professional away from the bedside and included the kinds of data that are routinely collected for the
purposes of clinical care.
Patient data items collected by the survey included demographics, relevant comorbidities, the number and
type of current wounds and current wound treatments; we also recorded wound duration at the time of
the survey. Information about individual wound dressings was summarised into different categories.
We also collected data about the care provided including the profession of the person completing the
form (e.g. nurse, podiatrist), his or her grade and the type of service provider for whom he or she worked.
Definitions
A complex wound was defined as one with superficial, partial or full-thickness skin loss and that was
healing by secondary intention.
Types of complex wound were categorised according to the following definitions (these were included in
the guidance notes for completion):
l Foot ulcer in person with diabetes – any open wound present on the foot below the level of the ankle
in a person with diabetes.
l Foot ulcer in person without diabetes – any open wound present on the foot below the level of the
ankle in a person without diabetes.71
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l Leg ulcer – an area of discontinuity of epidermis and dermis on the lower leg, persisting for ≥ 4 weeks.54
May be caused by venous disease or arterial disease alone or a combination of both.
l Venous leg ulcer – occurs when deep and/or superficial leg veins become incompetent due to
damaged valves or blockages, such as deep-vein thrombosis, leading to increased pressure in the
leg veins.54
l Arterial leg ulcer – a failure of, or reduction in, the nutritional blood supply to an area of skin, most
commonly because of atherosclerosis.54
l Arterial/venous leg ulcer – an ulcer caused by a combination of venous and arterial disease.
l Pressure ulcer – localised injury to the skin and/or underlying tissue usually over a bony prominence as
a result of pressure or pressure in combination with shear. A number of contributing or confounding
factors are also associated with pressure ulcers; the significance of these factors is yet to
be elucidated.83
l Dehisced surgical wound – a surgically closed wound (e.g. sutured) that has broken open because of,
for example, infection or poor healing.
l Pilonidal sinus – a sinus tract that commonly contains hairs. It occurs under the skin between the
buttocks (the natal cleft), a short distance from the anus.
l Abscess – collection of pus formed just under the skin. Symptoms include swelling, redness, pain and
warmth over the affected area.
l Traumatic wound – a traumatic wound is a contused wound characterised by torn and irregular edges,
the presence of devitalised tissue fragments and the presence of foreign matter (gravel, etc.).
l Other surgical wound – any other wound following surgical intervention that is healing by
secondary intention.
l Fungating carcinoma – a malodorous, exuding, necrotic skin lesion, the term ‘fungating’ referring to a
malignant process. Lesions that have a predominantly proliferative growth pattern may develop into a
nodular ‘fungus’ or ‘cauliflower’-shaped lesion.
l Burn – damage to the skin, and sometimes to underlying tissues, caused by contact of the skin with a
hot substance.
l Other – a complex wound that does not fit into any of the above categories.
Data collection
A pilot study of the data capture form was undertaken with care providers from a range of care settings
and professions and amendments were made in the light of feedback received (a substantial amendment
was submitted to and approved by Northern and Yorkshire Research Ethics Committee).
Data collection for the survey took place over 2 weeks from 28 February to 13 March 2011. Care providers
were asked to complete a data capture form for every patient with a complex wound on their caseload
using information from routinely collected data sources, for example case notes or electronic data sources.
They were requested to complete the form away from the ‘patient bedside’ and no wounds were
inspected for the purposes of the survey. Multiple forms for the same person were avoided by care
providers completing only one form per patient during the survey period; if care was shared between
services then one care provider was nominated to complete the form.
Reports of previous studies of this kind have discussed low response rates for completion of survey data
capture forms in some care settings, for example nursing homes.27,59 To minimise this we adopted a
number of strategies. The data co-ordinator (based in the NHS) identified and engaged with health-care
professionals in the months leading up to the survey to explain the survey and encourage their
participation. Educational sessions were provided for health-care professionals prior to the survey to
familiarise them with the data capture form. Finally, project team members were available during the
2-week survey to answer queries and provide further information on how to complete the data capture
form. The project team did not access case notes or have any form of contact with or undertake
observation of patients.
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Data handling and storage
At the end of the data collection period completed data capture forms were returned to the University of
York. Completed forms were scanned by York Trials Unit and the information was stored in a database.
Once scanned, the paper forms were locked in a filing cabinet within a locked room with only the
immediate research team having access. The database was stored on a password-protected computer,
again with access for the immediate research team only.
Analysis
As no hypotheses were formulated, the data were analysed descriptively. The overall point prevalence of
complex wounds was estimated using the Leeds population from the 2011 census as the denominator,22
along with prevalence estimates for each type of complex wound. The point prevalence of complex
wounds in intravenous drug users was estimated using the total population of intravenous drug users in
Leeds as the denominator (n= 5500) (Leeds Drug Service Team, personal communication, 2010). All point
prevalence estimates were produced using a binomial proportion and are presented alongside 95% Wilson
score CIs.
The following questions to ask of the data were generated through consultation with patients, clinicians
and NHS managers in Leeds:
1. What are the characteristics of people with complex wounds?
2. What are the characteristics of those managing the treatment of individuals with complex wounds?
3. What is the nature of the wound management currently provided for people with different types of
complex wound?
Ethics
The study was reviewed and approved by the Department of Health Sciences Research Governance
Committee, the University of York and the Northern and Yorkshire Research Ethics Committee (reference
10/H0903/41). Research and development departments of the following organisations approved the
research (with permissions co-ordinated by the West Yorkshire Comprehensive Local Research Network):
l NHS Leeds (reference P/0063)
l Leeds Teaching Hospitals NHS Trust [reference NU10/9532 (43641/WY)]
l Leeds Partnerships Foundation Trust
l 45 nursing homes in Leeds
l two hospices: St Gemma’s and Wheatfield’s
l non-NHS hospitals: the Nuffield Hospital and two Spire hospitals
l National Offender Management Service, Yorkshire region
l Her Majesty’s Prison (HMP) Leeds and HMP Wealstun.
Copies of all approvals (and amendments) are available on request.
Results
Leeds population estimates
Table 10 presents population estimates for Leeds based on 2011 census data,22 overall, by sex and by
10-year age category. Over half of the population was aged < 40 years.
Sample
In total, 1103 forms were returned, each reporting information on an individual with at least one complex
wound. Surveys were returned (including records of nil returns) from all services anticipated, reassuring us
that adequate data capture had been achieved.
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Point prevalence
Information was returned for 1103 individuals and the total population of Leeds using the 2011 census
estimate22 was 751,485. Hence, the point prevalence of complex wounds in Leeds was estimated as
1.47 per 1000 population (95% CI 1.38 to 1.56 per 1000 population).
Point prevalence by patient characteristics
The prevalence of complex wounds in females was 1.63 per 1000 (95% CI 1.51 to 1.77 per 1000),
whereas that in males was 1.28 per 1000 (95% CI 1.17 to 1.40 per 1000). The prevalence of complex
wounds increased with age, being most prevalent in the ≥ 90 years category, with an estimated
22.88 individuals per 1000 having a complex wound (95% CI 19.08 to 27.42 per 1000). The largest
number of individuals with a complex wound who were captured by the survey fell into the 80–89 years
age group (312/1103, 28.3%).
Point prevalence by wound type
Point prevalence estimates by wound type are presented in Table 11 based on the number of individuals
with at least one wound of the relevant type. Pressure ulcers were the most frequent wound type, with a
point prevalence of 0.31 per 1000 (95% CI 0.28 to 0.36 per 1000). Venous leg ulcers had a point
prevalence of 0.29 per 1000 (95% CI 0.25 to 0.33 per 1000). Fungating carcinomas and burns were the
least common wound types captured within the survey.
Pressure ulcers were the most prevalent complex wound in women, with a point prevalence of 0.39 per
1000 (95% CI 0.33 to 0.46 per 1000); in men they were the second most prevalent wound type, with a
point prevalence of 0.23 per 1000 (95% CI 0.19 to 0.29 per 1000). Venous ulcers were the most frequent
wound type in men, with a point prevalence of 0.25 per 1000 (95% CI 0.20 to 0.30 per 1000). Burns and
pilonidal sinuses were the least common wounds in females (both with an estimated point prevalence of
0.02 per 1000, 95% CI 0.01 to 0.04 per 1000 and 0.01 to 0.03 per 1000, respectively) and fungating
carcinomas were the least common wound type for males (point prevalence 0.01 per 1000, 95% CI 0.01
to 0.02 per 1000). Further details can be found in Appendix 2.
TABLE 10 Population of Leeds22
Category Population, n
Total population of Leeds 751,485
Male 367,935
Female 383,550
Age (years)
0–9 88,425
10–19 93,002
20–29 131,734
30–39 103,477
40–49 102,727
50–59 82,344
60–69 70,398
70–79 48,464
80–89 25,932
≥ 90 4982
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Diabetic foot ulcers were around twice as common in men (0.17 per 1000, 95% CI 0.13 to 0.22 per 1000)
than women (0.08 per 1000, 95% CI 0.05 to 0.11 per 1000). Traumatic wounds were around twice as
common in women (0.15 per 1000, 95% CI 0.11 to 0.19 per 1000) than men (0.07 per 1000, 95% CI
0.05 to 0.10 per 1000). Pilonidal sinuses were more than twice as frequent in men (0.05 per 1000,
95% CI 0.03 to 0.08 per 1000) as in women (0.02 per 1000, 95% CI 0.01 to 0.03 per 1000).
Point prevalence in intravenous drug users
Of the 1103 individuals with a complex wound, 31 were current (or previous) intravenous drug users.
The point prevalence of complex wounds among past or current intravenous drug users was estimated at
5.64 per 1000 (95% CI 3.97 to 7.99 per 1000). Drug use status was unknown for 116 individuals and
missing for 30 individuals, accounting for 13.2% of the sample population.
The most prevalent wound type in people with a history of intravenous drug use was venous leg ulcer,
with a point prevalence of 4.73 per 1000 (95% CI 3.23 to 6.92 per 1000). We used current local
estimates of the number of intravenous drug users in Leeds for the denominator (n= 5500; Leeds Drug
Service, personal communication, 2010).
TABLE 11 Prevalence by wound type
Wound type Frequency Point prevalence per 1000 95% CI per 1000
Abscess 33 0.04 0.03 to 0.06
Burn 15 0.02 0.01 to 0.03
Fungating carcinoma 14 0.02 0.01 to 0.03
Other 82 0.11 0.09 to 0.14
Pilonidal sinus 25 0.03 0.02 to 0.05
Pressure ulcer 236 0.31 0.28 to 0.36
Traumatic wound 81 0.11 0.09 to 0.13
Foot ulcers 166 0.22 0.19 to 0.26
Diabetic foot ulcer 95 0.13 0.10 to 0.15
Non-diabetic foot ulcer 71 0.09 0.07 to 0.12
Leg ulcers 335a 0.44 0.40 to 0.49
Arterial/venous leg ulcer 79 0.11 0.08 to 0.13
Arterial leg ulcer 38 0.05 0.04 to 0.07
Venous leg ulcer 218 0.29 0.25 to 0.33
Surgical wounds 156 0.21 0.18 to 0.24
Dehisced surgical wound 51 0.07 0.05 to 0.09
Other surgical wound 105 0.14 0.12 to 0.17
Wound type unknown 25
Total 1168b
a Individuals with at least one leg ulcer of any type.
b Wound types not mutually exclusive.
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Characteristics of individuals with complex wounds
The characteristics of individuals within the sample are presented in Table 12. There was a slightly higher
proportion of females than males (56.8% vs. 42.7%) and most people were white British (91.8%). The
youngest person with a complex wound was aged < 1 year and the oldest was aged 108 years. The mean
age was 70.06 years [standard deviation (SD) 19.41 years] and the median age was 76 years. Over 60% of
people with complex wounds were aged > 70 years.
TABLE 12 Characteristics of people with complex wounds (n= 1103)
Characteristic Frequency, n %
Sex
Female 627 56.8
Male 471 42.7
Missing 5 0.5
Ethnicity
White British 1013 91.8
White Irish 23 2.1
White other 14 1.3
Black Caribbean 11 1.0
Asian Indian 10 0.9
Asian Pakistani 6 0.5
Chinese 5 0.5
Asian other 4 0.4
Other 4 0.4
Black African 2 0.2
Asian Bangladeshi 2 0.2
White and black Caribbean 2 0.2
White and Asian 2 0.2
Other mixed background 1 0.1
Black other 1 0.1
Missing 3 0.3
Age (years)
0–9 3 0.3
10–19 20 1.8
20–29 30 2.7
30–39 50 4.5
40–49 61 5.5
50–59 99 9.0
60–69 137 12.4
70–79 256 23.2
80–89 312 28.3
90–99 110 10.0
≥ 100 4 0.4
Missing 21 1.9
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When each wound type was considered separately, those with arterial/venous leg ulcers had the highest
mean age at just below 80 years, whereas those with pilonidal sinuses were the youngest (mean age just
over 37 years) (see Appendix 2).
Wounds
Specific information was recorded on the questionnaire concerning 1416 wounds. The total number of
complex wounds reported in the sample population was 1479 (based on 1085 individuals), with data
missing for 18 individuals. Assuming (a conservative) one wound for each of these individuals, the sample
population was estimated to have a total of 1497 wounds.
Each person had a mean number of 1.36 (SD 0.99) complex wounds per person. The data were positively
skewed and the median number of complex wounds per person was one, despite the range being
between one and 20 (75.1% of the sample population had only one complex wound). Males had, on
average, more complex wounds per person [mean 1.40 (SD 0.94)] than females [mean 1.30 (SD 0.69)].
Duration of wound was recorded for 1374 of the 1416 wounds (97.0%) in the sample. The mean
duration in the sample was 67.5 weeks (SD 187.1 weeks). The median was much shorter (4 months),
indicating a positive skew (most wounds within the sample had a smaller than average duration).
The most common underlying cause of the complex wound (based on professional opinion) was
pressure/friction/sheer, which was recorded as a reason for 406 wounds (28.7%).
Comorbidities
Table 13 shows the frequencies of prespecified comorbidities. Cardiovascular disease (CVD) was the most
common comorbidity (44.8%) and stroke was the least common (8.3%). The numbers of comorbidities per
person are presented in Table 14. Most people captured by the survey had one comorbidity (330/1103,
29.9%); 313 people (28.4%) had two comorbidities.
TABLE 13 Proportions of people with prespecified comorbidities (n= 1103)
Comorbidity Frequency, n %
CVD 494 44.8
Arthritis 298 27.0
Diabetes 231 20.9
Peripheral vascular disease 216 19.6
Cancer 130 11.8
Airways 123 11.2
Orthopaedic 106 9.6
Neurological 100 9.1
Stroke 92 8.3
Total 1790a
a Many people had multiple comorbidities.
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One of the limitations of the survey was that it was not possible to distinguish between a person with no
comorbidities and a person with missing comorbidity data as both are classed as having no comorbidities.
This could have skewed the mean number of comorbidities towards zero, causing underestimation.
Because of this, the mean number of comorbidities is presented twice, once for all individuals and once
for individuals with at least one comorbidity. The mean number of comorbidities per person taking into
account all individuals in the survey was 1.62 (SD 1.21) and the median number was two comorbidities.
The mean number of comorbidities for individuals with at least one comorbidity was 2.01 (SD 1.00).
Diabetic foot ulcers were found to be associated with the highest average number of reported
comorbidities at 2.49 (SD 1.03), whereas individuals with pilonidal sinuses had the lowest average number
of comorbidities (0.32, SD 0.75).
Other health issues
Table 15 shows summary statistics relating to ‘other’ health issues such as incontinence and mobility.
Urinary incontinence was reported for nearly one-quarter of the sample (23%) and faecal incontinence
for approximately 12%, with 9.3% (103/1103) of the overall sample having both urinary and faecal
incontinence. Urinary incontinence was most frequently found in people with at least one pressure ulcer
(48.3%, 114/236), as was faecal incontinence (33.9%, 80/236).
The majority of people had not experienced recent weight change (73.4%) and were not currently taking
antibiotics (77%). In total, 41.0% walked with difficulty and 39.4% walked freely. Diabetic foot ulcers
were most commonly associated with difficulty with walking, with 58.9% (56/95) of individuals with at
least one wound of this type reported to have a problem. Non-diabetic foot ulcers, arterial leg ulcers and
traumatic wounds were also frequently associated with walking difficulties (53.5%, 52.6% and 51.9%,
respectively). Immobility was most frequently associated with pressure ulcers, with 48.3% (114/236) of
individuals with at least one pressure ulcer reported as being immobile. This is more than twice the
frequency of immobility as in those with non-diabetic foot ulcers (23.9%, 17/71).
TABLE 14 Numbers of prespecified comorbidities per patient (n= 1103)
Total number of prespecified comorbidities per patient Frequency, n %
0a 214 19.4
1 330 29.9
2 313 28.4
3 167 15.1
4 63 5.7
5 15 1.4
6 1 0.1
Total 1103 100
a Includes people for whom data are missing.
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Wound management
Health professionals providing care
Table 16 indicates both the professional background and the grade (Agenda for Change band) of those
completing the questionnaires. Health professionals caring for people with complex wounds were mainly
qualified nurses (accounting for around 66% of the individuals captured by the survey), with 5.9% being
podiatrists. The nurses providing care and completing the survey questionnaires were mainly district nurses
(reporting on 36.3% of people with complex wounds) followed by practice nurses (25.1%) and specialist
nurses (4.7%). Just over 85% (247/289) of the ‘other’ category were also nurses. Thus, 88% of people
with complex wounds were receiving nursing care from (and were reported into the survey by) a nurse.
The majority (74.4%) were seen by band 5 and band 6 staff (46.1% and 28.4%, respectively).
Wound consultations
Services providing wound care are presented in Table 17. Individuals were mainly cared for by community
NHS services (801/1103, 72.6%). Acute NHS services cared for 9.5% of individuals with complex wounds,
and nursing homes and hospices provided services for 7.3% and 0.8% of individuals, respectively.
Approximately one-quarter of patients were seen within more than one health-care setting.
TABLE 15 Other concurrent health issues (n= 1103)
Health issue Frequency, n %
Continencea
No incontinence 760 68.9
Urinary incontinence 254 23.0
Faecal incontinence 133 12.1
Missing 60 5.4
Nutritional status
No recent weight change 810 73.4
Recent weight loss 198 18.0
Recent weight gain 55 5.0
Missing 40 3.6
Mobility
Patient walks with difficulty 452 41.0
Patient walks freely 435 39.4
Patient is immobile 200 18.1
Missing 16 1.5
Currently on antibiotics
No 849 77.0
Yes 168 15.2
Don’t know 61 5.5
Missing 25 2.3
a Note that the total number of people in the continence section is > 1103 as some had both urinary and
faecal incontinence.
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TABLE 16 Care providers (n= 1103)
Care provider Frequency, n %
Job title
District nurse 400 36.3
Other 289 26.2
Practice nurse 277 25.1
Podiatrist 65 5.9
Specialist nurse 52 4.7
Missing 20 1.8
Band
3 27 5.4
5 508 46.1
6 313 28.4
7 77 7.0
8a 9 0.8
Other 110 10.0
Missing 59 5.3
TABLE 17 Services providing care (n= 1103)
Service Frequency, n %
Community NHS 801 72.6
Acute NHS 105 9.5
Nursing home 80 7.3
Missing 25 2.3
Hospice 9 0.8
Other 83 7.5
General practice 67 6.1
Prison 8 0.7
Residential home 2 0.2
CIC bed 1 0.1
ICT bed 1 0.1
Inpatient 1 0.1
Out-of-hospital care 1 0.1
Private hospital (outpatient) 1 0.1
Not specified 1 0.1
Total 1103 100.0
CIC, community intermediate care; ICT, intermediate care team.
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The frequency of wound consultations per week was recorded for 1066 individuals and ranged between
1 and 14. The mean number of consultations per patient per week was 3.15 (SD 2.15) (median of two per
week). The duration of the most recent consultation was recorded for 1083 individuals (98.2%) and the
mean duration was 28 minutes (SD 43.6 minutes). If it is assumed that the maximum recorded consultation
of 20 hours was a recording error, the mean duration was just below 27 minutes (SD 25.2 minutes).
Treatment objectives
The most frequent wound treatment objective was protection (66.5% of 1416 wounds). Encouraging
granulation was the second most frequent objective (49.3%), whereas reducing ‘overgranulation’ was the
least common treatment objective.
Wound dressings
A primary dressing was reported in 1326 (93.6%) of the 1416 wounds. The five most frequently reported
primary dressings were non- and low-adherence wound contact dressings (26.3%), foam (15.9%),
iodine-containing low-adherence wound contact dressings (12.4%), spun hydrocolloid/hydrofibre (8.4%)
and soft polymers (7.7%). Collagen dressings, hyaluronic acid, silicone sheets or gels, silver-containing
silicone sheets or gels and acrylic dressings were not reported as being used as the primary dressing for
any wound. A secondary dressing was reported for 678 (47.9%) of the 1416 wounds. The five most
frequently reported secondary dressings were non- and low-adherence wound contact (37.9%), foam
(30.5%), soft polymer (12.4%), vapour permeable/film (4.3%) and odour absorbent/charcoal (3.1%).
The three most frequently reported dressings for each wound type are presented in Tables 18 and 19 for
primary and secondary dressings, respectively.
A cavity wound dressing (either silver or non-silver containing) was used as the primary dressing for
35 wounds and was used most frequently in relation to ‘other’ surgical wounds and pilonidal sinuses.
Bandaging and hosiery
For all wound types, a non-compression bandage plus wadding was the most frequently reported
bandaging (16.5%). Approximately one-quarter of the 455 leg ulcers in the sample was treated using a
non-compression bandage (Table 20) and multilayer compression was used for just over one-fifth of these
wounds (22.6%).
Hosiery was rarely used in wound treatment (53/1416 wounds, 3.7%). When used as a treatment, hosiery
was most frequently used for venous leg ulcers (33/298, 11.1%) but was also used in the treatment of
some traumatic wounds, diabetic and non-diabetic foot ulcers, ‘other’ wounds, burns and arterial/venous
leg ulcers.
There were 218 individuals in the sample population with at least one venous leg ulcer. Of these,
176 (80.7%) were receiving at least one form of compression therapy, most frequently (34.4% of those
with a venous leg ulcer) multilayer compression (Table 21). Compression bandaging was used more
frequently than compression hosiery.
Equipment and footwear
Table 22 summarises all forms of equipment used. Equipment was mainly pressure-relieving equipment for
people with, or at risk of, pressure ulceration. The static, air-filled mattress overlay (Repose®, Frontier
Medical Group, Blackwood, South Wales, UK) was the most frequently reported pressure-relieving
mattress, used by 15.7% of the sample population. In addition, 8% of patients had a wheelchair and a
few used crutches (0.8%). Of the 236 individuals with at least one pressure ulcer, 173 (73.3%) were using
a pressure-relieving mattress, most commonly an alternating-pressure mattress replacement (41.6%). A
minority of people were using more than two types of mattress (5.2% of 173 patients).
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TABLE 19 Secondary dressings by wound type (top three most frequently used dressings)
Wound
type
Wounds
with a
secondary
dressing,
n (%)
NLA
wound
contact,
n (%)
Foam,
n (%)
Soft
polymer,
n (%)
Vapour
permeable/film,
n (%)
Odour
absorbent/charcoal,
n (%)
Iodine
NLA
wound
contact,
n (%)
Pressure
ulcer
118 (41.1) 15 (12.7) 60 (50.8) 17 (14.4)
Venous leg
ulcer
106 (35.6) 67 (62.3) 12 (11.3) 11 (10.4)
Other
surgical
wounds
58 (48.7) 24 (41.4) 15 (25.9) 9 (15.5)
Diabetic
foot ulcer
73 (65.2) 23 (31.5) 37 (50.7) 4 (5.5)
Other
wounds
39 (38.6) 15 (38.5) 11 (28.2) 7 (17.9)
Traumatic
wound
36 (41.4) 13 (36.1) 7 (19.4) 12 (33.3)
Arterial/
venous leg
ulcer
72 (64.3) 42 (58.3) 12 (16.7) 6 (8.3)
Non-diabetic
foot ulcera
33 (40.2) 14 (42.4) 10 (30.3)
Dehisced
surgical
wounds
35 (67.3) 8 (22.9) 14 (40.0) 6 (17.1)
Arterial leg
ulcer
25 (55.6) 13 (52.0) 8 (32.0) 2 (8.0)
Abscess 26 (72.2) 6 (23.1) 6 (23.1) 6 (23.1)
Pilonidal
sinus
16 (61.5) 4 (25.0) 4 (25.0) 6 (37.5)
Burn 10 (62.5) 6 (60.0) 3 (30.0) 1 (10.0)
Fungating
carcinomab
5 (35.7) 2 (40.0)
NLA, non- and low adherence.
a Tied for second most frequent dressing type.
b Tied for third most frequent dressing type.
Note
Shaded boxes indicate dressing not in the top three for that wound type.
TABLE 20 Bandaging for leg ulcers (n= 455)
Type of bandaging Frequency, n %
Non-compression bandage plus wadding 116 25.5
Multilayer compression 103 22.6
Three-layer reduced compression 67 14.7
Short stretch compression 50 11.0
Two-layer compression 36 7.9
Dressing retention bandage 8 1.8
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Use of orthotics is detailed in Table 23. Prescribed footwear was reported for 12.6% of people. Heel
pressure relief, footwear adaptations and insoles were reported much less frequently (2.7%, 2.5% and
0.9%, respectively). Of the 95 individuals with at least one diabetic foot ulcer, 62 (65.3%) were using an
orthotic device, whereas only 23 out of 71 (32.4%) people with a non-diabetic foot ulcer were using one.
Medication and other treatments
Topical steroids were being used in the care of 7.2% of people with complex wounds. In total, 19% of
patients were taking analgesics and 13.8% were taking antibiotics related to wound infection. Only one
patient (who had a venous leg ulcer) was taking pentoxifylline.
In terms of other treatments, a small number of people were reported to be having physiotherapy
(4.3%, 47/1103), occupational therapy (2.8%, 31/1103) or hyperbaric oxygen therapy (0.3%, 3/1103).
TABLE 21 Venous leg ulcers: compression therapy (n= 218)
Type of compression therapy Frequency, n %
Multilayer compression 75 34.4
Three-layer reduced compression 38 17.4
Short stretch 33 15.1
Two-layer compression 16 7.3
Class 2 hosiery over the counter 7 3.2
40mmHg made to measure 6 2.8
40mmHg over the counter 5 2.3
Class 1 hosiery over the counter 5 2.3
Class 2 hosiery made to measure 4 1.8
Class 3 hosiery made to measure 2 0.9
Class 3 hosiery over the counter 0 0
Total 191a 87.6
a Different types may have been used together, hence the total is > 176.
TABLE 22 Equipment used (n= 1103)
Equipment Frequency, n %
Pressure-relieving mattresses
Static, air-filled mattress overlay
(Repose®, Frontier Medical Group)
173 15.7
Alternating-pressure mattress replacement 99 9.0
High-specification foam mattress replacement 85 7.7
Foam mattress overlay 13 1.2
Alternating-pressure mattress overlay 10 0.9
Wheelchair 91 8.3
Other equipment 72 6.5
Crutches 9 0.8
DATA CAPTURE AND EPIDEMIOLOGY (WORKSTREAM 1)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
Pressure ulcer categorisation
Nearly 95% of all pressure ulcers (272/287) had been given a European Pressure Ulcer Advisory Panel
(EPUAP) severity classification (or had been classed as unstageable),83 in line with NICE guidelines.13
Discussion
We designed and implemented a survey protocol that included an explicit definition of a complex wound
and different types of complex wound. Our review of previous prevalence studies highlighted that most
estimates were usually based on either self-report by sampling the general population (or subpopulation,
e.g. limited by age) or the case loads of health-care providers. Although case load-based surveys will
always underestimate the prevalence because they do not capture people who self-treat, we chose this
approach as it was most likely to be practical, less expensive and satisfy the information needs of the NHS.
We aimed to be as comprehensive as possible in surveying all kinds of health-care provider and our survey
included hospitals, hospices, care homes and prisons.
The prevalence survey gave us up-to-date epidemiological data regarding the number and nature of
people with complex wounds in a large UK city (Leeds). These findings are likely to be applicable to other
places with a similar demographic profile. Although pressure ulcers, leg ulcers, foot ulcers and surgical
wounds were the most common complex wounds, a wide variety of less common complex wounds
accounted for one in five of the people identified. This suggests that a more complete understanding of
the extent of complex wounds and their impact on society is best achieved by approaching complex
wounds as a whole, particularly as people with complex wounds draw on the same services, irrespective of
the underlying cause.
To our knowledge, this survey is the first to estimate the prevalence of complex wounds among injecting
drug users. The prevalence of complex wounds was higher among injecting drug users than among the
general population and these wounds were most commonly venous leg ulcers. Injecting drug users can be
a difficult population to access and thus our prevalence estimate might be an underestimate, although
linking with services such as the No Fixed Abode team in Leeds likely improved our access to patients who
may otherwise have been missed. Use of techniques such as capture–recapture may have further
enhanced our estimates. Although most people with complex wounds were aged > 65 years, those with
pilonidal sinuses, complex surgical wounds, burns and abscesses were younger. Wound care services may
need to be geared towards a primarily elderly population but need the flexibility to deal effectively with the
potentially differing needs of a smaller but younger population. Most wound care in the city is undertaken
by nurses (in a variety of roles) within community NHS services; the remainder of patients are managed by
a wide variety of professions. Fewer than 10% of patients are cared for in acute NHS services and 8% in
nursing homes.
TABLE 23 Footwear used (n= 1416)
Footwear Frequency, n %
Prescribed footwear 179 12.6
Other types of footwear (not specified) 46 3.2
Heel pressure relief, e.g. Repose® Heel Trough (Frontier Medical Group),
PRAFO® boot (Anatomical Concepts, Inc, Clydebank, UK)
38 2.7
Footwear adaptation 36 2.5
Insoles 13 0.9
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Comparisons with other epidemiological studies
Overall, our estimate of the point prevalence of complex wounds is lower than relevant recent estimates
(range 2–3.55 per 1000 population). Our lower estimate probably reflects our case definition (several
previous studies have included uncomplicated surgical and other acute wounds or differed in other
ways28,31,32). Our definition of a complex wound was intended to capture those wounds for whom healing
is frequently protracted, for which there are usually comorbidities and for which NHS intervention is often
frequent and prolonged.
Our point prevalence estimates for specific wound types were similar to those in previous studies. For
example, a leg ulcer point prevalence of 0.44 per 1000 is within the range 0.39–4.8 per 1000 reported by
others.45,50 However, our pressure ulcer point prevalence estimate (0.31 per 1000) was lower than previous
estimates from studies using a geographically defined population. Previous estimates of pressure ulcer
prevalence have ranged from 0.4 to 230 per 1000 depending on the baseline risk in the survey population;
for example, rates in spinal injury patients are particularly high.27,73,74,79 Our low estimate is probably at least
partly due to the high priority placed on pressure ulcer prevention at local and national levels and early
implementation of local improvement tools in Leeds, leading to improvements in care.92 There were also
differences in study design, methods and reporting behaviour.
Quality of care
Venous leg ulcers
We were able to compare the management of venous leg ulcers in Leeds with elements of the Royal
College of Nursing93 and SIGN94 guidelines, specifically screening for arterial disease using Doppler-aided
ABPI; use of compression therapy; use of low-adherence/low-cost dressings; and prescription of
pentoxifylline. Overall, adherence to guideline recommendations was generally good. Nearly 70% of
people recorded as having at least one venous leg ulcer had an ABPI assessment recorded in their notes
(60% for people with at least one leg ulcer of any type). In total, 80% of people with a venous ulcer were
receiving some form of compression; 56% of primary dressings and 67% of secondary dressings were
non-/low-adherence wound contact dressings. The percentage of people recorded as having an ABPI
assessment may be an underestimate if, for instance, patients’ notes were not available when the survey
form was completed or the ABPI assessment was carried out by a specialist team (such as a vascular
secondary care team) and the recommended treatment was carried out by another care provider who
completed the survey form (with the ABPI assessment not necessarily recorded in the notes if carried out
by another provider).
Figures for the use of compression therapy and ABPI assessment in patients with venous leg ulcers are very
similar to those reported in previous studies in the UK and Ireland. In Bradford, Vowden and Vowden34
reported that a Doppler assessment had been performed in 66% of people with leg ulcers and 75% of
people with venous leg ulcers received some sort of compression therapy. A survey of leg ulcer
management in Ireland estimated that 75% of limbs with a venous leg ulcer had an ABPI recorded, 50%
were receiving high levels of compression therapy and a further 15% were receiving lower levels of
compression therapy.40
Royal College of Nursing guidelines93 recommend that simple low-adherent, low-cost dressings that are
acceptable to the patient are used in the management of venous leg ulcers. Similarly, SIGN guidelines94
also recommend the use of simple non-adherent dressings and, in addition, do not recommend the
routine use of either honey or silver dressings in the management of venous leg ulcers. The high use of
non-/low-adherence wound contact dressings in the management of venous leg ulcers in our survey is
particularly encouraging. In contrast, the studies by Vowden and Vowden34 and Clarke-Moloney et al.40
both reported that the most frequently used dressings for venous leg ulcers were antimicrobial products
(Vowden and Vowden34 reported that 41% of primary dressings were antimicrobials and in the Irish
survey40 silver-impregnated dressings were the most commonly used dressings). In our survey, antimicrobial
dressings were used relatively rarely for venous ulcer management (52/276 cases, 19%) when a primary
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dressing was reported. Reducing the use of antimicrobial dressings has been a priority in Leeds Community
Healthcare NHS Trust, with intensive efforts made to bring about change, and this strategy appears to
have been successful.
Scottish Intercollegiate Guidelines Network guidelines94 recommend the use of pentoxifylline in the
management of venous leg ulcers; however, we identified only one person who was reported to be receiving
pentoxifylline. However, there has been no particular effort to promote the prescribing of pentoxifylline
for people with venous leg ulcers in Leeds (or elsewhere as far as we are aware). In December 2012 NHS
Leeds recategorised pentoxifylline as suitable for prescribing for people with hard-to-heal leg ulcers in
primary care. The findings from our survey will provide a useful benchmark from which to monitor the use
of pentoxifylline in the management of venous leg ulcers in Leeds.
Pressure ulcers
We were able to assess adherence to NICE guidelines13 in the management of pressure ulcers in a number
of areas: ulcer categorisation, risk assessment, availability and suitability of pressure-relieving equipment
and use of suitable wound dressings. Overall, adherence to guidelines was good but some areas for
improvement were identified.
According to NICE guidelines, people with existing pressure ulcers should receive ongoing assessment,
although there is little evidence to support any particular method of assessment. The Braden risk
assessment tool95 is recommended for all Leeds NHS providers. Other care providers such as nursing homes
do not necessarily use the Braden risk assessment tool, for example some use the Waterlow score.96 The
survey captured information about those people who had a Braden risk assessment reported in their notes
in the last month. In people with at least one pressure ulcer, 57.2% (135/236) were reported as having
had a Braden risk assessment completed in the last month, 30.5% (72/236) had not and 12.3% (29/236)
of the data were missing. This percentage of those reported as having had a Braden risk assessment may
potentially be an underestimate if, for example, a risk assessment had been completed but not monthly or
patients’ notes were not available when the survey form was completed.
National Institute for Health and Care Excellence guidelines recommend that all pressure ulcers are
categorised according to EPUAP recommendations. We identified that 94.8% (272/287) of pressure ulcers
had been either categorised or classed as unstageable. It is encouraging that most pressure ulcers are
assigned a category from which clinicians can assess improvement or deterioration of the ulcer.
National Institute for Health and Care Excellence guidelines also recommend that patients with pressure
ulcers should have access to appropriate pressure-relieving support surfaces and strategies. In total, 77%
of people were reported as being in receipt of one of the listed pieces of pressure-relieving equipment
(high-specification foam replacement, static air-filled mattress overlay, foam overlay, alternating pressure
overlay, alternating pressure mattress replacement). It was not possible to estimate the proportion of
people who had declined pressure-relieving equipment and so the proportion of people having access to
pressure relief could be > 77%.
Based on professional consensus (as opposed to research evidence), NICE clinical guidelines recommend
the creation of an optimum wound healing environment using modern dressings, for example
hydrocolloids, hydrogels, hydrofibres, foams, films, alginates and soft silicones. The dressings identified in
this survey in the management of pressure ulcers were largely concordant with NICE guidelines (foam and
soft polymer were the most frequently reported dressings for both primary and secondary dressings).
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Review of registers
Background
Before developing and piloting our own complex wounds register in Leeds we aimed to learn as much as
we could from current and previous chronic disease registers, including how these were defined, how they
were operationalised and how data were collected and used. To obtain relevant literature we conducted a
systematic review of chronic disease registers (see Appendix 3 for the review protocol). Prior to the review
we were not aware of any UK registries of chronic wound care but wanted to confirm that this was the
case. We also felt that information from registries of other chronic diseases might provide valuable insights.
Aims and objectives
The aim was to identify, appraise and summarise reports of chronic disease registries.
Specific aims were to:
1. identify chronic diseases (and countries) for which a register had been utilised
2. identify the methods of data collection used
3. summarise the uses of register data
4. describe how the register (and data collection related to it) integrates with other data collection systems
in the organisation
5. examine the configuration of registries across multiple specialty teams or across health-care interfaces,
for example primary and secondary care.
Methods
Systematic search
Inclusion criteria
Any paper reporting a chronic disease register was included. A chronic disease was defined as a
long-lasting or recurrent condition. Registries relating to surgical procedures were excluded. A medical
register was defined as a database that met the six characteristics that define a medical database register:97
1. mergeable data: data from many users and patients can be aggregated
2. standardised data set: same variables collected for all patients
3. rules for data collection: protocol-driven data collection
4. observations associated over time: follow-up data for individual patients linked
5. knowledge about patient outcomes: complete ascertainment of end points of patients in the register
6. inclusion principle: the clinical characteristic or diagnosis on which the register is focused and which all
registrants share.
Search methods
A MEDLINE search was undertaken using OvidSP and the following search strategy:
1. exp Chronic Disease/ (182,090)
2. 2(chronic adj (illness$or disease$)).tw. (25,675)
3. 1 or 2 (199,178)
4. exp Registries/ (35,210)
5. (registr$or register$1).tw. (77,603)
6. 4 or 5 (92,049)
7. 6 and 3 (1409)
This searching was supplemented by less formal internet searching via the search engine Google
(Google Inc., Mountain View, CA, USA). Similar terms to those used in the MEDLINE search were used.
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Screening process
Screening stage 1
All study titles and abstract (when available) were reviewed. Full papers were obtained when the title
and/or abstract suggested that the paper reported:
(a) a review of medical registers
(b) a study in which a medical data register relating to a chronic condition was discussed or explicitly used
as a source of data.
The selection process was carried out by two reviewers. Any disagreement was taken to a third,
senior reviewer.
Screening stage 2
Full articles were then screened against the criteria of Drolet and Johnson97 and classified as medical data
registers or not. When a paper provided very limited information, that is, a register was mentioned only
briefly as a source of data without sufficient information to make an inclusion decision, we followed the
methods of Drolet and Johnson97 and searched for further information on MEDLINE and the internet. We
had also planned to contact authors if necessary. When no further useful information could be obtained
the study was excluded with regard to further data extraction. Again, all phases were conducted by
two reviewers.
Results
The MEDLINE search produced > 1400 references and after initial screening 30 potential papers of interest
were identified. Based on the available abstracts it was evident that the publications were likely to be of
limited value in addressing the aims of the review. Two-thirds of the papers were reports of analyses across
a wide variety of conditions using data from a register and were not about the register itself.
The internet search also produced a substantial number of ‘hits’, most of which were of limited relevance
because they did not relate to registries about chronic diseases.
However, two significant publications were identified (in addition to that by Drolet and Johnson97) and full
reports were obtained.98,99
Both the Newton and Garner98 and Raftery et al.99 papers were reviews of registers, clinical databases and
routine databases with similar aims and objectives to those of our planned review. In effect, these reviews
had already comprehensively addressed what we were setting out to do; therefore, to meet our objective
of informing our own register design, this project became a ‘review of reviews’, although this was not the
original intent. Drolet and Johnson97 developed a framework for classifying registries. We also identified,
through internet searching and reference checking, papers specific to reports of registers/databases of
people with complex wounds.100–108 The reviews identified sufficiently addressed our core questions and
provided an adequate basis for the design of our own register. The findings of the reviews are summarised
in Table 24.
Classification and definitions of registers
Newton and Garner98
In their report, Newton and Garner98 draw a distinction between ‘disease register’ (or ‘case register’) and
‘clinical database’. They reserve the term ‘disease register’ for those databases that have a clearly identified
denominator population. Clinical databases do not necessarily relate to a defined denominator population
and usually include cases from a particular institution or group of institutions. According to this definition,
registers can be used for epidemiological research and needs assessment as well as to improve clinical care
and service quality and for health technology assessment (HTA). Clinical databases generally have the
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TABLE 24 Summary of the findings of the reviews
Study Review aims and objectives Review methods
Newton 200298 Commissioned by the Department of Health
Policy Research Programme in 2000 in
support of the White Paper Saving Lives: Our
Healthier Nation.109 The objectives were to:
l outline the potential roles of disease- or
condition-based registers that would
serve not only clinical but also public
health purposes
l identify what is already being done at
local level
l identify which registers have been used
and how, including criteria and
conditions for a ‘useful’ register
l indicate the broad costs of setting up
and managing a register at local level
l indicate how ‘light-touch’ co-ordination
might take place regionally and nationally
The authors reviewed the literature, wrote to regional
directors of research and development, regional
directors of public health and district directors of
public health. They also contacted < 100 specific
individuals in relation to individual registers
Raftery 200599 This was a NIHR Health Technology
Assessment programme-commissioned study
with the following aims:
l to develop criteria for classifying
databases in relation to potential uses
for HTA
l to list relevant UK-based databases
l to apply the criteria for classifying to this
list and investigate those with most
scope for HTA
l to explore the extent to which they
could pick up the health technologies
prioritised by the Health Technology
Assessment programme
l to investigate the extent to which
routine databases have been used
for HTA
l for databases with most potential, to
explore the degree to which they have
been validated
l to estimate the cost of the main
databases
l to make recommendations
as appropriate
The authors detail the methods used for each
separate objective (see full report). In summary, they
used a combination of electronic databases, key
literature sources and information from experienced
users of routine databases to answer the questions
Drolet 200897 Aimed to develop a more useful
categorisation scheme for registries
The project was conducted in three phases
(identification of references, preliminary review and
framework construction and evaluation), largely
following the immersion/crystallisation process used
in qualitative research
HTA, health technology assessment.
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objectives of quality improvement and HTA and, although cases should be as representative as possible of
those in the target population, these databases are not suitable for epidemiological research because of
the lack of a clear denominator and they are potentially misleading as indicators of the need for care in
the community.
Raftery et al.99
Raftery et al.99 adopted the following key terms (or definitions) in their review:
l routine data – there is no unequivocal definition but important characteristics include regular/
continuous/periodic collection, use of standard definitions, degree of obligation to collect data
completely/regularly and collection at a national or regional level
l health technologies – all methods used by health professionals to promote health, prevent and treat
disease, and improve rehabilitation and long-term care
l HTA – includes the assessment of:
¢ efficacy (patient benefit/harm in experimental and closely monitored studies) and effectiveness
(benefit/harm when applied in everyday practice)
¢ equity (extent of use by different groups or particular health technologies in relation to some
measure of clinical need or perceived fairness)
¢ diffusion (factors influencing uptake of health technologies by place and time)
¢ costing (cost efficacy, cost-effectiveness, cost of illness, cost–consequences and cost impact).
Raftery et al.99 then developed a classification system for routine databases according to their potential use
in HTA (to assess efficacy or effectiveness and, to a large extent, equity and diffusion):
l Group I databases. These capture information on both the HTA being used and outcomes. They offer
the greatest potential for HTA and can be subdivided into three groups:
1. Ia – clinical registries are clinically rich databases that contain data on both the interventions (health
technology) and the outcomes (health states) at the patient level. These have frequently been
designed for research purposes
2. Ib – clinical administrative databases contain data on health technologies but only limited health
state data at the patient level. They are typically designed for administration purposes, for example
NHS Hospital Episode Statistics.
3. Ic – population-oriented databases identify the health technology and health state at the population
level, for example vaccination programmes.
l Group II databases. These contain information about health technologies in use but not the outcomes
associated with these technologies, for example prescribing data that summarise drugs prescribed but
not patient outcomes.
l Group III databases. These contain only health state information but no details of health technologies
or interventions received. Group III databases are further subdivided into:
¢ IIIa – adverse event reporting and confidential enquiries
¢ IIIb – disease/disability-only registers
¢ IIIc – health surveys.
When considering the use of databases to assess the costs of health technologies, Raftery et al.99 suggest a
classification system that distinguishes between the different ways that health technologies can be costed.
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Drolet and Johnson97
Drolet and Johnson97 created a detailed definition for registries in health care and outlined a set of
characteristics common to them all. Their framework [MDR-OK – mergeable data (M), data set
standardized (D), rules for data collection (R), observations associated over time (O) and knowledge of
outcomes (K)] includes six distinguishing features of registries, which were summarised in the
methods section.
Number of registers and databases in the UK
Newton and Garner98
Newton and Garner98 reported that the number of disease registers already in existence in England is large,
possibly larger than is generally appreciated. Their review was not exhaustive but identified approximately
250 registers. They noted the heterogeneity in every aspect of these registers, reflecting the fragmentation
of policy and lack of strategy in this area. Cancer registries were recognised as an exception because there
is now a developing national framework and regional structures to support it.
Raftery et al.99
This report identified around 270 databases at the level of the UK, England and Wales or England (> 1000
including databases specific to Scotland, Wales and Northern Ireland). The lack of detail in the review by
Newton and Garner98 meant that it was not possible to cross-reference the English registers identified in
both reviews, but we assumed that a large number of the registers would have been identified by both
reviews. Newton and Garner98 did list six national treatment and device registers by name and these were
all also included in the review by Raftery et al.,99 with Raftery et al.99 also presenting a more extensive list
of named registers from across the UK. Around 60 of the registers identified by Raftery et al.99 had the
potential for HTA and approximately half of these were group I registries. Eighteen clinical registries were
identified as having the greatest potential although only two could be directly used in costing. Review of
the potential capture of health technologies prioritised by the UK NIHR Health Technology Assessment
programme showed that only 10% would be captured in these databases, mainly drugs prescribed
in primary care (wound care, specifically for venous leg ulcers, would not be captured by any of
the databases).
Main uses of registers
Newton and Garner98
Newton and Garner98 identified the following current uses of registers:
l Patient care (regular review and recall, structured care programmes, monitoring high-risk groups,
managing demand and regulating access, communication and risk stratification).
l Public health (surveillance, planning the provision of health care, monitoring the impact of
preventative measures).
l Health technology assessment. Databases and registries can make a useful contribution to evaluation if
they conform to certain criteria (large numbers of patients defined in the same way, data collected in a
standardised fashion, followed over long periods of time using precise definitions applied uniformly).
As the authors indicate, although not as rigorous as RCTs for deriving comparative effect estimates,
registries have the advantage of being based on more representative populations and often include far
larger numbers of cases.
l Research (descriptive studies, improving the performance of other research designs, studies of
processes, hypothesis testing).
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Raftery et al.99
Raftery et al.99 examined the most promising databases that they had identified for the extent to which
they had actually been used for HTA. They concluded that:
l the use of databases for HTA has been limited
l clinical registers were mainly used for national comparative audits
l effectiveness assessment is more feasible when relevant outcomes can be readily included (most
databases contain insufficient data on health states and lack the detail required for risk adjustment)
l accessibility is a major barrier to using clinical registers, with their use largely limited to those who
‘own’ them.
Characteristics of successful registers
Newton and Garner98
Newton and Garner98 identified the following factors that seem to consistently predict success:
l Appropriate multidisciplinary team, including a computer scientist, a biostatistician and someone
trained in the clinical domain of the register.
l Stability of funding – challenging as it may be years before the benefits of a database
become apparent.
l Focused aims – a register should have initial aims that are clear and focused. Although there is often a
temptation to collect a large number of data, this may be of marginal value and questionable quality
and can interfere with the primary objectives.
l Data collection systems and a design that relate well to function.
l Leadership – there should be a clearly identified, senior professional in charge of a register plus a senior
administrative officer who is responsible for the quality of all aspects of the register.
l Ideal physical location (an academic environment, expertise available, ‘neutral ground’, all potential
users feel that they have equal access, all disciplines feel comfortable).
Setting up a disease register
Newton and Garner98
Newton and Garner98 identified a number of steps that might be considered when setting up a
population-based register:
l Establish an expert group who can ensure that a register has a sound financial and scientific basis and
decide on initial data collection processes and data content.
l Establish a steering group to ensure that a register is run according to its stated aims and objectives
and that the rights of patients are respected. This steering group should include patient/family
representation.
l Notify the information commissioner.
l Obtain approval from a research ethics committee if the register is to be used for research.
l Establish arrangements for access to the data.
l Consider arrangements for data security, including physical security (secure room in a secure building),
local security (encryption), technical security (passwords) and procedural security (staff training and
written records of procedures).
l Establish appropriate arrangements for accountability.
l Publicise the register and its findings. It is essential to promote the register among those who
contribute data. Some form of ‘corporate identity’ may be useful to reinforce the presence of the
register. The maintenance of good will requires frequent communication with participants and
appropriate reporting. It is very important to avoid the perception that data are collected for the sake
of it.
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
Methodological considerations
Newton and Garner98
Newton and Garner98 proposed the following:
l A clear case definition is fundamental to the success of any register.
l Methods used to ascertain cases need to be considered carefully. Diagnostic processes must be based
on a formal protocol. If clinical assessment is the basis for a diagnosis, it is good practice to assess the
reliability of the diagnostic protocol from the outset.
l Reliable identification of duplicates requires patient identifiers although this is not necessarily
straightforward even when these are available.
l Future development of disease registers should relate to the evolving NHS information strategy,110 for
example electronic patient records.
Evaluating the quality and value of registers
Newton and Garner98
Newton and Garner98 suggest the following as characteristics that can be used to assess the quality and
value of registers:
l the public health importance of the topic
l the system used and its objectives
l the uses and other outputs of the register
l an evaluation of the system against a set of technical attributes (sensitivity, timeliness,
representativeness, predictive value, accuracy and completeness of descriptive information, simplicity,
flexibility and acceptability)
l the resources used to operate the system and a summary of whether or not the system is meeting its
objectives and any modifications required.
Newton and Garner98 also describe methods for assessing the completeness and validity of register data:
l Completeness – the proportion of all cases in the population that appear in the register.
l Death certificate method – completeness is the proportion of cases not first identified from a
death certificate.
l Independent case ascertainment – completeness assessed by means of an independent survey, for
example a survey of part of the population covered by the register or capture–recapture techniques to
compare two incomplete registers (for this method to be valid, the two registers must be assumed to
have identified independent random samples of the population of true cases).
l Historic data methods – data from previous years or some other ‘known’ prevalence/incidence rate are
used to predict an expected rate of identification.
l Validity – the extent to which the information on the register agrees with some external source that
objectively measures the same variable.
l Diagnostic criteria method – register staff examine clinical records to assess the proportion of cases that
satisfy strict diagnostic criteria.
l Re-abstracted record method – a sample of case data is re-abstracted from the original source records
and compared with register records.
l Internal consistency method – a computer programme is used to check the register for illegitimate
codes and logical inconsistencies.
Raftery et al.99
Raftery et al.99 proposed criteria for assessing the validity of databases and then applied these criteria to
those routine databases identified as having the most potential for HTA. They distinguished two broad
dimensions for assessing validity: coverage and accuracy.
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Coverage addresses the following concepts:
l extent of the data set, that is, the completeness of variables or content validity
l completeness of data collection by variable, that is, the frequency of missing data
l completeness of recruitment of units and their representativeness, that is, the characteristics of patients
or delivery of the health technology may differ in selected units, giving different results, which could
reduce the external validity of the findings on effectiveness, equity and diffusion
l completeness of recruitment of patients or technologies in each setting (there is a risk of selection bias).
Accuracy relates to:
l the use of explicit definitions of variables, including in the coding system
l checks on the reproducibility of coding
l the extent to which data are audited, both internally (internal consistency) and externally (by an
external agency or by comparison with another database).
Raftery et al.99 reported that, although internal consistency checks of databases were common, relatively few
had any form of external audit. Issues around coverage and coding have, in general, received little attention.
Confidentiality and data protection
Newton and Garner98
Newton and Garner98 addressed several issues relating to confidentiality and data protection. Patient
consent should be obtained unless there is a good reason not to do so; however, there is empirical evidence
that the obligation to express consent results in levels of bias that could invalidate epidemiological research.
Registers can rarely be operated using fully anonymised data for four main reasons:
1. it is difficult to avoid or check for duplication of cases with anonymised data
2. construction of longitudinal records for linking exposure and outcome is harder with anonymised data
3. validation of a register against external data sets is more difficult
4. data linkage with other unrelated data sets is more difficult.
However, in the UK, the NHS number is beneficial because, being a unique identifier, it facilitates data
linkage even with anonymised data.
Registers must comply with current legislation on data protection (e.g. Data Protection Act 1998111 and
Human Rights Act 1998112) and take into account NHS policy on confidentiality. Newton and Garner98 noted
that, at the time of writing, the legal position regarding the use of register data was contradictory and
uncertain. However, since that time, legislation around confidentiality and data protection has been clarified
and amended. Current legislation means that there are only two classes of disease register using identifiable
data: those for which explicit consent of the patient is required and those for which it is impracticable to
obtain consent and which are covered by regulations under Section 251 of the NHS Act 2006.113
The important question for health researchers is whether or not registers should be used to support both
clinical care and research. It is likely that few registers are capable of both addressing service needs and
providing the basis for high-quality science. We were particularly interested in whether or not we could
use a wounds register for HTA purposes, including to derive treatment effect estimates in the absence of
RCT data. Registers have the advantage of greater external validity as there is likely to be less selection in
operation than for recruitment of participants into RCTs. Registers are also likely to have greater sample
sizes than many RCTs, particularly in wound care where our own work has shown a median sample size of
63.114 Of course, the major disadvantage of using such observational data sets for estimating comparative
effectiveness is the presence of selection bias and confounding. Furthermore, registers based on routine
data may lack the detailed information on comorbidities necessary to adjust for important confounders.
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Another question is whether or not the benefits of disease registers are worth the costs. There has been
little published on the cost of establishing and running a register. Newton and Garner98 have detailed the
costs that need to be considered including set-up costs (hardware, software, IT support and training),
ongoing costs (cost of full-time administrator, cost of routine procedures associated with data collection
and preparation), development costs (upgrading hardware and enhancements to data collection systems)
and private costs (incurred by health professionals, patients and carers, mostly in terms of time but also
travel, etc.). They suggest that a high-quality register generally requires a dedicated administrator and
therefore has a minimum cost of around £30,000 per annum.98 Most modest regional or district registers
cost between £50,000 and £80,000 per year to perform the central functions of the register. Size, in terms
of numbers of cases registered, partly determines cost, as does the desired quality of the data. Raftery
et al.99 also discussed the costs of those databases with the greatest potential for HTA. They reported that,
in 2005, the total central cost of health databases was > £50M or around 0.1% of the NHS annual spend.
Large variations exist in the annual estimated cost of each database, with the top four, which are clinical
administrative databases (Prescription Pricing Authority database, Hospital Episode Statistics, Cancer
Registers, General Practice Research Database), accounting for > 80% of the total cost. Most clinical
registers claim very low costs per record (possibly because of uncosted, local-level inputs). Many clinical
registers receive no formal Department of Health or NHS funding. It is not clear whose responsibility it is to
fund registers and stability of funding is crucial. Lead times are often long and substantial costs accrue
before useful outputs can be demonstrated. Newton and Garner98 recommend that registers used for
research purposes should be developed within integrated research programmes to make the most use of
them. They also suggest funding such registers as research infrastructure so that they are not competing
for funding with research project proposals.
Databases and registers specific to complex wounds
Our searching identified five registers or clinical databases specifically in the area of patients with complex
wounds. Reports of these registers are summarised in Table 25. Scrutiny of the relevant publications
suggested that this approach may have promise both for research purposes100 and for the quality of clinical
care,105 although it was also clear that there was no tried and tested UK-relevant complex wounds register
template that we could replicate locally.
Discussion
The review of registers highlighted a number of planning, design and methodological considerations that
were crucial to informing the development of our register pilot. We attempted to address and incorporate
these as far as possible (and appropriate) within the constraints of a pilot study using routine NHS data.
However, while conducting the review and planning the pilot study it became apparent that in the UK
there does not appear to be much expert guidance available for those establishing registers, unlike for
those planning clinical trials. Perhaps provision of this kind of guidance is worth considering as it could
help to ensure that all registers adhere to high-quality standards while also preventing unnecessary
duplication and developing a body of expertise. A national strategy for the development of registers along
with infrastructure was also recommended by Newton and Garner98 in 2002.
When designing our own register for piloting we endeavoured, when possible, to address those
characteristics that the review identified as being associated with successful registers, for example having
an appropriate multidisciplinary team and ensuring that there were clearly focused aims for the register.
We placed great emphasis on avoiding the collection of a large number of data that we would be unlikely
to use, however tempting that was. Instead, we used the findings of our review to stimulate the
development of a protocol for a register pilot that had very clear aims and objectives, together with
consideration of the more long-term objective of being able to use the register for HTA and quality
improvement. These decisions determined the type of data that we planned to collect, namely patient
health data, information about health technologies and patient outcome data (including health-related
quality-of-life data).
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TABLE 25 Summary of reports of registers of people with complex wounds
Register reference Brief summary
Margolis 2003,100 Kantor 2000101 A US-based project using an existing administrative database (primarily used for
‘billing’ purposes) to identify and track diabetic neuropathic foot ulcers. The papers
report findings on the development of a prognostic model to identify ulcers that are
not likely to heal and the accuracy of the database data compared with clinical
records. Although the database has been used for epidemiological research, there is
no discussion of the representativeness and generalisability of the findings or how
they dealt with any bias in the sample. An internet search did not find any
information about ongoing work
Golinko 2009102 A US-based diabetic foot ulcer database. A wound electronic medical record was
created [in Microsoft Access® (Microsoft Corporation, Redmond, WA, USA)] to
collect information to populate the database. Variables used in the database were
determined by treatment guidelines and protocols. Reports from the database
were exported into Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA).
The database was used for clinical purposes and as an aid in decision-making to
identify non-healing ulcers. An internet search did not find any information about
ongoing work
Coerper 2004103 Project based in Germany where 10 wound care centres formed a partnership called
German Wound Net that collected centralised and prospective computerised
documentation on 4175 patients with chronic wounds in a 2-year pilot study. The
published report used the data to produce some descriptive statistics and to conduct
a multivariate analysis to identify predictors of healing. The authors also identified a
number of other potential uses, including comparative audit between centres and to
identify potential participants for RCTs. There is no discussion of the ‘completeness’
(therefore representativeness) of the database or of any quality assessment. A search
for the German Wound Net website address detailed in the report was unable to find
the site or to identify any ongoing work by German Wound Net
Taylor 1999104 A UK (Salford)-based project in which leg ulcer service records were computerised to
improve clinical care and audit processes. Records were previously all paper based.
The database was a stand alone piece of work and was not integrated with any
broader organisational IT strategies. Unable to find any current details about the
database
RUT (Register Ulcer Treatment)106–108 A Swedish initiative developed by a GP, Dr Rut Öien, at the Blekinge Wound Centre.
Currently contains details of the majority of ulcer patients in Blekinge county (total
population 150,000; most patients with ulcers seen at the wound centre) but is in the
process of being rolled out nationally. One of a number of national quality registers
that are centrally funded. Infrastructure in the form of specialist centres are also
funded by government to start, develop, run and support national quality registers
and to improve analyses and use of outcome data. The aim of the quality register
is quality improvement of clinical care. RUT participants are assessed at initial
presentation/assessment and then at follow-up (healing, death) but not at every
treatment. Under Swedish law these national quality registers do not require
individual patient consent because of public interest, although recent legislation is
expected to include an obligation to let individuals know that their data will be
processed (not necessarily in writing) and that an individual’s data should be
withdrawn if the individual requests
GP, general practitioner.
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Specific methodological considerations raised by the review were also addressed. First, we had to develop
and agree a clear case definition that was relevant for both clinical service and research purposes. The
Leeds Community Healthcare NHS Trust Tissue Viability Service already had a working definition of
complex wounds and this was adopted for the purposes of the register.
Second, we wanted to be able to differentiate unique cases and avoid duplicates and this would be much
easier if data were not anonymised. In addition, we wanted to be able to collect health-related quality-of-life
data longitudinally (as the lack of these data is a major barrier to HTA and particularly cost-effectiveness
modelling). To do this we would require individual patient consent to participate in the pilot study. In
making these decisions we were troubled by the inevitable loss of potential participants that a consent
requirement would bring, together with possible selection bias. This selection bias (biased selection of
people into the register so that people with particular characteristics were more or less likely to be included)
will be a challenge for any future epidemiological research. For example, identification of factors prognostic
for specific wound outcomes could be biased and misleading if people with particular prognostic profiles
were systematically excluded from the register. However, we could not see a way round this problem and
felt that selection bias of this nature was less important in terms of quality improvement and HTA.
Recruitment of sufficient numbers of participants for clinical effectiveness and cost-effectiveness analyses
was important and therefore maximising recruitment (and understanding factors that promoted it) became
one of the specific aims of the pilot study.
Finally, the review by Newton and Garner98 encouraged that those developing registers should explicitly
consider the evolving NHS information strategy110 and specifically electronic patient records. It was
fortuitous that electronic patient records were evolving in the trust around the same time as the register
pilot and we were able to link into these developments.
Smart pen pilot study
Background
One of the perennial challenges of conducting research in real-life clinical settings is the need to balance the
requirements of research against the need to minimise the research burden on clinicians and patients. Data
collection in community nursing tends to be paper based as the nurses are working away from the office,
typically in patients’ own homes, and mobile computing for community nurses was almost non-existent at
the time of our prevalence survey and the planning for the register pilot. Furthermore, and crucially, clinical
notes tend to stay with patients in the home as an essential clinical reference for the next care provider who
visits, thus any method of data collection for both clinical and research purposes needs to reflect this.
Although we were developing a protocol for the complex wounds register, an opportunity arose to trial
smart pens for data collection purposes within the tissue viability service and we grasped this opportunity as
one of the original aims of the research programme was to investigate alternative data collection methods.
The smart pen explored in this pilot was a digitalised pen developed by a company called Destiny Wireless
plc [see www.destinywireless.com (accessed July 2011)]. The pen uses paper technology along with ‘Anoto
functionality’. It enables users to enter data into digitised forms, transmit the data electronically to the
company’s secure servers and then have the data relayed back to their own computer system or
destination of choice.
The smart pen looks and operates like an ordinary pen. It has an infrared camera in the nib that captures
pen strokes as text is being written onto the bespoke form. Data capture forms must be pre-digitised with
a unique dot matrix pattern; each pen stroke on the digitised paper is stored as digital data. Once the
‘send’ box on the form is ticked and the pen is ‘docked’, an automatic router sends the data to their
destination. We saw a potential advantage of this combined paper and electronic data capture method in
that it would meet the needs of the clinicians for a written clinical record and the needs of research for
rapid relay of accurate electronic data without an associated burden on health staff. The data are
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presented as PDF files and as a database that is populated by the information contained on the completed
assessment forms. Free text is ‘recognised’ and inserted into the data extracted.
Aims and objectives
Our overall aim was to establish if the smart pen offered a potential solution to the dual needs of clinical
record keeping and research data collection within the context of a complex wounds register.
We identified the following objectives:
l to trial the usability of smart pens within the context of clinical wound assessment
l to trial the usability of an adapted, revised wound assessment form suitable for use with the
smart pens
l to test the feasibility and reliability of the translation of paper records to electronic data and the
production of the form in PDF format
l to test the population of a database with wound assessment data
l to test the feasibility of extracting data from a smart pen-derived database to populate a
wounds register
l to test whether or not a PDF of the wound assessment form can be attached to a patient record on
SystmOne (the electronic patient record system used within Leeds Community Healthcare Trust;
TPP, Leeds, UK).
Methods
Preparatory work for the smart pen pilot
In preparation for the trial of the smart pen by the Leeds Tissue Viability Service, it was necessary to revise
the existing wound assessment chart into a format that was suitable for use with the smart pen. The form
had to be put onto paper that incorporated a unique dot matrix pattern.
The revised and reformatted wound assessment form was developed by Destiny Wireless over a few
weeks, with members of the clinical and research teams consulted with regard to its content and layout.
The form was finally signed off as fit for purpose and the necessary volume ordered prior to the beginning
of the pilot period.
The required software for the smart pen was downloaded onto the desktop computers used by
participating clinicians. Training in the principles of the smart pen and the process of information transfer
was delivered by Destiny Wireless on 23 November 2010 to members of the tissue viability service and
a member of the patient and public involvement team. Using fictional data, staff filled out wound
assessment forms, logged onto the smart pen programme and practised docking their smart pen so that
they were conversant with the process. Any technical problems were ascertained and dealt with prior to
commencement of the trial.
During the training session it was noted that the ink provided in the smart pens was blue and would
therefore not meet the documentation standard of Leeds Community Healthcare NHS Trust. Supplies of
black refills were forwarded by post from Destiny Wireless in the days following the training session.
The smart pen was trialled between 29 November 2010 and 13 May 2011, when smart pen use
was discontinued.
During the trial period, PDF files of the submitted wound assessment forms together with spreadsheets
populated with the data were sent by Destiny Wireless to the senior data analyst in the Leeds community
informatics team via a secure SystmOne NHS e-mail account. The senior data analyst managed the returns
of data and held them on a secure area of the organisation’s network. Each Monday during the pilot
period he received the previous week’s data from Destiny Wireless. The final electronic versions of the
forms were received on 23 May 2011.
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The senior data analyst checked the data for any anomalies; any found were fed back to the clinical team
who attempted to improve the quality and consistency of data collection.
Results
Between 29 November 2010 and 23 May 2011 the senior data analyst received 20 data extracts in
spreadsheet format and 437 forms in PDF format.
An initial problem that was encountered very early was that patients’ dates of birth were not represented
correctly if they were born before the year 2000. All dates of birth were interpreted and represented as
20**, even if patients were born in 19**. This was reported to Destiny Wireless and was rectified within a
few weeks of the start of the trial.
Further issues
Another fundamental problem was the ability of the system to correctly interpret clinicians’ handwriting.
Each clinician has a different handwriting style; however, the smart pen system was frequently unable to
accurately interpret the free text. In an attempt to improve handwriting recognition, clinicians were advised
to use lower case characters when completing the wound assessment form. This impacted on the time
taken to complete the forms as practitioners were required to pay more attention to the presentation
and legibility of the written characters and to spend more time addressing the presentation of
their handwriting.
There was frequently illogical output into the spreadsheet because the smart pen engine looks for words in
a dictionary and words could not be recognised if they were not in the dictionary; moreover, the system
could not interpret punctuation.
Text could also not be interpreted properly if it was not placed wholly within a box, but, unfortunately,
busy staff do not always write neatly in boxes.
The design of the smart pen wound assessment form required that it became a four-sided booklet-type
form that recorded data from only one wound episode, whereas the assessment form had previously
been a double-sided form that allowed the recording of multiple wounds and/or successive wound
reassessments. The adapted form did not really serve the clinical purpose: there was no space to record
multiple wounds and a consequent requirement for multiple forms. Clinicians felt that the layout of the
form was ‘unwieldy.’ As a result of the size of the form, and the increased number of forms required for
each patient, paper notes became much bulkier, which began to impact on storage facilities and would
have required further consideration in the future.
Direct population of patients’ records on SystmOne by the smart pen system would have been the ideal
but, unfortunately, this was not achieved during the trial phase.
Conclusions
Smart pen technology was trialled by clinicians within the Leeds Community Healthcare NHS Trust Tissue
Viability Service to test the feasibility of its future use for electronic patient records as well as to enter data
into a future complex wounds register. During a 4-month trial period, 437 forms were completed and the
data entered into a database. Although, ostensibly, smart pen data entry would meet the needs for a
clinical patient record that would remain with the patient and the timely return of clinical data for research
purposes, in reality the smart pen system did not meet either clinical or research needs and we decided
against its further use and it was therefore not used for data collection in this programme.
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Register pilot study
Background
Our review did not identify any recent UK-based registers or clinical databases relating to complex wounds.
Review work undertaken in relation to UK-based registers and clinical databases also failed to identify any
registers of complex wounds.98,99
On embarking on this work we saw a number of potential advantages to establishing a disease register for
complex wounds. Such a register would be able to provide basic information, currently lacking, concerning
the numbers of different types of wound, typical treatments used in the NHS, times to healing, costs of
disease and ultimately prognostic information. This type of information is essential for cost-effectiveness
modelling (to estimate the cost-effectiveness of treatments in use now) as well as for prioritising future
research. We also planned to cautiously investigate the potential for a wounds register to (ultimately)
estimate the clinical effectiveness and cost-effectiveness of wound treatments. However, we had no idea
whether or not a wounds register would be feasible (e.g. whether or not patients and staff would
participate) and what the barriers to establishing one might be. We therefore embarked on a pilot study to
investigate the feasibility of a register of people with complex wounds in a large community trust.
Aims and objectives
The overall aim of the pilot study was to assess the feasibility of establishing and populating a complex
wounds register. We saw the register as collecting data suitable for research and quality improvement
purposes. Aspects of a register that are fundamental to its future potential and which therefore need to be
addressed in a feasibility study include recruitment, consent, technical issues and the accuracy and
completeness of the data.98
This pilot study aimed to address the following research questions:
l Will patients consent to participate in a register of complex wounds and, if not, why not?
l Can data from consenting patients be accurately identified within routinely collected data?
l Are participants willing to provide additional self-reported health-state data [European Quality of Life-5
Dimensions (EQ-5D)] and can these data be correctly linked with their routinely collected data?
l Do health-care professionals collect the data that we need to populate a register? If they do not, what
are the reasons for this?
l How well do health-care professionals collect the data?
l Can data for the register be pulled out of the NHS databank and transferred safely to the University of
York for analysis?
l How much additional activity does the register generate?
l What can we do with the data that we have collected?
l Do the data have value that could pay for the register in the future?
Methods
A pilot study for a ‘register’ of patients receiving care for a complex wound was undertaken, populated by
prospective, routinely collected NHS data. Supplementary to the NHS data, self-reported health-state data
(EQ-5D) were collected directly from register participants. People were eligible for inclusion in the register if
they had a complex wound, that is, one that involved superficial, partial or full-thickness skin loss and was
healing by secondary intention (typically pressure ulcers, leg ulcers and dehisced surgical wounds).
The register pilot was to involve all relevant parts of Leeds Community Healthcare NHS Trust, that is, tissue
viability, district nursing, general practice-based practice nursing and podiatry.
Routine data collection in the NHS
Data collection was embedded in the routine data systems used by Leeds Community Healthcare NHS
Trust. Historically, administration, record keeping and patient case notes in Leeds Community Healthcare
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NHS Trust were largely paper based with limited use of IT (currently SystmOne software) to store and
retrieve detailed clinical information. Paper-based patient case notes were held in patients’ homes, clinics
or relevant administrative bases.
SystmOne
Leeds Community Healthcare NHS Trust uses SystmOne software to electronically record details of all
patients and basic information about the care that they are receiving, primarily to provide information for
commissioners and fulfil contractual obligations. SystmOne had not hitherto been used for the capture of
detailed clinical information or as a replacement for paper case notes. However, at the time of study, the
method of capture and storage of routine data within Leeds Community Healthcare NHS Trust was in a
process of change. SystmOne was being increasingly utilised to manage and store clinical information.
Trust services that are predominantly clinic based, such as podiatry, had already begun to use SystmOne to
store patient clinical information.
Mobile working practices
Mobile working practices for trust services in which care is provided largely in patients’ homes were also
being enhanced and phased in gradually across the trust, allowing increased utilisation of SystmOne.
The tissue viability service began to use mobile technology to capture all patient information at this time.
Since the introduction of new mobile working practices, the tissue viability service was operating a largely
paper-free clinical and administrative record process within SystmOne. Community matrons and the
intermediate care team were to be the next wave of services to implement the changes in mobile working.
The change in mobile working practices was made feasible through the use of semirugged computers
(ToughBook®, Panasonic). These laptops operate as a desktop, with the ability to withstand the ‘harsh’
environment of mobile working (according to the manufacturer they are capable of withstanding a 30-inch
drop). Health-care staff log on via a secure internet connection and input clinical information directly into
SystmOne, instead of using paper-based case notes.
Wound assessment form
Data variables required to populate the register consisted of a subset of all of the information routinely
collected by health-care professionals. Clinical information about the wound was collected on the wound
assessment form. Until recently, the wound assessment form was a paper form completed by the
health-care professional, which remained with the patient case notes. However, the advent of SystmOne
led to digitisation of the wound assessment form, although the paper form was still available for those
trust staff not currently using SystmOne. Tissue viability service staff worked closely with trust IT personnel
to develop and launch the wound assessment form in SystmOne for clinical use, at the same time ensuring
that the data were suitable to populate a register. The paper version of the wound assessment form was
also updated to reflect these changes. To minimise disruption to established practice, the definitions used
by the service before the pilot were upheld. Options for completion on most variables are standardised
(in drop-down boxes on SystmOne or tick boxes on the paper copy). A copy of the wound assessment
form can be found in Appendix 4.
Self-reported health state
Leeds Community Healthcare NHS Trust does not currently routinely collect patient self-reported health-state
data; however, collection of these data in the register was required for future cost-effectiveness analysis.
We planned to collect health-state data directly from consenting register participants using the
EQ-5D questionnaire.
Population
The study population consisted of Leeds residents who were receiving care for a complex wound from
Leeds Community Healthcare NHS Trust and/or general practices.
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Ethics approval
The study was reviewed and approved by the National Research Ethics Service Committee Yorkshire &
The Humber – Bradford (reference 12/YH/0353), the Department of Health Sciences Research Governance
Committee, the University of York and Leeds Community Healthcare NHS Trust (reference P/0138).
Copies of approvals and amendments are available on request.
Recruitment and consent
The decision for patients to consent to share their data in this study was entirely voluntary. This was made
clear in the information provided to them. It was also made clear that their decision would not affect the
treatment that they received and that they could withdraw their consent at any time without having to
state a reason for doing so. We also recognised that consent is not a ‘one-off’ action but is an ongoing
process; in recognition of this, consent would be affirmed every 12 months or each time a patient entered
care services when a complex wound developed (whichever came first).
Informed consent to participate in the feasibility study was sought from patients who presented to
participating services with a complex wound (incident cases). In addition to incident cases, when
recruitment from services commenced, all existing patients with a complex wound were also approached
to participate. The recruitment and consent process for existing patients was the same as for incident cases
and the process is detailed in the subsequent paragraphs.
An invitation to participate in the study was sent by mail to patients’ homes. This was generated
automatically by service administration teams when patients were registered with the service to receive
treatment. The mail-out consisted of an introductory letter from the tissue viability service clinical team
lead, an information sheet, a consent form and a prepaid return envelope. The information sheet
contained details about the study including why it was being undertaken, what the data would be used
for, implications for patients and contact details should they require further information or have any
questions. Further information was available from the wounds data co-ordinator who was based with the
tissue viability service in Leeds Community Healthcare NHS Trust. For patients who were themselves unable
to consent, we sought the advice of a consultee (usually a partner or a carer). We asked the consultee
whether they thought that the individual would be likely to have objected to taking part.
Patients who were willing to participate were requested to complete, sign and return the consent form in
the prepaid envelope to the data co-ordinator (or give the form to the health-care professional caring for
the wound, who returned it to the data co-ordinator). A copy of the signed consent form was forwarded
to the appropriate service administration team for storage with the patient records (paper or electronic).
Administrators were asked to indicate in patients’ individual health-care record within SystmOne that they
had consented to participate in the register pilot study. Individual patient consent was indicated using a
tick box (‘yes’ or ‘no’). Individual patient NHS numbers were used as unique identifiers and were recorded
(by a member of the administration team) on each signed consent form returned to the data controller.
A reminder letter was sent by administrative teams to potential participants 1 month after the initial
invitation if there had been no response. No further reminders were sent.
For those patients who did not wish to participate, we sought their reasons for refusal by adding to the
consent form a free-text box that they could complete, with the form returned to the data co-ordinator in
a prepaid envelope. They also had the opportunity to telephone or e-mail the data co-ordinator to discuss
their reasons for declining to participate.
The recruitment and consent process varied slightly depending on the clinical service configuration.
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Data collection
Routinely collected NHS data
This pilot study aimed to capture routine data from a variety of services. Because of differences in the
method of routine data capture, as outlined in the previous section, the data collection process for services
differed. For tissue viability and podiatry (whether clinic based or ‘mobile’), clinical information about the
wound was input directly into SystmOne on the wound assessment form at each wound consultation and
stored in the trust ‘databank’ (FRANK). District nurses and practice nurses continued to complete a paper
version of the wound assessment form. Forms were printed specifically for the pilot study to include a
‘carbon copy’ (or multiple copies). The original form remained with the patient notes and at each wound
consultation a carbon copy was returned to the data co-ordinator. Paper-based data from district nurses
were then entered into SystmOne. Data from practice nurses were entered into a separate spreadsheet.
Data were collected from participants for the duration of the study pilot or until wound healing or loss to
follow-up.
The SystmOne and paper-based data collection processes are detailed in Figures 3 and 4, respectively.
Self-reported health-state data
The EQ-5D form along with a covering letter were posted to the home address of register participants four
times per year. A prepaid envelope was included for return of the completed form to the University
of York.
Data variables
Routinely collected NHS data
Table 26 details the NHS data variables that were used to populate the register (some variables are
still under development as the wound assessment form continues to be developed for clinical use
in SystmOne).
Self-reported health-state data
The EQ-5D is a standardised instrument that includes the following five dimensions: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression.115–117 Each dimension has three levels: no problems,
some problems and extreme problems. The respondent is asked to indicate his/her health state by ticking
(or placing a cross) in the box against the most appropriate statement in each of the five dimensions.
Health-care professional sees patient with
complex wound for assessment and/or
treatment
Following assessment and/or treatment 
health-care professional enters information
onto wound assessment form in SystmOne
Patient data are stored securely in the Leeds
Community Healthcare NHS Trust
‘databank’
FIGURE 3 Electronic data collection process using SystmOne.
DATA CAPTURE AND EPIDEMIOLOGY (WORKSTREAM 1)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
Health-care professional sees patient with
complex wound for assessment and/or
treatment
Following assessment and/or treatment 
health-care professional enters data 
into paper-based WAF
Data co-ordinator receives carbon copy and
data entered into SystmOne for DN data and
spreadsheet for PN data
Carbon copy of WAF returned to 
data co-ordinator
Spreadsheet is sent by secure e-mail to the
University of York
FIGURE 4 Paper-based data collection process. DN, district nurse; PN, practice nurse; WAF, wound assessment form.
TABLE 26 Routinely collected NHS variables used to populate the register
Variable Available response choices (where appropriate and currently available)
Name
Address
Postcode
Date of birth dd/mm/yyyy
Sex Male/female
NHS number
Ethnicity
Risk factors
Chemotherapy/radiotherapy Yes
Continence/moisture issues Yes
Diabetes Yes
Elderly Yes
Immunosuppression Yes
Infection Yes
continued
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TABLE 26 Routinely collected NHS variables used to populate the register (continued )
Variable Available response choices (where appropriate and currently available)
Mobility Yes
Nutrition Yes
Peripheral neuropathy Yes
Poor blood supply Yes
Poor oxygen supply to wound Yes
Recent acute illness/surgery Yes
Steroids Yes
Smoker Yes
BMI Under development
Wound(s) detail
Wound type Leg ulcer (arterial, venous, mixed), pressure ulcer, diabetic foot ulcer,
non-diabetic foot ulcer, dehisced surgical wound, pilonidal sinus, abscess,
fungating wound, traumatic wound, burn, other
Wound size Maximum length, maximum width (mm)
ABPI < 0.4, 0.61–0.8, 0.81–1.0, 1.01–1.2, ≥ 1.21, not applicable
Start of episode (patient-reported
estimate)
Under development
Start of treatment dd/mm/yyyy
Treatment
Referral source
Date of wound-related consultation dd/mm/yyyy
Location of care
Consultation by whom Name of health-care professional
Primary wound dressing Applied (yes/no), name of dressing (free text for trade name)
Secondary wound dressing Applied (yes/no), name of dressing (free text for trade name)
Bandaging Applied (yes/no), name of bandaging (free text for trade name)
Hosiery Applied (yes/no), name of hosiery (free text for trade name)
Other current treatments/equipment Under development
Key events
Wound healed Yes/no, dd/mm/yyyy
Death dd/mm/yyyy
Wound-related admission to hospital –
admission and discharge dates plus
reason
Under development
Wound-related GP visit Under development
Wound-related specialist appointment Under development
Amputation Under development
BMI, body mass index; dd, day; GP, general practitioner; mm, month; yyyy, year.
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Data management
All register data referred to hereafter were considered ‘sensitive’ data; these data included personal data
that could be used to identify individuals.
Data required for the wounds register were taken from individual health-care records. The retrieval of
such data could occur only when patients had consented to the sharing of their data. Individual patient
consent was indicated using a tick box (‘yes’ or ‘no’). This tick box was located on a general consenting
questionnaire used by health-care practitioners and formed a part of the individual health-care record.
The health-care worker or a member of the administrative staff within the trust completed this tick box on
receipt of a signed consent form.
Data were drawn from the NHS databank by a senior data analyst (in the Community Informatics
Department of Leeds Community Healthcare NHS Trust) and provided by the Community Informatics
Department to the University of York every 3 months. The data analyst checked for and removed any
duplicate entries.
All data drawn from the NHS databank were transferred to the University of York via a secure NHS e-mail
account hosted at both institutions. EQ-5D data returned by participants to the University of York were
manually entered into a Microsoft Excel spreadsheet.
All electronic and manual data were securely stored with restricted access.
Third-party data sharing policy
Once patient data were provided to the University of York by Leeds Community Healthcare NHS Trust,
the trust was the data controller and the university became the data processor. A third-party data sharing
agreement was drafted to ensure safe and effective transfer of shared information.
As the owner of the wounds register, the university became a data controller. A third-party data sharing
policy ensured that data were shared with only (1) those organisations that had a legitimate right to view
and process that data, having signed up to a third-party data sharing agreement (i.e. Leeds Community
Healthcare NHS Trust) or (2) the individuals to whom the data related.
Data analysis
The analysis sought to answer the following research questions.
Will patients consent to participate in a register of complex wounds and, if not,
why not?
Patients with a complex wound were identified systematically by administrative staff and mailed
information about the register. When patients declined to participate we attempted to establish reasons
for non-consent; an opportunity to provide feedback on their reasons for non-consent was included on the
consent form and the form could be returned to the data co-ordinator in a prepaid envelope. Alternatively,
patients could telephone or e-mail the data co-ordinator with their feedback.
Can data from consenting patients be accurately identified within routinely
collected data?
It was important that patients who consented to participate were correctly identified on the routine data
system (SystmOne) to ensure that (1) their data could be ‘extracted’ from the NHS databank and (2) no
patient who had ‘not consented’ was incorrectly identified as ‘consented’. The signed paper consent forms
containing patient information were cross-referenced with information held in SystmOne and any
discrepancies reported.
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Are participants willing to provide additional self-reported health-state data and
can these data be correctly linked with their routinely collected data?
We report the proportion (%) of register participants who returned the EQ-5D questionnaire at each time
point. We also assessed the number of participants who could be correctly matched with the information
from the databank.
Do health-care professionals collect the data that we need to populate a register?
If they do not, what are the reasons for this?
To assess whether health-care professionals collect the data that we need to populate a register we
estimated the number (%) of missing data for each register variable. We also investigated differences in
the completion rate between the two methods of data collection (electronic data input into SystmOne and
paper-based data collection). Feedback sessions were held with the different staff groups to ascertain the
barriers and facilitators involved in collecting the data. The feedback sessions were facilitated by a member
of the research team (KL, based in the NHS) using a series of semistructured questions. Responses were
noted by the facilitator during the sessions. Topic headings were constructed (which were informed by the
questions) and populated with themes that were identified from the responses.
How well do health-care professionals collect the data?
To assess the ‘accuracy’ of data, variables were checked for logical inconsistencies and inaccurate codes.
For paper-based data, a random sample was selected and cross-referenced with case notes and
discrepancies noted. Accuracy of data input from paper copy to register was also cross-referenced in a
random sample and discrepancies noted.
Can data for the register be pulled out of the NHS databank and transferred
safely to the University of York?
We assessed the feasibility of the trust IT department generating data files for register participants from
their databank (FRANK). We also assessed the efficiency and safety of data transfer.
How much additional activity does the register generate?
We estimated the additional activities associated with running a prospective register, including both staff
time and resources and materials (disposable) required, for example for printing paper copies of the wound
assessment form.
What can we do with the data that we have collected?
We summarise the characteristics of the register population, their wounds and their care and investigate
variation based on sex, postcode, etc. The potential for analyses that utilise the longitudinal nature of the
data is considered. The rate of healing is explored and the potential to investigate the relative effectiveness
of different treatments for healing through propensity scoring and instrumental variable methods
is considered.
Do the data have value that could pay for the register in the future?
We originally intended to explore the potential for the register to become self-financing through revenue
generated by data access, for example by the pharmaceutical industry. Unfortunately, we did not have
sufficient time to complete this work.
Results
Anonymised data from the wound assessment form (pre-pilot data from the
tissue viability service only)
The major finding from the analysis of the pre-pilot study data (anonymised) was the difficulty in tracking
longitudinal wound data for individuals. This was particularly a problem when an individual had more than
one wound of the same type as it was not always possible to differentiate between them and hence follow
the trajectory of each wound. For individuals with only one wound similar problems were found in some
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cases as it was not always clear whether the wound being assessed was the same one as at the previous
consultation or was a new wound. The large amount of uncertainty surrounding wound tracking meant that
longitudinal methods could not be applied without assumptions relating to wound identity being made.
Over half of the individuals (58.5%) had only one consultation recorded because of the specialist
(assessment-focused) service provided by the tissue viability service.
Recruitment
Recruitment took place between September 2012 and September 2013. Recruitment of participants began
initially in the Leeds Community Healthcare NHS Trust Tissue Viability Service (from 24 September 2012),
followed by recruitment by district nurses (from 21 December 2012), the podiatry service (from
26 February 2013) and practice nurses (from 15 June 2013). Figures for recruitment overall and by
service are provided in Table 27. No information packs were sent out to practice nurse patients.
Reasons for declining to participate
Thirty-nine people (5% of all of the information packs sent out) who did not wish to or who were unable
to participate detailed the reasons for their decision. The most commonly cited reasons were:
l Other physical health problems and illness (e.g. ‘I have read the literature and appreciate your
objectives. During the last 2/3 years of cellulitis I have had angina problems, heart damage whilst
coping with diabetes, warfarin, insulin and been inundated by research studies, questionnaires etc.
I am not interested in further answers on the subject of my “complex wounds” which continue to
need bandaging twice weekly and I have appointments to keep with the surgical teams which oversee
the treatment’).
l Advanced age (e.g. ‘I am 93 years old, completely deaf and at the end of my life, everything is worn
out, sorry’).
l Person had dementia (e.g. ‘My mother is in her 98th year with dementia and would not understand
anything of this project’).
l Other reasons given were:
¢ just did not want to
¢ in hospital
¢ person had recently died
¢ the wound had healed
¢ taking part in other research studies
¢ felt unable to make a decision on behalf of the person (who had dementia).
Identifying participants on SystmOne
A total of 196 register participants were identified from a combination of the paper consent forms and the
extracted register data; 183 (93.4% of 196) had a signed consent form and their data were extracted from
the register, and 12 (6.1% of 196) had a signed consent form but their data were not included in the
register. Of the 12 people with paper consent forms but no register data, four had not been marked as
consented on SystmOne and eight had been marked as consented. One person was included in the
register data but did not have a signed consent form (0.5%) and was excluded from further analysis.
TABLE 27 Recruitment data
Recruitment activity Tissue viability service District nursing Podiatry Total
Information packs sent out 586 140 7 733
Consent forms received 170 25 0 195
Recruitment rate (%) 29.0 17.9 0 26.6
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The data set
A total of 195 individuals had given consent to being included in the register. Clinical data were collected
for 183 of 195 individuals and in total there were 652 clinical entries. There were 12 individuals for whom
no clinical data were available; five of these individuals did not have a consultation at which a wound
assessment form was completed within the study period and data on the remaining seven were not
downloaded (reason unclear, potentially an error during the data extraction process).
The number of entries per patient for those with clinical data ranged from one to 22, with a mean of 3.6
(SD 3.56) and a median of two entries. Approximately one-quarter of patients (47/183, 25.7%) had only
one entry in the register and a further quarter (25.7%) had two entries (Figure 5).
Potential duplicates with respect to clinical entries were explored based on wound type, date of
consultation, wound size and wound identifier. It was estimated that 552 of the 652 clinical entries were
unique, 97 entries were repeated once and one entry was potentially duplicated three times. As a wound
identifier was not available for all entries it was difficult to be certain which of the potential duplicates
were true duplicates. When we were confident that there was a true duplicate entry (because a wound
identifier and date of consultation matched), the duplicate was deleted. There were 17 such entries, each
of which was duplicated once, leaving 635 clinical entries.
Completeness
It was difficult to calculate a duration of follow-up for the participants in the pilot because when some
participants were referred for further wound care to a service not involved in the pilot then data collection
ceased or was interrupted. Given that wound care can be delivered by a range of services such as district
nursing, podiatry and tissue viability, this issue underlines the need for a system that can be used across
services, that is, full data collection coverage. Without this there is a risk, as may have occurred here,
of gaps in the data or complete cessation of data collection.
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FIGURE 5 Number of register entries per patient.
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Table 28 shows the completion rate (in relation to the 635 clinical entries) for each variable when data
were submitted.
Section B of the wound assessment form (see Appendix 4) asks the health professional completing the form to
select all appropriate risk factors from a list, meaning that a negative response was reported as ‘null’. Therefore,
it was not possible to distinguish between missing data and a negative response, and the assumption that a
null response implies a negative response has been made, meaning that the completion rate is classed as
100%. This was also the case in relation to the use of a primary or secondary dressing, bandaging or hosiery
and for wound healed status. Variables that this applies to are indicated using a footnote in Table 28.
TABLE 28 Completion rate by variable
Variable Completion rate (%)
Wound identifiera 37.5
ABPIb 50.8
Name of hosierya 68.3
Ethnicity 81.3
Wound maximum width 87.1
Wound maximum length 87.7
Wound healed 89.1
Type of wound 97.5
Date of wound-related consultation 98.0
Name of bandaginga 98.4
Name of secondary dressinga 99.5
Postcode 99.7
Name of primary dressinga 99.8
Consent date 100.0
NHS number 100.0
Date of birth 100.0
Sex 100.0
Location of care 100.0
Referral source 100.0
Event completed by 100.0
Chemotherapy/radiotherapyc 100.0
Incontinencec 100.0
Diabetesc 100.0
Elderlyc 100.0
Immunosuppressionc 100.0
Infectionc 100.0
Mobilityc 100.0
Nutritionc 100.0
Peripheral neuropathyc 100.0
continued
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The completion rate was lowest in relation to wound identifier, which was requested for the 499 entries
completed after the first download of data. An entry was provided in 187 of these cases (37.5%).
There was also a low completion rate for the ABPI; a measure was available for 171 of the 335 entries
relating to a foot or leg ulcer (51.0%). The ABPI was reported for a larger proportion of SystmOne entries
relating to foot or leg ulcers (53.4%, 156/292) than for paper wound assessment form entries (34.9%, 15/43)
and was recorded for 31 of the 300 wounds that were neither a foot nor a leg ulcer (10.3%).
Ethnicity data were missing for 43 individuals (22.1%) and a total of 119 entries (18.7%). Completion was
slightly higher for paper forms (87.5%) than for SystmOne entry (80.0%). Postcode data were missing for
two entries in relation to one individual.
An entry for the type of wound variable was missing for 28 of the 635 clinical entries; completion was
slightly higher on SystmOne than on the paper wound assessment form (96.6% vs. 90.3%). When wound
type was listed as ‘other’, details were required; there were 38 such wounds and further details were
provided for 30 (78.9%).
A numerical value (regardless of correct units) was recorded for 87.7% and 87.1% of entries in relation
to wound length and wound width, respectively; completion rates were similar between the different
methods of collection.
The name of the primary or secondary dressing was provided in a large proportion of relevant cases.
Completion was higher for name of bandaging (when relevant) for SystmOne entries than for paper entries
(99.5% vs. 94.3%). Name of hosiery was provided in fewer cases (68.3%), with completion higher on
paper wound assessment forms than when data were inputted directly into SystmOne (80.0% vs. 66.7%).
Date of wound-related consultation was missing for 13 entries (2.0%) in relation to three individuals
(1.5%), with data missing from a similar proportion of paper and electronic entries.
TABLE 28 Completion rate by variable (continued )
Variable Completion rate (%)
Poor blood supplyc 100.0
Poor oxygen supply to woundc 100.0
Recent acute illness/surgeryc 100.0
Smoking statusc 100.0
Steroids or NSAIDsc 100.0
Primary dressing usedc 100.0
Secondary dressing usedc 100.0
Bandage usedc 100.0
Hosiery usedc 100.0
Start of treatment date 100.0
Questionnaire start date 100.0
Wound healed datea 100.0
NSAID, non-steroidal anti-inflammatory drug.
a When appropriate (i.e. wound healed date required only when wound healed).
b For entries relating to leg or foot ulcers only.
c Null answer assumed to be negative, hence 100.0% completion rate.
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Accuracy
There were minor inconsistencies in how the NHS systems that we drew data from reported ethnicity.
For example, white British was reported as both ‘white British’ and ‘white British – ethnic category 2001’.
For 10 entries, ‘ethnic category – 2001 census’ was reported, without specification of ethnic category.
In relation to risk factors, most ‘other’ risk factors were additional to the prespecified list; however, one
entry listed chemotherapy under this heading and another detailed recent surgery despite there being
specific fields for this information. Another entry reported a wound type in this field.
There was a lot of inconsistency in the unit of measurement used for wound length and width despite
dimensions in millimetres being requested. Some entries were provided in centimetres and this was stated,
whereas for other entries the units were not specified and could have been either millimetres or centimetres.
A handful of entries reported wound dimensions using free text rather than as a numeric value. In addition,
some wounds that were reportedly healed had wound dimension recorded within the same entry.
Table 29 shows the numbers of entries in which a specific name was provided for primary and secondary
dressings, bandaging and hosiery despite a negative response being recorded for these items. This highlights
the difficulty in differentiating between missing and negative data when a response is either ‘yes’ or ‘null’.
Just under one-third of entries had actually named a specific dressing (17 entries, 30.4%) when a primary
dressing was not reported. Of these 17 entries, 13 were judged to be primary dressings. For secondary
dressings, a name of dressing was reported for 18 entries; of these 10 were secondary dressings and five were
dressings that are usually classed as primary dressings. A specific type of bandage was recorded for 23 entries
when a negative response was given with respect to presence and all of these were classed as bandaging.
Both entries specifying a hosiery type when a null response was provided were deemed to be hosiery.
All start of treatment dates seem reasonable; however, for 79 entries the questionnaire start date was
specified as being before the start of treatment date. Wound consultation was also reported as taking
place before the start of treatment for 70 entries.
Date of death was recorded for six individuals; two of these dates were after the study end date (and after
the date of analysis) and were assumed to be errors. A further two individuals consented and returned an
EQ-5D form after their supposed date of death.
Paper wound assessment forms for a randomly selected one-third (n= 9) of the individuals seen by district
nurses were checked and discrepancies between the paper form and the data entered onto SystmOne were
noted. There was a total of 15 forms for those nine individuals; notes were unavailable for one patient who
was in hospital at the time of the check and no paper questionnaires were available for another participant.
No discrepancies relating to study variables were found for 14 of 15 wound assessment forms (93.3%).
The only discrepancy was that the name of the primary dressing from one form had not been transferred
to SystmOne.
TABLE 29 Frequency of inconsistencies between specification and presence of treatments
Treatment
Entries in which treatment indicated to be
‘not present’, n (%) (n= 635)
Name of item recorded when treatment
‘not present’, n (%)
Primary dressing 56 (8.8) 17 (30.4)
Secondary dressing 426 (67.1) 18 (4.2)
Bandage 382 (60.2) 23 (6.0)
Hosiery 553 (87.1) 2 (0.4)
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The register population
Around half of register patients were male (51.4.8%) and just over 70% were white British or British/
mixed British. The minimum age within the sample was 21 years and the maximum age was 99 years.
The mean age was 72.4 years (SD 14.51 years) and the median age was 75 years. Over 70% of individuals
within the sample were aged > 70 years. No demographic data were available for patients with EQ-5D
data only.
Table 30 presents the proportions of register patients with certain risk factors at baseline. Just over
one-quarter of the register population had diabetes reported at baseline and one-fifth of the first entries
in the register for each individual reported an infection.
Table 31 shows the frequency of different types of wound as reported at the first visit. In total, 271
wounds were reported at the first visit in 183 patients. Tracking of wounds through the study was difficult
because of issues related to the wound identifier when a patient had multiple wounds.
TABLE 30 Baseline risk factors for the wound register participants
Risk factor Frequency (%)
Continence issues 14 (7.7)
Diabetes 49 (26.8)
Infection 37 (20.2)
Nutrition 31 (16.9)
Peripheral neuropathy 14 (7.7)
Poor blood supply 25 (13.7)
Smoker 11 (6.0)
TABLE 31 Frequency of wound types recorded at first visit
Type of wound Frequency
Venous leg ulcer 81
Pressure ulcer 52
Dehisced surgical wound 34
Non-diabetic foot ulcer 26
Arterial/venous leg ulcer 25
Other wound 24
Arterial leg ulcer 8
Diabetic foot ulcer 8
Traumatic wound 7
Abscess 2
Missing 2
Burn 1
Pilonidal sinus 1
Other surgical 0
Fungating carcinoma 0
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Wound length and width are not summarised because of lack of clarity regarding units of measurement in
many cases. Because of this and the difficulties in tracking wounds through time, longitudinal methods
were also not applied.
Referral source is summarised in Table 32 for each entry with clinical data in the register. Most individuals
had one referral source but eight individuals had entries after referrals from two services and one patient
was referred by three services. One-third of entries were the result of a referral from district nursing
services and a further one-quarter were the result of a referral from general practice.
Table 33 shows the location of care for patients by area; around two-thirds of consultations took place
within the home and the next most common locations were a nursing/residential home or a health centre,
accounting for approximately 10% of entries each.
Face-to-face contact data were available relating to 100 individuals from the date of their consent until
July 2013. The number of face-to-face consultations per month ranged from 0 to 30, with a mean of
1.8 (SD 4.93).
TABLE 32 Referral source by area
Referral source
North-west,
n (%)
North-east,
n (%) East, n (%)
South,
n (%)
West,
n (%)
Out of
area/missing,
n (%)
Total,
n (%)
District nursing
service
61 (53.0) 28 (30.4) 41 (31.3) 63 (29.3) 12 (15.4) 4 (100.0) 209 (32.9)
General practice 26 (22.6) 31 (33.7) 33 (25.2) 61 (28.4) 7 (9.0) 0 (0.0) 158 (24.9)
Acute trust 23 (20.0) 15 (16.3) 18 (13.7) 42 (19.5) 28 (35.9) 0 (0.0) 126 (19.8)
Private sector 5 (4.3) 1 (1.1) 4 (3.1) 27 (12.6) 8 (10.3) 0 (0.0) 45 (7.1)
Tissue viability
service
0 (0.0) 2 (2.2) 18 (13.7) 4 (1.9) 2 (2.6) 0 (0.0) 26 (4.1)
Podiatry service 0 (0.0) 10 (10.9) 7 (5.3) 0 (0.0) 8 (10.3) 0 (0.0) 25 (3.9)
Intermediate
care service
0 (0.0) 1 (1.1) 1 (0.8) 7 (3.3) 6 (7.7) 0 (0.0) 15 (2.4)
Residential care
service
0 (0.0) 0 (0.0) 7 (5.3) 1 (0.5) 4 (5.1) 0 (0.0) 12 (1.9)
Self-referral 0 (0.0) 4 (4.3) 0 (0.0) 2 (0.9) 3 (3.8) 0 (0.0) 9 (1.4)
Mental health
trust
0 (0.0) 0 (0.0) 0 (0.0) 4 (1.9) 0 (0.0) 0 (0.0) 4 (0.6)
Community
matron
0 (0.0) 0 (0.0) 0 (0.0) 3 (1.4) 0 (0.0) 0 (0.0) 3 (0.5)
Hospice 0 (0.0) 0 (0.0) 2 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.3)
Neurology
service
0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.2)
Total 115 (100.0) 92 (100.0) 131 (100.0) 215 (100.0) 78 (100.0) 4 (100.0) 635 (100.0)
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Data analyses (including feasibility of propensity scoring and instrumental
variables analyses)
There were 31 entries that reported a healed wound relating to 24 individuals. It is difficult to say how
many of these entries related to unique wounds because of the deficiencies in the wound identifier, the
fact that the type of wound was missing for many of these entries and the issue of possible missed healing
events if data collection ceased when a service not participating in the pilot took over wound care.
An issue with data transfer meant that on receipt all wounds had a healing date regardless of healing
status. These dates were replaced with missing values when wound healed status was not confirmed but
confidence in the accuracy of these dates is low. On top of this, five of the 31 entries reporting a healed
wound had a start of treatment date after the date of healing date, implying a negative healing time,
which is obviously not possible. After excluding these five entries, the minimum reported healing time was
4 days and the maximum was just over 1 year (420 days); the median healing time was approximately
100 days. Summary statistics were recreated once seven potential duplicate entries had been removed to
provide a conservative estimate of time to healing. Time to healing ranged between 4 and 420 days
although the median time to healing was 88 days. Because of the lack of available data it was not possible
to present Kaplan–Meier curves or estimate the median healing time. It was also not possible to examine
time to healing for wounds with different prognostic profiles, although this data set holds the potential for
the application of survival analysis techniques.
Approximately 30% (31) of the 104 entries with infection indicated as a risk factor were reported as being
treated with a silver-containing primary dressing and < 10% of primary dressings for these individuals (nine
entries) contained iodine. As only 40 entries (23 individuals) would be available for inclusion in a propensity
scoring approach to examine the relative effectiveness of silver- and iodine-containing dressings, the
propensity scoring method was not applied.
We estimated the proportion of people with venous leg ulcers who were receiving appropriate
compression therapy by analysing the compression used and the ABPI measurement. Of the 166 entries
relating to people with a venous leg ulcer, 59 limbs (37 individuals) were recorded as having an ABPI
between 0.8 and 1.2 (safe limits for the application of compression). Approximately 85% of these 59 limbs
were recorded as receiving compression therapy.
TABLE 33 Location of care by area
Location of
care
North-west,
n (%)
North-east,
n (%) East, n (%)
South,
n (%)
West,
n (%)
Out of
area/missing,
n (%)
Total,
n (%)
Home 80 (69.6) 56 (60.9) 80 (61.1) 168 (78.1) 40 (51.3) 2 (50.0) 426 (67.1)
Nursing/
residential home
7 (6.1) 2 (2.2) 12 (9.2) 28 (13.0) 12 (15.4) 0 (0.0) 61 (9.6)
Health centre 11 (9.6) 18 (19.6) 10 (7.6) 11 (5.1) 9 (11.5) 2 (50.0) 61 (9.6)
General practice 17 (14.8) 6 (6.5) 19 (14.5) 1 (0.5) 0 (0.0) 0 (0.0) 43 (6.8)
Clinic 0 (0.0) 10 (10.9) 7 (5.3) 0 (0.0) 17 (21.8) 0 (0.0) 34 (5.4)
Mental health
inpatient
0 (0.0) 0 (0.0) 1 (0.8) 4 (1.9) 0 (0.0) 0 (0.0) 5 (0.8)
South Leeds
Independence
Centre
0 (0.0) 0 (0.0) 0 (0.0) 3 (1.4) 0 (0.0) 0 (0.0) 3 (0.5)
Hospice 0 (0.0) 0 (0.0) 2 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.3)
Total 115 (100.0) 92 (100.0) 131 (100.0) 215 (100.0) 78 (100.0) 4 (100.0) 635 (100.0)
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Because of the limitations in the data and the number of data available, instrumental variables and
propensity scoring could not be explored. With a longer follow-up providing more data and a reliable
wound identifier, it is thought that this exploration might be possible.
European Quality of Life-5 Dimensions questionnaire data
Of the 198 consenting patients, 12 had EQ-5D data only. In total, 157 individuals returned an EQ-5D form
at some time point, with 21 individuals returning a form at all three time points. Six individuals returned
EQ-5D forms but were not listed as consented; it is believed that there was an error with the patient ID for
these individuals but data were deleted as this could not be proven. The response rate for the baseline
EQ-5D questionnaire was reasonably high at around 80% but the proportion of those responding then
fell rapidly to 40.0% at 3 months and 12.3% at 6 months (Table 34). For an EQ-5D form to be used in
analysis, one level had to be chosen for each dimension; if the form was only partially completed a utility
value could not be assigned. It was prespecified that if a form was returned > 1 month outside of the
expected return date then the data would be discounted to allow for comparability of response.
The baseline EQ-5D questionnaire was fully completed by 146 individuals and partially completed by
a further 11. The baseline questionnaire was completed before the consent date for four individuals
(this was either an error in the date of the questionnaire or on the consent form). It took, on average,
just over 1 month to return the baseline questionnaire (mean 1.2 months, SD 1.83 months). In total,
116 questionnaires were returned within 1 month of the expected date (based on date of consent), of which
111 (56.9% of the sample) were complete and hence could be used in the analyses.
The 3-month questionnaire was completed by around 35% of individuals. No questionnaires were
returned early but the longest time until return was 9 months after the date of consent. The average
return time was approximately 4.5 months (SD 1.05 months). Of the 43 who returned the questionnaire
1 month either side of the expected date, 38 (19.5% of those in the study) completed all dimensions and
hence could be included in the analyses.
The 6-month questionnaire was returned by just 24 individuals (12.3%). No questionnaires were returned
early but the longest time until return was 10 months after the date of consent. The average return time
was approximately 8.5 months (SD 1.06 months). Of the four who returned the questionnaire 1 month
either side of the expected date, three (1.5% of those in the study) completed all dimensions and hence
could be included in future analyses.
Table 35 shows the frequency of each response level for individuals who returned completed EQ-5D
questionnaires within 1 month of the expected date of return. No frequencies are presented at 6 months
to protect the anonymity of the three individuals who returned completed forms at this time point. At
baseline most of the population scored 2 for mobility; although this was still the most frequent score at
3 months, the proportion of individuals scoring 1 had increased, although at 3 months there was a much
smaller sample size. This increase in the proportion scoring 1 at 3 months compared with baseline was
seen across all dimensions.
TABLE 34 European Quality of Life-5 Dimensions questionnaire response rates
Questionnaire status Baseline, n (%) 3 months, n (%) 6 months, n (%)
Complete 146 (74.9) 71 (36.4) 20 (10.3)
Partially complete 11 (5.6) 7 (3.6) 4 (2.1)
Total returned 157 (80.5) 78 (40.0) 24 (12.3)
Total returned within 1 month of expected date 116 (59.5) 43 (22.1) 4 (2.1)
Returned on time and complete 111 (56.9) 38 (19.5) 3 (1.5)
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It is possible that the changes seen here could be an artefact of attrition as opposed to reflecting a true
change over time. To provide insight into this, the characteristics of EQ-5D respondents at baseline and
3 months were summarised and compared with those of the overall sample population.
Of those providing EQ-5D data at baseline, 51.0% were male, a similar proportion to that in the overall
register population; however, at 3 months, 65.7% of respondents were male. The mean ages of
respondents at baseline and 3 months (71.3 years and 73.3 years, respectively) were similar to the mean
age of 72.4 years in the register population. The median values were also similar. In relation to risk factors,
the proportions of smokers and those with a poor blood supply were similar at each time point to those
in the overall sample. There were, however, differences in the proportion with diabetes between those
providing EQ-5D data (22.5% at baseline and 13.2% at 3 months) and the overall register population
(26.8%). The higher proportion of males and lower proportion of people with diabetes at 3 months may
have led to the changes in responses, although it is not possible to say this definitively nor for the effect of
attrition to be disentangled from ‘true’ changes in the descriptive summary shown in Table 35.
Staff feedback
Four feedback sessions were held, one with tissue viability nurses (n= 6), one each with the two district
nursing pilot sites (pilot site 1, n= 2; pilot site 2, n= 12) and one with the podiatry service (n= 1 podiatrist).
The sessions took place face to face at ‘team meetings’ except for the podiatry session, which took place on
a one-to-one basis. Note that the views expressed relate to the electronic version of the wound assessment
form for the tissue viability and podiatry services, and the paper version for district nurses.
TABLE 35 Frequency of EQ-5D response at baseline and 3 months by dimension
Dimension Baseline (n= 111), n (%) 3 months (n= 38), n (%)
Mobility
1 24 (21.6) 12 (31.6)
2 80 (72.1) 24 (63.2)
3 7 (6.3) 2 (5.3)
Self-care
1 59 (53.2) 29 (76.3)
2 41 (36.9) 6 (15.8)
3 11 (9.9) 3 (7.9)
Usual activities
1 24 (21.6) 13 (34.2)
2 66 (59.5) 19 (50.0)
3 21 (18.9) 6 (15.8)
Pain/discomfort
1 21 (18.9) 11 (28.9)
2 76 (68.5) 23 (60.5)
3 14 (12.6) 4 (10.5)
Anxiety/depression
1 61 (55.0) 24 (63.2)
2 47 (42.3) 12 (31.6)
3 3 (2.7) 2 (5.3)
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In general, staff felt that the wound assessment form was too long, laborious and time-consuming to
complete. A particular issue was that only one wound could be recorded per wound assessment form and
this was a disadvantage when a patient had multiple wounds and hence multiple wound assessment
forms to complete. Generic information also had to be included each time a wound assessment form
was completed. For district nurses using the paper version, the writing did not always go through all the
carbon layers and some things did not fit into the categories provided and they needed a free-text option.
The ‘questionnaire viewer’ facility (introduced part-way through the pilot study) enabled clinicians to view a
summary of the electronic wound assessment form by ‘hovering’ the cursor over it and this was regarded
positively as an aid to identify the relevant wound assessment form without having to open them all.
Tissue viability nurses reported that they did not complete the wound assessment form if they were busy
and tended to record the information elsewhere in the patients’ records on SystmOne (in the patient
journal, which is a facility to record free-text notes). If they did complete the wound assessment form,
sometimes it would never be opened again and it was not easy to compare past assessments.
District nurses used the paper version and, although complicated at first, they got used to it (this applied
more to pilot site 2). They found that it prompted them to carry out wound assessments (and reassessments),
undertake Doppler-aided assessment of ABPI and think more about which dressings they used; they felt
confident that they were not missing anything. However, they did note that the forms were heavy to carry
around and bulky in the patient notes.
Podiatrists tended to use their own wound assessment form that was specific to feet.
The mobile technology (ToughBook) did not always work well for the tissue viability nurses; the signal was
sometimes poor and they were unable to complete the form while out in practice. The recent introduction
of electronic care plans for district nurses was complementary to the wound assessment form and also
prompted reassessment.
Barriers and facilitators
The drop-down boxes on the electronic version of the wound assessment form made it easier to complete.
District nurses found the paper version more spaced out than the previous form but were also pleased that
the number of reassessment columns had been reduced, as this reduced the number of carbon pages.
Having multiple pages/one wound per form made it more difficult to use and it was sometimes difficult to
know which wound was which.
District nurses in pilot site 2 addressed the need for extra time to complete the form by scheduling their
work to accommodate it.
Tissue viability nurses felt that they had become more comfortable with mobile working technology and
this had made it easier to complete the wound assessment form. However, they also felt that a new form
was needed that combined with systems already in place in SystmOne and linked with planned new IT
devices in the trust. The podiatrist felt that more work with SystmOne was needed to overcome the
barriers to using the wound assessment form.
District nurses would have liked the form to be a single page (paper version) or to be able to use the
electronic version (using mobile technology). They also wanted the facility to draw a sketch of the wound,
inclusion of a body diagram and to be able to include more than one wound on a single wound
assessment form. They felt that the description of wound location could be removed.
Tissue viability nurses generally felt that a new form was needed that had drop-down boxes but also
‘fewer clicks’ and the ability to reassess a wound within a single wound assessment form. The podiatrist
wanted the form to be simplified and integrated into the current system.
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Tissue viability nurses were very supportive of using future technology to develop the wound assessment
form, such as integrating more with SystmOne and using devices such as a tablet with a camera that could
be used to upload data to SystmOne. District nurses also wanted to be able to use mobile technology to
complete the wound assessment form.
Activities associated with the register
We have chosen to represent the resources associated with the establishment and running of the register
as ‘activities’ rather than monetary costs at this point as we think that this will be more meaningful and
relevant over time. Activities and tasks generated by the register are detailed in Table 36 and relate to
those directly associated with setting up and running the register. Other activities at the NHS site for
routine data collection and developments are not included here but are discussed in the following section.
TABLE 36 Register activities
Register activities
Location
(NHS or university) Function performed by
Set-up activities
Planning the aims, scope and methods in the form
of a protocol and related documents
NHS and university Collaboration between a number of
stakeholders
Preparing and submitting ethics application and all
other approvals
University Project support officer and research fellow
Liaison with NHS site and university IT department
to discuss/agree data transfer issues
NHS and university Wounds data co-ordinator, research fellow
and project support officer
Running activities
Preparing and submitting substantial amendments
to ethics committee and all other approvals
University Project support officer and research fellow
Identifying potential participants and preparing
and mailing out study information
NHS Administrator
Dealing with incoming paperwork from potential
participants and filing it safety and securely
NHS Administrator and wounds data co-ordinator
Recording recruitment details of consenting
individuals for upload to public research body
(UKCRN) and also NHS electronic patient records
NHS Administrator and wounds data co-ordinator
Data entry into SystmOne for forms completed on
paper version of wound assessment form
NHS Wounds data co-ordinator
Preparing and mailing out EQ-5D materials to
register participants
NHS Administrator
Data entry of EQ-5D data into spreadsheet for
register participants and filing the paper
documents safely and securely
University Project support officer
Preparing for and extracting participant data from
NHS data warehouse and transfer (via secure
e-mail) to register administrator
NHS Senior analyst in IT
Receiving register data and saving and storing
electronic files safely and securely
University Project support officer
Uploading recruitment data to public research
body (UKCRN)
University Project support officer
UKCRN, UK Clinical Research Network.
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Other activities
Some activities occurred within the NHS site itself and were not necessarily regarded as register activity.
Within the pilot study, the development and implementation of the routine collection of electronic
patient data necessitated a great deal of NHS staff engagement including clinical staff (tissue viability
service staff), the wounds data co-ordinator and NHS IT service staff. This joint working took place over an
extended period of time. There was also clinical staff time required to record patient data in the wound
assessment form.
Furthermore, there was an activity implication attached to the patient and/or carer time to read and
respond to the study invitation and complete the EQ-5D questionnaire every 3 months.
Discussion
Any register that relies on routine clinical data to populate it is dependent on the clinical and IT interface
within the source organisation. The use of IT in patient record keeping and the recording of clinical data
within nursing services were undergoing rapid change during the pilot study and continue to do so.
Our attempts to integrate the collection of complex wounds data into the clinical information system were
largely supported by enthusiastic clinical staff (both tissue viability specialists and general nurses), who
demonstrated a willingness to undertake wound assessments and treatment reviews as part of wound
management. Their accuracy and completion rates were also generally good. These attributes present an
important platform on which to build in the future, particularly if a wounds register is extended across the
trust and potentially to other areas/trusts. However, a number of challenges remain regarding the use of
routinely collected wounds data for a register. Although we were able to identify and track individual
participants using their NHS number, it was much more challenging to track individual wounds in people
who had more than one wound. Software limitations meant that each wound assessment form could not
be given an individual file name (with identifier) and we had to try to identify individual wounds using
information in the form (including wound type, size and location). When the problem was identified
(through the pre-pilot data), staff were requested to include Wound1, Wound2 etc. in the wound
description section. When this was completed it was possible to track longitudinal data; however, it was
not implemented until 3 months into the pilot study and the nurses were not always consistent in
recording the information. One possible solution might be further software development so that wounds
can be reassessed within the same wound assessment form rather than relying on nurses to manually
enter the information. An alternative would be to collect only information about a ‘reference’ wound,
perhaps the largest wound.
A key issue is that of coverage of the register and thus data collection. In some cases it was challenging to
track participants as they moved between different services for wound care. This made it difficult to report
an accurate duration of follow-up data. Full coverage of service providers would be required to ensure full
data collection.
Data analysis of the wounds register
A lack of data, because of both poor recruitment and the difficulty of tracking longitudinal data,
limited the analyses that we were able to undertake. We had planned to implement propensity scoring
and investigate the use of instrumental variables but this was not possible because of the limitations
of the data that were collected. Only one-quarter of those approached gave consent and future work
should consider alternative approaches to recruitment. It appears that some of the reasons why people
do not wish to take part may be because of old age and poor health, which are not easily modifiable.
A possible solution would be a two-tier model of participation, in which people could opt out of
completion of the EQ-5D (which would remove the need to identify participants). A two-tier model would
permit patients to choose their level of involvement while potentially enhancing the overall recruitment
rate and subsequent availability of core register data. Ethics approval for this pilot study was based on our
following a recruitment process of mailing study information to potential participants. Permission to
adopt a recruitment strategy similar to those that we use in wounds trials,18,19,118 which involve recruitment
via the clinical care team, would be likely to enhance overall recruitment. Another alternative would be to
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consider using pseudo-anonymised data, providing the risk of re-identification of participants could
be minimised. Although some ‘richness’ of data would be lost (including EQ-5D data), using
pseudo-anonymised data would enable larger numbers of participants and a more representative sample.
This pilot study has identified areas for improvement in the characteristics of routinely collected NHS data
that are suitable for use in a register. For example, the standardisation of data variables is a key feature of
register data. Many of the data variables on the wound assessment form were standardised, such as the
‘wound type’ variable, which had 13 available options for staff to choose from and a limited opportunity
for free text. Other variables were less standardised. For instance, the ‘wound length and width’ variable
required clinicians to insert numerical details in millimetres; however, this was not always carried out
accurately. Extending the standardisation of this variable to provide measurement options could potentially
increase its suitability for populating a wounds register. Similarly, because of the sheer number of potential
options, the ‘wound dressing’ variable was provided as free text, with clinicians entering the name of the
dressing. Further work could usefully investigate how wound dressing data could be further standardised
while remaining flexible, to incorporate new dressings as they emerge onto the market and into clinical
practice. The need for further data standardisation to populate a register creates an opposing tension with
clinical staff, who noted in feedback that they would like more free-text opportunities. Therefore, a careful
balance would need to be achieved to meet the needs of clinical record keeping by staff and the need for
high-quality data to populate a register.
Another characteristic of the NHS data used in this pilot study that would need to be enhanced if the
register was to be continued and/or expanded concerns the implementation of data definitions. Our review
work identified that explicit data definitions impact on the value and quality of register data. To date,
nurses have relied on clinical judgement when completing the assessment forms and few, if any,
operational definitions were available for variables. For the purposes of the complex wounds register pilot
we implemented a clear case definition of a complex wound (which was already in use within the trust
and wider region) and other wound definitions that had been used in the prevalence survey. Any future
wounds register using routinely collected NHS data would need to implement clear operational definitions
for all data variables.
Implications for future wounds registers
Wound care in the UK is something of a ‘Cinderella service’, subsumed in community nursing work and
captured only as crude activity data. Consequently, the planning of services and new research is hampered
by collective ignorance of the numbers of patients affected, treatments used and the likely value of new
research. We have previously shown that, historically, primary care databases (General Practice Research
Database and The Health Improvement Network) were suboptimal for exploring wound treatments and
outcomes because most care is delivered by community nurses and not accurately captured at the practice
level.119 The pilot register work was required because of concerns about the extensive challenges faced in
harmonising even routine data collection across the many health-care providers involved in complex
wound care. These concerns were borne out by our experience and the collection of data in our pilot
relied on the development of a complex infrastructure involving collaboration between multiple
stakeholders from the organisations involved. Full coverage of all providers was not possible within the
pilot study. Indeed, this infrastructure is a key programme output and, although we suggest that future
large-scale data collection is feasible based on the successful collection of valid pilot data, such data
collection would require similar close collaboration to support it.
Overall conclusions from workstream 1
A systematic review of previous prevalence surveys of complex wounds indicated a considerable
accumulation of published literature. All of the identified studies had methodological flaws that would
affect the validity of their prevalence estimates and/or were badly reported. Only a small number of studies
have investigated all complex wounds (or all wounds), with most focusing on wounds of a specific
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aetiology (usually leg ulcers). Estimates of the prevalence of complex wounds ranged between 0.24% and
1.4%. Most previous surveys appear to have used paper-based questionnaires and fewer than one-third
implemented any case validation. A defined geographical population was used for the denominator
population in half of the studies, with the other half examining a variety of populations. No studies used
the capture–recapture technique in hard-to-reach groups. Our scrutiny of the existing literature enabled us
to identify the core variables (a minimum data set) to be used in future studies. The findings of this review
also enabled us to design a prevalence survey that avoided most of the common pitfalls.
We had originally planned to use the capture–recapture technique to estimate complex wound prevalence
in hard-to-reach groups. In the event this proved unnecessary because the targeted provision of health
care for drug users and people of no fixed abode in Leeds meant that we had few doubts that we could
identify people with complex wounds from these populations. Our own prevalence survey estimated that
1.47 people per 1000 (95% CI 1.38 to 1.56 per 1000) in Leeds were receiving health care for some kind
of complex wound. Pressure ulcers were the most common complex wound (point prevalence of 0.31 per
1000) followed by venous leg ulcers (0.29 per 1000). We have produced the first estimate of which we are
aware of the prevalence of complex wounds in current or previous intravenous drug users (5.64 per 1000,
95% CI 3.97 to 7.99 per 1000). A clear picture emerges from these data of complex wounds mainly
affecting older people with multiple comorbidities. The mean age of those with a complex wound was
70.1 years (SD 19.41 years) and people with a complex wound had an average of two comorbidities,
with CVD and arthritis being the most common. Rates of urinary and faecal incontinence were also high
at 23% and 12%, respectively. Most people received their wound management from community nurses;
most patients received two to three wound care consultations per week, with a mean duration of
28 minutes.
Our review of registers and clinical databases identified five concerning patients with complex wounds,
although only one of these was UK based and this was > 10 years old. We designed a complex wounds
register with a view to future use in both clinical care and research (e.g. HTA). We worked closely with
clinical colleagues and NHS IT professionals to ensure that our register protocol had clear operational
definitions for most variables, clear recruitment and consent procedures and a data capture process that
would impact minimally on clinical work while providing clinically useful data.
We did not find any guidance and advice for people in the UK who are considering establishing a chronic
disease register and we think that such advice would be of enormous value. Such guidance should usefully
address important design features to be considered as well as issues around consent and data protection.
Our complex wounds register pilot demonstrated that recruitment to such a register is possible, although the
recruitment strategy that we used resulted in only approximately 26% of eligible patients being recruited.
Such a low recruitment rate would be unsatisfactory for a full register and would introduce selection bias.
A relatively small number of potential participants explained their reasons for non-participation, indicating
that recruitment would be likely to be negatively influenced by the age and general health of people
with complex wounds (i.e. primarily elderly people with other health conditions/poor general health
and dementia).
We found that it was possible to correctly identify the NHS records of consenting register participants,
extract data from the NHS databank and securely transfer and store register data.
The feasibility of data analysis could be assessed only to a limited extent within the pilot. We learned that
the tracking of individual wounds in patients with multiple wounds over time very difficult. The type of
complex wound reported for register participants was similar to what was expected from our prevalence
survey, with venous leg ulcers and pressure ulcers being the most frequently reported. Patients who
consented to participate in the register pilot were slightly older and more likely to be male when compared
with all people with complex wounds in the city.
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79
The median wound healing time for people in the wounds register was just under 3 months; however,
this was based on a small number of individuals. There were insufficient data to examine how this may
differ for people with different prognostic profiles.
The small number of participants whose wounds healed during follow-up may be because the tissue
viability service, by its nature, serves the more complex, hard-to-heal population and this was mainly where
we piloted the register. This was also evident in the pre-pilot data (which involved only the tissue viability
service), with over half of the individuals having only one consultation. However, expansion to other
services to improve coverage in the future would help overcome this issue.
Wound management of register participants was primarily delivered in patients’ own homes; this has
implications for the nature of the data collection for a register (currently likely to be on paper using some
method of duplication so that a copy stays with the patient and another is sent for data entry).
The day-to-day running of a register generates a considerable number of tasks and processes that require
at least one full-time individual with skills in project management, data management, data protection and
conducting quality procedures.
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Chapter 3 Service user and provider perspectives
(workstream 2)
Abstract
Background
Health care and research should be guided by the priorities of patients, carers, the wider public and the
NHS. Our objective was to explore the experiences of complex wound care, identify which outcomes
matter most to people with complex wounds, compare these with those reported in wounds research and
derive a prioritised list of research questions in the area of pressure ulcer prevention and treatment.
Methods
The methods used included semistructured interviews with people affected by complex wounds, carers and
health professionals regarding their experiences of complex wound care and desirable treatment outcomes;
a systematic review of the design and conduct of RCTs of complex wound treatments; and consultative
and deliberative research agenda setting in the area of pressure ulcer prevention and treatment.
Results
Most patients and health professionals viewed healing of the complex wound as the primary treatment
goal. Patients were greatly troubled by the socially inhibiting consequences of their complex wound, but
wound care services did not focus on the psychological or social impacts. The treatment model was geared
to healing, not ‘living with’ a long-term condition. In total, 167 RCTs of complex wound treatments were
analysed, of which 69 (41%) did not specify a primary outcome; 40 (24%) had complete healing as the
primary outcome, 47 (28%) used a surrogate measure of wound healing and 11 (7%) reported an
outcome unrelated to healing. A total of 960 treatment uncertainties were elicited and a top 12 prioritised
by patients, carers and health professionals.
Conclusions
There is a mismatch between the nature and quality of RCTs in complex wounds and the kind of research
evidence desired by patients, carers and clinicians. It was possible to work with patients, carers and health
professionals to identify and prioritise for research the uncertainties in pressure ulcer prevention and
treatment. Community nursing management of people with complex wounds may be improved by
adopting an approach aimed at helping patients live with a long-term condition.
Background
The primary stated purpose of the UK NHS is the improvement of health-care outcomes, with an
imperative to move towards systems of accountability that focus on outcomes achieved for patients rather
than on the processes by which they are achieved.120 Enhancing quality of life for people with long-term
conditions has been identified as a key ‘domain’ in the NHS Outcomes Framework.121 Workstream 2
focused on service user engagement in identifying, measuring and reporting outcomes in chronic wound
care and their involvement in the prioritisation of wound-related research questions.
Chronic complex wounds impact on patient morbidity, mortality, daily functioning and quality of life.9–12
There is evidence from research into other chronic conditions that the outcomes that matter most to
patients may not be the primary outcomes measured in RCTs. For example, findings from the OMERACT
(Outcome Measures in Rheumatology) collaboration suggest that clinicians and researchers may not realise
that certain outcomes are very important for patients.122 As a result, the OMERACT collaboration advocates
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the use of core outcome sets designed using consensus techniques.123 There has been no such initiative in
wound care and there has been no systematic exploration of the characteristics of outcomes reported
for wound trials and the factors that influence them. If the principal clinical objective in wound care is
complete wound healing, this in itself can be measured and presented in a number of ways in RCTs.124
Conducting trials with lengthy follow-up is costly and time to complete healing and the proportion of
wounds completely healed are difficult to measure in trials of short duration. Therefore, studies may opt to
report surrogate outcomes including surrogate measures of healing such as change in ulcer size or
area.125–127 A surrogate end point is described by Temple128 as ‘a laboratory measurement or a physical sign
used as a substitute for a clinically meaningful endpoint that measures directly how a patient feels, functions
or survives’. Surrogates are predictors for the clinically meaningful end point of complete healing. There is
evidence that some surrogate markers are robust predictors of healing126 but there may also be the potential
for false extrapolation. It is not clear how valuable such healing measures are judged to be by patients.
For example, Yudkin et al.129 warn that surrogates used in diabetes research commonly show much larger
responses to treatment than the ‘hard’ outcomes that matter to patients, such as renal and visual
impairment or quality of life. They argue that, as a result, widely accepted treatment strategies are based on
artificially inflated expectations. Researching surrogate outcomes in shorter trials can cause other problems,
for example it is difficult to accurately assess adherence to treatment over time and this may impact on
treatment effectiveness. Within this workstream we therefore sought to find out what the important
outcomes are from patient, carer and staff perspectives and then systematically summarise the outcomes
that are reported in wound trials and compare the two. We also sought to explore whether or not factors
such as industry funding of trials may influence outcome selection or some other aspect of trial quality.
As well as getting the outcomes and trial design right, another important aspect related to the conduct of
high-quality, relevant research is identifying the right question in the first place. Several authors have
written persuasively of the importance of gathering and prioritising patients’ research questions so that
future research assesses the things that matter to patients.130,131
The James Lind Alliance (JLA) was established in 2004 to encourage patients, carers and clinicians to work
together to identify and prioritise shared health-care uncertainties, arguing that medical consensus can
be flawed and that research into clinical practice and NHS services should identify and address the
uncertainties and investigate the outcomes that are of most practical importance to patients, their carers
and clinicians. Research priority themes emerging from the deliberations of JLA partnerships to 2012
(across asthma, incontinence, vitiligo, eczema, stroke, prostate cancer, schizophrenia, aspects of balance
and type 1 diabetes) emphasise the assessment of treatments in terms of long-term effects (wanted and
unwanted) and safety and adverse effects.132 All aspects of the management of complex wounds are
served by a poor evidence base; however, we selected pressure ulcer prevention and treatment as a
complex wounds topic on which to embark on a JLA Priority Setting Partnership (PSP). We selected
pressure ulcers because they are the most frequent type of complex wound (see Chapter 2) and because
their reduction is such a high priority for the NHS.133
In summary, workstream 2 employed mixed methods to explore the outcomes that matter most to patients
undergoing treatment for complex, chronic wounds and how these compare with the outcomes that
matter most to health-care professionals and those measured and reported in RCTs in wound care.
We also report on the James Lind Alliance Pressure Ulcer Partnership (JLAPUP). Methods and results are
reported separately for three studies:
1. The relative importance of wound treatment outcomes to patients, carers and health-care staff
(which outcomes would stakeholders like to see measured in wounds research?).
2. A systematic review of complex wounds research (which outcomes are currently measured in
wounds research?).
3. Involving patients and clinicians in developing research priorities: the JLAPUP (what are the pressure
ulcer research priorities of patients, carers and clinicians?).
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This workstream therefore analysed the research that is undertaken in complex wounds and compared it
with the research that patients, carers and clinicians want to see.
The relative importance of wound treatment outcomes to
patients, carers, health-care staff and policy-makers
Introduction
Although wound healing (a physiological end point involving close monitoring of the wound surface area,
wound depth and extent of tissue involvement) is often regarded as the main aim of treatment for health
professionals and patients, there has been little published work that identifies and compares the treatment
outcomes that matter most to different stakeholders. In addition to healing, other possible outcomes of
interest in wound care include the number of dressing changes required by patients and associated
resource use; exudate and odour management; product durability; levels of wound infection; and whether
or not the wound recurs. Outcomes perceived as being important from the patient perspective include
wound debridement,134 pain, dressing comfort, effects on mobility and in/dependence and health-related
quality of life.135 It is noteworthy, however, how absent the patient voice is from wounds research and
particularly from conversations about outcomes. For example, the European Wound Management
Association Patient Outcome Group is made up of clinicians, academics and industry representatives136
and did not involve patients in drawing up its guidance on wounds research.134
Objective
Our objective in undertaking this study was to identify the most important outcomes for complex wounds
from the perspectives of patients (including intravenous drug users), carers, health-care professionals and
policy-makers.
Methods
Interviews
Semistructured interviews using a topic guide were conducted with 33 people with complex wounds
receiving care from Leeds Community Healthcare NHS Trust. People were eligible for interview if they were
receiving care for pressure ulcers, leg ulcers, foot ulcers associated with diabetes or surgical wounds
healing by secondary intention. We particularly sought to include some people with complex wounds
associated with current or previous intravenous drug use. The interviews aimed to assess the wound
outcomes that mattered most to the interviewees. In contrast to previous research (e.g. Spilsbury et al.137)
the interviews did not focus on any one outcome (i.e. quality of life), but rather allowed participants to
generate naturalistic data on what they considered successful in terms of treatment outcomes. Interviews
lasting 30–60 minutes took place in participants’ own homes or, when an interviewee was of no fixed
abode, in a private room at a referring specialist general practice. One interview was conducted by
telephone. Interviews were digitally audio-recorded, transcribed verbatim and subjected to thematic
and comparative analyses.138,139 One interviewee preferred not to be recorded but consented for
contemporaneous notes to be taken instead. A written post-interview checklist was completed
immediately after each interview recording who was present, the main themes, a note on rapport and any
particularly sensitive issues.
Purposive sampling was used to ensure that as broad a range of patient experiences as possible was
recorded in the interviews and to meet the wider programme aim of including the views of intravenous
drug users, which are seldom recorded in the existing literature. The sample size aimed to maximise
diversity across the patient group.140 This meant adopting an iterative sampling approach, moving back
and forth (iterating) between sampling and analysing data so that preliminary analytical findings shaped
subsequent sampling choices. A sampling frame was drawn up by the researcher with NHS clinician
partners based on their patient profiles. The researcher had no access to patients’ medical records.
The clinician partners were asked to review patients and carers according to the sampling frame, make a
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list and from this list ask patients if they might be interested in taking part in the research. If a patient on
the list expressed an interest, a clinician partner approached him or her. Those who agreed were referred
to the researcher who then telephoned them to give more details and to ask if she might send out a
written information sheet. In addition, one patient participant self-referred to the study after hearing about
it at a patient and public involvement event. One carer self-referred and a patient and carer couple asked
to be referred by their district nurse in response to articles that they had read about the study in Multiple
Sclerosis Society and carer publications.
Eight carers were involved in interviews. Six joined in the interviews above or were asked for additional
thoughts after the interview. Two carers, one recruited through the local carers group newsletter, took
part in separate interviews in which they were the primary interviewee. Finally, 12 health-care professionals
of varying grades and length of service involved in the direct delivery of wound care services were
interviewed at their place of work. Three of these had managerial responsibility for teams. One member of
the executive management team was also interviewed.
Ethics and informed consent
The study was subject to full ethical review. It received approval from the University of York Department
of Health Sciences Research Governance Committee and York Research Ethics Committee (reference
09/H1311/88). The researcher telephoned every patient and carer initially referred to the study by the
on-site clinicians. Care was taken to ensure that potential participants did not feel pressured to become
involved in the study. They were given time to read through the available information, ask questions and
make an informed choice. The nature and design of the study allowed for a ‘cooling off’ period between
the patient/carer being approached (or, in some cases, approaching us) and the interview taking place.
Each patient participant had at least three opportunities to talk about the study before an interview was
arranged. Participants were informed that they could withdraw at any time without giving a reason. They
were assured that the decision to withdraw or to not take part would not affect the standard of care
received. A consent form was completed before each interview, which provided a fourth opportunity for
people to discuss the study and consider their participation. Participants could access further information
from the programme website and all additional relevant study information was made available to
participants on request. A £10 shopping voucher was given to each lay participant to thank them for
taking the time to participate.
To preserve anonymity, the responses of health professionals with very distinctive roles in identifiable
places are not linked to particular individuals and quotations refer to a randomly allocated numerical
pseudonym. The key for this is available only to the interviewer.
Interview analysis
The analysis of interviews had five stages: reading the text and coding for descriptive labels; sorting for
patterns within the data; identifying outliers or negative cases and revising theory accordingly; generalising
and refining constructs and theories; and more detailed reflection and revision. Additional fieldwork served
to further contextualise the interview data. This including shadowing a tissue viability nurse at another site,
attending wounds conferences and training events, recording patient experiences at public engagement
events and the development of the JLAPUP. Engagement with the wider sociological and health literature
enabled a consideration of the intersections between individual experience and collective practices and the
integration of micro-empirical study with macro-theoretical perspectives.141
Results
Patients
Interviews with 33 people (18 men and 15 women) elicited narrative experiences of developing, having
treatment for and living with a chronic, complex wound, The biographical details of the patient
interviewees are summarised in Table 37. Some interviewees had multiple wounds and/or more than one
type of wound. Fifteen interviewees were receiving treatment for leg ulcers; five of these interviewees had
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TABLE 37 Biographical details of the patient interviewees
Patient
ID Sex
Age
(years)
Ethnic origin
(self-description)
Age leaving
education
(years)
Number of
wounds
Type of
wound
Previous
chronic
wound
Duration of
wound
(months)
LU1 F 75 Scottish 15 2 healed LU – 6
LU2 F 80+ German 14 2 LU – 240
LU3 M 53 English 16 2 LU – 120
LU4 M 66 English 15 1 LU – 48
LU5 F 85 English 14 1 LU – 72
LU6 F 97 English 15 4 LU LU 456
LU7 F 88 English 14 3 LU LU 12
LU8 F 81 English – 9 LU – 8
A1 M 63 English > 18 1 SWHSI – > 12
A2 F 42 English 16 1 SWHSI – 8
A3 F 59 White British > 18 1 SWHSI – 8
A4 F 57 White British 15 1 SWHSI – 9
A5 M 35 White British > 18 1 SWHSI – 4
A6 M 41 Sudanese Student 1 healed SWHSI – 8
DFU1 M 55 English 15 2 DFU+ PU – 3
DFU2 F 80 English 14 1 DFU LU 5
DFU3 M 70 English 16 1 DFU DFU 48
DFU4 F 83 English 14 1 DFU – 8
LDFU5 M 72 English 14 4+ DFU+ LU LU+DFU 72
PU1 M 40 Indian born UK 16 2 PU PU 12
PU2 F 77 White British 15 1 PU – 12
PU3 F 90 English 14 1 PU LU ‘Years’
PU4 F 72 English 15 2 PU PU 24
PU5 M 57 English 15 1 PU PU 5
PU6 M 53 White British > 18 1 PU PU 10
PU7 F 65 English > 18 1 PU PU+ LU 39
IVG1 M 40 White British 15 2 GW – 4
IVLU1 M 35 White British 14 3 LU LU+GW 45
IVLU2 M 36 White British 16 2 LU LU 24
IVLU3 M 45 White British 16 2 LU – 24
IVLU4 M 21 English 15 1 LU – 36
IVLU5 M 33 White British 16 1 LU – > 84
IVLU6 M 39 English 16 1 LU GW 5
DFU, diabetic foot ulcer; F, female; GW, groin wound; LU, leg ulcer; M, male; PU, pressure ulcer; SWHSI, surgical wound
healing by secondary intention.
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previously received treatment for leg ulcers, as had two further interviewees. Six interviewees had post-
operative surgical wounds healing by secondary intention. These are either surgical wounds deliberately
left open following surgery to heal from the ‘bottom up’ or the result of closed wounds splitting open
because of infection, tissue loss or other factors that prevent them from being stitched or stapled closed
again. Five people had foot ulcers associated with diabetes and eight people had pressure ulcers, including
one who had acquired a pressure ulcer while in hospital receiving treatment for a diabetic foot ulcer. Two
of the eight had heel pressure ulcers, which could also be classified as foot ulcers. One interviewee had a
groin wound as a result of intravenous drug use. Six leg ulcers were associated with the interviewees’ use
of intravenous drugs.
Eighteen people reported one wound, eight reported two wounds and five reported three wounds or
more (maximum nine); two people were interviewed about wounds that had ‘healed’ but which were still
problematic or required ongoing maintenance. Wound duration ranged from a few months up to
38 years. Some people were unclear exactly how long they had had their wound(s) and provided an
estimate. Thirteen people previously reported having treatment for a different chronic wound and one
person had been experiencing constant quick recurrences of the same leg ulcer for 38 years. The majority
of interviewees were managing multiple long-term conditions and disabilities. Those reported included
vascular disease, diabetes, arthritis, cancer, opioid addiction, spinal cord injury, multiple sclerosis (MS) and
spina bifida. One woman described herself as ‘a walking medical dictionary’ because she had so many
conditions (DFU2, female, aged 80 years).
The mean age of interviewees was 60 years; the median age was 59 years, with a range of 21–97 years.
The majority of participants were white British (30/33), one was Asian British (Indian), one was Sudanese
(seeking asylum) and one was German. English was a second language for two of the interviewees. Five of
the interviewees had attended formal education beyond the age of 16 years, two of whom were educated
to degree level, and one was currently in higher education. The majority of participants were retired or
unemployed. Five were in employment when they developed their wound. Nine reported that they were
widowed, four were divorced or estranged from a partner, seven were single and 13 had partners. The
partner of one interviewee was in residential care. One interviewee had dependent children living with
them. One had been a cocarer for a parent but was recently bereaved. Six of the interviewees were
homeless and sleeping rough or in temporary accommodation.
Treatment outcomes most wanted by people with leg ulcers
Fifteen interviewees had leg ulcers. Six of these were men who regarded their leg ulcers as a consequence
of intravenous drug use; these men were among the youngest people in the sample. Of those without
intravenous drug use involvement, six were women in their 70s, 80s and 90s and three were men in their
50s, 60s and 70s with a range of comorbidities including arterial and venous disease, arthritis, Bowen’s
disease, thyroid problems, gout, leukaemia and lymphoedema. Eight out of these nine interviewees said
that what they most wanted from treatment was healing:
. . . get it healed up and dried up as quickly as possible.
LU1, female, 75 years
. . . to be cured . . . to be rid of the ulcer.
LU4, male, 66 years
. . . for them to get better.
LU6, female, 97 years
I just want them to heal.
LU7, female, 88 years
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. . . not to have the sores.
LU8, female, 81 years
. . . not to have a hole in my leg. For it to heal up.
LU3, male, 53 years
. . . what do I want most? Give me a miracle cure! That would be very welcome. Find a cure, that’s
what I want.
LU2, female, 80+ years
One of these interviewees with a leg ulcer for > 10 years was faced with the prospect of amputation but
was still hoping that his wound might heal:
Not to have a hole in my leg. For it to heal up. Or, like they did, they said, it’s never going to heal,
I think we’ll go down the amputation route . . . I just want it to heal up and that. And if it’s not going
to heal up a decision has to be made whether I’m going to have to carry on dressing it forever, or
what. But nobody seems to want to make that decision. Because it’s got smaller now . . . And the
bloke who were going to chop me leg off went, ahhh you see, good job we didn’t cut your leg off
now, isn’t it? And I thought, you were all for it at one bit. You were sat there with your meat cleaver
and your sharpener.
LU3, male, 53 years
Another of these interviewees, a man in his early 70s with bilateral leg ulcers and diabetic foot ulcers for
> 5 years, had refused amputation. What he most wanted was healing but he also acknowledged that
once one wound healed another might break out and that he could have recurrent ulcers until he died:
[What I most want from treatment is] to get them cured, right. You see that one . . . that was about
that long. That was painful, right. But it healed 100% up, right. But as that closes up, the other one
opens out. So what the hell, you know . . . You talk about throwing your hankie in the sky and
clapping hands, right. No . . . the same day as it healed, I got another one. This one I’ve got, nearly
6 years now . . . that can heal and another will break out . . . when’s it going to end? I don’t know.
It will end when I die, probably. I mean, I’m 72 now, which I’ve probably lived a bit over time. I think
to myself that I’ll take it with me.
LDFU5, male, 72 years
The exception was a woman aged 85 years who had had a leg ulcer for 6 months and had faced barriers
in getting access to treatment:
I felt as though I’d hit a brick wall. That nobody were listening to me. Now, I’m 85, but I’m not senile
and I’m not stupid.
LU5, female, 85 years
She said what she most wanted was to be listened to and to get it properly treated. Once it was being
treated, she most wanted to get the bandages off and ‘not look like Nora Batty’:
Well what I wanted – I didn’t want to be pushed off to one side; people saying, oh come back on . . .
And then, no you can’t come Wednesday because there won’t be a nurse here. And you had to fit in
round them . . . them receptionists, well [laughter] . . . I wanted access. And I wanted somebody to do
something about it. That’s all. I wasn’t asking for a miracle . . . But I just wanted somebody to get
something started. [Now] I just want to get these bandages off . . . And not look like Norah Batty.
LU5, female, 85 years
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All six men with leg ulcers who were or had been intravenous drug users said that what they most wanted
from their treatment was healing:
I just want it to be better, you know, I just want it to get better.
IVLU1, male, 35 years
. . . to heal up.
IVLU3, male, 45 years
. . . just to get them healed up . . . just generally make it better.
IVLU4, male, 21 years
. . . to get it right . . . Get my health back.
IVLU2, male, 36 years
. . . just to get it healed up, and that’s it . . . I just want to get rid of it.
IVLU5, male, 33 years
I basically just want to get better.
IVLU6, male, 39 years
One of these interviewees with a leg ulcer for > 3 years wanted his ulcer to heal but talked about how
attending appointments and waiting for it to heal was putting his life on hold:
I just want it to be better, you know, I just want it to get better . . . If that’s [healing] not going to
happen, I’d rather have that knowledge now so I know where to take my life in what direction, you
know, even if I have to just have it done once a week at least I could go back to some part-time work
. . . All I want to do is go back to work. I don’t want to be on the dole . . . make sure it’s clean and
doesn’t smell.
IVLU1, male, 35 years
He was coming to terms with possibly irreversible damage caused by intravenous drug use and wanted
resolution of his chronic ulcer even if that meant amputation:
I thought I’d done everything right . . . with 5 years of being totally clean after I had the bust artery.
Everything felt all right and then all of a sudden I got this just because I scratch my leg basically . . . I’ve
even thought about having my leg chopped off and just saying, sod it, just get the leg chopped off
and have it healed up as a stump rather than be like I am. I mean the worst I’ve been I’ve wanted that
to happen.
IVLU1, male, 35 years
The interviewee with a groin wound had experienced barriers to accessing treatment. What he most
wanted was to be listened to and get the treatment he needed:
They doubt your pain . . . Their attitude was that I were a smack head – a heroin addict – nobody says
that, ‘a smack head’ . . . You’ve brought it on yourself, tough. Eventually I got what I wanted. I
wanted it cut out [groin infection] and I got it cut out.
IVG1, male, 40 years (from contemporaneous notes)
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Treatment outcomes most wanted by people with pressure ulcers
Seven interviewees had pressure ulcers. Three were men, all of whom used wheelchairs, two because of
spinal cord injury and one because of spina bifida and hydrocephalous. Of the four female interviewees,
one had MS and three had multiple comorbidities including cancer, cardiovascular conditions, chronic
obstructive pulmonary disease, arthritis and asthma. All required a wheelchair or other mobility aids. Three
of the interviews took place at the interviewee’s bedside. Six out of seven interviewees said that what they
most wanted from treatment was for their pressure ulcer to heal:
For it [the treatment] to work! . . . [G]et it over and done with . . . I just want rid.
PU1, male, 40 years
I want it clearing up. I want the ulcer to go.
PU2, female, 77 years
I just wish it would hurry up and get better . . . get it right.
PU4, female, 72 years
Ideally get rid of it.
PU5, male, 57 years
To have it operated on . . . I just want it [surgery] to be done as quickly as possible and I want it to be
successful and to be mobilised again as fast as I possibly can.
PU6, male, 53 years
To heal and be finished with.
PU7, female, 65 years
Healing and/or getting access to treatment was seen as the key to getting mobile and getting on with life,
especially for those forced to live much of their lives in bed. For example:
I just wish it would hurry up and get better and then I can sit up all day . . . I want to go back to going
to the day centre as well but I can’t see that happening before Christmas.
PU4, female, 72 years
One interviewee with previous experience of pressure ulcers was frustrated with the time that he had
waited to receive surgical treatment:
It was quite obvious by Christmas time that it wasn’t going to heal. It was so deep . . . I would like to
know, and I’m going to ask them when I go in, have they ever seen a sore this big, this deep that’s
healed itself? I’ve a sneaky feeling the answer is no. So why don’t they operate in the first place
because it’s wasting time, wasting money, wasting National Health effort, you know, nurses coming
here . . . I just want it [surgery] to be done as quickly as possible and I want it to be successful and to
be mobilised again as fast as I possibly can.
PU6, male, 53 years
Most interviewees talked about the difficulty of achieving healing and the fact that even if this wound did
heal, they were at risk of developing new ulcers. For example:
I just want it over and done with and hopefully not get another pressure sore again. I know that’s not
going to happen, I probably will get another pressure sore.
PU1, male, 40 years
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I want the ulcer to go, you know, to not be there anymore. I suppose that’s wishful thinking.
PU2, female, 77 years
One interviewee with a current ulcer for 5 months, experience of previous ulcers and an ongoing risk of
pressure ulcers because of spinal cord injury said:
Ideally get rid of it If that can’t happen, to manage it so it doesn’t interfere with your life . . .
[What I most want is] the treatment that allows you to get on with living.
PU5, male, 57 years
The exception to the expressed desire for healing was one woman who spent most of her time in bed.
She most wanted to keep the wound clean and dressed, fearing neglect, that is, that the nurses would no
longer come and attend to it:
I’ll have it for the rest of my life, well what life I’ve got left. It won’t go away love . . . I wouldn’t like to
go about without nothing on, a pad on, you know . . . I sometimes think to myself, oh they’ll stop
coming soon, you know, they’ll stop coming. It’s got down to twice a week.
PU3, female, 90 years
Five of the seven interviewees with pressure ulcers linked their acquisition to medical interventions
including hospitalisation, radiotherapy and an accident with a shoe horn while being fitted for special
shoes by orthotics. Two interviewees expressed frustration at not being turned in hospital after being
placed on surfaces on which they could not turn themselves. When asked whether he had any coping
strategies or advice for others, one of these interviewees (PU1, male, 40 years), who had spina bifida and
hydrocephalous, and therefore a lifetime of managing pressure ulcers, said, ‘stay out of hospital’. Although
some interviewees were concerned that their ulcers may have been avoidable, one elder interviewee was
resigned to acquiring pressure ulcers during hospitalisation: ‘it’s just one of them things that happened you
know’ (PU3, female, 90). An interviewee who had heel pressure ulcers from tight leg bandaging while in
hospital with pneumonia, acquired during respite care, focused the interview on another ulcer, which she
blamed on her own tendency to scratch. Interviewees who were wheelchair users all talked about risk and
the complexities of avoiding pressure ulcers while still being able to live a full life.
Treatment outcomes most wanted by people with diabetic foot ulcers
Four out of five interviewees with diabetic foot ulcers said that what they most wanted from treatment
was healing:
I want it to get better . . . Just get it healed.
DFU2, female, 80 years
. . . what I most wanted is for them to heal up quickly, which they haven’t done . . . Get them healed
fast and get home.
DFU3, male, 70 years
I’m hoping it’ll heal.
DFU4, female, 83 years
To get them cured.
LDU5, male, 72 years
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One of these interviewees also said, ‘I want them to take the pain away’ and ‘to make me walk’ (DFU4,
female, 83 years). One persisted with treatment rather than amputation despite the gradual loss of toes
and a long experience of leg ulcer recurrence:
. . . and then again it’s knowing it’s not going to be a success . . . because it’s like cancer. Although
many, many years and moons have gone by, they’re still struggling to find that cure, right, and they
haven’t found it yet.
LDFU5, male, 72 years
The exception here was one man facing the prospect of amputation who said what he most wanted was
to get mobile again. At the time of the interview he had his wound for 3 months. A severe foot infection
resulting in surgery for the removal of toes had been the trigger to finding out that he also had diabetes
and needed a coronary artery bypass operation:
. . . so within a week of finding an infection, half my foot’s gone . . . I want to get mobile again . . . I’ve
been sat here for 3 month now and it’s doing my head in . . . If you said to me right now, I’m going to
perform an operation this afternoon, I’d say take that foot off because I can’t walk on it far, so it
might as well not be there, do you know what I mean? I don’t [won’t] class myself as a cripple, alright
I’ve had an operation. I might be disabled, I might not be able to drive a wagon again but I’m not
housebound and I need mobility, you know, that’s what I need.
DFU1, male, 55 years
He was left with doubts about whether or not the surgeon should have tried to save his foot in the
first place:
He was the only doctor available [an accident and emergency rather than diabetes specialist] and they
have said, he was thorough and did them a favour . . . [he] is what they call a conservationist, he likes
to conserve stuff instead of chop off, get rid. But the amount of money that it must cost the health
service to do this, all that time because the [negative pressure wound therapy] you had to pay for
daily. The medication that I’m on, the attendance by the nurses, it’s all expenses.
DFU1, male, 55 years
Treatment outcomes that matter most to people with surgical wounds healing by
secondary intention
All six of these interviewees wanted healing:
The flesh has merged and we just want that final closure of an epidermis to finish it off.
A1, male, 63 years
I need it to close. I just want it to close. I need to be comfortable. I need it to be quick.
A2, female, 42 years
I just want it over and done with . . . just get rid of it all . . . to heal where it’s going to heal for life and
I don’t have to worry about it any more.
A3, female, 59 years
. . . you just want it to heal and, you know, get better.
A4, female, 57 years
. . . to see light at the end of the tunnel . . . a resolution to it . . . I can start doing all the things I used
to do.
A5, male, 35 years
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One of these interviewees, who was left with a small wound 12 months after treatment, weighed his
concern about his wound healing against his cancer survival: ‘these other things [the wound and stoma]
are really more secondary. The fact that you’re alive still is the number one consideration’ (A1, male,
63 years). However, he was also concerned about being left with bodily disfigurement:
[T]here wasn’t really a good successful outcome to the healing of my wound anyway because I was
still going to be left sort of body dysmorphic at the end of it . . . So other than the healing aspect, I
had to deal with the other issues of the muscles not being joined together and just having to accept
that situation as being . . . [it’s] the least worst case scenario. I’ve not had a recurrence of cancer, so
you’re thankful for that . . . there were six of us [in hospital at the same time] and there are only two
of us that are still alive, so you know, it puts it all into perspective.
A1, male, 63 years
This interviewee and two others were also coming to terms with having a colostomy:
[There was] very little preparation beforehand regarding how mentally it would affect me having a
colostomy. And the consequences you know of the cancer treatment as well . . . very little counselling
other than the night before. Even then I was given some news, he said ‘you realise you could be
impotent and lose all erectile function’. I mean these things were just thrown at one.
A1, male, 63 years
All of these interviewees had undergone abdominal surgery. Two interviewees had undergone surgery for
a perforated bowel and were being investigated for possible Crohn’s disease or colitis. A woman with an
open wound for 8 months was trying to reconcile herself to accepting that there was little that could be
done to speed up healing:
It’s like, you know it’s there [the open wound] and you’re putting up with it but it’s very frustrating
that it is there and that nobody is doing anything about it but in some ways they can’t. So you’d like
somebody to magically do something. Stitch it up and get rid of it but they can’t do it. It’s impossible
to do.
A3, female, 59 years
She and others reflected on how the wound had happened and whether or not it might have
been prevented:
. . . maybe if they’d stapled it, it wouldn’t have popped. I don’t know. Maybe it would, maybe it
wouldn’t, I don’t know. I’d perhaps like to think that it wouldn’t have done because when it’s been
cut three times in the same place, to stick it with glue seems a bit – I don’t know. It just literally ‘pfff’
all the way down. Whereas when it was stapled before at least it had a bit of a chance.
A3, female, 59 years
Now I’ve read from doing research from other parties that do colorectal cancers that what is supposed
to be a good thing is for you to have a series of antibiotics before you go down to theatre. Now that
wasn’t offered to me and neither was it suggested . . . So I do think that if I’d had . . . It would
have helped.
A1, male, 63 years
The nurses were a bit concerned because there was a small internal stitch that had been left inside the
wound and they thought maybe that was why it wasn’t healing, that maybe this stitch needed
taking out.
A4, female, 57 years
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I just think to myself if I’d been operated on at the time when they’d seen me and they probably
would have saved themselves so much money, so it’s not a complaint about how the treatment went
or anything like that or the surgery that I’ve had, it’s just the waiting time that I had to wait to have
the initial operation. If that waiting time had been decreased, I don’t think we would have had all the
subsequent problems that we’ve had afterwards.
A5, male, 35 years
One woman suspected that a short-term determination to cut costs meant rationing of more-expensive
dressings, which she assumed would help her to heal more quickly:
Like I say, a lot of it is down to money, you know, like wasting time with all different dressings and I
think they started with the cheapest first and worked their way up to the most expensive. Whereas if
somebody has got a reaction to a dressing, try the more expensive one and if that works, well that’s
good. It means it’s going to heal quicker. I mean maybe if they’d have done that, put the more
expensive one on me first, they might have been able to leave it, you know, a couple of days and it
might have healed quicker, so they would have saved money in the long run because, I mean they’re
buying dressings all the time.
A4, female, 57 years
Three interviewees developed their wounds after what they had anticipated to be relatively routine or
minor operations: a hernia operation, removal of the appendix and a keyhole sterilisation procedure, which
‘failed, so they had to cut me open’ (A2, female, 42 years). There were lots of comments from these
interviewees about how waiting for the wound to heal was putting their lives on hold – they had a feeling
that they were in limbo and wanted to get back to being able to carry out their usual activities:
[I want] to see light at the end of the tunnel . . . my life has stood still for about 12 months and I’d like
to think that there is a resolution to it . . . I can start looking for work again. I can start exercising
again. I can start doing all the things I used to do. That’s what I’m looking for more than
anything else.
A5, male, 35 years
I need it to be quick . . . and not painful . . . when it’s closed I can get my life back on track and go
back to work properly and go back to my job, my friends and I can’t [becomes tearful].
A2, female, 42 years
[I want] speed [laugh]! Because you think, god, how long is it going to take?
A4, W, 57 years
One interviewee who self-referred to the study said that, although his wound was healed, it still caused
him pain. He did not know why he had developed the wound in the first place and suspected it was
implicated in other health issues currently affecting him:
They have to tell me what is going on . . . why still now I’ve got that [wound] and why my tissue is not
healing. Everyone tells me something different . . . Only I want them to, you know, provide for me
[answers] like why my wound has been – that pain because sometimes pain is killing me and, you
know, I can’t eat and I can’t – so that most I want from them is the treatment . . . to treat my wound
[2 years after closure of a wound that was open for 5 months].
A6, male, 41 years
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Summary of key findings
When asked what they most want from treatment:
l Most people (29 out of 33) said that what they most wanted from treatment is healing.
l Two people who had experienced barriers to getting treatment said that what they most wanted was
access to treatment, ‘to be listened to’ (LU5, female, 85 years; IVG1, male, 40 years).
l One man, who was deciding whether or not to have his foot amputated, said that what he most
wanted from treatment was to become mobile again (DFU1, male, 55 years).
l One woman, who thought she would die with her pressure ulcer, wanted it to be managed and not
neglected (PU3, female, 93 years).
When asked what bothered them most about the wound itself, six people said pain, five people said the
social embarrassment of the smell, three people said the social embarrassment of leakage, two people said
the boredom caused by confinement to the bed/house, two said itching, two said the threat of infection,
one said the strangeness of not having pain (neuropathy), some gave more than one answer and some did
not answer or said ‘everything’:
. . . how would you like to stand in front of a friend when you smell, it’s like you’ve got body odour or
something like that. It’s not nice and then you’ve got the pain as well, so you’re always rubbing it or
trying to do something to make yourself comfortable, it’s not right when you’re being out with people
to be in that situation. So it’s left me at home, you know . . . For the last 5 years I haven’t had a
girlfriend. I’ve just got one recently . . . She said to me that she can smell it but she’s not bothered
about it because she knows it’s such and such. She said to me, got to get something sorted out about
it. I said I want to do, I don’t want to be like this forever.
IVLU1, male, 35 years
When asked if they could change one thing about the wound what that would be, most people did not
opt for incremental change. Instead, they said that they wanted:
To get rid of it.
LU2, female, 80+ years
Take it away. Completely.
LU4, male, 66 years
Just to heal.
LU5, female, 85 years
To heal properly, but to heal properly and to have your legs back.
LU7, female, 88 years
Not to have it full-stop. I don’t want it full-stop. I wouldn’t wish it on my worst enemy.
IVLU1, male, 35 years
Get rid of them.
IVLU2, male, 36 years
I’d make my legs better.
IVLU3, male, 45 years
A new leg. With that not there.
IVLU5, male, 33 years
SERVICE USER AND PROVIDER PERSPECTIVES (WORKSTREAM 2)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
I’d take it away.
IVLU6, male, 39 years
If I could change it? Just not have it.
DFU2, female, 80 years
Others said that they would speed up healing, pay for skin grafts or go back in time and prevent the
triggering incident/injury that started the wound. One interviewee said ‘make me walk’ (DFU4, female, 83)
and one said ‘change the pain’ (A6, male, 41 years).
In summary, interviewees wanted to have access to treatment, to be healed and to ‘get their life back’ as
soon as possible. The one exception was an elderly woman with pressure ulcers who thought that she
would have her ulcer until she died and she most wanted to ensure that the wound would continue to be
managed and not neglected. The social consequences of the wound were as troubling to many
participants as the physical pain and discomfort.
A shared desire for fast healing and a return to mobility was common among people with different wound
types, along with a shared frustration that life had to be put on hold pending healing. Those facing
amputation of a limb wanted to know when to give up their hope of healing. Some of those with wounds
associated with intravenous drug use were coming to terms with the fact that the underlying damage to
their venous system might not be reversible once they stopped injecting drugs. Those with pressure ulcers
and a leg ulcer ‘ambassador’ spoke most about their desire for healing in the context of managing the
ongoing risk of acquiring another wound once their current ulcer was healed. Many of those with pressure
ulcers and surgical wounds were left with patient safety concerns about the cause of wounds that were
acquired while in health and care services and whether or not these could have been prevented.
Carers
Eight carers were interviewed; most contributed to an interview with the person they cared for and
consented for these comments to be used. Two people were interviewed in their own right, with the
person who they cared for being present on both occasions. The biographical details of the interviewed
carers are summarised in Table 38.
TABLE 38 Biographical details of the carer interviewees
Carer ID
Carer age
(years)
Relationship
to patient Patient ID Patient sex
Patient age
(years)
Type of
wound
C1 – Wife A1 M 63 SWHSI
C2 55 Daughter DFU2 F 80 DFU
C3 70 Wife LU4 M 66 LU
C4 46 Sister PU5 M 57 PU
C5 – Son LU6 F 97 LU
C6 – Husband PU7 F 65 PU
C7 86 Wife – M 89 LU, PU
C8 – Wife DFU3 M 70 DFU
DFU, diabetic foot ulcer; F, female; LU, leg ulcer; M, male; PU, pressure ulcer; SWHSI, surgical wound healing by
secondary intention.
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Ideal treatment outcomes
Most carer interviewees said that ideally what they most wanted from treatment was for the wounds of
the person who they were caring for to heal and for things to go back to how they were, but they knew
that this was unlikely to happen:
Well, the impossible – as was [things as they were]. But that will never be.
C8
Take them off [her] and put them on me!
C5
Well best of all I would like him to be walking again, but I don’t think that will ever happen now . . .
sometimes it seems to bother him a bit and I’d just like it to heal for his sake.
C7
This is rather dwarfed into insignificance compared to the other problems . . . You’re still stuck with
it . . . Like old friends who won’t be parted. But we would quite happily be parted . . . I should imagine
we’re always going to have to be very careful of it. It’s going to need protecting with a lot of care. But
let’s get there first . . . The target’s moving back a bit. It’s moved back hundreds of times, but nevertheless
it still would be nice if something could be done [to heal it] . . . [It’s been] three and a quarter years!
C6
The following interviewee was the carer of someone with a pressure ulcer and said that he wanted these
wounds to be prevented in the first place:
Yes, we think prevention. It’s a bit annoying that these things are happening so much in hospitals. They
do need to be reducing them, because it’s costing the NHS so much . . . orthopaedic people and plastic
surgeons. The cost is just ridiculous to be quite honest. I know money’s short but you could save on
that if you could stop this sort of thing. But maybe that’s the Holy Grail, that’s easier said than done.
C6
Disagreements about treatment
There were points of conflict between carers and the people they cared for about some interventions. Two
were concerned about the reluctance of the person cared for to seek help. One, who feared losing his
independence, was reluctant to call the doctor in ‘in case they cart him off’ (C4). Another refused to leave
the house for appointments to treat multiple underlying conditions:
I think he’s just given up . . . This is the trouble. This is the worst thing for me. Because I can’t get him
to go out . . . every year he’s supposed to go to the eye clinic [because of diabetes] and they would
provide an ambulance but he won’t go. And he won’t have his ears tested . . . that’s the thing that I
find frustrating. Well you can’t get any further, can you?
C7
Carers also sometimes feared the consequences of the surgical interventions that the person being cared
for hoped would help resolve problems with the wound:
And that is the fear. He [the surgeon] can’t control your healing process. You’re diabetic. You’re
classed as obese in the sense that you are not the skinniest thing . . . [as a consequence of inactivity
because of the wound] so even that is another additional risk problem. The fact that you’ve had all of
this . . . if you are worrying about appearances . . . from my point it does not worry me at all. I am
probably the only one that sees that and I’m not saying it to make you feel better. I’d rather have you
here than take the risk of a cosmetic situation and that’s how I feel and I still feel like that.
C1
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C8: You just go from week to week waiting for another ulcer to appear and it dries up and then it
comes back and to me, that will be it. That’ll be what his feet will be doing now.
DFU3: Not when I’ve had my feet straightened.
C8: I don’t know. I don’t know.
DFU3: Well, hopefully, anyway.
C8: That’s all you can say, but you don’t know, do you? But you see, when he’s [had the operation] –
what is it, you’re about 6 weeks aren’t you with them pegs in? So it’s [going to be] even harder.
Some carers had gone through periods when they felt that they were drifting along and there was
treatment activity but no real treatment plan. This carer wished he had pushed more to see a tissue
viability nurse but he did not know about them at the time:
It just seemed to be a bit of a – not a losing battle, but we weren’t really getting anywhere. It would
have been nicer if we could have a tissue nurse in, if there was such a thing . . . We just seemed to be
plodding on and not getting anywhere. ‘Til that setback came [heel damage caused by orthotics] and
the really prompt reaction – I’m not criticising anybody, but it’s just the way that it . . . We should have
pushed more . . . The district nurses, one of them came one day and said . . . I think we’ll be coming in
years to come unless we do something. I should have thought of that and pushed it myself earlier on.
I didn’t know what to expect. I didn’t know anything about pressure sores at all. I didn’t know much
about them other than they were a nuisance.
C6
Most interviewees praised the treatment that the person they cared for had received but some were
ambivalent about the effectiveness of the interventions they had seen:
I think she’s always had fairly good treatment from the surgery and the doctors and nurses who have
been to her. They’ve always given her – everything that’s new that’s come out, they’ve tried. So I
mean, there’s not much else they can do really . . . They actually just heal themselves, I think. They use
something that will heal up, and then the next time she gets one they’ll try it and it doesn’t work.
So then they try other different things.
C5
Nevertheless, carers appreciated someone coming to ‘keep an eye on it’:
Well all she does, she looks at it, measures it sometimes and changes the plaster and puts cream on
his legs. Because his skin’s very dry. But apart from that, nothing. I think more or less to keep an eye
on it . . . I don’t know enough about it, really . . . I would have thought that if they cleaned whatever
the debris is there it would perhaps heal better, but I don’t know. She did put a little pad on today,
because it wasn’t healing, as well as the plaster. So, you know, they do try different things now and
again . . . the advantage to them coming, you see, is they can keep an eye on it. Because I mean,
I don’t know enough about them.
C7
Over the longer term some of the carers felt that there was a lack of interest in the outcome and that they
were being left to get on with it:
But sometimes though because it’s so long and it’s so chronic and these wounds are chronic whether
they’re ulcers or . . . you sometimes have to re-address them a little bit further on . . . and you can only
re-address them if somebody bothers to ask or if somebody asks, ‘oh has he healed yet?’ or
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something like that. Nobody knows whether he’s healed or not. I’m sorry but this sounds terribly like
moaning and it’s not moaning but how can you possibly know whether a patient has recovered from
that unless you enquire to what the outcome is.
C1
The following carer cared for someone with a surgical wound healing by secondary intention. She said that
at first there had been lots of people around, to the point when it sometimes felt that ‘your life is not your
own’ (C1); however, over time she felt that she lacked the reassurance of nursing back-up or follow-up:
[At the start] you have a lot of support – I don’t know whether you have support but you have a lot of
people around you, so you feel like you’ve got that support. Then it became obvious that once . . . in
that respect, I think I felt let down . . . in the sense that you needed that kind of nursing support.
We didn’t need the physicality, the fact of a nurse being able to do it. I’m perfectly able to do that
[change dressings]. If somebody says to me, look let’s try this, do this, I’m perfectly able to do it . . .
I wasn’t to start off with . . . I was looking through my fingers when I had to look at him, that’s how
scared I was but it’s not a problem anymore. It’s become second nature but I just think maybe a
phone call might have been to see how he’s getting along or whatever. I suppose they could feel that
if you need them you’ll ring but sometimes that’s not what you want to do . . . Just somebody to pick
the phone up and say, do you need anything and then I can say, ‘no I don’t’ or I can ask them, ‘what
do you think?’ . . . I know everybody is stretched every which way with whatever and I know there is
an older lady on her round that hasn’t got anybody to come in and has to take priority. No harm is
going to befall [him].
C1
Some carers performed no physical wound care. This carer had been specifically told not to:
I’ve only changed the plaster once . . . occasionally the catheter leaks – it [the dressing] was wet and
came off. So I stuck another one on. They told me off about it. They said, ‘oh you mustn’t do that.
You must ring us’. Well, I mean, it doesn’t take a science degree to do that, does it? I thought I’d
done quite well . . . I’m not supposed to touch them at all.
C7
Other carers had become used to applying dressings:
When it [pressure ulcer] first appeared it’s not normal for somebody to have a big hole, is it? It was a
bit scary at first but obviously over time you get used to it . . . I wouldn’t say that I know too much
about them . . . I know how to change his dressing and basically [he] relays it to me and I get all my
information from [him].
C4
The following carer said that nurses would answer her questions if asked but, especially as she was
involved in dressing the wound, she would like to be more actively included in discussions: ‘the key thing is
[to feel] trust’ (C4). Some carers felt cautious about annoying health professionals and the person who
they were caring for with their questions:
I think me mam’s one of these, she doesn’t tend to ask. It’s me who asks. Me mam’s more laid back
than me. I want to know everything . . . I get worried over her and I’m asking all the time.
C2
We always get a list of questions, don’t we? They think, ‘oh, he’s one of them’.
C6
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One couple spoke about the difficulty of having to watch their ‘p’s and q’s’ to not offend health
professionals with questions and comments while also being worried about the consequences of
disagreements and conflicting advice:
. . . one [surgeon] wanted to take it out and drain it and another one said, no we won’t and . . . and
then he thought maybe it would heal on its own. Well it didn’t heal on its own because he had to
come home and I had to empty the bag . . . with an abscess . . . oh the stench of that was bad.
C1
One carer felt that she was not very good at asking questions and that health professionals were mostly
too busy to talk:
. . . an odd one will say something. Mostly they’re so busy they just come in and bang bang . . . There
are some that are very good and talk, but mostly they . . . I mean, they are quite friendly, but they are
so busy . . . I think most of them take the attitude that they don’t expect you to understand really.
They just sort of get on with their job. An odd one will say something, but not really . . . I’m always
interested. I mean, you learn things that way don’t you? . . . I’m not very good at asking questions.
C7
One carer was applying support stockings and compression bandages and felt that she needed more
support to make sure she was doing the right thing:
I’m shown something, how to do it, then I can do it . . . I never know, with not being a professional, I’m
doing it the right way; the correct way. But obviously, I have been doing it the correct way . . . he can’t
bend . . . I mean [he] couldn’t do it himself. But I don’t mind doing it, you know, as long as, shall I say,
we both get support . . . And quite frankly, I feel that . . . we’ve been let down by the district nurses.
I feel as though, yes, there’s probably other people more important than we are, but for something as
serious as [leg ulcers and] lymphoedema, you have to have proper bandaging done, and because, yes,
I can do it, but am I doing it right? Am I doing it correctly? Do I know what I’m looking for once the
bandages come off and [he] gets a shower and you know he showers his legs. Do I know what I’m
looking for? Because I don’t. I don’t know if it’s good or bad. We’ve said this before, haven’t we? . . .
And as regards feedback, the only feedback we did get is from [nurse] at the lymphoedema clinic. And
she said, yes, they’re going on all right. And she automatically says, but your ulcer is not healing. Have
you been to your GP [general practitioner]? . . . And what does the practice nurse do there? ‘Oh yes it’s
okay, so don’t bother coming again’. So I mean, honestly, it seemed as though we were between a
rock and a hard place.
C3
One carer said that what she would really have liked was a care plan:
. . . it would be wonderful if they could have . . . A care plan and we don’t have that because you do
need it. You are scared. You think, what’s going to happen if . . . I mean basically you’re just waiting
to see if something rears it head again and then you deal with it. There is none of that continuity
there . . . There’s nobody to ask . . . your GP doesn’t know.
C1
There was a lot of sympathy for how busy nurses were and a sense that they were fulfilling physical care
tasks but concerns that there was no clear treatment pathway for patients engaged with many different
services and that no one was overseeing or managing cases:
I suppose you’re thinking that the district nurse should cover all of those things but sadly a district
nurse really goes out to do wound care, this or that. They really can’t go beyond that. They don’t
know anything about stomas . . . They certainly can’t deal with psychological issues or anything like
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that or feelings, so it is a tough one . . . because of the volume of patients that they have and they
have to spread themselves thinly, [they] are literally going in . . . to deal with just wound care . . .
They’re there to do that specific one task and we’ve had to find out different things even from all your
sexual issues and urinating and all that and we had to branch out in all these different directions.
Nobody could deal with it and it would have been lovely if somebody could have given us some
pointers . . . There’s no one point where you can say, I’ll point you in that direction and I know it’s
possible to do it . . . You have to find your own support network basically.
C1
Carers in the study were more likely than patients to express doubt that the interventions being applied
to patients would lead to healing. Nevertheless, they wanted health professionals to ‘keep an eye’ on
the wound. Patients and carers both felt that waiting for the wound to heal left them in limbo. Carers
expressed frustration at a lack of overall case management of the wound and feelings of being abandoned
by health professionals and being left to cope with the wound.
Staff
Twelve health-care professionals with responsibility for wound care were interviewed, one man and
11 women. The biographical details of the professional interviewees are summarised in Table 39.
Eleven participants described themselves as white British and one as white Irish. The mean age of staff
participants was 44 years and the median age was 47 years (range 23–53 years). The mean length of
service with the NHS was 19 years and the median was 22 years (range 1–32 years).
Treatment outcomes aimed for and considered most important by staff
Health professionals aimed to make a positive difference for patients although many of them rarely saw the
final outcomes of their interventions. When asked what treatment outcomes they aim for, most health
professionals said healing, but this was often qualified: ‘you find out that that’s not realistic’ (H3) and
‘there’s clearly going to be some chronic wounds where that’s not a realistic outcome’ (H5). Outcome aims
then became ‘improvement’ (H3, H2, H5, H4), for the ‘patient to feel positive’ (H2) and (for tissue viability
nurses) determining the cause of the wound and why it is not healing. There were two mentions of finding
a treatment with which the patient is able to comply and one mention of the prevention of recurrence.
TABLE 39 Biographic details of interviewed health-care professionals
Staff ID Sex Age (years)
Ethnic origin
(self-description) Occupational title (band) Years in NHS
HPTVN1 F 47 White British Team leader for tissue viability (8a) 29
HPNFA2 F 48 White British Specialist practice nurse (6) 25
HPPOD3 F 52 White British Podiatry specialist team leader (8a) 22
HPPOD4 F 23 White British Community podiatrist (5) 1
HPPOD5 F 53 White British Community podiatrist (6) 25
HPENDQ F 50 White British Executive nurse, director of quality 32
HPTVN7 F 47 White British Clinical nurse specialist, tissue viability (7) 22
HPTVN8 F 37 White British Clinical nurse specialist, tissue viability (7) 15
HPCN09 F 43 White Irish Community staff nurse (5) 22
HPTVN10 F 50 White British Clinical nurse specialist, tissue viability (7) 28
HPCN11 M 26 White British Community nurse specialist (5) 1
HPDN12 F 48 White British District nurse (7 protected) 10
F, female; M, male.
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Methods described to determine the cause of wounds included assessment of circulation, nutrition,
sources of pressure damage and levels of activity. Investigation was also said to involve checking that the
treatment given is appropriate, advising on lifestyle changes to promote wound healing and referring
patients on to appropriate sources of treatment and support including vascular surgeons, smoking
cessation services and dieticians.
All health professionals aimed for symptom management outcomes that focused on the removal of slough
and the reduction of pain, odour and exudate. If a wound was the result of pressure damage, health
professionals ensured the provision of appropriate offloading and pressure-relieving devices and services.
Infected wounds were treated with antibiotics.
Two podiatrists said that that the outcome that they aimed for was to find a treatment with which the
patient was able to comply. One health professional in a predominantly preventative role (H1) described
most of the healing that could be achieved as ‘fragile healing’ and identified the prevention of recurrence
as an important treatment outcome.
One tissue viability nurse said that sometimes she thought goals for treatment outcomes were different for
patients and health professionals:
I think sometimes our goals are different to their goals . . . Well our goal is we want to heal it but the
patients might not be. They might just want . . . I’ve had a patient before in a wheelchair . . . They can’t
feel half their body, so they’re really not that fussed. It doesn’t give them any pain but what they don’t
want the wound to be, they don’t want to be wet through with exudate and they don’t want it
smelling and as long as that’s contained, they can carry on doing what they’re doing and they’re happy.
H10
Most challenging aspects of wound care for staff
Many of the health professionals interviewed said that one of the most challenging things about working
with patients with chronic wounds was not seeing or knowing if patients heal. For example, two tissue
viability nurses and a podiatrist said that it was challenging not knowing whether or not their work made a
difference because they did not find out the outcomes for patients who they had treated:
We don’t get to know what’s happened with them . . . what’s the outcome.
H2
Just finding out when they heal would be helpful . . . do patients that come under our umbrella have
different outcomes to the patients that don’t? . . . We don’t know what our outcomes are really . . .
we don’t have a service model that takes all patients with wounds [and] follows them through to
healing and it’s not really right that we do in lots of ways because otherwise you just end up with a
very de-skilled generic nursing population.
H12
. . . you want to see the end of the tale kind of thing.
H10
Most health professionals discussed how repetitive and time-consuming wound care could be and the
difficulty of keeping themselves and their patients motivated over long periods of uncertainty about
the outcome:
It can be a really slow moving thing . . . it’s having the patience.
H2
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The longevity of the wound.
H11
It’s time-consuming [and] trying to keep motivated yourself that this is actually going to heal and
hence motivate them.
H1
Most challenging thing is probably . . . Sometimes you feel like you’re going in day in and day out . . .
even though you’ve got all the various people on board . . . you’re just going in there and it looks
exactly the same and it’s not changing and it’s not getting any better and . . . it’s kind of out of my
hands because there is vascular people involved, tissue viability nurses involved and I’m just going in
there and just doing what the care plan says basically and you kind of think, it’s up to them isn’t it
what they do at the top. I’m just going in bandaging and not seeing any improvement. There is
nothing else that you can particularly do really.
H8
Most health professionals described the challenge of getting patients to comply with their advice:
Very challenging is when you can see that you are not going to heal this wound and that is
challenging, especially if . . . it’s because they make unhealthy choices . . . this is his choice . . .
But we cannot be effective, we cannot help this person, that’s challenging.
H1
. . . sometimes it’s hard to get patients on your side, you know, make them understand that you’re
trying to help them . . . You have patients who don’t want to listen, don’t want to help themselves . . .
you’ll find those are the ones who have chronic ulcers a lot longer than others.
H2
If they’re non-compliant with their diabetes, if they’re smoking and not looking after themselves or if
they’re walking about barefoot and neuropathic, you’re sometimes up against it with people.
H6
In particular, they described the challenges they faced getting people to attend appointments and to
comply with advice about managing blood glucose levels and weight, moisturising skin and wearing the
right footwear. Nurses raised the challenge of getting leg ulcer patients to go to bed rather than ‘insisting
on sitting in a chair’ (H10). Some interviewees acknowledged that it could be difficult for patients to
comply with some of the advice they gave:
they’re human beings after all.
H1
One of my most frustrating things is weight management . . . because the [chronic wounds on the]
legs are the main concern we tend to be the main person managing . . . care when [actually] . . . The
legs are a knock-on effect. The diet and other support and psychological support need to be the main
thing . . . it’s really frustrating . . . because they need not just dietary input, they need psychological
input as well, support. I think they get a raw deal . . . They don’t get much here . . . just get a dietician
visiting every month to 6 weeks when they need somebody going in every week going you’re doing
really, really well. Like Weight Watchers at Home service, you know, somebody coming around and
giving you loads of encouragement.
H10
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Some of the interviewees discussed the challenging issue of ‘ownership’ of the wound and whether or not
their services were creating a culture of dependency rather than encouraging behaviour change:
I think as nurses we own patients’ problems, we own their wounds, you know, it’s like if things aren’t
improving, you hear district nurses saying all the time, ‘oh well I’ve tried everything, I don’t know what
else we can do, I’m really sorry this hasn’t worked, oh let’s try this new dressing’ and yet . . . standing
back from it, kind of observing this situation that the patient sat at the side of an ashtray spurring
forth tab ends or . . . they’re still grossly obese . . . yet nothing is said about the bit that the patient can
do. But you also haven’t done your bit and I think patients do need to do their bit because there is
only so much we can influence and control.
H12
Sometimes they don’t think it’s about them, it’s what are people doing for them.
H6
It’s difficult because some patients will come in . . . and you can tell they’re . . . really aggravated with this
ulcer and they have, I’d probably say a poor attitude, they just don’t care. Just let you get on with it and
they don’t say anything to you and it’s really hard because you want to know what’s going on . . . and
especially how they’re dealing with it at home because . . . we find that a lot of patients self-neglect . . .
I think it’s denial a lot of it and then some patients will come in and just be like, I really need your help.
H2
. . . we sometimes say the leg belongs to them and not to us because I think over the years and
months nurses go in and take over this bandaging and the elderly frail lady at home that doesn’t get
any visitors . . . thinks very much the nurses keep coming . . . I think we take over where . . . the leg
belongs to the patient and not us . . . we forget to step back . . . you get into this routine.
H4
I think all they think of is, ‘oh well the dressing they’re going to put on there is going to cure it’. Well
it’s not, it’s actually . . . them . . . kind of taking control of their treatment in a way, helping themselves
and a lot of patients you find really don’t do that. They don’t really help themselves that way.
H8
The challenge of dealing with patient expectations for healing came up in many of the interviews:
Just dealing with their expectations, you know, with them thinking, ‘oh I should be healed by now
and it isn’t healing’. I think it’s important that you’ve got to remember that, that ulcer is their ulcer . . .
It’s not just what everybody else can do for them.
H6
. . . you go in and you know they’ll go, ‘is it getting any better?’ and it clearly isn’t. Whereas the
district nurses might go, ‘oh yeah, yeah’, you know, just to keep them [happy] . . . [the patient] chose
to listen to the ones who said it was getting better.
H11
Their expectation I think is quite challenging . . . you can’t dash people’s hopes . . . sometimes they get
really frustrated if you keep changing the treatment but if you don’t change it . . . it might end up
being a chronic wound that you’re managing forever but when new treatments come out and you try
it, you know, that can be quite challenging. You’ve got to really draw on change management
techniques haven’t you to change people’s attitudes. If they’ve been having four-layer bandaging
forever and we actually turn round and say, oh that’s no good now, I think we’re going to change the
dressing – I think that’s probably frustrating.
H9
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Many of the responses reflected the difficulties of what one interviewee described as ‘more pressure for
delivering complex care in the community at both policy and demographic level’ (H5). The professional
motivation of being able ‘to make a difference’ or ‘see people heal’ was particularly challenging when
working with some groups of patients:
. . . pressure ulcer patients definitely are, your immobile pressure patients with lots of different
comorbidities are sort of heart sink and your grossly obese patients as well like with their swollen wet
legs are heart sink because even if you get them to recognise they need to lose weight that’s not
something that happens overnight and therefore you’re going to manage the problem in the
interim period.
H12
Nurses discussed the challenges of working with people exhibiting signs of self-neglect, for example
‘bad hygiene and [a] house . . . you can’t go into’ (H7), and also issues of safeguarding and the challenges
of dealing with particularly unpleasant surgical wounds in a patient’s own home:
So we actually had to go in and open it up like a sandwich and fill it . . . with a filler, fasten it back up,
pull it over and tape it on with Hypafix to keep it together, it was disgusting. It wasn’t nice. That was
quite difficult for some members of staff because as soon as you take the Hypafix off it just went
‘phew’ . . . there are lots of wounds like that . . . [and] the possibility of safeguarding or, you know, it’s
an unstageable wound that we’ve found. Could we have done anything about that? There’s a lot of
reflection around wound cause analysis, you know.
H9
Some health professionals described the challenge of delivering a good service within current resources
and sometimes the difficulty of understanding the reasoning behind the treatment decisions colleagues
were making:
. . . in terms of nurses having enough time and . . . [their] knowledge base . . . are they assessing and
picking up what they really need to pick up and then if it starts to deteriorate do they act on it?
Or why do people take the decisions that they have taken?
H4
A key consideration in choosing treatments was to minimise the number of visits to patients or
appointments at a clinic. Two reasons were given for this: one was to reduce patient disruption and the
other was to minimise clinical costs. Health professionals therefore sought ‘products that are going to have
the biggest impact on improvement as quickly as possible’ (H5). Some interviewees found it particularly
challenging to select the correct treatment choice and to apply their knowledge of the evidence base to
patients eager to see healing:
. . . making sure you get the right dressing and the most appropriate for that patient.
H7
. . . for me the challenging one is knowing sometimes what the evidence might say and therefore how
do we follow that because . . . you can’t just immediately put the compression on because you need to
do pain first and you need to manage the exudate but I need compression but I can’t do that because
the patient is in too much pain. What’s causing that pain and how do we unpick that or maybe
they’ve got arterial problems, a mixed leg ulcer arterial and venous and how do I balance both or am I
waiting for them to go to vascular? But in the meantime a good patient that’s desperate that they’re
wanting to move things on.
H4
SERVICE USER AND PROVIDER PERSPECTIVES (WORKSTREAM 2)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
Sometimes it’s very obvious what needs to be done, you know . . . you’ve got very sort of tangible
outcomes . . . Other times it’s not at all easy because there isn’t the armament. You don’t have the
armaments available to manage the problem or the things that you’ve got available to you have been
rejected by the patient and they’re not interested in pursuing that kind of treatment because they’ve
had a bad experience with it previously or they’re quite nervous. So then, you know, you’ve got to do
quite a lot of investing time to try and explain the rationale and the research evidence behind things
and how you know [that] it’s worked before with other patients and how it’s probably worth a try
even though they’ve had an unsuccessful attempt previously.
H12
Some tissue viability nurses expressed frustration at expectations from colleagues who expected them to
have a ‘magic dressing’ to cure a chronic wound:
Because we’re the experts, we’ve got the magic dressing haven’t we in our bags! We’ll get tissue
viability in, they’ll sort it, there’s the magic dressing. There isn’t one, you know, and they still say that
now even when you’re doing the study days. ‘We want to know what dressings to put on’? ‘What
dressing for what type of wound’?
H11
. . . when you do training, they often come with this idea that you’re going to tell them what dressing
to put on everything and they come with that expectation and when they leave without that
information, they’re always desperately disappointed. So we’ve started almost saying, you will not
leave today knowing what dressing to put on what wound for every patient because it isn’t about the
dressing, it’s about the assessment of the patient and identifying what needs to be sorted out in order
to enable healing and the dressing is like your last consideration in a way. It’s just the best plug for
the hole.
H12
One interviewee felt that access to dressings was restricted and found this frustrating. She had previous
experience at a trust that allowed direct access to a wider range of dressings. These dressings were
thought to be effective based on her previous experience of using them:
. . . sometimes it can get quite frustrating when you’re putting on the same dressing all the time and
you know that this is really not doing anything and something else would really benefit this patient,
but we’re not allowed to access that because those specific dressings and resources are only for
specific people in specific teams. I find that really frustrating because . . . I suppose you’ve got to look
at cost and all the rest of it . . . [but] I’ve seen something work elsewhere . . . [they] had a cupboard full
of all these fantastic dressings, not necessarily expensive but just really good and I saw that first hand
that those worked. So I think coming here, it was hard . . . we only have three types of dressings . . .
that’s really difficult when you know that these [other] dressings really work on patients . . . when I
refer people on, I do make suggestions and say, look I know this works, perhaps try that.
H2
There was a sense from tissue viability nurses that patients shared the idea that there was a ‘magic
dressing’ and that this was reinforced by dressing manufacturers and some health-care professionals:
. . . as my colleague . . . says, ‘you wear your glasses to create vision and you’re wearing your bandages
to create your circulation’. If you take them off, your circulation will just go back to where it was
because [patients] they’ll come to us and say, ‘oh is there not a cream I can put on it or a dressing’
and you’re like, nothing is going to fix it from the outside and it’s the same with pressure if you’re
going to sit on your bottom all day, it’s going to be there. No plaster can fix that. There is not a
wonder dressing out there that’s going to make that better.
H10
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I mean I suppose they [patients] expect a solution and if they’ve got a wound, I suppose they expect
some part of that solution is going to be whatever covers the hole. But I think the myth the patients
[have] is just reinforced by staff . . . all the adverts that you see, you know, these beautiful bodies that
have got dressings on, you know, that just got better magically . . . Nobody ever has the kind of
bottom that I have to put dressings on [laugh]. Not on any advert that I’ve ever seen. So it’s just
marketing isn’t it and it’s pedalled by industry that the dressing is the solution. Wound care solutions,
you know, that’s often what the mantras are of the various companies. They provide wound
care solutions.
H12
What most bothers patients (from the staff perspective)
When asked which aspects of having a chronic wound they thought most bothered their patients, the
health professionals all identified pain, smell and exudate. Much of the pain and discomfort discussed was
associated with compression bandaging and dressing changes. Most also identified restrictions in mobility
caused by the wound and by their treatment interventions. Restricted mobility was associated with social
isolation, a lack of independence and disengagement from society as a consequence of, for example,
being unable to work, being advised to stay in bed or fear that the wound (signified by having to wear
potentially leaky and smelly, bulky, pink or brown bandaging, not being able to wear ‘normal’ shoes or
carrying a portable negative pressure wound therapy machine) might be negatively perceived by others.
Some health professionals identified patients as being most bothered by feeling fed up and frustrated with
waiting for the wound to heal. One tissue viability nurse described some patients enduring ‘an endless
rollercoaster of optimism and despair’ (H12). She attributed this to:
. . . new products . . . being prescribed and applied and then that not working and then another
product being prescribed, recommended and applied and the optimism raises and then drops again
. . . I think because we’re not able to say who won’t heal.
H12
In addition, some nurses identified restrictions on showering and bathing because of the need to keep
dressings and bandages dry, the chore of having to ensure the correct dressing supplies were available in
the house and occasional discomfort caused by wrongly applied dressings. A podiatrist identified the fear
of losing a limb.
Some interviewees identified patients as being most bothered by feelings of intrusion from lots of
appointments with different health professionals: ‘I would be very frustrated if I had a lot of different
clinicians coming in with perhaps different levels of competency’ (H5). Some said that intrusion into the
private space of the home or ‘living at the clinic’ (H1) could leave patients feeling that ‘their life is not their
own’ (H1), although others said that they thought some patients particularly welcomed home visits. One
community nurse thought that constant appointments could lead to patients ‘feeling old’ and as if they
are ‘sponging off the system’ (H8).
Good outcomes from interventions
Health professionals described the personal satisfaction that they felt when patients were ‘pleased with the
outcome’, ‘valued your intervention’ and have ‘had a positive outcome as a direct result of your
intervention’ (H12). A speedy outcome was particularly welcome:
. . . anything within a reasonable time, if you can get some success and improve their comfort, then
that’s what it’s all about really . . . improving people’s lives.
H6
. . . any patients whose wounds have healed are a success story. I mean the quicker the better!
H7
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There was a particular sense of satisfaction if the professional’s own intervention was perceived as the one
that made a direct difference, resulting in a positive outcome for a patient previously treated unsuccessfully
for some time. Examples included:
l Getting leg ulcer patients into compression who had previously been treated only with dressings:
‘eventually [they] get referred and . . . you get them in[to] compression and then you heal them really
quickly’ (H12).
l Choosing a key dressing or topical treatment: ‘They may have had lots of antibiotics but actually it
wasn’t cellulitis it was wet eczema . . . prescribe some topical steroid and come back a week or
2 weeks later and you can clearly see that the patient is a completely different person and their leg is
completely different and you go away and say, job well done’ (H4); ‘I packed it with iodine . . . I packed
it from the inside and it just healed in no time’ (H2). The subsequent reoccurrence of this wound did
not diminish a sense of achievement.
l Dexterity with dressings: ‘It was such a complicated dressing to get a seal on [negative pressure wound
therapy to anus and perineum] . . . It was only me who could ever do it or that’s what they’ve told
me!’ (H9).
l Getting patients with foot ulcers into the right footwear and offloading damaging pressure.
A sense of satisfaction at a good outcome also came from effectively liaising with other health-care
services, ‘put[ting] all the things in place’ (H8) and getting agreement to progress a treatment plan. Some
health professionals reported satisfaction from identifying the root cause of the problem and from
increasing the mobility of patients who are not going to heal: ‘it was never going to heal but she did
manage for quite a while and she managed to get out again’ (H9). A health professional who said that the
people she saw heal were ‘few and far between’ regarded patients changing some aspects of their
damaging lifestyle as a good outcome, for example:
We’ve got one guy . . . he’s been coming to us for about, 6, 7 years . . . and he’s had this chronic leg
ulcer and it has actually got smaller and smaller and it’s almost healed and that’s largely because he’s
changed his lifestyle. He’s stopped injecting and he’s eating healthier and actually he’s put on an
immense amount of weight. He’s trying to reduce his smoking at the moment and he’s actually taken
it a bit further, he’s getting quite involved and quite vocal in some of the groups that are going on . . .
I consider him a success really if we can just get this last bit of wound healed then I would consider
him a success.
H3
Concerns about negative outcomes from interventions
Table 40 summarises the range of concerns that staff raised about the potential negative outcomes for
patients associated with particular wound care interventions used.
All of the health professionals dealing with people with leg ulcers recognised four-layer compression
bandaging as the evidence-based gold standard treatment for achieving healing as an outcome in venous
leg ulceration. However, compression bandaging was contraindicated in some cases because of arterial
disease or the risk of deep-vein thrombosis, and many interviewees reported examples of patients not
being tolerant of it because of discomfort or because they were not able to wear their shoes. This
impacted on their mobility and desire to go out:
. . . unless you . . . prescribe special footwear then you’re actually perhaps consigning the person to be
stuck in their own home . . . you wouldn’t necessarily need to be house bound if you didn’t have
four-layer bandaging. I think some of the things that we do prescribe can really challenge somebody’s
lifestyle and sense of independence.
H5
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As noted previously, there was also concern about the quest for the ‘magic dressing’ and the potentially
disruptive impact of ongoing interventions on patients in terms of being able to get on and live their lives.
There was also a concern that the ‘emotional roller coaster . . . cycle of optimism and despair’ may have a
negative impact on healing outcomes:
. . . and we don’t have any concept of what the impact of despair has on healing and kind of feeling
that everything that everyone has tried is useless and that they’re in a hopeless situation. We haven’t
really got an understanding of how that affects us metabolically, physiologically but I think that’s
ultimately what we put our patients through a lot of the time.
H12
TABLE 40 Summary of health-care professionals’ concerns about potential negative outcomes associated with
different treatments for complex wounds
Number of staff
reporting concerns Intervention Negative outcomes
7 Compression bandaging Pain, discomfort, reduced mobility, social
embarrassment leading to reduced social
engagement, fixed ankle
7 Prohibitions and limiting recommendations
on footwear
Social embarrassment leading to reduced mobility
and reduced social engagement, loss of the
freedom to walk barefoot
5 Dressings Allergic reactions
4 Support stockings No benefit or skin trauma because of an inability
to get them on or difficulty with getting them
on, social embarrassment for men, wrinkles
forming dangerous tourniquet
3 Negative pressure wound therapy Reduced mobility/social engagement
3 Prohibition on getting dressings and
bandaging wet
Discomfort of being unable to bathe or shower,
social embarrassment, reduced social
engagement
3 Bed rest Reduced mobility/social engagement, laundry
burden for those with leaky legs
3 Rearranging domestic sphere, e.g. special
seating, rearranging furniture, sleeping
downstairs
Family disruption, potential expense
2 Analgesia Side effects, no benefit because of poor
prescribing for neuropathic pain, potential abuse
of pregabalin and gabapentin
2 Contradictory advice on the importance of
undertaking exercise for vascular health,
keeping limbs raised and keeping off ulcers
for wound healing
Confusion and uncertainty, further physiological
damage, reduced mobility/social engagement
1 Antibiotics Side effects
1 Topical antiseptics Side effects
1 Topical barrier creams Allergic reactions
1 Prescription costs Expense for paying patients
1 Contradictory advice from the clinical team
on limb conservation or amputation
Confusion and uncertainty, reduced mobility/
social engagement
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Discussion
Most patients and health professionals in the study identified healing as a primary treatment outcome
and were focused on achieving that healing as quickly as possible while managing pain, infection and
discomfort. Most also spoke about the difficulties that they were experiencing achieving that healing and
their concerns about preventing recurrence. Health professionals reported a lack of sense of achievement
because they rarely saw the outcomes of their interventions, whereas many patients and carers reported
feeling left ‘in limbo’ and as if their lives were ‘on hold’. They wanted to ‘get their lives back’.
The treatment model described in the interviews was in keeping with the ‘specialist healing’ rather than
‘chronic care’ route identified by Briggs and Flemming142 in their synthesis of qualitative research on living
with leg ulceration. Wound care interventions were largely targeted at the acute phase of what was, for
most, a long-term condition, often symptomatic of other underlying conditions. Health professionals
reported frustration with unrealistic expectations from patients of short-term healing. However, the
specialist healing treatment model may in itself raise or reinforce expectations for fast and complete
healing. Some tissue viability nurses identified a cycle of optimism and despair that left patients feeling
hopeless and some said that this was fuelled by a futile quest for a ‘magic dressing’ to ‘fix wounds from
the outside’. A short-term technical focus on finding the right product to heal the wound also gave rise to
concerns about health professionals taking ‘ownership of the wound’ themselves and becoming frustrated
with patients not doing more to enable their own healing.
Some carers in the study questioned whether or not the treatment activity that they witnessed was actually
leading to any particular outcomes. However, patient and carer interviewees appreciated that health
professionals were very busy and were trying different things and welcomed the reassurance of someone
‘keeping an eye on it’. Carers expressed concerns about the difficulty of navigating health services for
patients with multiple conditions and the possible negative outcomes for those they cared for of refusing
or seeking further interventions. There were also fears from carers about health professionals losing
interest over the long term and being left to get on with it, a sense of being abandoned with the wound.
The patients in our study were as troubled by the socially inhibiting consequences of their wound as by the
wound itself. This is in keeping with the finding of Corbin and Strauss143 that ‘the main issue for people
who are chronically ill is not sickness but their body failure and what it does to their activities and their
lives’ (p. 278). Health professionals and patients associated many treatment interventions with negative
outcomes including reduced mobility and social embarrassment leading to reduced social engagement. In
this broader context, some of what may be viewed as ‘non-compliance’ by a health professional may feel
like a strategy of self-care from a patient’s perspective to minimise the impact of a condition and/or a
treatment on daily life. Surgical wounds healing by secondary intention and pressure ulcers raised
particular safety concerns for patients and their carers when these were thought to be an outcome of
health intervention.
Most of the patients in the study were living with multiple conditions that presented a complex mix of
physical, social and psychological challenges for them.144 Wound care services were focused on the
physical but not the psychological or social impacts of having a wound. This is part of a wider debate
about whether or not the current design of NHS care delivery is suited to the needs of people with
chronic conditions and multimorbidity and whether or not these patient groups face barriers to effective
self-management/self-care.145
Health professionals in the study discussed the changes to services that they would like to see to improve
outcomes but expressed uncertainty about the future design and direction of wound care services. The
study took place during the passing and implementation of the Health and Social Care Act 2012,146 which
brought in the most wide-ranging reforms of the NHS since it was founded in 1948 at a time when the
UK economy was experiencing one of the most prolonged economic downturns since the economic
depression of the 1930s. Concerns about the costs to the NHS of preventing and treating their wounds
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were raised in many of the patient and carer interviews. One health professional with a managerial
overview discussed the problems of a short-term, technical focus on outcomes and expressed a need to
make more moves towards a social rather than medical model of care:
. . . [there are] too many people [health professionals] down the garden path all doing a little bit of
something . . . if you’re thinking it’s going to be a relatively short-term curative outcome then you
perhaps wouldn’t invest quite as much in the self-care approach . . . So I don’t know, perhaps . . . you
should always be invested in the self-care approach because actually by people being well informed,
they’re more likely to be able to manage prevention in the future . . . we’ve got very much a medical
model . . . I think still and although we work towards more social models of care, I think for most
people, for myself, as members of the public, you know, I would want something that was healed and
so it would take me a little while to accept perhaps that I was in a position where it was chronic and
wasn’t going to heal . . . it’s really essential for the future that we start to do that and to change our
horizons because there’s no point in setting unrealistic goals.
H5
The study demonstrates the frustrations felt by health professionals, patients and carers in seeking to
achieve the desired outcome of healing. It raises questions about determining the balance between care
and cure in services for people with chronic, complex wounds who want healing but also want to be able
to live as full a life as possible while managing wounds. A short-term focus on achieving a quick technical
fix through dressings and other wound care devices relies on the assumption that these devices are
effective at achieving healing. A more socially reflexive approach to wound care would consider
interventions in the context of the wider impacts of the condition on patients’ lives and seek to mitigate
any negative outcomes from interventions for patients and their own capacity for self-care.
Finally, our in-depth qualitative study of patients, carers and health professionals makes no claims to be
representative of the views of all people delivering and receiving care for chronic, complex wounds at
home. The breadth gained by covering a range of chronic, complex wounds in the study may be at the
expense of the particularity and diversity of experience within particular wound types. Intravenous drug
users with complex wounds constitute 21% of the sample of people interviewed compared with a point
prevalence of 5.64 per 1000 in the prevalence survey. This inclusion brought down the mean age of the
overall sample, which is 10 years younger than that captured in our prevalence survey. Referrals of
intravenous drug users to the study were exclusively male and increased the proportion of men in the
sample (54.54% vs. 42.7% in the prevalence survey).
Funding sources and the quality of reports of complex wounds
trials: 2004–11
(Adapted from the previously published paper by Hodgson et al.114)
Introduction
Randomised controlled trials within the field of complex wounds, as within all areas of medicine, represent
an essential part of the evidence base because of their ability to provide unbiased estimates of relative
treatment effects. The generation of such unbiased estimates depends on adequate steps being taken to
minimise bias. For example, it has been demonstrated that failure to conceal allocation and failure to blind
outcome assessors and participants results in biased, larger estimated effect sizes.147,148
The failure to specify a primary outcome a priori can also introduce bias as authors are free to cherry-pick
outcomes for reporting that show a statistically significant difference.149 As well as methodological features
of RCTs that can minimise bias, other elements of study design also impact on the overall quality of
evidence generated. These design features include sample size, choice of primary outcome and the
duration of post-randomisation follow-up. Trial sample size is important because, although estimates from
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small trials are not necessarily biased, they will be underpowered to detect anything but the largest
treatment effects, also leading small trials to have been associated with publication bias.150 The choice of
primary outcome is similarly important and needs to be meaningful to both clinicians and patients.
Duration of follow-up is linked to issues of study power and outcome selection. Important outcomes such
as wound healing can take a long time to achieve (often months for chronic wounds). Studies with a short
duration of follow-up will potentially miss outcome events and be underpowered. One approach is the
selection of other surrogate outcomes that can be measured over a shorter period; however, these may
not be valid proxies for, or may be harder to interpret than, clinically meaningful outcomes.
The importance of methodological characteristics such as those outlined above has led to a number of
studies being conducted that seek to quantify the methodological quality of samples of RCTs from across
medicine151 and within specific areas.152–154 However, despite the methodological concerns described
above, no such overview exists within the area of chronic wounds, an area of medicine in which most
treatments are medical devices for which RCT data are not necessary for licensing and marketing.
Previous research in other areas of medicine suggests that funding can have an important impact on a
number of trial characteristics. For example, studies have observed that industry-funded drug trials are
more likely to report in favour of (the sponsored) treatment than research that is not funded by a
commercial organisation.155,156 Research has shown that commercially funded studies are associated with a
shorter duration of follow-up,157 more frequent use of non-active comparators158,159 and lower risk of
bias.156,160,161 In the area of chronic wounds there are few data on the prevalence of industry-funded trials
or the influence of industry funding on trial design.
Objectives
l To critique and summarise the methodological characteristics of RCTs in complex wound care.
l To determine the prevalence of industry-funded trials in chronic wound care.
l To investigate whether or not funding source is associated with features of methodological quality in
complex wound RCTs.
Methods
Study selection
A library of eligible RCTs in chronic wound care was assembled and used. Eligible studies were:
l randomised comparisons of treatments for foot, leg or pressure ulcers in any setting and for any
category of patient (studies that included other wound types as well were excluded)
l published between 2004 and 2011 (inclusive)
l reported in English (because of a lack of translation resources).
Studies were excluded if they were:
l secondary reports in which the primary report of the main study was referenced
l conference abstracts (as these typically do not contain sufficient methodological information to assess
risk of bias)
l a trial protocol with no results
l a cost-effectiveness study (unless they also reported the effectiveness of an intervention)
l a phase I trial (as these are not aimed at determining effectiveness).
Trials were considered to be a RCT and included if they were described as ‘randomised’ either in the title
or in the text of the paper. If no randomisation process was referred to, they were excluded.
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This library was constructed by searching the Cochrane Wounds Group Specialised Register of Trials. The
register is maintained by the Cochrane Wounds Group and aims to identify all randomised and quasi-RCTs
in the area of wounds research. Reports are identified for inclusion in the register by regular searches
of a number of databases including MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health
Literature (CINAHL) and Cochrane Central Register of Controlled Trials (CENTRAL) along with periodic
searches of other databases. Studies included in the register have been coded on several criteria including
wound type. A search was therefore carried out using the search terms Pressure* or Venous or Leg* or
Ulcer* or Diabet* in the condition field and Treat* in the intervention field.
The titles and abstracts (when available) of the identified studies were screened by a single author to
exclude studies that obviously did not meet the inclusion criteria. The full text was obtained for all studies
that were potentially relevant. Two authors independently checked the full papers for eligibility. At this
stage duplicate reports of the same trial were identified and grouped prior to extraction. These reports
were thus extracted as one study with maximal data extraction across all reports available. Any
disagreements regarding inclusion/exclusion were resolved through discussion and when agreement could
not be reached a third author acted as arbitrator.
Data extraction
For each eligible study relevant data were initially extracted by one of seven authors. A second
independent extraction was completed by a single author (blinded to the initial extraction). Any
disagreements were resolved through discussion between reviewers. When agreement could not be
reached, a single third reviewer arbitrated. The process of data extraction was extensively piloted with data
recorded on a Microsoft Access database, using drop-down menus when possible.
Data were extracted on the following characteristics (Table 41):
l the publishing journal and its impact factor (when multiple reports of the same study were available we
used the publication with the highest impact factor here)
l journal specialty
l trial design (parallel or other)
l number of randomised groups
l wound type
l treatments evaluated
l sample size
l duration of follow-up
l primary outcome if defined with type of outcome also extracted
l funding source
l information on study methodology.
When classifying funding source in the absence of a funding disclosure in study reports, we did not
consider any of the following as constituting funding by a commercial organisation (i.e. we took a
conservative approach):
l declarations of consulting
l speaking fees
l honoraria
l stock ownership
l commercial funding of a study product in the absence of other commercial funding for the study.
When a paper explicitly stated that the study was independent, non-commercial funding was recorded,
even if the funding source was not provided (as long as there was no evidence in the paper that authors
were employed by a commercial organisation). In the absence of a funding disclosure, employment of an
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author by a commercial enterprise was considered commercial funding even in the presence of any other
funding statements. When a conflict of interest statement was recorded as ‘none’, non-commercial was
recorded even if the funding source was not reported.
When no funding information was found in a paper, the reviewers checked the International Standard
Randomised Controlled Trial Number (ISRCTN) database for a record of the study. When the source of
funding field contained relevant information this was extracted. If funding details were not provided in the
paper and were not found on this database then ‘not reported’ was recorded.
In situations in which the reviewer was unsure how to class a funding body that had been provided in a
report, a Google search was conducted to locate further information to help establish whether the body
was commercial or non-commercial. If there was no further information then funding was reported as
unclear. If information was found the two reviewers discussed the nature of the funder and classification.
When they were unable to make a decision regarding a funder’s status, details were discussed with a third
reviewer. A central log of funders was kept for reference so that all reviewers could ensure consistency.
The risk of bias for each study was also assessed using the Cochrane risk-of-bias tool162 for the domains of
sequence generation, allocation concealment and blinding of outcome assessors. An overall assessment
risk of bias was also made following Cochrane guidelines163 (see Table 41 for definitions used
in assessments).
TABLE 41 Variables for which data were extracted in the funding review
Extracted item Brief description
Journal specialty Journals were categorised as general medicine, wounds journal or other specialty journal using
MeSH data from the National Library of Medicine
Funding We defined funding source as commercial, non-commercial, mixed commercial and
non-commercial, not reported or unclear. The decision regarding funding source was based
on published disclosures of full or partial funding. In the absence of a funding disclosure,
employment of an author by a commercial enterprise was considered commercial funding even
in the presence of any other funding statements. When a conflict of interest statement was
recorded as none, ‘non-commercial’ was recorded even if the funding source was not given
Primary outcome Primary or main outcomes defined explicitly or an outcome used in a power calculation or a
main outcome described explicitly in primary study objectives
Type of outcome When defined primary outcomes were classified as complete healing if primary outcome was
proportion healed or time to complete healing; surrogate healing if the primary outcome was
any other healing-related outcome; and non-healing if the primary outcome was a non-healing
outcome such as the presence of infection or pain
Sequence generation Method described for generating the randomisation sequence used to allocate participants to
study groups, including computer-generated sequences, random number tables and coin toss
Allocation concealment Method described to prevent the individual responsible for enrolling trial participants from
knowing or predicting the allocation sequence in advance, including central randomisation or
sealed, opaque, sequentially numbered envelopes
Blinding of assessors Outcome assessors had no knowledge of group allocation or it was judged that the outcome
and the outcome measurement were unlikely to be influenced by lack of blinding (e.g. mortality)
Overall risk Low risk of bias: study was at low risk of bias in all three domains (sequence generation,
allocation concealment and blinding of outcome assessors); unclear risk of bias: study was at
unclear risk of bias in one or more domain and at high risk of bias in no domains; high risk of
bias: study was at high risk of bias in one or more domains
MeSH, medical subject heading.
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Data analysis
Descriptive summary statistics were calculated for each of the general and methodological items specified
and outcomes were stratified by wound type and by funding source. The descriptive summary statistics
were then used to compare the methodological quality of commercially funded and non-commercially
funded RCTs for which mean differences or odds ratios (ORs) (as appropriate) with 95% CIs were
calculated. To assess the difference in study duration between studies with different funding sources mean
differences were logged. The results were initially recorded in Microsoft Access and Stata 12 (StataCorp LP,
College Station, TX, USA) was used for data analysis.
Results
The results of the study selection process and reasons for exclusion are presented in Figure 6. We identified
647 potentially eligible studies. After an initial assessment of titles and abstracts, 385 studies were
excluded and full-text copies of the remaining 262 potentially eligible studies were obtained. Ninety-five
studies were excluded for the following reasons: 36 concerned an ineligible wound type; 26 concerned an
ineligible study type/design; three were duplicate publications of existing studies; 23 were secondary
reports of included studies; one paper was not in English; two were trial protocols; and four studies were
excluded because of exceptionally poor reporting that made judgement of whether or not the study met
the inclusion criteria impossible. The remaining 167 studies met the inclusion criteria.
Table 42 presents the general characteristics of the 167 included studies stratified by wound type. Leg
ulcers were the most frequently investigated of the three wound types (38%; 63/167), closely followed by
foot ulcers (34%; 57/167). Only 19% (31/167) of the studies focused on pressure ulcers over the 8-year
period investigated. A further 10% (16/167) of trials investigated more than one wound type.
Records identified by search
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Records screened by title/abstract
(n = 647)
Records excluded
(n = 385)
Full-text articles assessed for eligibility
(n = 262)
Studies included in analysis
(n = 167)
Full-text articles excluded
(n = 95)
• Study design, n = 26
• Wound type, n = 36
• Secondary paper, n = 23
• Duplicate, n = 3
• Non-English language, n = 1
• Protocol, n = 2
• Unclear report, n = 4
FIGURE 6 Study selection process.
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TABLE 42 Overview of included studies
Characteristic
All (n= 167),
n (%)
Leg ulcers
(n= 63), n (%)
Pressure ulcers
(n= 31), n (%)
Foot ulcers
(n= 57), n (%)
Journal type
General medical 11 (7) 3 (5) 4 (13) 2 (4)
Wounds specialty 57 (34) 26 (41) 10 (32) 13 (23)
Non-wounds specialty 99 (59) 34 (54) 17 (55) 42 (74)
Impact factor, median (IQR) 1.93 (1.21–3.01) 2.38 (1.26–3.21) 1.63 (1.36–2.48) 1.48 (0.80–2.90)
Funding
Commercial 58 (35) 24 (38) 7 (23) 16 (28)
Mixed 10 (6) 3 (4.8) 2 (7) 5 (8.8)
Non-commercial 55 (33) 20 (32) 14 (45) 16 (28)
Unclear/not reported 44 (26) 16 (25) 8 (26) 20 (35)
Study design
Parallel 160 (96) 58 (92) 30 (97) 56 (98)
Other 7 (4) 5 (8) 1 (3) 1 (2)
Study groupsa
2 144 (90) 52 (90) 27 (90) 51 (91)
3 14 (9) 6 (10) 2 (7) 4 (7)
4+ 2 (1) 0 (0) 1 (3) 1 (2)
Intervention
Bandages/stockings 14 (8) 14 (22) 0 (0) 0 (0)
Dressings/topical agents 42 (25) 20 (32) 10 (32) 10 (18)
Drugs 33 (20) 8 (13) 4 (13) 16 (28)
Growth factors 16 (10) 0 (0) 0 (0) 13 (23)
Tissue grafts 11 (7) 4 (6) 1 (3) 5 (9)
Other 51 (31) 17 (27) 16 (52) 13 (23)
Comparators
Placebo 50 (30) 14 (22) 12 (39) 18 (32)
Usual/standard care 43 (26) 20 (32) 8 (26) 12 (21)
Named comparison 74 (44) 29 (46) 11 (35) 27 (47)
IQR, interquartile range.
a Parallel trials only.
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The majority of trials were parallel in design (96%, 160/167), with only 4.2% (7/167) using other trial
designs (either crossover or factorial). Most (parallel) trials had just two intervention arms (90%, 144/160),
9% (14/160) had three arms and 1% (2/160) had four arms. The most frequent intervention types
investigated were dressings and topical agents (25%, 42/167), drugs (20%, 33/167), growth factors
(10%, 16/167), bandages and stockings (8%, 14/167) and tissue grafts (7%, 11/167). There were a
further 23 different technologies investigated.
The majority of trials were reported in specialty journals (93%, 156/167), with 34% (57/167) published in
wounds journals. The remaining studies (7%, 11/167) were published in general medical journals. Of the
included studies, 77% (128/167) were published in a journal with an Institute for Scientific Information®
impact factor. The median impact factor for the 128 studies was 1.93 [interquartile range (IQR) 1.21–3.01].
In total, 35% (58/167) of the studies were reported as having been commercially funded, 33% (55/167)
were not commercially funded and 6% (10/167) had funding from both commercial and non-commercial
sources. For the remaining 26% (44/167) of studies either the source of funding was not reported or the
status of the funding source was unclear.
Table 43 presents information on a number of methodological characteristics of the included trials. The
median number of participants was 60 (IQR 35–99) and there was a median of 28 (IQR 16–48) participants
per treatment arm.
The median duration of trial follow-up was 2.8 months (IQR 1.6–5.6 months) and varied significantly
depending on the nature of the primary outcome. Studies reporting surrogate measures of healing
(e.g. change in ulcer size) had a median follow-up of 2.8 months (IQR 1.7–3.7 months), whereas studies
with a primary outcome of either time to complete healing or proportion of wounds completely healed
had a median follow-up of 5.6 months (IQR 3.0–6.1 months).
The proportion of trials that defined a primary outcome measure was 59% (98/167). Of those that
defined a primary outcome, 41% (40/98) reported a measure of complete healing as the primary outcome
(either time to complete healing or proportion of wounds completely healed), 48% (47/98) reported an
intermediate (surrogate) measure of healing (e.g. change in ulcer size/area) and 11% (11/98) reported a
primary outcome that was unrelated to healing (e.g. pain).
The Cochrane risk-of-bias assessment162 revealed that, of the 167 included trials, only 40% (67/167)
described an appropriate method of random sequence generation; in 59% (98/167) of studies the method
of random sequence generation was unclear or was not reported and 1% (2/167) of studies reported
using inappropriate methods of sequence generation such as alternation or date of birth. Only 25%
(41/167) of studies reported adequate methods of allocation concealment such as remote telephone
randomisation or sealed, opaque, sequentially numbered envelopes; in 74% (123/167) of studies the
method of allocation concealment was unclear or not reported and 2% (3/167) of studies did not
adequately conceal allocation. With regard to blinding of outcome assessors, 34% (56/167) of studies
were classified as being at low risk of bias, 38% (64/167) had an unclear risk of bias and 28% (47/167)
had a high risk of bias. Following Cochrane review guidelines to construct an overall risk-of-bias
assessment,163 30% (50/167) of studies were judged to be at high risk of bias, 64% (107/167) had an
unclear risk of bias and only 6% (10/167) had a low risk of bias.
Table 44 presents the methodological quality of the included studies stratified by funding source. The
sample sizes of commercially funded trials were not statistically significantly different from those of
non-commercially funded trials (difference 8 participants, 95% CI –25 to 41 participants). Differences
in duration were modelled using a log model because of the data being highly skewed. There was
no statistically significant difference in the duration of follow-up between commercially funded and
non-commercially funded trials (with commercially funded studies having, on average, 1.3 months less
follow-up, 95% CI –1.8 to 1.06 months). Commercially funded trials were no more or less likely to specify
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TABLE 43 Methodological study features
Characteristic
All (n= 167),
n (%)
Leg ulcers
(n= 63), n (%)
Pressure ulcers
(n= 31), n (%)
Foot ulcers
(n= 57), n (%)
Number of participants, median (IQR)
Overall 60 (35–99) 81 (43–126) 44 (26–60) 50 (30–86)
Per treatment arm 28 (16–47) 37 (21–62) 21 (7–30) 27 (15–43)
Duration of follow-up (months), median (IQR)
All 2.8 (1.6–5.6) 3.0 (2.8–6.0) 1.9 (0.9–3.3) 3.0 (1.4–4.7)
Primary outcome: complete healing 5.6 (3.0–6.1) 6.0 (3.0–12.0) 3.9 (1.3–6.0) 4.7 (4.7–5.6)
Primary outcome: surrogate healing 2.8 (1.7–3.7) 2.8 (1.9–3.0) 1.6 (0.93–2.8) 1.9 (1.1–3.4)
Primary outcome: non-healing 1.7 (1.4–2.1) 1.9 (1.6–36.0) 1.4 (1.4–1.4) 1.9 (1.4–3.9)
Primary outcome: not defined 2.8 (1.3–4.3) 3.0 (1.6–5.6) 1.8 (0.85–3.0) 2.8 (0.93–3.7)
Primary outcome
Complete healing 40 (24) 18 (29) 4 (13) 16 (28)
Surrogate healing 47 (28) 15 (24) 14 (45) 12 (21)
Non-healing 11 (7) 3 (5) 1 (3) 6 (11)
None 69 (41) 27 (43) 12 (39) 23 (40)
Sequence generation
Low RoB 67 (40) 27 (43) 15 (48) 19 (33)
Unclear RoB 98 (59) 36 (57) 15 (48) 37 (65)
High RoB 2 (1) 0 (0) 1 (3) 1 (2)
Allocation concealment
Low RoB 41 (25) 22 (35) 5 (16) 11 (19)
Unclear RoB 123 (74) 41 (65) 24 (77) 45 (79)
High RoB 3 (2) 0 (0) 2 (7) 1 (2)
Blinding of assessors
Low RoB 56 (34) 13 (21) 15 (48) 23 (40)
Unclear RoB 64 (38) 24 (38) 13 (42) 22 (39)
High RoB 47 (28) 26 (41) 3 (10) 12 (21)
Overall RoB
Low RoB 10 (6) 4 (6) 2 (7) 3 (5)
Unclear RoB 107 (64) 33 (52) 24 (77) 41 (72)
High RoB 50 (30) 26 (41) 5 (16) 13 (23)
RoB, risk of bias.
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a primary outcome than non-commercially funded trials (OR 1.48, 95% CI 0.74 to 2.94) and were no
more likely to identify a surrogate healing measure as their primary outcome (OR 0.68, 95% CI 0.29
to 1.57).
There was no statistically significant difference between commercially funded and non-commercially
funded trials with regard to the likelihood of being classified as having either a high or an unclear risk of
bias in the domains of sequence generation (OR 0.63, 95% CI 0.34 to 1.16), allocation concealment
(OR 1.08, 95% CI 0.62 to 1.88) or blinding of outcome assessors (OR 0.84, 95% CI 0.47 to 1.50). There
was no statistically significant difference between industry-funded and non-industry-funded trials in the
odds of being classified as having a high or an unclear risk of bias overall (OR 0.91, 95% CI 0.54 to 1.52).
TABLE 44 Study features presented by funding source
Characteristic
Fully or partly commercially
funded (n= 68), n (%)
Non-commercially
funded (n= 55), n (%)
Funding unclear/not
reported (n= 44), n (%)
Number of participants, median (IQR)
Overall 63 (40–117) 52 (28–91) 60 (29–98)
Per treatment arm 30 (18–51) 26 (14–44) 23 (14–41)
Duration of follow-up overall
(months), median (IQR)
2.8 (1.9–5.6) 3.0 (1.9–6.0) 2.0 (1.2–3.5)
Primary outcome
Complete healing 17 (25) 15 (27) 8 (18)
Surrogate healing 26 (38) 11 (20) 10 (23)
Non-healing 5 (8) 4 (7) 2 (5)
None 20 (29) 25 (45) 24 (55)
Sequence generation
Low RoB 23 (34) 31 (56) 14 (32)
Unclear RoB 43 (63) 24 (44) 30 (68)
High RoB 2 (3) 0 (0) 0 (0)
Allocation concealment
Low RoB 21 (31) 13 (24) 7 (16)
Unclear RoB 45 (66) 41 (75) 37 (84)
High RoB 2 (3) 1 (2) 0 (0)
Blinding of assessors
Low RoB 23 (34) 23 (42) 10 (23)
Unclear RoB 19 (28) 20 (36) 25 (57)
High RoB 26 (38) 12 (22) 9 (20)
Overall RoB
Low RoB 3 (4) 5 (9) 2 (5)
Unclear RoB 37 (54) 37 (67) 33 (75)
High RoB 28 (41) 13 (24) 9 (20)
RoB, risk of bias.
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Discussion
There is clearly a ‘disconnect’ between the number of people with complex wounds and the huge impact
that these wounds have on patients and services, and the volume and quality of the evidence base.
Our review of the quality and relevance of complex wounds trials revealed a number of problems.
Although our prevalence study found that pressure ulcers were the most prevalent type of wound, our
methodological review found that only 19% of recent chronic wounds trials investigated pressure ulcers
and many of those trials were of poor quality.
A significant proportion of complex wounds trials did not specify a primary outcome, raising the risk of
authors cherry-picking results (i.e. presenting outcomes for which there were statistically significant
differences). In a related study, Lockyer et al.164 found that 86% of wound trials that did not define a
primary outcome claimed a significant treatment effect. This raises deep suspicion of bias given the
inadequate statistical power of trials in this field.
The use of surrogate healing measures (e.g. change in ulcer size) is widespread and the majority of studies
that defined a primary outcome used these intermediate measures of healing. The cost of longer-term
follow-up is likely to be the primary reason for this. Clearly cost savings are an advantage of using
surrogate outcomes and there is some evidence that a number of surrogate end points, such as initial
change in ulcer size, are good predictors for the clinically meaningful end point of complete healing for
some wounds.126,127,165 There are, however, a number of reasons to remain cautious about using surrogate
end points. First, surrogate measures of healing, such as change in ulcer size or area, introduce the
complex issue of how to measure ulcer size and have the potential for inaccuracies and lack of reliability in
systems of measurement. A recent systematic review into the performance of instruments for the
measurement of pressure ulcers revealed little evidence to support the reliability of different methods of
measurement, particularly with regard to ulcer depth and volume.165 Second, although some studies have
shown surrogate healing measures to be good predictors of complete healing, what is less clear is their
ability to differentiate between treatment effects. It is not enough that a surrogate predicts the clinical
end point, it must also be able to predict changes in the clinical end point because of different
treatment effects.125,166
The average sample size observed in our review was very small. The statistical power of a hypothetical trial
involving 60 participants (the median sample size) in which approximately 50% of ulcers heal in 12 weeks18
(the median duration of follow-up) and in which it is assumed that there is a modest effect size of 15%18
would be just 21%. In other words, only one in five of the trials in our sample is sufficiently large to detect
a statistically significant treatment effect should one exist. The vast majority of chronic wounds trials are
therefore underpowered to detect all but very large effects. Although there is some debate regarding the
importance of adequately powering a trial to detect a difference, there is evidence that published small
trials yield larger effect sizes than large trials,150 most likely as a result of publication bias. The fact that
many chronic wounds trials are small means that it is very important that systematic reviewers check for
publication bias whenever possible. Equally, it is important that authors register trials so that reviewers can
identify ongoing and potentially unpublished material.
The risk of bias in the reviewed studies was a concern, with only a minority of studies being at low risk of
bias. Assessment of bias was, however, hindered by poor reporting, with the vast majority of studies at
unclear risk of bias for at least one domain. Although it is encouraging that only a small minority of studies
were at high risk of bias for either sequence generation or allocation concealment, it is impossible to make
any judgement about the prevalence of high risk-of-bias trials in these domains when such a large
proportion of trials are poorly reported. Previous research has suggested that reporting is worse than
conduct167,168 and perhaps the majority of studies are at low risk of bias; however, the previous studies167,168
were conducted in highly regulated fields and it would be inappropriate to generalise to the area of
chronic wounds trials. Even under the most optimistic scenario (that the unclear risk trials reflect poor
reporting rather poor trial methodology) there remains a substantial risk of bias in chronic wounds trials
because of almost one-third of trials not blinding outcome assessors.
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The methodological quality of commercially funded trials and non-commercially funded trials was not
significantly different across all of the included measures of methodological quality. Based on current
evidence it is not possible to draw conclusions regarding the influence of funding source on the
methodological quality of chronic wounds trials, although we acknowledge the limited power in these
analyses, which in turn also limits the conclusions that can be drawn. Furthermore, the overall standard of
trial quality was very poor and wound triallists share a culture that international trial design, conduct and
reporting standards do not seem to have penetrated. Almost one-quarter of the sample had an unclear
funding source – more transparency in declaring support for research will allow more studies to be
included in future analyses of this type.
Our results are very similar to those obtained in other methodological reviews that used samples of trials
from across medicine, for example that by Hopewell et al.168 Chronic wounds trials are, therefore, not
considerably methodologically weaker than trials conducted in some other areas of medicine. The cohort
assessed in the study by Hopewell et al.,168 however, was much older and dated back to 2000, whereas
this study includes trials up to 2011, thus limiting comparability, particularly as the impact of the
Consolidated Standards of Reporting Trials169 may mean that trials are now of higher methodological
quality than observed by Hopewell et al.168 It should also be noted that the methodological quality of
reports assessed by Hopewell et al.168 was poor and the fact that chronic wounds trials may be of
comparable quality is no reason for complacency or celebration.
James Lind Alliance Pressure Ulcer Partnership
Background
The role of people with chronic, complex wounds in wounds research is usually limited to ‘being objects
of study and beneficiaries of research results’.170 Complementary to our research into which outcomes
matter to patients, carers and clinicians, and our analysis of the nature and quality of completed wounds
research, we embarked on a study to determine the patient, carer and clinician research priorities in
pressure ulcer prevention and treatment. We situated this work firmly within the JLA and chose pressure
ulceration as the focus of this work (as opposed to leg ulcers or any other kind of complex wound)
because they are the most common complex wound type (see Chapter 2) and because they are a high
priority for the NHS.133 We adopted a mixed-methods, participatory research framework for this priority-
setting work. There is no gold standard method for health research topic identification and priority setting
and reporting in this area is predominantly descriptive rather than evaluative.171,172 The JLA approach
follows an open and consultative model in which patients, carers and health professionals work together
in PSPs to encourage those directly affected by a specific condition to submit their key ‘uncertainties’
(normally in relation to treatment effects).173 These are then ranked and widely disseminated.
Objectives
Our objectives in this study were to:
l bring patients, carers and health professionals together to identify and prioritise the top 10
uncertainties, or ‘unanswered questions’, about the effects of pressure ulcer interventions that they
agree are most important
l investigate methodology for patient and public involvement in research priority setting in wound care.
Methods
We began this work by developing a protocol in close consultation with advisers from the JLA (a JLA
guidebook has subsequently been published173). Although this work was conducted in close collaboration
with the JLA and our methods were informed by the emergent JLA approach, we were also influenced by
other approaches and in particular the dialogue model, another framework for research agenda setting,
which includes both consultative and deliberative methods and allows for emergent and flexible design.170
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Emergent and flexible design was considered important because a significant proportion of people with
pressure ulcers find it difficult to participate in activities outside the home because of their age and
comorbidities. Furthermore, and distinct from most other PSPs, there were no existing patient groups
specifically representing the interests of people with (or at risk of) pressure ulcers. These factors indicated that
it would be necessary to try more than one method and to vary methods between groups to develop an
accurate understanding of the clinical uncertainties of pressure ulcer patients, carers and health professionals.
The process, outlined in the protocol and which we followed, is summarised in Figure 7.
Exploration
During the exploration phase, potential partner organisations and individuals with an interest in pressure
ulcers were identified through peer consultation, an internet search and the JLA register of affiliates. An
initial search of research recommendations from systematic reviews and informal conversations with health
professionals and researchers in the field provided exploratory information about the clinical uncertainties
that might concern different stakeholders. A lack of good-quality research evidence and the absence of a
patient stakeholder voice in the field were quickly apparent.
Initiation
During the initiation phase, interested organisations were invited to appoint a representative to attend an
exploratory meeting. A press release was issued and paper and e-mail invitations were widely disseminated
to advertise the event. People with experience of pressure ulcers (either as recipients or as providers of
care) came together with representatives of groups/charities with an interest in the management and
treatment of pressure ulcers, the JLA and researchers and clinicians from this research programme at a
meeting to (1) identify treatment and prevention uncertainties associated with pressure ulcers, (2) identify
opportunities for and challenges to the establishment of the JLAPUP, (3) identify ways in which
organisations and individuals could be involved in the JLAPUP and (4) establish a steering group to guide
the development of the JLAPUP.
It was agreed at the launch meeting that collaboration between parties would be fostered by an independent
facilitator from the JLA with no stake in the content of the outcome. We felt that this facilitation would
ensure that the priority-setting process was not dominated by any particular interest group and would help to
create the conditions for successful participation and dialogue. It was agreed at the first steering group
meeting to adopt the draft protocol and to define ‘active partners’ in the partnership as:
i. organisations that were prepared to ask their members to submit uncertainties about pressure ulcer
prevention and treatments to help decide priorities for future research
ii. supporters who were interested individuals who could inform and support the partnership.
The JLAPUP established a website to promote the partnership’s work, house surveys and encourage wider
involvement. Social media were used extensively. A Facebook page (Facebook, Inc., Menlo Park, CA, USA;
www.facebook.com) [see www.facebook.com/pages/James-Lind-Alliance-Pressure-Ulcer-Partnership/
307879132584509 (accessed 11 May 2016)] and a Twitter account (Twitter, Inc., San Francisco, CA, USA;
www.twitter.com) (@JLAPUP) were established and used with press releases to encourage participation
and dissemination.
Consultation: uncertainty gathering
A range of different methods was used to gather patient, carer and health professional uncertainties.
At the beginning of the process, uncertainties were gathered at the launch meeting and some were
submitted by e-mail and through a contact form on the JLAPUP website. Paper and online surveys were
then developed as the principal means of gathering uncertainties. The paper survey was distributed via
active members and at the following NHS sites in the north of England, for which we obtained necessary
ethical approval (see Ethics and governance): Leeds Teaching Hospitals NHS Trust, Leeds Community
Healthcare NHS Trust and the Golden Jubilee Spinal Injuries Unit, James Cook University Hospital,
Middlesbrough. York Teaching Hospital NHS Foundation Trust granted research approval but not until
after the survey closing date and so surveys were not distributed there as intended.
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The online survey, accessible nationally, was created using SurveyMonkey® (Palo Alto, CA, USA). The
online version differed from the paper version because it included a ‘question builder’ option that sought
to inform and encourage participants to use a PICO (population, intervention, comparison, outcome174)
format when possible. The link to the online survey was widely distributed through a press release, e-mails,
Twitter, Facebook and partner organisations. It was live for 4 months. Limited population data were
collected from respondents alongside their treatment uncertainties. Participants were asked to identify
themselves as someone having or at risk of pressure ulcers, a carer or a health professional. Those who
belonged to more than one category were invited to complete the survey from both perspectives. Health
professionals were asked for their professional role. Patients were asked for information on age, sex,
ethnicity and home/care setting. Carers were asked to complete this information about the person who
they cared for.
Uncertainties were gathered face-to-face at a number of relevant patient, carer and health professional
events. An interactive stall was set up at large events. Gathering sites included a link nurse training event
at Leeds Teaching Hospitals NHS Trust; a nurse training event for staff at the James Cook University
Hospital; the Multiple Sclerosis Society Conference in Manchester (13–15 April 2012); the Tissue Viability
Society Conference in Kettering (18–19 April 2012); and the York Carers’ Forum (May 2012).
Articles about the JLAPUP and calls for uncertainties were placed in a range of media targeted at
stakeholders including the Spinal Injuries Association online newsletter, the magazine of the Multiple
Sclerosis Society and Carers News.
Records were kept of the source of all submitted uncertainties (whether patients, carers or health
professionals) to enable the uncertainties submitted by different stakeholders to be compared and
contrasted and as a means of generating dialogue between stakeholders.
Collation
Paper survey results were manually entered into SurveyMonkey for subsequent analysis. Submissions were
categorised as follows:
l intervention/non intervention
l originator
l submission group
l broad intervention taxonomy derived from the Cochrane Wounds Group
l detailed intervention taxonomy derived from the Cochrane Wounds Group
l outcome.
Once all submissions were received, uncertainties/questions were combined when there were duplicates,
counted and organised into four data sets, by originator and taxonomy of interventions derived from the
Cochrane Wounds Group. The taxonomy was adapted to accommodate the range of submissions
received. When the questions related to interventions, these were analysed to form a PICO-style question
(noting the journey from initial submission to question) and duplicates combined to form a list of
‘indicative uncertainties’.
Checks were performed on the interpretation and categorisation of submissions by comparing treatments of
the same submission by different coders (members of the programme research team and steering group
members). These checked for categorisation errors and whether or not the question produced remained
faithful to the submission without overinterpreting what was expressed. An ‘uncertainty analysis’ exercise
was conducted at a steering group meeting to discuss the interpretation of submissions and their translation
into PICO-style uncertainties. A sequential sample showing the journey from submission to question was
sent to steering group members including the Programme Grants for Applied Research programme chief
investigator, the chair and the JLA representative, to check for ‘justifiability’ of interpretation.
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To ensure that identified intervention questions were genuine uncertainties and not answered by existing
research, ‘indicative uncertainties’ were then checked against existing systematic reviews by performing an
individualised search for each uncertainty in The Cochrane Library. The following databases were accessed:
the Cochrane Database of Systematic Reviews; the Database of Abstracts of Reviews of Effects; the Health
Technology Assessment database; and, if the uncertainty related to cost-effectiveness, the NHS Economic
Evaluation Database. The search was carried out by an experienced systematic reviewer and checked by
another. Genuine uncertainties were prepared for publication in a pressure ulcer module within the NICE
UK Database of Uncertainties about the Effects of Treatments (UK DUETs).
Research recommendations from systematic reviews were not included in the gathering, analysis or
prioritisation process. The steering group decided that the focus of the PSP was collecting and prioritising
uncertainties from patients, carers and health professionals, rather than research recommendations arising
from systematic reviews (which would be researcher-derived uncertainties).
Research questions that were not about treatment interventions were categorised using the health
research classification system of the UK Clinical Research Collaboration [see www.ukcrc.org/
research-coordination/health-research-classification-system/ (accessed 11 May 2016)].
Prioritisation
The long list of genuine (rather than ‘indicative’) uncertainties that remained after the evidence check was
then reduced to produce a workable shortlist for prioritisation. Questions were ranked and grouped in
order of number of times submitted. When there were strong similarities some uncertainties were
combined. The criteria for inclusion in the shortlist agreed by the steering group were:
i. all questions that had been submitted more frequently than once by any category (patient, carer or
health professional)
ii. all questions appearing on more than one list (submitted by one or more categories of patient, carer or
health professional)
iii. all questions originating from mixed meetings (where patients, carers and health professionals had
discussed the uncertainty together)
iv. all questions submitted by carers (because there were far fewer of these).
When they felt strongly, steering group members gave each other the opportunity to advance a case for
the reinclusion of an excluded question. Questions could only be reincluded if the case was found
convincing enough to secure agreement from a majority of the group.
A prioritisation survey was designed in paper and electronic formats in consultation with survey
methodologists within the programme team. The aim was to enable stakeholder groups to value the
different uncertainties identified during the previous phases and rank these in order of importance, resulting
in group-specific research agendas. Discussions extended to consideration of discrete choice experiments
and best–worst scaling techniques;175 however, resource constraints meant that the survey had to be
designed within the constraints of SurveyMonkey software. The survey design asked people to rate
uncertainties according to their importance on a scale of 1–10, to encourage a greater differentiation in
responses, with 0 being not at all important, 5 being of average importance and 10 being extremely
important, with there also being an option of ‘no view’ or ‘don’t know’. The question order was
randomised. Some limited demographic data were collected, in line with the gathering survey but with the
addition of a question about wheelchair use. The survey instruments were piloted with a panel of patients
to gain feedback on ease of use and clarity of understanding. The survey was amended in the light of the
pilot and measures were taken to ensure security and the prevention of multiple entries in the online survey.
The survey was launched with a widely distributed press release. The website was amended with links to
the online questionnaire and a Twitter and Facebook campaign was launched. A brief explanatory
YouTube video (YouTube, LLC, San Bruno, CA, USA) was created and linked to the online survey and
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JLAPUP website. Explanatory text for the online survey was amended a number of times in light of
comments received from respondents. Online and paper surveys were open for 5 weeks.
Paper survey responses were input into SurveyMonkey and three data sets were produced using Stata 12
for patient, carer and health professional respondents. Data sets included aggregate rankings, average
score rating, total number responding, Cochrane broad taxonomy and category of intervention and the
frequency with which a question was answered.
Integration
The first stage of the integration phase involved examining the similarities and differences in responses
from separate stakeholder group prioritisations. Questions covering similar areas but asked by different
groups were thematically combined. As broader questions emerged, efforts were made to retain some of
the granularity, the subtle differences and nuances of specific questions being lost through combination.
The steering group and other stakeholders were asked to choose three prevention and three treatment
uncertainties from a list of treatment uncertainties that had been raised and prioritised by only one
stakeholder group. This gave stakeholders the opportunity to consider the importance of, and a chance to
include, uncertainties that may not have occurred to them from their own patient, carer or health
professional perspective. These selections were included in a final shortlist of uncertainties agreed as
important by all stakeholder groups for deliberation at a final priority-setting meeting. Selections were
made using two methods. A facilitated questionnaire was administered at stakeholder events and
meetings including events on Worldwide STOP Pressure Ulcer Day. Far fewer patients than health
professionals attended these events so an integration workshop was run with the Pressure Ulcer Research
Service User Network for the UK (PURSUN UK), which had recently been set up to improve the quality of
patient and public involvement in pressure ulcer research.
The second stage of the integration phase involved the conduct of home and bedside interviews with care
home residents who are key stakeholders but who are often not included in studies about older people’s
health176 and who were under-represented in our consultation phase. Visits to care homes and a
rehabilitation centre were arranged to ask which of the treatment uncertainties gathered so far mattered
most to residents and whether or not they had others they would like to include. The necessary
permissions were secured for these visits (see Ethics and governance).
The final stage of the integration phase was a priority-setting meeting to choose the top 10 treatment
uncertainties for future research. The format of the meeting was adapted from the format for final JLA
meetings.173 New methods for use in the meeting were piloted in mini mock workshops and facilitators
were given the opportunity to help develop the workshop process through comment and discussion on
the workshop outline.
All active members and supporters were invited to take part in the final priority-setting meeting, as were
people who had taken part in the process to date who had submitted their details and expressed an
interest in future involvement. Before the meeting participants were asked to complete a pre-workshop
exercise to choose and rank their top 10 preferred uncertainties from the 30 most frequently submitted
and highly ranked questions. Facilitators were given written and oral briefings.
The meeting was staffed by facilitators, a statistician to rank uncertainties, a qualitative researcher who
hosted a ‘listening/experience corner’ (which afforded an opportunity for participants to talk outside the
confines of the demands of the workshop) and an independent observer. Researcher members of the
meeting were non-voting and were asked to act as jargon de-buggers and to offer research clarification
when this was requested from members of the meeting (a written glossary of key terms in wounds research
was also made available at the meeting). In addition, two people took on the role of Twitter correspondent
and photographer. With the meeting’s permission, facilitators made a digital audio-recording of the
sessions. Facilitators each had a set of cards that detailed the rankings by stakeholder group to date of each
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prioritised uncertainty. Facilitators also had a ‘back story’ book that detailed the history of each of the
30 shortlisted uncertainties.
On arrival, participants were greeted, given a workshop pack and directed via a colour-coded badge to a
place at one of four tables of mixed groups, which were balanced as far as possible between patients,
carers, health professionals and researchers. If participants had not completed the pre-meeting exercise,
they were encouraged to do so during arrival refreshments.
The meeting began with a welcome, an explanation of the structure and ground rules for the day and the
roles that people would play and a presentation summarising the reasons for forming the PSP, the
prioritisation process to date and the task in hand. The four groups then went into breakout groups for
round 1. The objectives of round 1 were:
i. introductions
ii. identifying similarities and differences between participants’ individual rankings so that they could
appreciate the different (or similar) points of view in the group
iii. discarding questions not selected by group members as part of their top 10.
After introductions and a recap of the ground rules, group members took turns to place a numbered
sticker representing their top-ranked uncertainty on a flip chart display and explain why they had chosen it.
The group continued explaining and debating individually ranked uncertainties in rounds until 15 minutes
before the end of the session, when everyone was asked to use their numbered stickers to record their full
top 10 on the poster. If an uncertainty did not appear on the display, it was eliminated. The rest went
forward into round 2. The display gave a picture of shared and divergent priorities. During the refreshment
break facilitators divided the 30 A4 uncertainty cards into a pile of uncertainties identified in round 1 and a
pile of uncertainties to be eliminated. The uncertainties still in play were represented for the next round by
laying out the uncertainty cards in ranking order.
The same groups reconvened for round 2. This focused on creating a group rank order of 15 uncertainties
from the shortlisted cards using a ‘diamond nine’ approach. The results from the four workshops were
collated over lunch to produce an aggregated top 15. The aggregation process was conducted using a
simple points system in which the first-placed uncertainty received 15 points, the second 14 and so on,
with uncertainties outside the top 15 receiving a score of zero. The points for each uncertainty were then
added together to produce an overall ranking. This was calculated using a Microsoft Excel spreadsheet into
which the rankings from each group were entered. The spreadsheet was then linked using a pivot table to
a Microsoft PowerPoint® (Microsoft Corporation, Redmond, WA, USA) presentation, which could be
updated automatically and allowed for the quick presentation of the results of the ranking process to
those attending.
A plenary session was then held to report back the results of the first sessions, to reveal the aggregated
top 15 and deliberate the results. Participants were allowed to make a case for the reintroduction of
excluded uncertainties, with decisions made by airing objections and a show of hands. After lunch
participants formed new mixed groups (indicated by a second colour on their badge). Using the
aggregated rankings from the morning sessions (with the addition of any uncertainties reintroduced after
deliberation) members were asked to rank their top 15 questions. Results were collated and an aggregated
ranked top 15 was produced. Groups were asked to particularly aim for agreement about the top 10.
An aggregated ranked top 15 was produced during the refreshment break.
The meeting concluded with a final plenary session that presented and deliberated the results. It
considered cases for ranking uncertainties more highly and for combining uncertainties. The aim of the
session was to choose a final top 10; however, the meeting agreed to adopt a top 12. The meeting was
reminded that all of the uncertainties are a resource for researchers, including the original data set, the
shortlist and the top 12.
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Reporting
All intervention questions without a reliable or complete answer and for which further research is called for
were published on NHS Evidence in the UK DUETs at www.library.nhs.uk/duets/SearchResults.aspx?
tabID=294&catID=15594 (accessed 20 June 2016).
A press release, newsletter and Twitter campaign were used to publicise the top 12 uncertainties. The
results were made available to the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC).
Representatives from NETSCC attended a steering group meeting with a view to developing a
commissioning brief.
The results have been presented at academic and clinician conferences and published for clinician and
academic audiences.177–179 Non-intervention uncertainties have been collated and are available on request.
Evaluation
Feedback from participants was invited at all meetings and in surveys. Data were used to refine and
amend future plans. Steering group members took part in a final evaluation that sought their views on the
effectiveness of the process and their levels of involvement. A JLA PSP reporting proforma has been
completed. An academic paper critically reflecting on the methodology has been published.177
Ethics and governance
A submission to the National Research Ethics Service for ethical approval was made to distribute the survey
and recruit patients to discussion groups through NHS sites. The Proportionate Review Sub Committee of
the NRES Committee East of England – Hertfordshire Research Ethics Committee reviewed the application
and gave approval (reference 11/EE/0551). All required research and development approvals were
obtained. Ethical approval was also received from the University of York Health Sciences Research
Governance Committee.
Results
Consultation: uncertainty gathering
We received 359 submissions from the uncertainty-gathering process, which together generated a total of
960 treatment uncertainties. There were 83 paper survey submissions and 180 online survey submissions
(the site was visited 344 times). The remaining submissions were made at meetings, at stalls at events,
by telephone, e-mail, on Twitter and at webinars. The number of submissions is not the same
as the number of people participating because each meeting, event or webinar counted as one
submission source.
Respondents to the consultation were health professionals (43%), patients (37%) and carers (11%), with
the remainder from mixed groups (Table 45). The majority of health professionals (45%) were tissue
viability nurses. No GPs responded (Table 46).
TABLE 45 Uncertainty submissions by originator
Originator n %
Health professional 409 42.6
Patient 354 36.9
Carer 101 10.5
Mixed group 96 10.0
Total 960 100.0
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The number of paper survey returns (n= 83) was disappointing given the investment of time to obtain ethics
and governance approval for distribution to patients and carers through the NHS. In total, 49% of completed
paper surveys were from patients, 16% were from carers and 35% were from health professionals.
In total, 62% of patient respondents to the survey were female and 38% were male, with 94.3%
describing their ethnicity as ‘white British’. The second largest group identified as ‘white – any other
background’ (1.9%). Patient respondents to the survey were generally younger and more likely to be living
at home than the pressure ulcer population as a whole (Figure 8). People in more formal care settings
(including people in nursing homes and hospital inpatients) were under-represented relative to the
prevalence survey outlined in Chapter 2 (Figures 9 and 10). Most patient respondents did not describe any
comorbidities; 30% said that they had MS and 10% spinal injury (Figure 11).
TABLE 46 Categories of health professional respondents to consultation with numbers of submissions
Health professionals n %
Tissue viability nurse/wounds specialist nurse 143 45.0
Hospital nurse 47 14.8
Community-based nurse 16 5.0
GP 0 0
Hospital doctor 14 4.4
Care assistant 7 2.2
Dietitian 4 1.3
Physiotherapist 9 2.8
Other/not specified 78 24.5
Total 318 100.0
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FIGURE 8 Age distribution of patient respondents to the uncertainty-gathering survey compared with that of
people with pressure ulcers in the prevalence survey (see Chapter 2).
SERVICE USER AND PROVIDER PERSPECTIVES (WORKSTREAM 2)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128
92.1%
5.2%
1.4% 1.4%
0
10
20
30
40
50
Pe
rc
en
ta
g
e 60
70
80
90
100
At home living
independently or supported
by family or carers
Nursing home Residential home Sheltered accommodation
FIGURE 9 Patient home/care setting of respondents to the JLAPUP uncertainty-gathering survey.
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FIGURE 10 Leeds prevalence survey: location where care delivered.
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The survey comments sections were well used. The range of responses included requests for information,
comments on the importance of the uncertainties submitted, views on the priority-setting process and the
sharing of experiences. Examples include:
More consultation exercise with no realistic changes to current practices?
Patient comment JLAPUP survey, 3 March 2012
We are confused as to the contradictory responses we have received to our questions about pressure
sores and do not know how best to get a real, current one to heal. This is despite at least weekly visits
from a district nurse and doctors appointments.
Patient comment JLAPUP survey, 21 February 2012
Feel questions are important. There is currently to my knowledge no accurate and objective way of
measuring the changes in pressure ulcer volume or size over time which would give a good indicator
of healing and how this relates to the many products all proposing to heal these wounds.
Hospital doctor comment JLAPUP survey, 24 February 2012
My mum was in bed at home for years, and I helped look after her. She was unable to communicate,
move etc. due to having Primary Progressive Multiple Sclerosis. She could not say that she was in pain,
or communicate with us in any way. We were not told about the possibility or likelihood of her
developing pressure ulcers or how to prevent them – and she consequently developed one
unfortunately. As many people who develop pressure ulcers will have another condition and may be
unable to care for themselves or tell anyone how they are feeling, I think that it is vital that research
looks at this aspect, how to care for people, preventing pressure ulcers, helping people to know what
to look for and what to do, thinking more about the elderly or people with underlying conditions who
aren’t able to say what they need or are feeling, and also making sure that carers understand the risks
and how to prevent them.
Carer comment JLAPUP survey, 2 March 2012
Further analysis of the comments may cast some contextualising light on the uncertainties gathered and
how people participating understood and engaged with the survey.
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FIGURE 11 Comorbidities specified in the uncertainty-gathering survey.
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Collation
Submissions from all sources were categorised as intervention or non-intervention questions, reworked into
a PICO format when possible and categorised according to the adapted Cochrane taxonomy: 960
uncertainties were produced. The majority of uncertainties related to the effectiveness of interventions
(71.9%). Of these, the most frequently submitted uncertainties related to methods of pressure and shear
reduction and relief (30%) and the organisation of care (30%) (Table 47). Prevention was identified as an
outcome in 61% of the intervention uncertainties and healing in 32% (Table 48).
Intervention uncertainties were checked against the evidence base to ensure that they were ‘genuine
uncertainties’, that is, that there was not an existing, reliable answer in the research literature. All were
found to be genuinely uncertain with the exception of one patient submission. A systematic review found
reliable evidence for the use of medical grade sheepskins for the prevention of pressure ulcers180 and so
this was removed from the list. Partial evidence was found to answer two uncertainties submitted by
patients and clinicians: the effectiveness of support surfaces for prevention and the use of nutritional
interventions for prevention. The limited nature of the evidence meant that these remained on the list of
uncertainties published on UK DUETs.
In total, 270 non-intervention questions were categorised by research activity category according to the UK
Clinical Research Collaboration health research analysis taxonomy. Duplicates were combined and those
too poorly specified to categorise were removed. This resulted in a final list of 220 unique questions, the
majority of which were about the aetiology/prognosis of pressure ulcers (Table 49).
Prioritisation
In combining questions for the longlisting and shortlisting processes, there was a tension between
producing broader issues for prioritisation and maintaining the specifics and authenticity of uncombined
questions. The approach taken aimed to maintain a balance between identifying themes and maintaining
finer details (specific populations and interventions) to help retain the richness of the submissions because
this fine detail would be useful in the design of any subsequent trials. In total, 141 participants completed
the online and paper prioritisation surveys in which patients, carers and health professionals prioritised
uncertainties that had been raised by their peers (56 from patients, 14 from carers and 71 from
health professionals).
TABLE 47 Interventions by broad taxonomy
Interventions n %
Organisation of care 204 29.6
Pressure and shear reduction and relief 207 30.0
Local wound treatment 70 10.1
Managing patients with limited mobility 51 7.4
Risk assessment 51 7.4
Nutrition 41 5.9
Local skin care 34 4.9
Surgery 10 1.4
Other 15 2.2
Physical therapies 4 0.6
Massage 2 0.3
Smoking cessation 1 0.1
Total 690 100.0
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In total, 50% of people who completed the survey were health professionals, 40% were patients and
10% were carers. Of the patient respondents, 80% said that they were wheelchair users, 93% were living
at home independently or supported by family or carers and 59% were aged 40–64 years. Of the health
professionals taking part, 39% were tissue viability nurses, 22% were community nurses and 17% were
hospital nurses. Of the carers, 75% were caring for someone who uses a wheelchair, 75% were caring for
someone living at home and 44% were caring for someone aged 40–64 years.
In total, 33% of respondents to the online survey used the question builder, with 10% using it for more
than one question, and 81% of the people who started the online survey completed it (Table 50).
Respondents rated the majority of uncertainties as being of above average importance. On the 10-point
scale, patients’ average responses were in the range 6.05–9.14; carers’ average responses were in the
range 4.00–9.64 (with 4.00 being an outlier and the remaining uncertainties ranging from 6.62 to 9.64);
and health professionals average responses were in the range 6.18–8.80.
TABLE 48 Outcomes identified in intervention uncertainties
Outcomes n %
Prevention 422 61.2
Ulcer healing 218 31.6
Value for money to the NHS 4 0.6
Ulcer-related pain 6 0.9
Patient safety 4 0.6
Reduction in number of dressing changes that an ulcer requires 5 0.7
Secondary prevention 4 0.6
Ability to undertake normal activities 4 0.6
Quality of life 4 0.6
Speed of ulcer healing 3 0.4
Ulcer-related infection 3 0.4
Other 10 1.4
Ulcer-related odour 2 0.3
Ulcer-related leakage 1 0.1
Total 690 100.0
TABLE 49 Breakdown of non-intervention uncertainties by UK Clinical Research Collaboration health research
analysis taxonomy
Non-intervention questions n %
Aetiology/prognosis 120 54.5
Health and social care services research 43 19.5
Management of diseases and conditions 40 18.2
Underpinning research 16 7.3
Evaluation of treatments and therapeutic interventions 1 0.5
Total 220 100.0
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The online and paper surveys contained comments and feedback boxes. There were some comments on
the difficulty of judging the importance of uncertainties:
You say not to rate all the questions as ‘very important’ but that is difficult when they are!
Patient comment from prioritisation survey, November 2012
This questionnaire for me was pointless as all areas of research are important and how can you value
one over the other.
Health professional from prioritisation survey, November 2012
The comments boxes also identified three key issues for the priority-setting process:
1. Some respondents wanted to answer the questions rather than choose which should be researched.
2. Some were not reading the explanation in the website text so the text was enhanced and a brief
explanatory video created, linked to the survey and JLAPUP website. This was viewed 93 times and had
an impact in reducing the number of telephone and e-mail queries.
3. Throughout the process, the concept of ‘treatment uncertainty’ was a difficult one to explain and
people sometimes responded by sharing a range of concerns and experiences or asking for advice.
For example:
I have answered a large amount of questions as don’t know, I’m not a professional carer and therefore
don’t feel equipped to answer these questions fully. I do care for my mum 55 hours per week and she
has a pressure sore on her heel which began during a 15 week stay in hospital and 20 month on it still
hasn’t healed. We are therefore now obsessed with any red mark and ensuring she is repositioned at
least every 3–4 hours. In recent weeks my aunt following an operation has developed pressure sores
within a month of the operation and I’m alarmed that the nurses visiting are suggesting she put E45
cream onto the sores which is now broken skin, and 2 weeks after these were identified she still doesn’t
have any proper antiseptic cream or dressing to help heal. I’m really alarmed that more urgency isn’t
taken to try to heal pressure sores immediately they become apparent and that appropriate pressure
relieving items are not made available to people at high risk of developing them as a preventative action,
there seems to be a view of waiting until the problem has arisen rather than trying to prevent it. That
said I’m not a NHS professional and can only provide a view based on my own experiences.
Carer comment from online prioritisation survey, November 2012
TABLE 50 Breakdown of those completing the prioritisation survey
Originator Number starting survey Number completing survey % completing survey
Patient 76 56 73.7
Carer 16 14 87.5
Health professional 83 71 85.5
Total 175 141 80.6
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Integration
Identifying agreements and disagreements in survey results
The rankings from the prioritisation survey were integrated to provide a picture of the most highly rated
kinds of questions that had been identified by all three groups. The shortlist for final deliberation was
based on the most highly ranked questions raised and ranked by all three groups. There were 10 topics
that were identified and agreed as being very important by all three groups.
1. Repositioning for prevention and healing.
l How effective is repositioning in the prevention of pressure ulcers?
¢ for those in bed – turning self, being turned and changing position (sleep disruption)
¢ for wheelchair users repositioning self or being repositioned in chair
¢ for people with contracted limbs.
Ranking health professionals 1; patients/service users 3, 4, 6 and 9; carers 2 and 16.
l Does regular turning of patients in bed promote healing of pressure ulcers? How often is it best to turn
people? For people who require a carer to help them move what is the most effective means of
repositioning? For people with limited memory as well as limited mobility would a ‘prompt of routine’
tool that reminds people to reposition themselves help to heal pressure ulcers?
Ranking health professionals 2; patients/service users 6; carers 10.5 and 18.
2. Support surfaces for prevention and healing.
l What is the relative effectiveness of the different types of pressure-relieving beds, mattresses,
overlays and cushions (including cushions for electric and self-propelling wheelchairs) in preventing
pressure ulcers? Do they meet the needs of the full range of patients at risk?
¢ compared with conventional and other specialist surfaces
¢ for those who share a mattress with a partner, people with MS
¢ for those with contracted limbs.
Ranking health professionals 6, 8 and 9; patients/service users 2, 8, 10 and 15; carers 1, 3 and 14.
l Do pressure-reliving support surfaces, particularly mattresses, help ulcers heal? Are they appropriate
and effective for treating the frail and elderly and those with MS?
Ranking health professionals 5 and 8; patients/service users 7; carers 1 and 13.
3. Involvement for prevention.
l How effective at preventing pressure ulcers is involving (informing/educating/motivating)
patients/family/lay carers in patient care?
Ranking health professionals 2, 16 and 18; patients/service users 1, 5, 7 and 18; carers 6.5 and 8.
4. Eating and drinking (nutrition/hydration) for prevention and healing.
l Does improving diet (nutrition) and hydration promote pressure ulcer healing?
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Ranking health professionals 1; patients/service users 2; carers 5.
l Does improved diet (nutrition) and hydration promote the prevention of pressure ulcers?
¢ for people with MS, spina bifida and spinal injury
¢ including effectiveness of high-protein diet, micronutrients and effects of weight loss and gain.
Ranking health professionals 7; patients/service users 13 and 21; carers 4.
5. Staff training/education for prevention.
l Does the education of health and social care staff on prevention lead to a reduction in the
incidence of pressure ulcers? If so, which are the most effective education programmes (at
organisational and health/social care level)?
Ranking health professionals 3; patients/service users 12; carers 6.5.
6. Service models and healing outcomes.
l What are the best service models (and are they sufficiently accessible) to ensure that patients with
pressure ulcers receive the best treatment outcomes, for example awareness of and access to tissue
viability nurses, and do people with specialist conditions (e.g. spinal injury) receive the best pressure
ulcer treatment at specialist centres rather than at generalist services?
Ranking health professionals 9; patients/service users 4; carers 3.
7. Surgery for healing.
l How effective are surgical operations to close pressure ulcers? What is the most appropriate surgical
referral for people with MS and ulcers that will not heal?
Ranking health professionals 14; patients/service users 1; carers 14 (note highest for patients).
8. Bed rest for healing.
l For wheelchair users sitting on a pressure ulcer, how effective is bed rest in promoting pressure ulcer
healing? Is it safe for those with MS who have been advised to keep moving? Is it detrimental to
mental health? How does its effectiveness compare with sitting on a pressure-relieving cushion? Is
sitting for a small time (e.g. to eat a meal) likely to substantially increase pressure ulcer healing time?
Ranking health professionals 3 and 12; patients/service users 13, 17 and 18; carers 19.
9. Debridement for healing.
l Does (surgical and non-surgical) debridement promote healing in patients with pressure ulcers?
What is the most effective debridement strategy?
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Ranking health professionals 11; patients/service users 14; carers 2 and 10.5.
10. Dressings for healing.
l How effective are wound dressings in the promotion of pressure ulcer healing, including honey
dressings? What is the optimal number of times that dressings should be changed to promote
pressure ulcer healing?
Ranking health professionals 10 and 13; patients/service users 11; carers 7 and 8.
The following three topics were raised by all three groups but were ranked lower:
11. Dressings and zero friction products for prevention.
l How effective are dressings and zero-friction fabric products in preventing pressure ulcers?
Ranking health professionals 26; patients/service users 16; carers 16.
12. Heel protectors for prevention.
l How effective are heel protectors in preventing pressure ulcers?
Ranking health professionals 15; patients/service users 20; carers 9.
13. Topical products and skincare regimes for prevention.
l How effective are topical skincare products at preventing pressure ulcers, for example the
application of barrier creams or sprays [Sudocrem® (Allergan plc) and CavilonTM (3M)], methylated
spirits and moisturisers? Does the use of skincare regimes diminish the likelihood of pressure ulcer
occurrence, for example, for patients confined to bed, does treating with washing, surgical spirit
and/or talcum powder at all pressure areas prevent the occurrence of pressure ulcers?
Ranking health professionals 24; patients/service users 25, 26 and 27; carers 12 and 17.
Nine topics were raised by just two groups and were lower ranked:
14. Exercise for prevention.
l For people with limited mobility, does exercise coaching help in the prevention of pressure ulcers?
Do community physiotherapy interventions change the incidence of pressure ulcers?
Ranking patients/service users 14; carers 10 and 15.
15. Risk assessment scale/tool.
l Is using a pressure ulcer risk rating scale/tool better than clinical judgement in preventing pressure
ulcers and is there a best scale?
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Ranking health professionals 23; patients/service users 19.
16. Service models for prevention.
l What impact do different service models have on the incidence of pressure ulcers? For people with MS
or spinal injury, is working with specialist clinicians more effective for prevention than working with
generalists? Does access to a specialist wound prevention service improve pressure ulcer prevention?
Ranking health professionals 15 and 22; patients/service users 11.
17. Incontinence products for prevention.
l How effective are incontinence devices in the prevention of pressure ulcers? Do cheap incontinence
pads cause more irritation than expensive pads?
Ranking health professionals 19.5; carers 13.
18. Involvement and healing outcomes.
l Does getting people with pressure ulcers and their carers more involved in their own pressure ulcer
management improve ulcer healing? If so, what are the most effective models of engagement, for
example what is the most effective way for family carers to be involved to help ulcer healing and
how effective is education for lay carers in promoting pressure ulcer healing including
understanding and concordance to recommendations (like turning regimes, diet, fluids)?
Ranking health professionals 6 and 7; carers 6 (note patients raise this in terms of prevention
not treatment).
19. Continuity of care and healing outcomes.
l How does continuity of care impact on treatment of pressure ulcers?
Ranking patients/service users 8; carers 4.
20. Pain relief.
l For people with pressure ulcers (including people with MS), which analgesics are effective and safe
for the treatment of pressure ulcer-related pain?
Ranking patients/service users 3; carers 15.
21. Topical agents for healing.
l What is the value of topical agents in promoting pressure ulcer healing (including honey-based
treatments and the application of sugar)?
Ranking patients/service users 15 and 19; carers 16.
22. Negative pressure wound therapy for healing.
l How effective is negative pressure wound therapy as a treatment for pressure ulcers?
Ranking patients/service users 16; carers 20.
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These topics indicated shared levels of agreement between stakeholders. In addition, there were a number
of uncertainties that had been identified and ranked by one group only.
In a voting sheet exercise (see Appendix 5) conducted at events on Worldwide STOP Pressure Ulcer Day,
60 stakeholders ranked the three most important prevention and three most important treatment
uncertainties that had been submitted by one stakeholder group only. The events attracted more health
professionals than patients or carers, with 50 votes cast by health professionals, six by patients and four
by carers.
The most highly ranked uncertainties raised by one group but agreed by all three groups were:
l Do staffing levels have an impact on the incidence of pressure ulcers (originally raised by health
professionals and ranked joint 4th)?
l Is staff training effective in improving pressure ulcer healing (originally raised by patients and
ranked 5th)?
l What is the most effective way of keeping clean (personal hygiene) to aid pressure ulcer healing
(originally raised by patients and ranked 9th)?
l For people in hospital at risk of developing pressure ulcers, is the current organisation of nursing care
effective as best practice in the prevention of pressure ulcers (originally raised by patients and
ranked 24th)?
l How effective are pressure ulcer grading systems in determining the amount of skin damage and does the
use of such scales improve ulcer healing (originally raised by health professionals and ranked joint 4th)?
There was no clear agreement across groups on the following uncertainty but it gained a high number
of votes:
l How does continuity of care impact on the prevention of pressure ulcers (originally raised by carers and
ranked 5th)?
Eight members of PURSUN UK took part in a workshop at Leeds Centre for Independent Living to hear
about the process so far, identify any gaps and rank the three most important prevention and three most
important treatment uncertainties that had been submitted by only one stakeholder group. The most
highly ranked treatment uncertainties were:
l How effective are pressure ulcer grading systems in determining the amount of skin damage and does
the use of such scales improve ulcer healing (originally raised by health professionals and ranked
joint 4th)?
l Is staff training effective in improving pressure ulcer healing (originally raised by patients and ranked 5th)?
l What is the most effective way of keeping clean (personal hygiene) to aid pressure ulcer healing
(originally raised by patients and ranked 9th)?
These had also been selected in the voting exercise above. Participants also ranked the following
prevention uncertainties highly but did not agree on a whole group set of priorities:
l How effective in preventing pressure ulcers is having a wound care champion (particular staff,
managers or personal carers responsible for the prevention of pressure ulcers) (originally raised by
health professionals and ranked 17th)?
l For wheelchair users at risk of developing pressure ulcers, what is the most effective method of
pressure mapping to assess pressure areas at risk to prevent the development of pressure ulcers
(originally raised by patients and ranked 17th)?
l For people in hospital at risk of developing pressure ulcers, is the current organisation of nursing care
effective as best practice in the prevention of pressure ulcers (originally raised by patients and
ranked 24th)?
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l Do staffing levels have an impact on the incidence of pressure ulcers (originally raised by health
professionals and ranked joint 4th)?
l How does continuity of care impact on the prevention of pressure ulcers (originally raised by carers and
ranked 5th)?
Two uncertainties were identified by PURSUN UK that were different from those in the first exercise and
the results were fed into the shortlisting process.
Home and bedside interviews
Although there had been success in engaging, as primary participants, specific patient/service user groups
(including wheelchair users, those at home, living independently or supported by family or carers, and
people aged 40–64 years), there had been less success in engaging with older people and those living in
care settings. We knew from the Leeds prevalence survey (see Chapter 2) that older people and particularly
those in nursing homes were under-represented in the prioritisation process. To address this, efforts were
made to interview people at risk of pressure ulcers in care homes and a rehabilitation centre. Permission
was granted to access three sites and two site visits were made. The rehabilitation centre could not identify
anyone at risk who was able to participate. We also found that the formal consent processes required by
the conditions of ethics approval were off-putting to residents of care homes, who were willing to speak
informally. Although the steering group agreed that this work was important because of the effective
disempowerment of people in care settings, the complexity of the task required more resources than
available and the group felt that this was something that should be addressed in future research. Health-
care professionals and carers had also taken part in the survey, generating uncertainties about all patient
groups, and it was hoped that this would, at least to some extent, make up for these missing voices.
Final priority-setting meeting
The pre-workshop questionnaire can be found in Appendix 6. The voting scores from each round are
available on request.
Top 12 uncertainties
The top 12 uncertainties chosen at the final meeting were ranked in order of decreasing priority as follows:
1. How effective is repositioning in the prevention of pressure ulcers?
2. How effective at preventing pressure ulcers is involving patients, family and lay carers in patient care?
3. Does the education of health and social care staff on prevention lead to a reduction in the incidence
of pressure ulcers and, if so, which are the most effective education programmes (at organisational
and health/social care level)?
4. What is the relative effectiveness of the different types of pressure-relieving beds, mattresses, overlays,
heel protectors and cushions (including cushions for electric and self-propelling wheelchairs) in
preventing pressure ulcers?
5. What impact do different service models have on the incidence of pressure ulcers including staffing
levels, continuity of care (an ongoing relationship with the same staff members) and the current
organisation of nursing care in hospitals?
6. What are the best service models (and are they sufficiently accessible) to ensure that patients with
pressure ulcers receive the best treatment outcomes (including whether or not getting people with
pressure ulcers and their carers more involved in their own pressure ulcer management improves ulcer
healing and, if so, the most effective models of engagement)?
7. For wheelchair users sitting on a pressure ulcer, how effective is bed rest in promoting pressure
ulcer healing?
8. How effective are wound dressings in the promotion of pressure ulcer healing?
9. Does regular turning of patients in bed promote healing of pressure ulcers?
10. Does improving diet (eating) and hydration (drinking) promote pressure ulcer healing?
11. How effective are surgical operations to close pressure ulcers?
12. How effective are topical skincare products and skincare regimens at preventing pressure ulcers?
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The results of group votes in the final priority-setting meeting are available on request. Each uncertainty
is made up of many individual broad and nuanced questions that have been condensed and combined
throughout the process. A summary of the range of specific interventions, comparators and population
groups behind each question, which may be useful for commissioning and designing specific research
projects, is available on request.
Evaluation
Sally Crowe, the JLA representative and ‘honest broker’ for the process, told the steering group that she
‘thought that the process had demonstrated integrity and authenticity in what was a particularly difficult
patient group to reach, and that it had used interesting innovative methodologies including the Dialogue
model and social media’. The full steering group evaluation is available on request.
Discussion
Given the relative scarcity of high-quality research evidence for pressure ulcer management and finite
funding for health research, competing research topics need to be prioritised to ensure investment yields
maximum benefit. The JLAPUP produced an agreed, ranked list of condition-specific intervention
uncertainties, which are being disseminated to funders and the wider research community. These were
submitted to NICE as part of its pressure ulcers guideline consultation. Two of the five research
recommendations made by NICE in the updated clinical guidelines,181 namely repositioning to prevent
pressure ulcers and pressure-redistributing devices for prevention, were from the JLAPUP top 12 questions
for research. The remaining three NICE research recommendations: pressure ulcer wound debridement,
negative pressure wound therapy and risk assessment appeared in the JLAPUP top 30.
The majority of uncertainties (71.9%) related to the effectiveness of interventions. Of these, the most
frequently submitted uncertainties related to methods of pressure and shear reduction and relief (30%)
and the organisation of care (30%). In total, 61% of research questions generated focused on prevention
as an investigative outcome and 32% focused on healing. Research into pressure ulcer prevention was
therefore identified as an important research gap in the consultation phase. However, in the deliberative
phase, research into treatment was also given high priority on the basis that some pressure ulcers are
unavoidable and in light of the enormous level of uncertainty about treatment effectiveness in this area.
In addition to the effectiveness of treatment and prevention interventions, stakeholders also placed high
priority on research concerned with causes, diagnosis and prognosis of pressure ulcers and other aspects
of pressure ulcer care. In keeping with previous PSPs, the JLAPUP also raised questions about the
effectiveness and harmonisation of NHS service models and the best means of supporting patient and
family self-care within those models.
The JLAPUP faced the particular challenges in developing patient and public involvement because those
affected by pressure ulcers are often elderly, immobile, unrepresented and unwell, with many living with
concurrent long-term conditions. In the absence of patient groups and charities with a wound care focus,
the JLAPUP provided a point of focus, developing ‘live’ and virtual networks with individuals and groups
affected by, but not organised around, the topic of pressure ulceration (e.g. the Multiple Sclerosis Society
and the Spinal Injuries Association) and with the newly emerging PURSUN UK. Participants in the process
were generally younger and more likely to be living at home than the pressure ulcer population as a
whole. People in more formal care settings (including people in nursing homes and hospital inpatients)
were under-represented compared with the pressure ulcer population as a whole. These omissions may
be offset to some extent by the inclusion of uncertainties from health professionals and carers for
these groups.
Decision-making in the JLAPUP was carried out by patients, carers and clinicians working together but
supported by researchers and a patient and public involvement officer with expertise in participatory
research methods, systematic reviews, survey design and the conduct of RCTs. The JLAPUP process
revealed the level of difficulty in structuring meaningful conversations with patients, carers and health
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professionals about uncertainty as a concept and also the difficulty for stakeholders in acknowledging that
some strongly held beliefs about wound care are actually big research uncertainties. The strengths and
weaknesses of the JLAPUP approach have been discussed in a separate methodological paper.177 An
important limitation of this approach to research prioritisation, however, is that it prioritises research within
a narrow topic and only from the perspective of those directly affected (and relevant clinicians) rather than
from wider societal perspectives. This approach also avoids any consideration of the economics of research
and the comparative efficiencies of investing to reduce uncertainty in one area relative to another.
Alternative approaches to research prioritisation, specifically value of information approaches, apply these
other perspectives.182
Overall conclusions from workstream 2
In-depth interviews with people with different complex wounds, carers and health professionals aimed to
elicit the views of as wide a range of people as possible on the relative importance of different outcomes
of wound treatments. We particularly wanted to hear the views of past and current intravenous drug users
with complex wounds as their voices had not previously been heard. We heard from them that it can be a
struggle coming to terms with the fact that they may have inflicted irreparable damage to the veins in their
legs such that chronic ulceration may be a permanent feature.
Most patients and health professionals identified healing as a treatment outcome of primary importance.
Patients and professionals were focused on achieving healing as quickly as possible while managing pain,
infection and discomfort. Most also spoke about the difficulties that they were experiencing in achieving
healing as well as concerns about preventing recurrence. Health professionals reported a lack of sense of
achievement because they rarely saw the outcomes of their interventions, whereas many patients and
carers reported feeling left ‘in limbo’ and as if their lives were ‘on hold’. They wanted to ‘get their lives
back’. Wound care was largely targeted at trying to heal the wound rather than helping the patient live
with a long-term condition and its consequences.
Our review of the funding source and quality of reports of trials of complex wound interventions was
driven by several factors. First, we had a perception, but no evidence, that most of the trials in wound
management were undertaken by the pharmaceutical and devices industry as part of marketing strategy.
Knowing who funds wound treatment studies is important because then we can know who to influence
to improve the overall quality of the research. We also wanted to know whether industry-funded research
was of higher or lower methodological and reporting quality than non-industry-funded research. However,
particularly important in the context of this workstream, we wanted to know whether or not the outcomes
that wounds researchers are measuring and reporting in treatment trials bear any resemblance to those
regarded as most important by patients, carers and health-care professionals.
Our review of RCTs of complex wound treatments indicated that, although 41% declared a commercial
funding source, 26% did not report any funder or the commercial status of the funder was unclear. Trials
of complex wound treatments suffer from a range of methodological deficiencies: they have small sample
sizes (median of 60 participants), short follow-up periods (median of 2.8 months), widespread use of
surrogate healing measures (28% of trial primary outcomes) and frequently no primary outcome specified
(41% of trials). Of those trials that specified a primary outcome, 89% specified some measure of healing,
although this was a surrogate measure in approximately half of cases. An astonishing 94% of the trials we
examined were at unclear or high risk of bias for selection and/or detection bias. Funding source was not
associated with any difference in study quality; commercially funded studies had similar sample sizes,
durations of follow-up, outcomes and risk of bias.
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The JLAPUP process revealed the extent of research uncertainty about pressure ulcer treatment and
prevention. An existing, reliable answer in the research literature was found for only one of the 960
intervention uncertainties submitted in the process. A prioritised list of 12 uncertainties in pressure ulcer
prevention and treatment was successfully determined by a collaborative and consultative process involving
patients, carers and clinicians.
Given the relative absence of high-quality research in complex wound prevention and treatment, the
research agenda is infinite. Complex wounds research is also an area of research without a rich history of
patient and public involvement. We therefore conceptualised a JLA PSP as a good way of addressing these
two deficiencies. We selected pressure ulcer prevention and treatment as the focus of this work because
those affected (people at risk, not just people with existing pressure damage) are probably the hardest to
reach group of people affected by complex wounds. The majority of people with, or at risk of, pressure
ulcers tend to be very elderly, with multiple comorbidities and by definition with very limited mobility.
Pressure ulcers have not been seen as a unifying force for patient allegiance, probably because, apart from
the poor general health of those affected, they are a consequence of other health deficits rather than
being the primary diagnosis. This became particularly apparent when a colleague on the JLAPUP steering
group tried to discuss pressure ulcer research with people in a nursing home at high risk. These people,
perhaps understandably, could not see the point of a conversation about something that had not yet
happened to them when so many other things already had. These contextual factors mean that our
research priorities for pressure ulcers largely reflect the views of younger disabled people, carers and health
professionals rather than those of older people at high risk of pressure injury. They are nonetheless a great
step forward.
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Chapter 4 Evidence synthesis for clinical decision-
making (workstream 3)
Abstract
Background
Up-to-date summaries of current research evidence are needed to inform clinical decision-making.
A variety of methodologies is now available for synthesising the data from different primary intervention
studies including traditional meta-analysis, IPD meta-analysis and mixed-treatment comparison
meta-analysis. Our objectives were to identify areas of high decision uncertainty in collaboration with
our NHS colleagues and summarise the best available evidence using appropriate techniques.
Methods
Methods included stakeholder consultation to identify decision uncertainties; a scoping review of the
evidence for silver-containing wound dressings for treating venous leg ulcers; application of Cochrane
methods of systematic review to 11 complex wound topics; and mixed-treatment comparison meta-
analyses of dressings for diabetic foot ulcers and venous leg ulcers.
Results
Techniques involving facilitated, face-to-face contact with health professionals performed best in
generating clinical uncertainties as topics for evidence synthesis. The relative effectiveness of different
wound dressings for different wound types had high priority. There was no evidence that silver dressings
were more effective than non-antimicrobial dressings for healing venous ulcers; however, variability in the
existing trials precluded IPD meta-analysis. A series of Cochrane reviews in prioritised topics identified
several wound treatments that appear to be more effective than others in different wound types. The
matrix hydrocolloid dressing was associated with the highest probability (70%) of being the best dressing
for diabetic foot ulcers, whereas a hyaluronan fleece dressing had the highest probability (35%) of being
the best for venous ulcers; however, in both cases there was high uncertainty and poor-quality evidence.
Conclusions
A range of approaches to evidence synthesis was applied to complex wound treatments across a broad
range of topics that had been prioritised by health-care professionals. This approach identified some
treatments associated with the highest probability of effectiveness.
Background
To date, the Cochrane Wounds Group has identified around 9500 clinical trials in wound management
and assembled them on its Specialised Wounds Register [see http://wounds.cochrane.org/ (accessed
11 May 2016)]. Evidence synthesis methods, such as systematic review, enable the management of
information from multiple primary studies by identifying, summarising, appraising and pooling groups of
primary studies in relation to a predefined research question.183 The standard systematic review approach
detailed in the Cochrane Handbook for Systematic Reviews of Interventions163 describes methods to
manage information, reduce subjectivity, establish generalisability and consistency, improve power and
precision and identify gaps in the research. The aim is usually to derive a summary estimate of effect from
multiple primary studies (e.g. in terms of treatment effectiveness) while minimising bias in the review
process. To date, systematic reviews conducted under the auspices of the Cochrane Wounds Group have
contributed important information to the evidence base in wound management. For example, we know
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that compression is an effective intervention for healing venous leg ulcers184 and that higher-specification
foam mattresses reduce the incidence of pressure ulceration compared with standard hospital foam
mattresses.180 This said, it should be acknowledged that the standard systematic review methods can be
restrictive as they are based mainly on pairwise comparisons and group-level data. Other, more advanced,
systematic review and meta-analysis methods are now available that may be more informative in areas of
persisting uncertainty. These include those based on IPD and those involving mixed-treatment comparison
meta-analysis.
Individual patient data meta-analysis involves the identification and retrieval of original patient-level data
from the primary investigators, who are invited to become research collaborators along with the review
team. Data are recoded, checked, cleaned and reanalysed. Advantages include the potential to conduct
powerful time-to-event analyses adjusted for predictive patient-level covariates. This helps to obtain a more
precise estimate of treatment effect and so reduce uncertainty. Other advantages include opportunities to
conduct meaningful subgroup analyses based on patient-level factors, reinstate patients who the primary
investigators have excluded from their own analyses, include updated data on the event in question from
follow-up beyond the trial end point and combat poor reporting through close collaboration with the
primary investigators.185 As such, IPD meta-analysis has been proposed as the ‘gold standard’ among
systematic reviews because of its potential to generate estimates on the most complete and clean data set
possible with full adjustment for predictive covariates.186 It is particularly useful when there is considerable
uncertainty (imprecision) despite the existence of a good-quality systematic review of trial-level data,
together with a suspicion that important patient-level covariates are contributing to the imprecision.
One such example from wound care relates to the comparison of the effects of the four-layer compression
bandage and the short-stretch bandage on the healing of venous leg ulcers. In this case, an earlier
Cochrane review had not shown a difference in healing between the two bandages when trial-level data
were pooled,184 whereas a subsequent IPD meta-analysis of the same comparison, involving estimation
from an adjusted Cox proportional hazards model, showed that, on average, patients healed faster with
the four-layer bandage.187 The main issue with undertaking IPD meta-analysis is that the success of the
endeavour is contingent on the review team being able to access the original data for each eligible primary
study, although IPD meta-analysis may still be beneficial even if data can be obtained for only a subset of
eligible studies. Access to the original patient-level data may not always be straightforward; for example,
data may no longer be available for older studies. In addition, such reviews take longer and are more
resource intensive than standard systematic reviews of group-level data.
Pairwise comparisons of several types of interventions within a review can provide some useful
information, depending on the number of different interventions available. However, when there is a
range of competing interventions, multiple pairwise comparisons may not be informative for decision-
makers, particularly when active treatments are always compared with placebo or usual care. In such cases
it can be impossible to draw valid conclusions regarding the relative effects of several competing
technologies and standard meta-analysis does not lend itself to the ranking of treatments in terms of their
estimated effectiveness. Wound dressing selection is an aspect of health care, like many others, in which
there are many competing interventions for the same indication, in which strong claims are made in the
marketing literature regarding relative treatment effects and in which clinicians understandably struggle to
make informed choices.188 Mixed-treatment comparison systematic review and meta-analysis enables more
than two different interventions to be compared simultaneously by extending the standard method of
meta-analysis using a Bayesian model to utilise both direct and indirect comparisons within a network
of evidence. Mixed-treatment comparison meta-analysis also provides the opportunity to rank interventions
according to their probability of being the best intervention relative to the others in the network.189 Issues
with the mixed-treatment comparison approach include the need to meet assumptions such as consistency
between evidence derived from direct and indirect comparisons190 and how to deal with variation in risk of
bias across different parts of the network.191 As with standard meta-analysis, variation in risk of bias across
trials is always a concern as is variation in any other characteristic that influences treatment effects.
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With a choice of possible review methods in mind, workstream 3 began with a consultation exercise with our
NHS partners to identify high-priority topics for evidence synthesis. This was followed by consideration of
suitable topics for advanced methods of evidence synthesis, as well as earmarking those appropriate for new
and updated Cochrane reviews. The aims of this were to provide some immediate evidence to inform practice
by making maximum use of existing evidence as well as to identify gaps in the evidence to inform future
research. In this chapter we report the methods and results of the following four pieces of work:
1. the identification and prioritisation of topics for evidence synthesis
2. selecting candidate topics for IPD meta-analysis
3. undertaking new and updating existing high-priority Cochrane systematic reviews
4. mixed-treatment comparison meta-analysis in high-priority topic areas.
The identification and prioritisation of topics for
evidence synthesis
Introduction
Evidence synthesis methods such as systematic review facilitate information management and clinical
decision-making through the selection, appraisal and synthesis of primary studies that address a common,
predefined question. Advantages of evidence synthesis include the potential to derive a summary estimate
of treatment effect from multiple primary studies, improved precision, reduction of bias and the
identification of gaps in the evidence base.183 Such review work is resource intensive and it is important
therefore that systematic review topics are important and meaningful to health-care decision-makers.
For the purposes of this programme grant it was essential that topic selection for evidence synthesis was
service led (as opposed to researcher led) to provide the most pertinent research-based information to
the NHS.
A key feature of workstream 3 was the early identification and prioritisation of evidence synthesis topics
through detailed consultation with our NHS collaborators (Leeds Community Healthcare NHS Trust).
The main focus was on identifying areas relating to treatment effectiveness but other types of research
questions were also considered. Topics could relate to any type of complex wound. The purpose of this
was to identify areas that were deemed important for informing clinical practice and implementation,
and for which health professionals felt that there was current uncertainty in terms of the evidence for
best practice.
Objective
The objective was to identify a clinician-led, prioritised list of topics for evidence synthesis across all
complex wound types, particularly those in relation to treatment effectiveness.
Methods
The identification and prioritisation process was carried out in two stages: harvesting of topic ideas and
matching of ideas against currently available literature.
Harvesting of topic ideas
Topic ideas were obtained in three ways: by talking to participants at the programme grant’s launch event;
by consultation with community clinical teams; and from enquiries sent via the programme grant’s website.
Consultation with participants at the launch event
The launch event for this programme grant took place during September 2009 and consisted of
presentations, dedicated stands for each workstream, refreshments and opportunities for informal
networking. The stand for workstream 3 included demonstration of, and access to, The Cochrane Library
where delegates could attempt searches on research questions of interest to them if they wished.
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This helped to stimulate informal discussion about what could be important topics for evidence synthesis
and provided a valuable opportunity to discuss possible uncertainties relating to practice. Delegates were
invited to leave their contact details indicating an interest in contributing to workstream 3 in terms of
further follow up, discussion and consultation. During the launch day presentations, delegates were invited
to put forward topic ideas for evidence synthesis; some ideas came to light in the discussion period
immediately following the presentations, whereas others filtered through to the programme grant team
after the launch day, either directly (e.g. by e-mail or via the website) or via the clinical teams.
Consultation with community clinical teams
During January 2010, SO’M attended two routine meetings of community clinical teams in Leeds:
podiatry and nursing (consisting of members of the tissue viability nursing team, community nurses and
intermediate care nurses). In both instances, clinicians had been provided with details of the consultation
exercise in advance and had been asked to reflect on possible topic ideas and uncertainties for evidence
synthesis prior to the meetings. During both meetings, SO’M explained the purpose of the consultation
exercise, emphasising the importance of having a list of ideas that had originated from health practitioners
rather than from researchers. She then explained that, in particular, questions and uncertainties relating to
treatment effectiveness were sought, but that any type of research question could be considered in the
wider context of the programme grant and future research agenda. She made a brief presentation in
which the following were explained: the purpose of the programme grant; the collaboration between
Leeds NHS and the University of York; the focus on complex wounds; and a brief overview of the three
workstreams. Finally, a structure for research question formulation was presented, based on the key
domains of PICO.174 Participants were invited to use this if they wished, to help structure research ideas.
Relevant examples were provided (Tables 51 and 52) and hard copies of similar information were tabled,
having already been circulated prior to the meeting. There then followed a period of discussion during
which participants raised and discussed ideas; all were noted for later collation and assessment against
existing literature. A follow-up e-mail was sent to group members during February 2010 to capture ideas
emerging later and to target those who had been unable to attend the team meetings. In addition, the
leaders of each clinical team forwarded any other ideas expressed to them by team members individually
that had not already been captured.
TABLE 51 Example of using PICO: nursing team
PICO component Definition Example
P Participants Patients with venous leg ulceration
I Intervention Four-layer bandage
C Comparator Short-stretch bandage
O Outcome Complete healing of ulcer
TABLE 52 Example of using PICO: podiatry team
PICO component Definition Example
P Participants Patients with diabetic foot ulcers
I Intervention Silver-impregnated dressing
C Comparator Povidone iodine dressing
O Outcome Complete healing of ulcer; resolution of ulcer infection
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Enquiries sent via the programme grant website
During February 2010, follow up e-mails were sent to delegates who had indicated an interest in
workstream 3 during the launch event and also to members of the two clinical teams to invite submission
of later ideas. Web pages were set up to enable submission of ideas online and information about PICO
was posted on the website to assist with question formulation and focusing of uncertainties.
Matching of ideas against currently available literature
All ideas were summarised and tabulated, with grouping according to wound type. Database searches
were then undertaken to seek relevant evidence addressing the uncertainties raised. The databases
accessed included MEDLINE and those housed in The Cochrane Library; all were searched from inception
to February 2010. Results were tabulated, with this then being circulated to the programme grant working
team to discuss appropriate actions.
Results
Overall, 26 research questions were identified. Nine emerged from consultation with the community
podiatry team, 10 from consultation with the nursing team and three from discussions with delegates
during the launch event, and four came from a community dietitian. The research questions are listed in
the following sections, grouped according to wound type.
Research questions relating to foot ulcers and other foot conditions
1. What is the best package of care for people with non-diabetic foot ulcers?
2. What is the impact of the time lag involved in obtaining the dressing, antibiotic or other treatment that
the podiatrist feels is clinically indicated?
3. What is the relationship between debridement and healing in all types of foot ulcers?
4. What is the effectiveness of a silver dressing compared with a povidone iodine dressing for treating
diabetic foot ulcers?
5. What are the best strategies for detecting and treating infection in diabetic foot ulcers?
6. What is the cost-effectiveness of different dressings for healing after nail surgery (silver, povidone
iodine, non-adherent)?
7. What is the best way to diagnose osteomyelitis in patients with diabetic foot ulcers?
8. What is the acceptability of different dressings for those with foot ulcers who self-care?
9. What is the significance of locus of control issues regarding the patient’s view of his or her own
adherence with foot ulcer treatment [e.g. ‘It doesn’t matter what I do, you (i.e. the podiatrist) have to
make it heal’]?
Research questions relating to leg ulcers
1. What is the effectiveness and cost-effectiveness of ‘breathable’ foam film dressings (e.g. Allevyn®, Smith
& Nephew, London, UK) compared with absorbent dressings used with leg ulcers?
2. What is the effectiveness of silver dressings used with venous leg ulcers?
3. How does obesity affect healing of leg ulcers?
Research questions relating to pressure ulcers
1. What is the best management of underweight patients deemed to be at risk of pressure ulceration in
relation to support surfaces?
2. What are the best ways to measure shear force in wheelchair users in relation to preventing and
treating pressure ulcers?
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Research questions relating to surgical wounds
1. What is the effectiveness of topical negative pressure compared with conventional dressings such as
hydrocolloid or alginates when treating dehisced abdominal wounds?
2. How does obesity affect healing of dehisced abdominal wounds?
3. What are the best strategies for post-operative care of pilonidal sinus? Is it better to pack or not
to pack?
Research questions relating to all wound types
1. What role should Edinburgh University Solution of Lime (EUSOL) have in wound management?
2. Is direct application of steroids and antifungal preparations to the wound bed effective?
3. What is the role of protease-modulating matrix dressings (e.g. Promogran®, Systagenix, Gargrave, UK)
in wound management?
4. What is known about overgranulation (or hypergranulation)?
5. What is the best way to manage wounds in mental health patients who have dementia?
6. How many of those with complex/chronic wounds also have nutritional risks (e.g. poor hydration,
undernutrition, 10% unintentional weight loss, poorly controlled diabetes, artificial feeding
and obesity)?
7. Do complex wounds have an impact on patients’ ability to shop, prepare, cook or eat all their meals
and drink all their drinks throughout the day and hence their overall food and fluid intake, resultant
nutritional status and quality of life?
8. Which nutritional interventions aid wound healing?
9. Could food fortification using dried milk powder promote wound healing?
Actions taken following identification of relevant literature
Several research questions were identified as being of high priority and these resulted in new reviews or
review updates. These included questions relating to choice of dressings for diabetic foot ulcers and
venous leg ulcers. The following new reviews and review updates were conducted:
l a series of Cochrane systematic reviews on dressings for diabetic foot ulcers192–195
l a systematic review and mixed-treatment comparison meta-analysis of all dressing types in patients
with diabetic foot ulcers196
l two Cochrane reviews of non-antimicrobial dressings in venous leg ulcers197,198 and a substantive
update of a Cochrane review on antimicrobial interventions for venous leg ulcers199
l a scoping review of silver-impregnated dressings used with venous leg ulcers (see Chapter 4, Discussion)
l a substantive update of a Cochrane review on nutritional interventions for preventing and treating
pressure ulcers200 (note: this publication is not claimed as an output of the programme per se; however,
the high priority of the topic stimulated us to strongly encourage the Cochrane reviewers to update the
review and we expedited the editorial process to facilitate this).
The question on whether or not complex wounds impact on patients’ quality of life was addressed in
workstream 2. Relevant and informative literature was identified for two questions on foot ulceration
(namely care of people with non-diabetic foot ulcers and debridement of all types of foot ulcers) and the
pertinent documents were forwarded to the podiatry team of Leeds Community Healthcare NHS Trust.
Several other topics did not appear ripe for evidence synthesis because there was no, or very little,
available primary research and no further action could be taken in terms of systematic review:
l cost-effectiveness of different dressings for healing after toenail surgery
l obesity as a risk factor for delayed healing in leg ulcers
l management of underweight patients at risk of pressure ulceration
l post-operative strategies for pilonidal sinus
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l the role of EUSOL in wound management
l topical application of combined steroids and antifungal treatments to the wound bed
l overgranulation
l management of wounds in patients with dementia
l prevalence of nutritional risk factors in people with complex wounds.
Several other research questions were considered to be outside of the remit of the programme and were
not progressed further. Examples include locus of control issues for people with foot ulcers, measurement
of shear forces in wheelchair users and treatment of dehisced surgical wounds (covered by another
programme grant [see www.nihr.ac.uk/funding/funded-research/funded-research.htm?postid=2194
(accessed 2 June 2016)]. Further details are shown in Appendix 7.
Discussion
While working closely with our NHS partners to prioritise topics for evidence synthesis we found
face-to-face contact with clinicians was the most fruitful approach. Participants were facilitated in
formulating PICO questions within the context of team meetings and at the research programme’s
launch event we provided opportunities to view and use The Cochrane Library, which provided a useful
focus for discussion about uncertainties.
The research questions obtained reflected much uncertainty around the best choice of dressings for
different wound types. These uncertainties were addressed through a series of new systematic reviews and
systematic review updates undertaken during the course of the programme. Several topic areas emerged
for which there was very little primary material and research funders may wish to consider these.
Several would appear to be of importance given demographic changes and the increasing proportion of
older people with multiple morbidities.201 These could include the management of complex wounds in
people with obesity or mental illness or both. A further potential area for future primary research is
postoperative care of patients undergoing toenail surgery (most frequently for ingrown toenails). Such
surgery is common and complications such as delayed healing, infection and poor cosmesis can occur.202
There is no relevant national clinical guideline and much uncertainty remains in terms of optimum methods
of avulsion and post-operative care, for example choice of dressings.203 Finally, there remains much
uncertainty around the relationship between nutritional status and wound healing. Evidence suggests that
malnutrition is common in community-based patients with wounds;204 however, the effect of specific
nutritional interventions remains unclear.200,205 Future research should address the prognostic performance
of different nutritional risk factors in predicting ulcer incidence and healing. Also, efforts should be made
to identify specific nutrients most likely to promote effective wound prevention and healing.
Selecting candidate topics for individual patient data
meta-analysis
Background
Venous leg ulcers are common, costly and impact adversely on patients’ health-related quality of life.206–209
Many of these wounds are colonised by bacteria or show signs of clinical infection and the presence of
infection may delay healing.210,211 The classic signs of infection include local pain, heat, redness, swelling
and purulence; however, it has been suggested that these may not always be present in patients with
venous leg ulcers. In light of this, other signs and symptoms have been proposed as an alternative method
of assessment. These include delayed healing, unexpected pain, abnormal odour, pocketing at the base of
the wound, discoloured (i.e. unusually dark) granulation tissue, friable granulation tissue and devitalised
(sloughy or necrotic) tissue. These characteristics are sometimes referred to collectively as the signs and
symptoms of critical colonisation.212,213
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Strategies for treating infected wounds include systemic antibiotics and topical antimicrobial agents.
Silver-impregnated dressings are examples of topical antimicrobial applications; this intervention emerged
as a priority topic for systematic review during consultation with clinicians. The history of using silver
applications to treat infected leg ulcers dates back to at least the early twentieth century.214 Recent years
have seen a resurgence of interest in these products, together with intensive marketing by manufacturers;
this has coincided with increased prescription. Silver-impregnated dressings are used frequently in the NHS
and are costly, accounting for approximately £26M in prescription costs (representing 22% of the total
cost of advanced wound dressings) for primary care in England during 2008/9.215
Most evidence from systematic reviews does not suggest a benefit of using silver compared with other
types of dressings in terms of healing venous leg ulcers.216–218 However, the current evidence is based
on group-level data and it is possible that true treatment effects can be concealed when important
patient-level prognostic factors are not controlled for. A more powerful analysis based on IPD may be
more informative and therefore aid clinical decision-making.186
Aim and objectives
This study had the aim of establishing the value and feasibility of conducting an IPD meta-analysis of RCTs
of silver-containing wound dressings for the treatment of venous leg ulcers. To meet this aim we had the
following objectives:
l to estimate the numbers of available RCTs of silver dressings and trial participants
l to characterise the comparisons made within existing trials
l to analyse the group-level data from trial reports of silver dressings
l to explore trial-level covariates
l to consider the clinical heterogeneity between existing trials.
Methods
A scoping review of the literature was undertaken. A single reviewer undertook study selection, data
extraction, risk-of-bias assessment and data synthesis.
Study selection criteria
Randomised controlled trials evaluating silver-impregnated dressings used in people with venous leg
ulceration and which reported an objective assessment of healing were included. Evaluations of topical
silver sulfadiazine were excluded because this is used mainly as a treatment for burns. Comparator
interventions included non-antimicrobial dressings of any type including a policy of applying dressings
chosen according to clinicians’ judgement, as may be used in pragmatic RCTs. RCTs involving comparisons
with alternative antimicrobial products were excluded, as were comparisons between different silver
applications. Evaluations involving concurrent therapies such as compression were included as long as
there was no systematic difference in cointerventions across treatment arms. For the purposes of this
review, trial outcomes relating to resolution of wound infection were noted but not explored in terms of
meta-analysis. RCTs were included only when the full report was available to allow a meaningful
assessment of comparisons, outcomes and risk of bias.
Search strategy
The Cochrane Central Register of Controlled Trials was searched from inception to October 2009.
In addition, MEDLINE, EMBASE and CINAHL were searched from the start of 2006 to October 2009 to
cover any gaps on CENTRAL caused by a time lag in indexing references derived from other databases.
The search string for MEDLINE is shown in Appendix 8. The reference lists of existing reviews were
also examined.
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Data extraction
For each eligible trial the following data were extracted:
l study identifier (first author and year of publication)
l number of randomised patients/limbs/wounds
l leg ulcer aetiology (e.g. purely venous or mixed venous/arterial)
l other wound characteristics serving as patient selection criteria in trials
l baseline ulcer infection status
l whether or not predictive covariates for healing were reported (baseline wound area and duration)
l number of patients/limbs/wounds per treatment arm
l details of interventions in each arm
l details of cointerventions used for all patients, for example compression
l frequency of dressing changes
l duration of treatment
l healing outcomes (time to healing, complete healing at given time points, change in ulcer area,
healing rate)
l outcomes relating to resolution of infection
l brief mention of other reported outcomes
l number of withdrawals per group
l funding source of trial.
Risk-of-bias assessment
The Cochrane risk-of-bias tool was used as a basis for assessment.219 Assessment focused on domains that
have been empirically demonstrated as having the potential to generate biased estimates of effect when
improperly handled, including allocation concealment, blinding of outcome assessors and handling of
incomplete outcome data.148,220–223 Details of the following were recorded from each included RCT:
l method of randomisation
l method of allocation concealment
l method of blinded outcome assessment
l methods for handling incomplete outcome data.
For each domain, an assignment of low, high or unclear risk of bias was allocated, together with the
rationale for the reviewer’s judgement. In addition, an overall risk-of-bias judgement was assigned to each
RCT according to the following decision rules. RCTs were classified as being at overall high risk of bias if
they were rated as having high risk in relation to at least one of the three key domains (allocation
concealment, blinding of outcome assessors and handling of outcome data). If none of the key domains
was rated as high risk but one or more were rated as having an unclear risk of bias, the RCT was rated
overall as having an unclear risk of bias. To attain an overall low risk of bias, all three key domains had to
be rated as low risk individually.
Data synthesis
For the purposes of this review, healing data only were analysed. The reporting of other outcomes was
described and tabulated. Methods for estimating measures of effect from individual RCTs and for pooling
data were based on standard meta-analysis methods, as described in the Cochrane Handbook for
Systematic Reviews of Interventions.224
For dichotomous data (e.g. complete healing during the trial period), the risk ratio (RR) with 95% CI
was estimated for each RCT for the comparison of silver-impregnated dressing compared with
non-antimicrobial dressings using the number of patients healed per treatment group and the total
number randomised in the group. In instances in which more than one RCT reported similar outcomes at
similar time points, the RRs were pooled using an inverse variance method to provide an overall estimation
of treatment effect. For the pooled analysis, studies were grouped according to length of follow-up
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(4–6 weeks, 9–12 weeks, 6 months and 1 year). A test of statistical heterogeneity was generated for each
pooled outcome. Statistical heterogeneity was defined as a chi-squared p-value of ≤ 0.1 and the I2 test was
undertaken to estimate the percentage of the variability in estimates of effect due to heterogeneity rather
than chance. When the I2 estimation was equal to zero, a fixed-effects model was undertaken. When I2
was greater than zero, both fixed-effects and random-effects analyses were undertaken and any difference
in estimates was noted.
It was planned to pool hazard ratio (HR) estimates if available from RCT reports. Otherwise, any data
relating to time-to-healing outcomes were recorded.
For continuous outcomes (e.g. absolute or percentage change in ulcer surface area, healing rate) the
difference in means with 95% CI was calculated for each RCT individually using the mean and SD value
per group for the reported measure, together with the number randomised to that treatment group.
When appropriate, trials were pooled using the mean difference, weighted by the inverse of the variance.
Statistical heterogeneity was assessed and managed as described above.
Exploration of potential data required for individual patient data
meta-analysis
As is the case for other types of systematic review, IPD systematic review and meta-analysis requires a
predefined protocol to set out methods and decision rules in advance of carrying out the research to
minimise bias.183 A protocol for an IPD meta-analysis describes the data that would be requested from each
participating triallist in terms of baseline and outcome variables. Many of the important data requirements
for venous leg ulcer research have already been established from prognostic research, experience with large
RCTs and an existing example of IPD meta-analysis in wound management.18,19,187,225,226 For example, larger
ulcer area and longer ulcer duration at the outset of treatment are known to be independent and significant
predictors of delayed healing.225,226 In terms of outcome assessment, time to healing is considered as much
more informative than frequency of complete healing at fixed time points or intermediate healing measures
because it provides information not only on whether or not healing occurs but also on how long it takes to
occur. This provides important insights for resource use and clinical and policy decision-making.
This review investigated further data that may be required that are more specific to the topic of silver,
particularly given its role in the management of infection. The likely availability of patient-level data was
considered in light of information from trial reports and through contact with the primary investigators.
In addition, differential treatment effect was examined in relation to several trial-level covariates. This was
an attempt to inform the set of variables required for an IPD meta-analysis by highlighting important
clinical differences between and within trials. The following variables were explored within the limits of
available data from trial reports.
Participant characteristics
Treatment effects were considered for the following subgroups:
l RCTs restricting selection to patients with venous leg ulcers as opposed to those also allowing inclusion
of individuals with mixed ulcer aetiology (venous and arterial)
l baseline ulcer infection status (e.g. defined as clinically infected, critically colonised or colonised).
Intervention characteristics
Differential treatment effects were considered for:
l different types of silver dressing
l different types of comparator dressings
l use of compression as part of the trial treatment regimen.
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Methodological considerations
The following risk-of-bias domains were examined in terms of their impact on treatment effect:
l use of a true method of randomisation compared with no specified method
l implementation of a robust allocation concealment method compared with a high-risk or an
unclear strategy
l blinding of outcome assessors compared with non-blinded or an unclear method of assessment
l analysis by intention to treat compared with a high-risk or unclear strategy for handling incomplete
outcome data.
Funding source
Treatment effect was examined in relation to the funding source. The main distinction made was funding
by a manufacturer of one of the products under investigation in the trial as opposed to funding by an
independent sponsor.
Results
Results of the literature search
The search strategy generated 355 records. Following examination of titles and abstracts, seven RCTs were
identified as being eligible for inclusion227–233 (Table 53). Two RCTs recruited people with other wound
types in addition to venous leg ulcers: pressure ulcers230 and burns, donor sites, surgical wounds, pressure
ulcers and diabetic foot ulcers.232 All seven RCTs included two treatment groups and all recruited patients
as the unit of randomisation. The total number of patients with venous leg ulcers was 1012. Data
extraction of the trials is provided in Appendix 9, presented alphabetically by first author.
Comparisons undertaken in the trials
An initial scrutiny of the trials revealed that there were differences between trials in terms of the silver
dressings, comparator dressings and the use of compression (Table 54).
The base used for the silver-impregnated dressings included foam, alginate, hydrocolloid and charcoal.
One trial of pragmatic design allowed the choice of the silver-impregnated dressing to be in accordance
with the clinicians’ judgement; options for the base material included foam, alginate, hydrocolloid,
low-adherent and non-adherent dressings.231
TABLE 53 Eligible trials identified from the search
Trial Country
Number of
patients (all)
Number of patients
(leg ulcers only)
Dimakakos 2009227 Greece 42 42
Jørgensen 2005228 Canada, Denmark, Germany, Italy,
The Netherlands, UK, USA
129 129
Lazareth 2008229 France 102 102
Meaume 2005230 France 99 71
Michaels 2009231 UK 213 213
Münter 2006232 Germany, UK, Denmark, Italy, Switzerland,
Belgium, Slovenia, Brazil, Canada
619 415
Wunderlich 1991233 Germany 40 40
Total 1244 1012
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The comparator intervention also varied across trials. Four RCTs used the non-impregnated version of the
silver dressing in the trial.227–230 Two pragmatic trials allowed participating study centres to deliver care
according to the clinicians’ choice.231,232 In one instance, 17% of patients in the control group also received
a silver-impregnated dressing.232 Another trial used various topical applications administered according to
the observed stage of healing (granulation or epithelialisation).233
In all RCTs apart from one233 it was clear that compression had been used as a standardised concurrent
therapy. In one RCT, compression was not mentioned.233 Previous research has shown that different types
of compression may perform differently in terms of promoting healing.184,187 In the context of an IPD
meta-analysis, it would be important to take account of clinically significant differences in treatment
comparisons and to include type of compression as a covariate when modelling the estimate of
treatment effect.
The duration of treatment varied across the RCTs, with four trials treating ulcers for 4 weeks,228–230,232
one for 6 weeks,233 one for 9 weeks227 and one for 12 weeks231 (see Table 54).
Analysis of healing outcomes
The following analyses are based on group-level data gleaned from trial reports. It was not feasible
to analyse all seven RCTs together because of differences in outcome measurement and duration of
follow-up. One RCT assessed the time taken for the wound to heal (time-to-event data),231 others
measured the proportion of patients with healed wounds at defined time points (dichotomous data)
227,228,231,233 and others assessed intermediate outcomes such as the change in wound surface area during
the trial or the healing rate over time.228–230,232,233 For some RCTs it was not possible to estimate measures
of treatment effect because of a lack of data.
Time to healing: one randomised controlled trial (210 patients analysed)
One RCT presented data on time to healing.231 The difference between treatment groups was not
statistically significant according to estimates of median time to healing (based on Kaplan–Meier survival
curves) or HR. The estimate for median days to healing was 67 days (95% CI 54 to 80 days) for the silver
dressing and 58 days (95% CI 43 to 73 days) for various non-antimicrobial dressings (p= 0.408, derived
from the Cox proportional hazards model). The reported HR estimate for the silver dressing compared with
the comparators was 1.13 (95% CI 0.85 to 1.15). Details of analyses based on time to healing were not
available for the other RCTs, despite several requests for details from the primary investigators.
TABLE 54 Treatment comparisons and use of compression
Trial, duration of
intervention Silver application Comparator Compression
Dimakakos 2009,227
9 weeks
Silver foam dressing Non-adhesive foam dressing Yes (short-stretch bandage)
Jørgensen 2005,228
4 weeks
Silver foam dressing Non-adhesive foam dressing Yes (according to best practice at each
study centre)
Lazareth 2008,229
4 weeks
Silver hydrocolloid
dressing
Hydrocolloid dressing Yes (according to clinicians’ choice)
Meaume 2005,230
4 weeks
Silver hydroalginate
dressing
Calcium alginate dressing Yes (system not defined but designed to
deliver 15–35mmHg ankle pressure)
Michaels 2009,231
12 weeks
Various silver dressings Various non-adherent
dressings
Yes (multilayer according to best practice
at each study centre)
Münter 2006,232
4 weeks
Silver foam dressing Local best practice
(including silver)
Yes (according to best practice at each
study centre)
Wunderlich 1991,233
6 weeks
Silver charcoal dressing Various topical agents Not mentioned
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Complete healing during the trial period: four randomised controlled trials
(424 patients analysed)
Four RCTs reported complete healing at various time points ranging from 4 weeks to 1 year.227,228,231,233
Data were grouped according to different periods of follow-up: 4–6 weeks, 9–12 weeks, 6 months and
1 year. There was no evidence for a difference between groups at any time point (Figure 12). Figure 12
shows estimates derived from fixed-effects models. Statistically significant heterogeneity was detected for
the analysis of complete healing at 9–12 weeks and so a random-effects analysis was generated that
showed a similar estimate to the fixed-effects model (RR 1.27, 95% CI 0.79 to 2.03). The observed
heterogeneity may have arisen from participant, comparator or methodological differences, or may have
occurred by chance because of the small number of RCTs included in the meta-analysis.
Intermediate measures of healing
Five RCTs reported intermediate healing outcomes, namely absolute change in ulcer area, percentage
change in ulcer area and healing rate over time.228–230,232,233 Two RCTs provided sufficient data for pooling
all three outcomes at 4 weeks.229,230 The estimate for mean absolute change in ulcer area was in favour of
silver (difference in means –4.70 cm2, 95% CI –8.46 to –0.94 cm2) (Figure 13). Estimates for mean
percentage change in ulcer area and healing rate did not suggest differences between treatment groups.
Statistically significant heterogeneity was detected for one analysis (mean percentage change in ulcer
area). The estimate from the random-effects model did not change the finding (difference in means
–6.13 cm2, 95% CI –32.59 to 20.32 cm2). As before, this heterogeneity may have arisen by chance.
A further three RCTs reported the percentage change in ulcer area but did not provide sufficient
information to plot estimates.228,232,233 Two reported a median percentage change in ulcer area at 4 weeks
in favour of silver-impregnated dressings: –45% for silver and –25% for non-antimicrobial dressings
(p= 0.034)228 and –46% and –27%, respectively (p= 0.0001).232 Both p-values are as reported by the trial
authors. The third RCT reported respective mean changes of –75% and –60% at 6 weeks, describing the
between-group difference as not statistically significant (although no p-value was provided).233
Exploration of potential data required for individual patient data
meta-analysis
Two RCTs included patients with venous leg ulcers and those of mixed arterial/venous aetiology.228,232 One
RCT did not report the numbers with different types of leg ulcers and did not stratify results accordingly.228
It was included in a meta-analysis with two other trials that recruited solely venous leg ulcer patients227,233
and there was no evidence of statistical heterogeneity between studies (see Figure 12 – complete healing
at 4–6 weeks). The second trial recruited 415 patients with different types of leg ulcers, of which 297 had
venous leg ulceration.232 The primary outcome for this trial was the median percentage reduction in ulcer
area at 4 weeks. As reported earlier, for those with venous leg ulcers the median change in ulcer area at
4 weeks was –46% for silver dressings and –27% for comparator dressings (p= 0.0001, as reported by
the trial authors). The respective values were similar when all types of leg ulcers were taken into account
(–46% vs. –29%, respectively, p= 0.0001). In an IPD meta-analysis, ulcer aetiology could be included as a
patient-level covariate, perhaps by using the ABPI.
The included RCTs varied in terms of the patients’ baseline ulcer infection status (Table 55). One RCT
recruited only those with clinically infected ulcers227 and another recruited patients with clinical infection or
critical colonisation of the ulcer but did not explain the distribution.232 Three RCTs stipulated presence of
critical colonisation of the ulcer as an eligibility criterion but also stated that those with clinically infected
ulcers were excluded.228–230 One RCT stated that patients receiving systemic antibiotics at baseline were
excluded; this presumably would also exclude those with any type of clinical infection, including ulcer
infection.231 The last RCT did not provide any information about baseline ulcer infection status.233
With one exception,229 the RCTs recruiting patients with clinically infected ulcers, critically colonised ulcers
or both did not report directly related outcomes, that is, the resolution of signs and symptoms of infection or
critical colonisation. Lazareth et al.229 recruited patients characterised as having ‘critical colonisation’ of their
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ulcers and reported the number of patients with remaining signs of heavy bacterial colonisation during
follow-up. The other RCTs sometimes reported outcomes linked to infection status but these did not always
relate directly to the baseline variable. For example, one RCT restricting inclusion to patients with clinically
infected ulcers reported the presence of specific bacterial species on the wound bed during the trial but there
was no report of resolution of clinical infection.227 Other examples are shown in Table 55.
Critical colonisation
In wound care, wound infection is commonly conceptualised as being at the far end of an infection
continuum. The continuum, as defined by Kingsley,234 starts with sterility (a brief period that might follow
surgery), moving to contamination (defined as the presence of microbes but little active growth) and then
colonisation (considered as the normal status quo with growth wound flora being managed by the host
immune system) and finally to critical colonisation and infection. Kingsley234 defines critical colonisation as
a point between colonisation and infection in which the ‘healthy’ balance of wound flora is no longer
maintained by the host and the bacterial load and/or species present in the wound shifts away from a
so-called safe level. More recently, others have conceptualised critical colonisation as invasion of the
wound surface by micro-organisms.235 There is currently no standard way to diagnose critical colonisation;
rather, it is generally noted as being associated with delayed healing in the absence of overt signs of
wound infection,234,236 possibly with other symptoms such as increased exudate (to a lesser extent than in
infection) and hypergranulation/friable tissue.235 There are no robust clinical research data to support
associations between a state defined as critical colonisation and wound outcomes; critical colonisation in
wound care is a concept that still requires definitive characterisation.237
Given the variation in these group-level data and the small number of RCTs identified, it is difficult to
determine any relationship between ulcer healing and presence of infection or critical colonisation at
baseline or persisting during the trial period. IPD meta-analysis is often based on regression analysis
incorporating adjustment for patient-level baseline covariates.185 In this instance it would be useful to
explore the influence of baseline ulcer infection status on healing. However, the information in Table 55
indicates that definitions of infection and colonisation vary enormously across trials and this would be
problematic for coding and analysis. Ideally, each patient would be coded as having confirmed clinical
infection (yes/no) at baseline, using standardised criteria. Definitions of infection-related outcome variables
also differ across trials and this would cause difficulties in exploring resolution of infection as an outcome.
TABLE 55 Baseline and outcome assessment of wound infection reported in silver dressing RCTs
Trial Assessment of wound infection at baseline Assessment of wound infection as an outcome
Dimakakos
2009227
All wounds infected and had signs of clinical
inflammation
Reported some data on presence of specific
bacterial species; nothing on resolution of infection
Jørgensen
2005228
Recruited patients with critical colonisation of
ulcer; excluded patients with clinical infection
of the ulcer
No outcomes reported that related to resolution of
critical colonisation
Lazareth 2008229 Recruited patients with critical colonisation of
ulcer; excluded patients with clinical infection
of the ulcer
Local signs of heavy bacterial colonisation
Meaume 2005230 Recruited patients with critical colonisation of
ulcer; excluded patients using systemic
antibiotics within 5 days of recruitment
Incidence of systemic antibiotic use during the trial;
number of wounds developing clinical infection
(determined by cultures)
Michaels 2009231 Excluded patients receiving systemic antibiotics
at baseline
None
Münter 2006232 Recruited patients with critically colonised
ulcers or clinically infected ulcers
Reported change in use of systemic antibiotics
during the trial period
Wunderlich
1991233
No information provided Bacterial colony growth during the trial period
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The variation in silver-impregnated dressings, comparators and use of compression has already been
discussed (see Comparisons undertaken in the trials and Table 54). There were no apparent differences
between trials in terms of estimated treatment effect that could have been accounted for by different
types of silver dressing or comparator, or different use of compression.
The included RCTs varied in terms of overall risk of bias. Only one was classified as being at low risk of
bias,231 one was at high risk of bias228 and the risk of bias in the others was unclear because of poor
reporting228–230,232,233 (see Appendix 9).
In terms of individual domains, three RCTs were assigned a low risk of bias for the method of
randomisation as they had described the use of computerised sequence generation;228,231,232 the remaining
RCTs were assigned an unclear risk of bias as they had mentioned randomisation but not specified the
actual methods used to generate the sequence. One RCT was allocated a low risk of bias for allocation
concealment because it described the use of a centralised telephone service231 but all of the other RCTs
were assigned an unclear risk of bias. Two trials included clear statements indicating that outcome
assessors were masked to treatment allocation229,231 but the other trials had an unclear risk of bias for this
domain. For handling incomplete outcome data, five RCTs had a low risk of bias as all had indicated that
analyses were by intention to treat.227,229–232 One trial was at high risk of bias for this domain because
withdrawal rates were different across groups and analysis was clearly not by intention to treat.228
The remaining trial did not provide any information about the method of analysis and was rated as
having an unclear risk of bias.233
Many risk of bias judgements resulted in an unclear rating because of poor reporting of the relevant
details. When carrying out an IPD meta-analysis, there is scope to elicit further information because of the
close collaboration with participating triallists. In our previous meta-analysis, it was possible to establish
details of the methods of randomisation and allocation concealment, and whether or not outcome
assessment was masked as information was available on request that had not been published.187 There is
also the opportunity to reinstate patients excluded from the primary investigators’ own analyses and to aim
for an analysis by intention to treat for the full data set.185
It was difficult to judge whether or not source of funding influenced the trial results because of the limited
available information. For two trials the funding source was not reported.227,233 A large independently
funded trial (by the UK NIHR Health Technology Assessment programme) found no difference in healing
between silver and non-silver dressings.231 The remaining four trials were funded by the manufacturers of
the study dressings228–230,232 and generated mixed results. Pooled data from two RCTs found a difference in
favour of silver for the intermediate outcome of mean absolute change in ulcer area at 4 weeks229,230
(see Figure 13). Two further RCTs each reported results that suggested a greater reduction in ulcer area
with silver dressings than with non-antimicrobial dressings;228,232 however, both of these trials reported
limited data, which precluded our plotting of it. All other analyses did not indicate a difference between
treatment groups (see Figures 12 and 13).
It is notable that the one trial at overall low risk of bias did not detect a difference between groups for
longer-term complete healing (up to 1 year) or for time to healing.231
Likely availability of data for individual patient data meta-analysis
Tables 56–58 summarise the variables required for a patient-level analysis and judgements about their
potential availability from each of the seven identified trials. These judgements were made using
information from the trial reports and from contact with the original investigators. These summaries
indicate that there was uncertainty about the availability of some variables that would be essential
to perform a meaningful IPD meta-analysis. A particular concern was the uncertainty relating to
time-to-healing data, for which the date of randomisation, healing status and date of healing
(or date of withdrawal) would be required for each patient (see Table 57).
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TABLE 56 Availability of baseline variables in trials of silver dressings
Variable
Dimakakos
2009227
Jørgensen
2005228
Lazareth
2008229
Meaume
2005230
Michaels
2009231
Münter
2006232
Wunderlich
1991233
Sex Y Y Y Y Y Y Y
Patient age Y Y Y Y Y Y Y
Primary or recurrent ulcer ? ? Y Y Y ? ?
Ulcer duration Y Y Y Y Y Y Y
Ulcer surface area Y Y Y Y Y Y Y
Ulcer infection statusa Y Y Y Y Y ? ?
ABPI Y Y Y Y Y Y ?
Comorbidities ? ? Y Y Y ? ?
?, not mentioned in trial report or only a vague reference; Y, yes, mentioned in the trial report.
a Often an inclusion or exclusion criterion.
TABLE 57 Availability of outcome variables in trials of silver dressings
Variable
Dimakakos
2009227
Jørgensen
2005228
Lazareth
2008229
Meaume
2005230
Michaels
2009231
Münter
2006232
Wunderlich
1991233
Healing status (yes/no) Y Y ? ? Y ? Y
Date of healing or time
to healing
? ? ? ? Y ? ?
Resolution of clinical
infection
? ? ? ? ? ? ?
Development of clinical
infection during trial
? ? ? Y ? ? ?
Adverse events Y Y Y Y Y ? ?
?, not mentioned in trial report or only a vague reference; Y, yes, mentioned in the trial report.
TABLE 58 Availability of other variables including treatment-related variables in trials of silver dressings
Variable
Dimakakos
2009227
Jørgensen
2005228
Lazareth
2008229
Meaume
2005230
Michaels
2009231
Münter
2006232
Wunderlich
1991233
Patient identifier Y Y Y Y Y Y Y
Centre identifier Y Y Y Y Y Y Y
Date of randomisation ? ? ? ? ? ? ?
Allocated treatment Y Y Y Y Y Y Y
Use of compression Y Y Y Y Y Y ?
Received allocated
intervention
? Y ? Y ? ? ?
Whether or not excluded
from analysis
NA Y Y Y Y Y Y
Reasons for exclusion
from analysis
NA Y Y ? Y Y ?
Date of last follow-up ? ? ? ? ? ? ?
?, not mentioned in trial report or only a vague reference; NA, not applicable because it was clear that there were no
exclusions; Y, yes, mentioned in the trial report.
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Discussion
A scoping review identified seven RCTs comparing silver-impregnated dressings with non-antimicrobial
dressings in 1012 patients with venous leg ulcers. The type of analysis varied across trials and included
time to healing, complete healing during the trial period and intermediate measures such as change in
ulcer area and healing rate over time. Apart from some short-term (4-week) intermediate measures
(absolute and percentage change in ulcer area), the group-level data did not suggest a difference in
healing between silver-impregnated dressings and non-antimicrobial dressings. These findings are broadly
in agreement with those from relevant systematic reviews.216–218 Only one systematic review considered
infection-related outcomes218 despite silver-impregnated dressings being indicated for use in infected
wounds.238 This scoping review considered the reporting of infection-related variables and found
considerable variation at baseline and in terms of outcome definition.
Individual patient data meta-analysis normally focuses on time-to-event outcomes. Use of statistical
techniques such as the Cox proportional hazard model provides the advantage of being able to adjust
estimates of treatment effect for the influence of predictive covariates, generating a more precise
estimate.185 The lack of reported data on time to healing is a cause for concern in this body of literature,
with only one RCT reporting this outcome.231 Of the other RCTs, three reported frequency of complete
healing during the trial period227,228,233 and three reported an intermediate measure of healing as the trial’s
primary outcome.229,230,232 This includes the largest RCT, which recruited 415 patients with venous and
venous/arterial leg ulcers and reported percentage change in ulcer area at 4 weeks as the main outcome,
with no information on follow-up to complete healing.232
Prescribing guidelines state that silver-impregnated dressings should be restricted to use in wounds with
identified clinical infection.238 Another source suggests that silver dressings could be of value in managing
critically colonised wounds and that resolution of infection should be considered as the primary outcome
rather than healing.239 Restricting inclusion to trials recruiting patients with confirmed clinical infection or
critical colonisation would have resulted in the exclusion of two RCTs and 253 patients from this scoping
review.231,233 Even allowing for this, analysis of infection-related outcomes in a meta-analysis would still be
difficult because of the variation in measures used (identification of bacterial species, presence of signs of
critical colonisation, use of systemic antibiotics and incidence of clinical infection) and this could not be
easily resolved, even with the provision of IPD.
In light of these factors, it was decided that this topic was unlikely to be a suitable candidate for IPD
meta-analysis, despite the clear importance of the question for clinical practice. A previous IPD meta-analysis
in venous leg ulcers was initiated with knowledge that time-to-healing data were likely to be available for
most of the included trials because the primary investigators had described their own time-to-event analyses
in published trial reports.187 In addition, most trial reports indicated that information on predictive covariates
would also be available, later confirmed through the collaboration with the triallists. IPD meta-analyses entail
considerable effort, not just on the part of those undertaking the systematic review and meta-analysis but
also by those who agree to share primary data. Therefore, it is essential that the likely benefits of such
research are established prior to undertaking the project. First, it needs to be a research question for which
there is current uncertainty in clinical practice despite the availability of an up-to-date and good-quality
systematic review of group-level data. Second, the proposed meta-analysis should have sufficient statistical
power to detect a clinically important difference. Finally, the correct type and quality of data are required.
Advanced methods of evidence synthesis such as IPD meta-analysis are likely to become more frequent as it
becomes increasingly important to derive value for money from research expenditure. Those undertaking
clinical trials should ensure that outcomes are meaningful and informative and that the relevant baseline
data are collected for each patient, focusing on variables that may influence the outcome of treatment.
The Cochrane Collaboration has described the method of prospective meta-analysis whereby a collaborative
group undertakes several clinical trials, applying design features so that meaningful pooled analyses can be
designed in advance of knowing the results of individual trials.240 They are usually based on IPD. Prospective
meta-analyses have been used in fields such as CVD241 and cancer,242 and are planned in childhood
obesity.243 It may be useful to consider the feasibility of this method for future wound management topics.
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Undertaking new and updating existing high-priority Cochrane
systematic reviews
Introduction
We earlier described the identification and prioritisation of topics for systematic review. As a result of this,
several topics were pinpointed as suitable candidates for Cochrane reviews, either as new reviews or
updates of existing reviews. Eleven reviews were undertaken overall on interventions for diabetic foot
ulcers (five reviews192–195,244), venous leg ulcers (five reviews184,197–199,245) and surgical wounds (one review246).
All used standard Cochrane systematic review methodology as described in the Cochrane Handbook for
Systematic Reviews of Interventions163 and all were carried out under the auspices of the Cochrane
Wounds Group (see http://wounds.cochrane.org/). These Cochrane reviews have already been published in
full in The Cochrane Library [see www.thecochranelibrary.com (accessed 12 May 2016)] and we summarise
them more concisely here.
Reviews of interventions used with diabetic foot ulcers
l Alginate dressings for healing diabetic foot ulcers.194
l Foam dressings for healing diabetic foot ulcers.195
l Hydrocolloid dressings for healing diabetic foot ulcers.192
l Hydrogel dressings for healing diabetic foot ulcers.193
l Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus.244
Reviews of interventions used with venous leg ulcers
l Alginate dressings for venous leg ulcers.198
l Foam dressings for venous leg ulcers.197
l Compression for venous leg ulcers.184
l Antibiotics and antiseptics for venous leg ulcers.199
l Topical agents or dressings for pain in venous leg ulcers.245
Review of interventions used with surgical wounds
l Pre-operative skin antiseptics for preventing surgical wound infections after clean surgery.246
Objective
Our objective for this research was to provide valid, reliable information for wound care decision-making
by undertaking systematic reviews in aspects of wound care prioritised by our NHS collaborators.
The specific objectives for each review are shown in Table 59.
Methods
Each review was preceded by the development, peer review and publication of a protocol that set out
detailed methodology in advance (as per established Cochrane Collaboration methodology163).
Criteria for considering studies for the reviews
Each review included only RCTs that evaluated the intervention of interest in participants with the
condition of interest, irrespective of publication status or language. The eligible comparisons and primary
and secondary outcomes for each review are summarised in Table 60. Each review avoided imposing
narrow participant eligibility criteria to ensure that the evidence reviewed was as broad and pragmatic as
possible (i.e. studies were accepted on the basis of the primary study authors’ definitions of diabetic foot
ulcers and venous leg ulcers).
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TABLE 59 Objectives of the 11 Cochrane reviews completed or updated in the programme grant
Review Objective Review status
Diabetic foot ulcer reviews
Alginate dressings for healing diabetic
foot ulcers194
To compare the effects of alginate wound dressings
with those of no dressing or alternative dressings on the
healing of foot ulcers in people with diabetes mellitus
New review
Foam dressings for healing diabetic
foot ulcers195
To determine the effects of foam wound dressings on
the healing of foot ulcers in people with diabetes
New review
Hydrocolloid dressings for healing
diabetic foot ulcers192
To compare the effects of all types of hydrocolloid
wound dressings with those of no dressing or
alternative dressings on the healing of foot ulcers in
people with diabetes
New review
Hydrogel dressings for healing diabetic
foot ulcers193
To assess the effects of hydrogel wound dressings
compared with alternative dressings or no dressing on
the healing of foot ulcers in people with diabetes
New review
Negative pressure wound therapy for
treating foot wounds in people with
diabetes mellitus244
To assess the effects of negative pressure wound
therapy compared with those of standard care or other
therapies in the healing of foot wounds in people with
diabetes mellitus
New review
Venous leg ulcer reviews
Alginate dressings for venous leg
ulcers198
To determine the effects of alginate dressings compared
with those of alternative dressings, non-dressing
treatments or no dressing, with or without concurrent
compression therapy, on the healing of venous leg
ulcers
New review
Foam dressings for venous leg
ulcers197
To determine the effects of foam dressings on the
healing of venous leg ulcers
New review
Compression for venous leg ulcers184 To undertake a systematic review of all RCTs evaluating
the effects on venous ulcer healing of compression
bandages and stockings
Update
Antibiotics and antiseptics for venous
leg ulcers199
To determine the effects of systemic antibiotics and
topical antibiotics and antiseptics on the healing of
venous ulcers
Update
Topical agents or dressings for pain in
venous leg ulcers245
To determine the effects of topical agents or dressings
for pain in venous leg ulcers
Update
Surgical wounds review
Pre-operative skin antiseptics for
preventing surgical wound infections
after clean surgery246
To determine whether or not pre-operative skin
antisepsis immediately prior to surgical incision for clean
surgery prevents surgical site infection and to determine
the comparative effectiveness of alternative antiseptics
Update
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TABLE 60 Eligible comparisons and primary and secondary outcomes of the 11 Cochrane reviews completed or
updated in the programme grant
Review Comparisons Primary outcomes Secondary outcomes
Diabetic foot ulcer reviews
Alginate dressings for
healing diabetic foot
ulcers194
Any comparison with alginate
dressings including no dressing
TTH, RH HRQoL, amputations, adverse
events, costs, recurrence,
change in ulcer area
Foam dressings for healing
diabetic foot ulcers195
Foam dressings compared with
other types of dressing or
compared with non-dressing
treatments
TTH, RH HRQoL, amputations, adverse
events, costs, recurrence
Hydrocolloid dressings for
healing diabetic foot
ulcers192
Hydrocolloid dressings compared
with other types of dressing or
non-dressing treatments
TTH, RH HRQoL, amputations, adverse
events, costs, recurrence,
change in ulcer area
Hydrogel dressings for
healing diabetic foot
ulcers193
Any comparison with hydrogels
including no dressing
TTH, RH HRQoL, amputations, adverse
events, costs, recurrence,
change in ulcer area
Negative pressure wound
therapy for treating foot
wounds in people with
diabetes mellitus244
Any negative pressure wound
therapy vs. standard care or
alternative treatments
TTH, RH, change in
wound size, rate of
change in wound size,
amputation
HRQoL, adverse events,
resource use, recurrence
Venous leg ulcer reviews
Alginate dressings for
venous leg ulcers198
Alginate dressings vs. other
wound dressings (including
alternative alginate dressings),
non-dressing wound treatment
(e.g. topical application) or no
dressing
TTH, RH, change in
wound size/rate of
change
HRQoL, cost, pain,
debridement, control of
bleeding, dressing
performance, adverse events
Foam dressings for venous
leg ulcers197
Foam dressings vs. other wound
dressings (including alternative
foam dressings), non-dressing
treatments or no dressing
TTH, RH, change in
wound size/rate of
change
Adverse events, HRQoL, costs,
pain, dressing performance
Compression for venous
leg ulcers184
Any form of compression
bandage or stocking vs. no
compression or alternative
compression
TTH, RH, change in
ulcer size, rate of
change of size
Recurrence, costs, HRQoL,
pain, adverse events, patient
withdrawal
Antibiotics and antiseptics
for venous leg ulcers199
Antibiotics (via any route) or
antiseptics (topical) vs. placebo,
alternative antibiotic or antiseptic
or none
Wound healing
(preferably TTH, RH,
change in size)
Change in symptoms of
infection, change in
microbiology, bacterial
resistance, ulcer recurrence,
adverse events, patient
satisfaction, HRQoL, costs
Topical agents or dressings
for pain in venous leg
ulcers245
Topical analgesic or anaesthetic
or dressing applied for pain relief
(vs. placebo or alternative
treatment – this comparison is
implied rather than explicit)
Pain TTH, RH, HRQoL, adverse
events
Surgical wounds review
Pre-operative skin
antiseptics for preventing
surgical wound infections
after clean surgery246
Antiseptic vs. control, antiseptic
vs. another antiseptic, single
application vs. multiple
applications of antiseptic,
multiple applications vs. multiple
applications of antiseptic
Risk of SSI HRQoL, adverse events,
resource use
HRQoL, health-related quality of life; RH, rate of healing; SSI, surgical site infection; TTH, time to healing.
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Searching for eligible studies
The search strategies used in the reviews have been developed by the Cochrane Wounds Group (see
http://wounds.cochrane.org/) and are based on access to several bibliographic databases as follows:
l Cochrane Wounds Group Specialised Register
l CENTRAL
l MEDLINE
l EMBASE
l CINAHL.
In each instance, search strings were designed initially for CENTRAL and were then adapted to be used
with the other databases. As study inclusion was restricted to RCTs, methodological search filters were
employed for use with MEDLINE, EMBASE and CINAHL.247,248 Ongoing research was sought from clinical
trial registries as follows:
l World Health Organization International Trial Registry Platform [see www.who.int/ictrp/en/ (accessed
12 May 2016)]
l ISRCTN register [see www.controlled-trials.com/isrctn/ (accessed 2 June 2016)]
l ClinicalTrials.gov [see www.clinicaltrials.gov (accessed 12 May 2016)].
In addition, reference lists of included trials and review articles were scanned to identify articles not
retrieved by database searching. Attempts were made to contact trial authors and manufacturers
(when relevant) to identify unpublished material.
Data extraction and management
Data to be extracted were specified in the protocol of each review and tailored to the requirements of
each review. Attempts were made to contact study authors to obtain any missing data. Data from RCTs
published in more than one paper were included once, using all associated documents to extract the
maximum amount of information while ensuring that data were not duplicated in the review.
Assessment of risk of bias in included studies
Assessment of risk of bias in each included trial was carried out using the Cochrane Collaboration’s
risk-of-bias tool.219 This tool is based on the following domains: the randomisation sequence; allocation
concealment; blinding of participants and care providers; blinding of outcome assessors; incomplete
outcome data; selective outcome reporting; and other sources of bias (to be predefined in the context of
each review). A judgement of ‘high’, ‘low’ or ‘unclear’ risk of bias was assigned for each domain, together
with evidence and the rationale relating to each judgement. Most of the reviews included an overall
risk-of-bias rating for each trial, based on key domains, which varied slightly according to the review but
could include, for example, domains that have been empirically demonstrated to be associated with biased
estimates of effect when improperly handled. These included allocation concealment, blinding of outcome
assessment and handling of incomplete outcome data.148,220,223
Review processes
The processes of study selection, data extraction and assessment of risk of bias were performed by at least
two review authors working independently. Any disagreements in study selection decisions, data extracted
and risk-of-bias judgements were resolved by discussion.
Measures of treatment effect
The reviews considered a range of outcomes relating to different types of data: dichotomous, continuous
and time to event. When appropriate data were available from trial reports or through contact with trial
authors, estimates for dichotomous outcomes (e.g. number of patients with complete healing) were
reported as RRs with associated 95% CIs. Estimates for continuous data outcomes (e.g. change in ulcer
area) were calculated as the difference in means with associated 95% CI. Measures of time to healing and
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
165
HR estimates were extracted from trial reports. In cases in which HRs were not available but the reports
provided other pertinent information in relation to time to healing, estimates were extrapolated in
accordance with published recommendations.249
Unit of analysis issues
Each review noted cases in which the unit of randomisation and unit of analysis did not match (e.g. legs or
ulcers randomised but patients analysed). In trials in which multiple limbs or ulcers on the same individual
were studied, a note was made regarding whether the trial authors’ analysis was appropriate (i.e. correctly
taking account of highly correlated data) or inappropriate (i.e. considering outcomes for multiple ulcers on
the same participant as independent).
Dealing with missing data
Some reviews attempted analyses by intention to treat in instances in which the triallists had excluded
patients from their own analyses. This was generally only feasible for the outcome of risk of healing for
which, provided the number of patients randomised per group was known, a conservative assumption
could be made that the excluded patients did not heal, so that they were included in the denominator but
not the numerator. In other situations we used complete case analysis (i.e. measures of effect were based
on patients who completed the trial) and this was highlighted in the review.
Assessment of heterogeneity
All reviews considered both clinical (the degree to which RCTs vary in terms of participant, intervention
and outcome characteristics) and statistical (variation in estimates of effect across trials) heterogeneity.
Statistical heterogeneity was assessed using the chi-squared test (a significance level of p< 0.10 was
considered to indicate statistically significant heterogeneity) in conjunction with the I2 statistic. The I2
statistic examines the percentage of total variation across RCTs that is due to heterogeneity rather than
chance. Different thresholds of the I2 statistic can be predefined to help describe different amounts of
heterogeneity. Thresholds used in some reviews were as follows: I2 values of ≤ 40% indicated a low level
of heterogeneity and values of ≥ 75% indicated a very high level of heterogeneity.224
Assessment of reporting biases
Most reviews planned to present funnel plots for meta-analyses including ≥ 10 RCTs using RevMan 5.1
(The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). This proved to be
unfeasible as all meta-analyses were based on small numbers of studies.
Data synthesis
All reviews presented a narrative synthesis of included RCTs, grouped by comparison. Statistical pooling
of outcome data was undertaken on groups of RCTs with available data that were considered to be
sufficiently similar in terms of design and characteristics of participants, interventions and outcomes. The
decision to undertake meta-analysis depended on the availability of outcome data and assessment of
heterogeneity. In the I2 threshold example explained in Assessment of heterogeneity, the choice of
meta-analysis model was as follows. For comparisons in which there was no apparent clinical heterogeneity
and the I2 value was ≤ 40%, a fixed-effects model was applied. When there was no apparent clinical
heterogeneity and the I2 value was > 40%, a random-effects model was undertaken. However, data were
not pooled when heterogeneity was very high (I2 values ≥ 75%). Pooled dichotomous outcomes were
presented as a summary RR estimate with 95% CI. When continuous outcomes were measured in the same
way across RCTs, a pooled difference in means was presented with 95% CI. When outcomes shared the
same underlying concept but were measured using different instruments (e.g. quality-of-life scales), the
standardised mean difference was the pooled summary measure of choice. For time-to-event data, HR
estimates and 95% CIs were pooled as presented in the RCT reports using the generic inverse variance
method in RevMan 5.1. When HRs were not provided, estimates were extrapolated, when possible,
using other reported data.249 Individual and pooled estimates of treatment effect were generated using
RevMan 5.1.
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Some reviews also planned to include subgroup analyses (e.g. to explore the impact of sources of
heterogeneity) and sensitivity analyses (to investigate the effects of parameters such as risk of bias on
estimates of treatment effect).
The above analyses relate to group-level data for pairwise comparisons. Two reviews included more
advanced meta-analytical techniques to complement the existing standard meta-analyses. These included a
meta-analysis of IPD for one comparison184 and a mixed-treatment comparison meta-analysis.196 Several of
the reviews incorporated summary of findings tables.250 These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the interventions examined and the sum of the
available data for the main outcomes.251 The summary of findings tables also include an overall grading of
the evidence related to each of the main outcomes using the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) approach.252 The GRADE approach defines the quality of a body of
evidence as the extent to which one can be confident that an estimate of effect or association is close to
the true quantity of specific interest. The quality of a body of evidence involves consideration of within-trial
risk of bias (methodological quality), directness of evidence (which might relate to indirect comparisons or
differences between the populations, treatments or outcomes measured in studies and the populations,
treatments or outcomes of interest), heterogeneity, precision of effect estimates and risk of publication
bias.251 Each review selected key outcomes to be represented in the summary of findings tables;
these included the primary outcomes and selected secondary outcomes such as quality of life and
adverse events.
Here, rather than reproduce each Cochrane review in full, we present a summary of the reviews in table
format (Tables 61–63). It should be noted that some reviews include trials with more than two treatment
arms and therefore more trials may be listed in the ‘Comparisons’ column than are indicated in the ‘Number
of RCTs included’ column. We have emphasised estimates of proportions of wounds completely healed in
these summaries; complete wound healing is the outcome that matters to patients (see Chapter 3) and was
the primary outcome for the reviews. However, wound healing can (and is) captured in trials in different
ways (including time to complete healing and proportion of wounds completely healed). We have
emphasised the latter here as it is the most frequently measured and reported measure (although time to
complete healing with survival analysis is the better approach). Durations of follow-up varied considerably
across trials. The information on quality of the evidence was drawn directly from the summary of findings
tables in reviews when available. For reviews without summary of findings tables, each GRADE criterion was
assessed against information presented in the review report and a summary rating of overall quality derived
from the available details.
Discussion
Eleven Cochrane reviews were undertaken or updated: five in diabetic foot ulcers, five in venous leg ulcers
and one in surgical wounds. The number of included RCTs ranged from 5 to 48. The evidence suggested
that hydrogel dressings may heal more diabetic foot ulcers than basic wound contact dressings193 and
that negative pressure wound therapy may be an effective treatment for healing debrided diabetic foot
ulcers and post-operative amputation foot wounds in people with diabetes mellitus.244 The review
of compression in venous leg ulcers184 suggested that compression increases healing compared with no
compression; multicomponent compression systems are more effective than single-components systems;
and multicomponent systems containing an elastic bandage are more effective than those composed
mainly of inelastic constituents. The four-layer bandage heals ulcers faster and is more cost-effective than
the short-stretch bandage. Two-layer stockings (high compression) appear more effective than the short-
stretch bandage. In terms of systemic antimicrobial agents,199 there is some evidence that levamisole may
be effective for healing venous leg ulcers; this treatment is normally used to treat roundworm infection
and has restricted availability. In terms of topical antimicrobials for venous leg ulcers,199 cadexomer iodine
may heal more wounds than standard care. There was no evidence for a difference between honey- and
silver-based products compared with non-antimicrobial interventions. Foam dressings impregnated with
ibuprofen may reduce pain for some people with painful venous leg ulcers and Eutectic Mixture of Local
Anaesthetics (EMLA) cream reduces pain during debridement of venous leg ulcers compared with placebo
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
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or no anaesthetic.245 A review evaluating pre-operative skin antiseptics for preventing surgical wound
infection after clean surgery found that 0.5% chlorhexidine may be more effective than alcohol-based
povidone iodine paint.246 Most findings should be viewed with caution because of the poor quality of
much of the evidence base. This particularly related to risk of bias and imprecision. It was difficult to
conduct a full risk-of-bias assessment for many RCTs because of poor reporting. In addition, the frequent
lack of information on reported outcomes meant that some data could not be converted to the reviews’
pre-specified measures of treatment effect (and therefore could not be pooled).
In some cases, the patient characteristics of those recruited to included trials hindered generalisation to
real-life clinical practice. The four reviews focusing on dressings for diabetic foot ulcers noted that most
included trials recruited patients with non-complex foot ulcers and, therefore, the current evidence may be
of limited utility to health professionals when treating patients with harder-to-heal foot ulcers. The two
reviews on dressings in venous leg ulcers noted that many trials restricted the baseline ulcer area as a trial
entry criterion, so that the wound fitted the dimensions of the study dressings. It is likely that patients with
a wide range of wound sizes, including larger wounds, would be seen in clinical practice and the relevance
of the evidence is unclear for patients with larger ulcers and, therefore, a less favourable prospect of
healing.226 This also applied to some trials in the compression review.184 A major issue in the review of
antimicrobial agents was that most trials did not recruit patient with infected wounds at baseline and,
therefore, we cannot know if the interventions reviewed can promote healing in patients with clinically
infected wounds. In light of the current global concern about the misuse of antibiotics and resistance to
antimicrobial treatment, clinical and prescribing guidelines suggest that the application of both systemic
and topical antimicrobial agents should be restricted to patients with confirmed clinical infection and,
therefore, the relevance of this evidence is in question.94,238 In the review of topical agents and dressings
for treating pain in venous leg ulcers, it was noted that the trials evaluating relief of persisting ulcer pain
were of short duration (a matter of a few weeks), whereas the nature of the wounds was chronic;
therefore, it is uncertain how effective pain relief may be in the longer term.245
Applying different techniques of evidence synthesis
Earlier in this chapter we showed how health professionals expressed uncertainties about the effectiveness
of different dressings for healing foot ulcers in people with diabetes and venous leg ulcers.
In wound care, decision-makers have several treatment options to choose from, typically involving the
choice of alternative devices, for example negative pressure wound therapy and dressings. When selecting
a dressing there are not only several classes to choose from but, within these classes, there are several
dressing types (as well as competing products within these types). Table 64 summarises the dressing choices
available to decision-makers in the UK using information from the British National Formulary (BNF).238
Dressings as a treatment for chronic wounds
Arguably, wound dressings are perceived as cheap and ‘inert’ items and thus their use in relation to existing
evidence receives limited attention. However, as dressing types grow in number and complexity, and with
corresponding claims of promoting healing, expenditure also increases. Of the 201 BNF chapters in 2010,253
the community prescribing cost of the ‘Wound management and other dressings’ chapter was £136M,
making it the 17th most costly (the most costly chapter being ‘Drugs for diabetes’ at > £700M). There is
also considerable variation in the cost of dressing types. For example, in 2013 a silver low-adherent dressing
(10 cm × 10 cm) cost £8.07, whereas a similar-sized standard low-adherent dressing cost £0.35.238
When selecting from so many competing treatment options (with some having large differences in unit
costs), the evidence base is an important decision-making resource. However, a difficulty in the current
evidence base for dressings in wound care (as with several other areas) is that most of the trials in this
field are pairwise, that is, they compare one treatment with another in a head-to-head comparison.
Looking again at Table 64 we can see that with so many different treatments types available, the number
of trials required to produce relative effectiveness estimates for all possible comparisons would be huge.
Previously, systematic reviews of the evidence for the effects of wound dressings on healing have focused
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TABLE 64 Wound dressing categories from the BNF238
Class of dressing Number of different products
Basic wound contact dressings
Low-adherence dressings
Knitted viscose primary dressing 4
Paraffin gauze dressing Several – not all listed
Atrauman® (Hartmann, Heywood, UK) 1
Absorbent dressings
Absorbent perforated dressing with adhesive border 12
Absorbent perforated plastic film-faced dressing 8
Absorbent cellulose dressing with fluid-repellent backing 6
Absorbent dressings for heavily exuding wounds 4
Advanced wound dressings
Hydrogel dressings
Hydrogel sheet dressing 9
Hydrogel application (amorphous) 9
Sodium hyaluronate dressing 1
Vapour-permeable films and membranes
Vapour-permeable adhesive film dressing 15
Vapour-permeable adhesive film dressing with absorbent pad 10
Soft polymer dressings
Without absorbent pad 9
With absorbent pad 10
Cellulose dressings 2
Hydrocolloid dressings
Without adhesive border 11
With adhesive border 5
Hydrocolloid fibrous dressings 3
Polyurethane matrix dressing 1
Foam dressings
Polyurethane foam film dressing with adhesive border 16
Polyurethane foam dressing 3
Polyurethane foam film dressing without adhesive border 26
Cavi-Care® (Smith & Nephew) 1
Alginate dressings 12
Capillary-action dressings 4
Odour-absorbent dressings 6
continued
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on the available pairwise comparisons, showing that data on some head-to-head comparisons are
lacking.254 Although useful, such analysis can be of limited value to decision-makers who, when
comparative trial data are not available for specific comparisons, are, essentially, required to make
qualitative relative treatment estimates indirectly using the data available to them.
Mixed-treatment meta-analysis
An extension to standard meta-analysis of relative effectiveness evidence (healing data in this case) is
mixed-treatment meta-analysis (sometimes called network meta-analysis or mixed-treatment
comparison).189,255 This approach formally links data from multiple relevant trials via common comparators
to form a network of evidence. The network allows the direct comparisons of treatments for which
pairwise data exist (as would normally happen in a standard meta-analysis) but also allows indirect
comparisons to be made for treatments that have not been compared in a trial (Figure 14).
Mixed-treatment meta-analysis is a powerful evidence synthesis tool although, as with standard
meta-analysis, assumptions are required when combining data in this way. A key assumption for
mixed-treatment meta-analysis is that of transitivity, that is (for a fixed-effects model), all networked trials
would be expected to estimate the same relative treatment effect for a treatment had that treatment
been included in the trial. Another way of conceptualising this is that we are assuming that the network
represents one big trial with the missing trial arms missing at random.256 Essentially, this assumption relies
on there being no important differences between trials (e.g. characteristics of patient populations or
treatments) that would impact on relative treatment effects. In mixed-treatment meta-analysis there is a
particular focus on assessing whether or not the assumption of transitivity holds through assessment of
consistency between direct and indirect data when possible; for a full overview of this issue see Dias et al.190
TABLE 64 Wound dressing categories from the BNF238 (continued )
Class of dressing Number of different products
Antimicrobial dressings
Honey
Sheet dressing 7
Topical 5
Iodine 5
Silver
Low-adherence dressings 2
With charcoal 1
Soft polymer dressings 4
Hydrocolloid dressings 3
Foam dressings 5
Alginate dressings 9
Other antimicrobials 8
Specialised dressings
Protease-modulating matrix dressings 7
Silicone keloid dressings
Silicone sheets 8
Silicone gels 7
EVIDENCE SYNTHESIS FOR CLINICAL DECISION-MAKING (WORKSTREAM 3)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
Assessing the quality of pooled estimates
With any evidence synthesis it is important to present the output data with due consideration and
communication of the data quality used in its calculation. Although this is recognised with pooling of
pairwise data through GRADE,252 there has been less focus on systematic approaches to support the
assessment of the relative effect estimates for the outputs of mixed-treatment meta-analysis that include
indirect as well as direct estimates. However, this is an important area for further research as presenting
network findings without an assessment of quality (especially in a Bayesian framework in which the
probability of a treatment being ‘the best’ may be the output) may encourage an overly simplistic
interpretation of the evidence.
Within this work we therefore planned to conduct mixed-treatment meta-analysis to fully synthesise
evidence from RCTs in areas of clinical decision uncertainty identified by health professionals within the
programme grant. These uncertainties were in the selection of dressings for treating people with diabetic
foot ulcers and venous leg ulcers. We planned to situate the estimates of dressing effectiveness in the
context of the quality of the evidence.
Dressings to heal ulcers of the foot in people with diabetes
(Adapted from the previously published paper by Dumville et al.196)
Objectives
Our objectives were to assess the relative effectiveness of dressings for the healing of foot ulcers in people
with diabetes using a mixed-treatment comparison meta-analysis and to assess the quality of relative
effective estimates produced in the mixed-treatment meta-analysis.
Dressing A
Dressing B
Dressing C
No trials
Two trials
Three trials
FIGURE 14 Example of a simple evidence network. The solid lines show pairwise RCT data on the effectiveness of
dressing A compared with dressing B and dressing A compared with dressing C. Although no RCT data for dressing
B compared with dressing C are available, a relative effect estimate can be calculated indirectly using dressing A as
the common comparator.
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Methods
Study selection
This review was based on a pre-specified protocol. We included published or unpublished reports of RCTs,
in any language and conducted in any country or setting, that evaluated the effects of wound dressings on
the healing of foot ulcers in people with diabetes. We accepted study authors’ definitions of what
constituted a diabetic foot ulcer and included trials that recruited patients with any type of diabetic foot
ulcer. There was no restriction in relation to participant age.
The interventions of interest were dressings (including those impregnated with antimicrobials or moistened
with saline). All forms of hydrogel were considered a dressing. Dressings that consist of a topical agent being
spread or poured onto a proprietary dressing fabric were not included nor were other topical treatments. We
included only RCTs that compared dressings with other dressings or dressings with no dressing. We did not
include trials comparing dressings with topical treatments or other adjuvant therapies, for example:
l growth factors
l skin replacements
l extracts of placenta or amniotic sac
l herbal preparations
l negative wound pressure therapy
l systemic interventions (e.g. antibiotics, pentoxifylline)
l surgical interventions.
We also excluded trials that compared different brands of the same dressing type.
Our primary outcome was ulcer healing, measured using the number of ulcers completely healed within a
specific time period (we assumed this period to be the trial follow-up time unless otherwise stated).
Data sources and searches
The search string for CENTRAL (see Appendix 10) was adapted for use in the following databases, which
were all searched from inception to June 2011: Cochrane Wounds Group Specialised Register, MEDLINE,
EMBASE and CINAHL. The MEDLINE search was combined with the Cochrane Highly Sensitive Search
Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008
revision).247 The EMBASE and CINAHL searches were combined with the trial filters developed by SIGN.248
Reference lists of included studies and previous systematic reviews were also searched. We contacted
appropriate manufacturing companies for details of any unpublished studies. Two review authors
independently assessed the titles and abstracts of retrieved studies for relevance. After this initial
assessment, we obtained in full all studies felt to be potentially relevant. We attempted to contact
researchers to obtain any additional information required but not contained in the trial report.
Data extraction
Details of the eligible studies were extracted and summarised using a standardised data extraction sheet.
Two review authors extracted data independently and disagreements were resolved by discussion. If data
were missing from reports then attempts were made to contact the study authors to obtain further
information. Studies published in duplicate were included once but a comprehensive data set was
compiled from all publications.
Risk-of-bias assessment (individual studies)
Two review authors independently assessed each included RCT using the Cochrane Collaboration tool for
assessing risk of bias.219 This tool includes the following domains: sequence generation, allocation
concealment, blinding of participants and care providers, blinding of outcome assessment, incomplete
outcome data and selective outcome reporting. In line with recently published Cochrane reviews on foam
and alginate dressings,198,199 we classified RCTs as being at overall high risk of bias if they were rated as
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high for any one of three key domains (allocation concealment, blinding of outcome assessors and
completeness of outcome data). If none of the key domains was classified as high risk but at least was
unclear, the RCT was judged to be at overall unclear risk of bias. To have an overall rating of low risk of
bias, all three key domains needed to be classified as low risk.
Relative treatment effects on ulcer healing: statistical analysis of direct data
When pairwise (direct) treatment comparisons were reported in one trial only, ORs and 95% CIs were
calculated. When direct comparisons of dressings were available from more than one trial, appropriate
standard meta-analyses (using ORs) were undertaken using WinBUGS (version 1.4.3) [Medical Research Council
Biostatistics Unit, Cambridge, UK; see www.mrc-bsu.cam.ac.uk/bugs (accessed 13 May 2016)]. Results were
reported with 95% credible intervals (CrIs), the Bayesian equivalent of CIs reflecting the uncertainty
surrounding estimates. Unlike 95% CIs, 95% CrIs can be interpreted as follows: the (posterior) probability these
limits contain the parameter mean is 95%. Fixed- and random-effects models were considered and model fit
was assessed using the posterior mean of the residual deviance and the deviance information criterion (DIC).
Quality assessment of evidence generated using direct data
The overall quality of evidence surrounding estimates of effect using direct evidence only was assessed
using GRADE.252 GRADE assessment focuses not on individual studies but on a body of evidence and
considers issues wider than threats to interval validity, including imprecision, inconsistency, indirectness and
publication bias. Problems in any category lead to the quality of the evidence being decreased (we did not
consider increasing quality of evidence options). In reflecting the quality of an estimate drawn from
multiple sources in a systematic review, GRADE aims to help the reader consider how confident we are
that an effect estimate is correct. Quality of evidence can be rated as high, moderate, low or very low.
Direct and indirect data: mixed-treatment meta-analysis
To maximise the use of all available trial data and to facilitate decision-making regarding dressing choice
we conducted a mixed-treatment meta-analysis.189,257 The mixed-treatment meta-analysis used the OR as
the measure of effectiveness and was conducted from a Bayesian perspective, again using WinBUGS
(version 1.4.3). Fixed- and random-effects models were fitted to these data with model fit assessed using
residual deviance and DIC as before.
The treatment with the highest OR estimate in the mixed-treatment meta-analysis is expected to have the
highest likelihood of healing diabetic foot ulcers. However, it is important to fully comprehend the
uncertainty around such estimates. In addition to presenting CrIs, we represented uncertainty regarding
treatment choice as the probability that each dressing was the ‘best’ treatment in terms of being the most
likely to heal diabetic foot ulcers (when compared with all other evaluated treatments). To provide a
complete overview of the spread of decision uncertainty around the choice of a ‘best’ treatment we then
presented the probability of each treatment being the second best treatment and the third best and so on.
Alternatively, this can be conceptualised for each treatment as a cumulative probability at each rank,
summarised numerically as surface under the cumulative ranking (SUCRA) for each treatment.258 Thus, a
SUCRA would be 1 (or 100%) when a treatment was certain to be the best and 0 (0%) when a treatment
was certain to be the worst.
Consistency of evidence
When direct and indirect evidence exist (i.e. a loop of evidence in the network diagram), inconsistencies
between the ORs and intervals of these two sources may arise. We formally assessed for inconsistencies
using the back calculation method,190 which is an extension to the method suggested by Bucher et al.259
Briefly, when direct and indirect values could be compared, these values were calculated for each
treatment, compared statistically against a null hypothesis that there would be no difference between
them and a p-value for this test was presented. We also extended the analysis to include an inconsistency
model, which omitted consistency equations.260 Finally, potential inconsistencies between our direct and
mixed-treatment meta-analysis estimates were also assessed by qualitatively comparing estimates of
standard meta-analysis (direct) and mixed-treatment meta-analysis (direct and indirect).
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Sensitivity analysis
We evaluated the sensitivity of the network to individual trials; when links were informed by more than
one trial, we removed each trial one at a time (therefore, n – 1 for each analysis) and investigated the
impact on the probability of which treatment was ‘best’.
Quality assessment of evidence generated from the mixed-treatment
meta-analysis
We were also keen to reflect the quality of the evidence provided by the mixed-treatment meta-analysis
so that this quality was transparently reflected in the strength of the conclusions made, as would be
expected in other forms of evidence synthesis; however, there is no established method for doing this in
mixed-treatment meta-analysis. We therefore modified the GRADE approach (we called this ‘iGRADE’) to
allow us to access and communicate the quality of this mixed-treatment meta-analysis-derived evidence.
We worked with the five categories in GRADE that allow the quality of evidence to be decreased; however,
we altered the focus of some categories so that they were relevant for assessing a mixed-treatment
meta-analysis (see Appendix 11 for a full description of the iGRADE tool). Briefly, the approach assessed risk
of bias for links observed as informing specific mixed-treatment comparison estimates. We explored
heterogeneity using a sensitivity analysis approach; indirectness was assessed by looking at the type of
direct and indirect data informing estimates; precision was assessed using the size of intervals around
estimates; and publication bias was assessed by looking at the studies used to inform relevant links in the
mixed-treatment comparison. Estimates could be classed at being of high, medium, low or very low quality.
No formal down-weighting of evidence was undertaken based on this assessment.
Results
Study characteristics
Fifteen eligible studies were included.261–275 A Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flowchart is presented in Appendix 12 and a summary of study characteristics for
the included studies is presented in Table 65. All 15 included studies reported the number of ulcers healed,
whereas only three262,264,266 reported median time to healing. We therefore focused our analyses on the
proportion of ulcers healed (or risk of healing). In terms of ulcer severity, four studies263,268,269,273 reported
the inclusion of people with Wagner grade 1 or 2 ulcers and one study264 specified that ulcers were
superficial. A further three studies specified that people with ulcers involving tendons, joint spaces and/or
bone were excluded.261,267,268 Only one study275 specifically included people with more severe grade 3
and 4 ulcers. Eight studies262,264,265,267,269,271–273 clearly excluded people with arterial disease. Eight
studies262,264–268,271,273 excluded participants with infected or sloughy ulcers. Only one study,274 comparing a
basic wound contact dressing with a hydrogel dressing, clearly specified the inclusion of people with
necrotic and infected wounds. The evidence base therefore overwhelmingly relates to people with less
severe and less complex diabetic foot ulcers.
In terms of risk of bias, four included studies261,264,265,274 were deemed to be at high risk of bias. Only one
study267 was deemed to be at low risk of bias. The remaining 10 studies were rated as being at unclear risk
of bias for one or more key domains (see Table 65).
Relative treatment effects on ulcer healing: direct data
A summary of the network of dressing trials that measured healing in participants with diabetic foot ulcers
is provided in Figure 15. Ten direct treatment comparisons were made in the 15 included trials; only five
comparisons were informed by more than one trial for which standard meta-analysis could be conducted
(all fixed effect). The overall quality of evidence for each direct link was assessed using the GRADE quality
of evidence scale (Table 66): four links were formed by low-quality evidence and six by moderate-quality
evidence. It is important to note that three of these four links formed by low-quality evidence were
informed by the same three-arm trial assessed as being at low risk of bias.267
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TABLE 65 Characteristics of the studies included in the mixed-treatment comparison meta-analysis of dressings for
diabetic foot ulcers
Study Treatment
Follow-up
(weeks) n
Durationa
(weeks)
Sizea
(cm2)
Agea
(years)
Number
healed
Risk of
biasb
Ahroni 1993261 Basic wound contact 4 19 10.7 1.68 65.4 7 U, U, H
Alginate 4 20 19.0 1.93 61.2 5
Donaghue 1998265 Basic wound contact 8 25 32.1 2.99 60 9 U, U, H
Alginate 8 50 20.9 2.60 59 24
Blackman 1994263 Basic wound contact 8 7 28 1.81 51 0.5a U, U, U
Alginate 8 11 25 2.67 59 3.5a
Mazzone 1993270 Basic wound contact 8 8 NA NA NA 2 U, U, U
Foam 8 11 NA NA NA 7
Roberts 2001272 Basic wound contact 13 16 NA NA NA 4 U, U, U
Foam 13 14 NA NA NA 6
Jeffcoate 2009267 Basic wound contact 24 106 NA NA 61.9 41 L, L, L
Fibrous hydrocolloid 24 103 NA NA 58.8 46
Iodine-impregnated
dressing
24 108 NA NA 59.5 48
Piaggesi 2001271 Basic wound contact 350 10 5.9 NA 61.3 10 L, U, U
Fibrous hydrocolloid 350 10 6.8 NA 63.1 9
Jensen 1998268 Basic wound contact 16 17 NA NA NA 6 U, U, U
Hydrogel 16 14 NA NA NA 11
Vandeputte 1996274 Basic wound contact 12 14 NA NA 65.3 7 U, U, H
Hydrogel 12 15 NA NA 62.6 14
D’Hemecourt 1998275 Basic wound contact 20 68 42 3.5 NA 15 U, U, L
Hydrogel 20 70 52.8 3.2 N 25
Veves 2002273 Basic wound contact 12 138 NA 3.1 59 39 U, U, U
Protease-modulating
matrix
12 138 NA 2.5 58 51
Baker 1994262 Alginate 12 10 26.3 0.82 54.1 4 L, U, U
Foam 12 10 19.8 0.89 58.9 9
Foster 1995266 Alginate 8 15 24.3 0.79 70 8 U, U, U
Foam 8 15 15.3 0.88 61 9
Jude 2007269 Alginate 8 67 62.4 3.1 58.9 15 L, U, U
Silver fibrous
hydrocolloid
8 67 72.8 4.2 61.1 21
Clever 1996264 Foam 16 20 23.6 2.78 53.2 14 U, U, H
Hydrocolloid matrix 16 20 23.2 2.51 58.9 16
H, high risk of bias; L, low risk of bias; NA, information not available; U, unclear risk of bias.
a Averages (per arm for per study) are shown for duration (in weeks), size (in cm2) and age (in years).
b Risk-of-bias categories from left to right: randomisation sequence, allocation concealment and blinded
outcome assessment.
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FIGURE 15 A network summary of all comparisons informed by direct trial data comparing wound dressings for
diabetic foot ulcer healing. All linked by one trial unless otherwise stated. One three-arm trial was included that
randomised to hydrocolloid (fibrous) dressing, iodine-impregnated dressing and basic wound contact dressing.
ALG, alginate; BWC, basic wound contact; HYDRO, hydrocolloid; HYDRO(F), fibrous hydrocolloid; HYDRO(M),
hydrocolloid matrix; HYDRO(SF), silver fibrous hydrocolloid; II, iodine impregnated; PMM, protease-modulating
matrix.
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There was evidence that hydrogel dressings were associated with significantly higher odds of ulcer healing
than basic wound contact dressings (OR 3.10, 95% CI 1.51 to 5.50) (see Table 66). However, this finding
was driven by low-quality evidence, that is, two small studies (sample sizes of 31 and 29 participants),
one with an unclear risk of bias and one at high risk of bias.268,274 Foam dressings were also associated
with higher odds of ulcer healing than basic wound contact dressings (OR 4.01, 95 CI% 1.07 to 10.7)
(see Table 66); however, again, the estimate was considered to be of low quality. In the remaining five
single-study comparisons there was no evidence of any difference between one dressing and another.
In general, estimates had large uncertainty because of small sample sizes.
Mixed-treatment meta-analysis
Based on assessment of fit, a fixed-effects model was employed. There was a minimal difference in mean
residual deviances and DIC between the different models tested (fixed effect and random effects, the latter
accounting for correlation within the three-armed trial); thus, the least complex model, given the limited
data available for analysis, was applied.
There was a high degree of uncertainty in the many links in the network, especially those that were not
informed by direct data (see Table 66). Evidence remained that both foam and hydrogel dressings were
expected to be associated with higher odds of ulcer healing than basic wound contact dressings, although
uncertainty was high (see Table 66). Foam and hydrogel dressings were estimated to be more effective
than fibrous hydrocolloid and iodine-impregnated dressings; these results were driven by the more certain
finding from a large, three-arm trial that there was no difference in ulcer healing between fibrous
hydrocolloid dressings and basic wound contact dressings and iodine-impregnated dressings and basic
wound contact dressings. In this situation we must consider the quality of the evidence provided in these
analyses (results of the iGRADE scale are presented in Table 66). In general, the network included several
small studies leading to high imprecision; additionally, estimates were informed by studies with a high risk
of bias. We stress that the research used for deriving the estimates for fibrous hydrocolloid and iodine-
impregnated dressings was regarded as higher quality, whereas evidence on hydrogel and foam dressings
was regarded as being of more limited quality (see Table 66).263,268,270,272,274,275
A valuable feature of Bayesian methods is the ability to illustrate the impact of uncertainty on
decision-making by assessing the probability that each dressing treatment included in the network is the
best in terms of ulcer healing. Notably, the treatment associated with the greatest probability of healing
was hydrocolloid matrix (70%; Table 67). This result reflects the high relative effect estimates generated by
the mixed-treatment meta-analysis from available indirect evidence (OR 10.38, 95 CrI 1.19 to 42.1; see
Table 66); hydrocolloid matrix had a higher odds of healing than foam and foam had a higher odds of
healing than basic wound contact. Again, when interpreting the evidence its quality must also be
considered; these results are drawn from low-quality evidence and this limits the confidence that we have
in the strength of the conclusions that can be drawn from them. Estimates for the three dressings with
the highest probability of being the best (hydrocolloid matrix, foam and hydrogel) were informed by
low-quality evidence, whereas estimates for some dressings with a 0% probability of being the best were
informed by moderate-quality evidence. SUCRA estimates reflect these findings considered cumulatively
across the ranks 1–9: hydrocolloid matrix dressings had a SUCRA of 92%, foam dressings 83% and
hydrogel 78%, whereas basic wound contact dressings had a SUCRA of 11% (see Table 67) (a SUCRA of
100% means that a treatment is certain to be the best and a SUCRA of 0% means that a treatment is
certain to be the worse).
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Consistency of evidence
There was one data loop in which both direct and indirect data informed relative treatment effectiveness
estimates and the possibility of inconsistency was investigated. Although there was no evidence of
statistically significant discrepancies between the direct data and the indirect data, given the uncertainty in
the data only very large differences were likely to result in statistical significance. However, the
inconsistency model returned DIC estimates that were very similar to those in the base-case model.
Assessing the data qualitatively we noted that only one link, that between basic wound contact dressings
and foam dressings, had an indirect point estimate that differed considerably from the direct data; this was
likely driven by the high and uncertain estimates in two of the three studies that contributed direct
evidence. For the basic wound contact–alginate link, although the direct and indirect estimates were close,
the indirect estimate was much more uncertain. Interestingly, this link was the only one to have conflicting
direct evidence. The direct and indirect estimates for the alginate versus foam comparison were close, with
the indirect link having slightly more uncertainty. The direct evidence in this link had very differently sized
estimates, although this might be explained by the large uncertainty in one study, which had only
20 participants.
Sensitivity analysis
The sensitivity of the network to specific studies was also investigated. In total, 11 analyses with 14
included studies (rather than the total 15 studies) were performed and the probability of each dressing
being the best was assessed. Basic wound contact, alginate, fibrous hydrocolloid, iodine-impregnated and
silver fibrous hydrocolloid dressings continued to have a very low or zero probability of being the ‘best’
treatment in any sensitivity analysis. Hydrocolloid matrix remained the most likely ‘best’ treatment in 10 of
the 11 analyses (probability of being ‘best’ ranging from 62% to 75%) (Table 68). The exception was
when the largest study comparing hydrogel with a basic wound contact dressing was removed.275 This
resulted in the direct odds of healing with hydrogel (and the uncertainty around this estimate) increasing
dramatically as the two remaining small trials both significantly favoured hydrogel, with hydrogel having
the highest probability of healing (62% vs. 35% for hydrocolloid matrix).
TABLE 67 Treatment rankings in the main mixed-treatment meta-analysis model (fixed effects): dressings to heal
foot ulcers in people with diabetes
Dressing
Probability of being the best treatment
choice in terms of healing (%) SUCRA value (%)
Matrix hydrocolloid 70 92
Foam 14 83
Hydrogel 14 78
Silver fibrous hydrocolloid 2 55
Protease modulating 0 43
Impregnated iodine 0 30
Fibrous hydrocolloid 0 30
Alginate 0 27
Basic wound contact 0 11
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Dressings to heal venous leg ulcers
Objectives
Our objectives were to assess the relative effectiveness of dressings for healing venous leg ulcers using a
mixed-treatment meta-analysis and to assess the quality of relative effective estimates produced in the
mixed-treatment meta-analysis.
Methods
Study selection
We included published and unpublished RCTs (i.e. must be described as randomised in the report)
reported in any language and conducted in any country and setting. RCTs recruiting participants with
venous leg ulcers were included, with venous leg ulcers defined as an inclusion criterion of ABPI > 0.8 and
studies having a clear focus on populations with venous leg ulcers only. When the ABPI was not reported
as an inclusion criterion, studies that clearly considered the included wounds to be only venous leg ulcers
were also included.
The interventions of interest were dressings (including those impregnated with antimicrobials or moistened
with saline). Trials of dressings that consisted of a topical agent being spread or poured onto a proprietary
dressing fabric were excluded as were trials of topical treatments per se. We included only RCTs that
compared dressings with other dressings or dressings with no dressing. We did not include trials
comparing dressings with topical treatments or other adjuvant therapies, for example:
l growth factors
l skin replacements
l extracts of placenta or amniotic sac
l herbal preparations
l negative wound pressure therapy
l systemic interventions (e.g. antibiotics, pentoxifylline)
l surgical interventions.
We also excluded trials that compared different brands of the same dressing type.
We excluded RCTs in which the dressing comparison was not the only systematic difference between
treatment groups. This decision rule has been used in other recent systematic reviews of wound
management.197,198 As a result of this rule, we included only RCTs in which compression therapy was
deemed to have been standardised across trial arms. Compression therapies of any level of pressure were
included, that is, compression did not have to be high-level compression for studies to be included.
Our primary outcome was ulcer healing, measured using number of ulcers completely healed within a
specific time period (we assumed this period to be the trial follow-up period unless otherwise stated).
Data sources and searches
The search string for CENTRAL (see Appendix 13) was adapted for use in the following databases, all
being searched from inception to 31 May 2013: Cochrane Wounds Group Specialised Register, MEDLINE,
EMBASE and CINAHL. The MEDLINE search was combined with the Cochrane Highly Sensitive Search
Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008
revision).247 The EMBASE and CINAHL searches were combined with the trial filters developed by SIGN.248
Reference lists of included studies and previous systematic reviews were also searched. Two review authors
independently assessed the titles and abstracts of retrieved studies for relevance. After this initial
assessment, we obtained all studies felt to be potentially relevant in full. These were then screened
as before.
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Data extraction
This was undertaken following the same methodology as in the previous section (dressings for healing foot
ulcers in people with diabetes).
Risk-of-bias assessment (individual studies)
This was undertaken following the same methodology as in the previous section (dressings for healing foot
ulcers in people with diabetes).
Relative treatment effects on ulcer healing: statistical analysis of direct data
Where direct comparisons of dressings were available from two or more trials, appropriate pairwise
meta-analyses were undertaken using WinBUGS (version 1.4.3).
All evidence synthesis was conducted using an extended approach that allowed time of study follow-up
to be taken into account in the analysis even though healing data were reported (and extracted) as
proportion of ulcers healed.276
This methodology utilises a binomial likelihood to estimate the probability of participants being healed.
The approach then assumes that the probability of healing can be related (algebraically) to a distribution
of time to healing, allowing proportion healed to be defined as time to ulcer healing (see Soares et al.276
for a more detailed description of the method). Thus, this approach reports the HR as a measure of relative
effectiveness. This synthesis model used the uniparametric exponential distribution, which imposes a
constant healing hazard over time. For the direct comparisons informed by a single trial, HRs and 95% CrIs
were estimated using the same approach.
Results were reported with 95% CrIs, the Bayesian equivalent of CIs, reflecting the uncertainty
surrounding estimates. Unlike 95% CIs, 95% CrIs can be interpreted as follows: the (posterior) probability
these limits contain the parameter mean is 95%. All direct meta-analyses were fixed-effects models.
Quality assessment of evidence generated using direct data
The overall quality of evidence surrounding estimates of effect using direct evidence only was assessed
using GRADE.252 The quality of evidence was rated as high, moderate, low or very low.
Direct and indirect data: mixed-treatment meta-analysis
Fixed- and random-effects models were considered and model fit assessed using the posterior mean of the
residual deviance and the DIC.
As for the standard meta-analysis of direct data, the mixed-treatment meta-analysis used the modified
approach in which time of study follow-up was accounted for and findings are presented as HRs. We
compared the findings of this modified method against the findings of a more standard mixed-treatment
meta-analysis approach (reporting the odds of healing).
An important feature of the Bayesian framework employed here is the ability to assess the probability that
each treatment is the best (considering its HR), reflecting the impact of uncertainty on the relative
treatment effects, and this is important in informing recommendations on which treatment to use.
Quality assessment of evidence generated from the mixed-treatment
meta-analysis
The quality of the data included in any synthesis model is key in determining the validity of the results and
of inferences made. The iGRADE tool196 was used to assess the overall quality of evidence surrounding
estimates of effect from the mixed-treatment meta-analysis (see Appendix 11).
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Contributions of direct evidence in the network
The contributions of direct estimates to each of the estimates in a network of evidence are not all the
same. Rather, contribution is a function of an estimate’s statistical precision (which is an indication of the
amount of information available) and of its relative position in the network. A recently published tool
allows the contribution of each direct estimate to each overall mixed-treatment pairwise effect size to be
determined, as well as allowing the contribution of each direct estimate to the network as a whole to be
assessed.258,277 Estimating the contributions is only relevant for links in a network informed by mixed
evidence (direct and indirect) or when multiple loops of indirect evidence inform the same link. Estimated
contributions may be interpreted as weights, providing percentage contributions of both direct and indirect
estimates to particular network estimates. When possible we applied these methods to the evidence loops
in our network. We acknowledge that this approach is based on a frequentist rather than a Bayesian
approach and thus returns approximate weights.
Consistency of evidence
We formally evaluated statistical inconsistency by estimating the inconsistency factor, that is, the absolute
difference between the direct and the indirect estimates on the log scale (or the logarithm of the ratio of
the two ORs/HRs) for each of the comparisons in a loop.278 A statistically low-powered z-test and a 95% CI
of the inconsistency were computed.
Results
Data were obtained from 22 RCTs (see PRISMA diagram in Appendix 14). In compiling these studies into a
network of evidence three studies279–281 were excluded as the treatments evaluated in them did not
connect to the main network. Thus, the final data set included 19 RCTs evaluating 39 unique treatments
(Table 69).227,231,282–298 The evidence in the final data set was organised in the network, shown in Figure 16.
This network encompassed 10 non-silver treatments and two trial arms of silver-containing dressings
(various ‘silver-donating’ dressings and silver foam).
TABLE 69 Randomised controlled trials included in the mixed-treatment comparison of dressings for venous
leg ulcers
Study Treatment
Follow-up
(weeks) n
Durationa
(weeks)
Sizea
(cm2)
Agea
(years)
Number
healed
Risk of
biasb
Backhouse
1987282
Basic wound contact 12 28 NA 3.1 67.5 22 U, U, U
Hydrocolloid 12 28 NA 3.4 69.9 21
Blair 1988283 Basic wound contact 12 30 84 3.1 67.5 23 L, U, U
Hydrocolloid 12 30 88 3.4 69.9 22
Nelson 2007284 Basic wound contact 24 118 59.2 9.1 69.7 69 L, L, U
Hydrocolloid 24 127 45.2 7.9 70.3 72
Moffatt 1992285 Basic wound contact 12 30 NA NA NA 7 L, U, U
Hydrocolloid 12 30 NA NA NA 13
Callam 1992286 Basic wound contact 12 66 44.8 8.4 63 23 U, U, U
Foam 12 66 46.8 10.9 64 31
Michaels 2009231 Basic wound contact 12 106 NA NA 72.4 59 L, L, L
Silver-donating
dressing
12 107 NA NA 68.8 62
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TABLE 69 Randomised controlled trials included in the mixed-treatment comparison of dressings for venous
leg ulcers (continued )
Study Treatment
Follow-up
(weeks) n
Durationa
(weeks)
Sizea
(cm2)
Agea
(years)
Number
healed
Risk of
biasb
Moffatt 1992287 Basic wound contact 12 30 NA NA NA 24 U, U, U
Alginate 12 30 NA NA NA 26
Bowszyc 1995288 Hydrocolloid 16 41 36.1 3.5 55 24 U, U, U
Foam 16 41 26.2 4.0 64.2 24
Charles 2002289 Hydrocolloid 12 60 99.4 9.8 72 34 L, U, U
Foam 12 31 137 8.8 71 18
Thomas 1997290 Hydrocolloid 13 50 NA 3.4 75.3 19 U, U, U
Foam 13 50 NA 4.3 73.4 17
Vanscheidt
2004291
Hydrocolloid 12 55 171.6 11.7 62.8 20 U, U, U
Foam 12 52 67.6 10.9 68.4 20
Zuccarelli 1992292 Hydrocolloid 12 19 37.4 6.9 77.3 9 U, U, U
Foam 12 19 48.9 9.8 70.1 9
Arnold 1994293 Hydrocolloid 10 35 46.2 21.0 65 11 U, U, U
Paraffin-impregnated
gauze or betadine/
saline-impregnated
gauze
10 35 47.8 19.8 60 14
Dimakakos
2009227
Foam 9 21 NA NA 61.2 10 U, U, U
Silver foam 9 21 NA NA 58.7 17
Mulder 1995294 Foam 16 19 NA NA NA 17 U, U, U
Alginate 16 20 NA NA NA 10
Vin 2002295 Paraffin gauze
dressing
12 36 39.6 9.5 71.7 12 U, U, U
Protease-modulating
matrix
12 37 34 7 74.1 18
Taddeucci 2004296 Paraffin gauze
dressing
8 12 NA NA NA 1 U, U, U
Hyaluronan fleece 8 12 NA NA NA 2
Schmutz 2008297 Protease-modulating
matrix
12 60 48.4 10.4 71 8 U, U, U
Nano-oligosaccahride
technology lipido-
colloid
12 57 41.6 11.4 71.5 10
Hansson 1998298 Hydrocolloid 12 48 NA 10.7 NA 5 U, U, U
Cadexomer iodine 12 56 NA 20.6 NA 8
Paraffin gauze
dressing
12 49 NA 8.8 NA 7
L, low risk of bias; NA, information not available; U, unclear risk of bias.
a Averages (per arm for each study) are shown for duration (in weeks), size (in cm2) and age (in years).
b Risk-of-bias categories from left to right: randomisation sequence, allocation concealment and blinded
outcome assessment.
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
195
Within the network, the most populated comparisons were foam compared with hydrocolloid (five RCTs)
and hydrocolloid compared with basic wound contact (four RCTs). The remaining 13 links were informed
by summary estimates extracted from one trial in each case, except for the comparison (loop) between
hydrocolloid, paraffin gauze dressing and cadexomer iodine, which was informed by information from a
single, three-arm trial.
Statistical analysis
The analysis evaluated the network in Figure 16. There were two trials evaluating silver-containing
dressings. One of these evaluated a treatment arm in which health professionals could select from a wide
range of types of silver dressing. For this reason, we could not assess the effectiveness of individual
silver-based treatments. Also, we did not feel that it would be interpretable if we combined these
treatment arms as if they were homogeneous. The decision was made to model the treatments jointly as
an incremental effect of silver. By incremental we mean that the effect of silver was estimated over and
above any potential relative effects of dressing type when compared with basic wound contact dressings.
For example, a silver foam dressing may be estimated to be more (or less) effective than a non-silver foam
dressing, which may, in turn, still be considered more (or less) effective than basic wound contact
dressings. Given the limited data available this effect was also assumed to be common across treatments;
thus, the HR of silver was the same for all dressing types. This means that the incremental effect of silver
for foam (i.e. silver foam vs. foam) is equivalent to the incremental effect of silver for alginates (silver
alginate vs. alginate). This approach was considered to be conservative as it uses any effect of silver but
also any effect of the dressing type (non-silver) over that of a basic wound contact dressing to contribute
to the estimate.
N-OLIG
PMM
CADEX CADEX
BWC
ALG
PAR-
BET
n = 5
n = 4
PAR FOAM
SILVER
DD
SILVER
FOAM
HYALU
FIGURE 16 Network of RCTs of dressings for venous leg ulcers. In the network, a unique treatment category is
indicated by an ellipse. Arrows between ellipses indicate that these treatments were compared in a trial. The
number of trials is one unless otherwise stated. ALG, alginate; BWC, basic wound contact; CADEX, cadexomer
iodine; HYALU, hyaluronan fleece; N-OLIG, nano-oligosaccahride technology lipido-colloid; PAR, paraffin gauze;
PAR-BET, paraffin-impregnated gauze or betadine/saline-impregnated gauze; PMM, protease-modulating matrix;
SILVER DD, silver donating.
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Relative effectiveness results with quality assessment
For the mixed-treatment meta-analysis the fixed- and random-effects models provided very similar results.
The between-study variation was estimated to be 0.05 (95% CrI 0.0 to 0.39). The DIC statistic was
marginally lower for the fixed-effects than for the random-effects model (DICs of 221.6 and 222.5,
respectively), indicating that the former model, being less complex, may be a more parsimonious
representation of the data. Fixed-effect models were used throughout.
We also compared the modified approach that we adopted with the standard method used to model
dichotomous (healed yes/no) data, that is, without taking time into account. From the results (see
Appendix 15) we deemed the modified approach to be the most appropriate. Thus, the proportion healed
was defined as time to ulcer healing and reported using the HR alongside the 95% CrI.
Table 70 shows the HR estimates for the analyses of direct and mixed data. Estimates are for each
alternative non-silver dressing compared with basic wound contact and are presented alongside the results
of quality assessment. Because of the large volume of information from small single trials there was high
imprecision around point estimates for the majority of the relative treatment effects derived from the
network meta-analysis. This was particularly notable in the treatment with the highest point estimate, that
is, the treatment that was shown to be most effective (a hyaluronan fleece dressing vs. basic wound
contact: HR 3.92, 95% CrI 0.24 to 175.2). This was also the case for the other two treatments that had
high point estimates (nano-oligosaccharide technology lipido-colloid vs. basic wound contact: HR 3.55,
95% CrI 0.63 to 22.0; collagen/cellulose vs. basic wound contact: HR 2.6, 95% CrI 0.64 to 11.5).
The most precise treatment effect was obtained for the treatment comparison populated by data from
four trials (hydrocolloid vs. basic wound contact: HR 1.11, 95% CrI 0.88 to 1.41). The alginate dressing
was expected to be less effective than basic wound contact (HR 0.82, 95% CrI 0.48 to 1.35), although the
CrI did include 1.
However, it is important to consider the point estimates alongside the quality of the estimates provided by
these analyses. In general, the network estimates were affected by high imprecision. No included studies
were deemed to be at high risk of bias, but all were at unclear risk of bias for some or all domains
(because of poor reporting). Because we took a conservative approach in the iGRADE assessment and
studies at unclear risk of bias were assumed to be conferring no serious risk of bias, most studies were
considered to be at moderate or low risk of bias.
Incremental effect of silver
The mixed-treatment meta-analysis model estimated the incremental effect of silver on ulcer healing as a
HR of 1.24 (95% CrI 0.88 to 1.72). Thus, there was significant uncertainty regarding an effect of silver.
A quality assessment was not conducted for this estimate; however, we noted that the two studies
contributing to the silver effect produced very different estimates. The first study231 included 213
participants (with infected and non-infected ulcers) and was deemed to be at low risk of bias and had a
HR of healing of 1.07 (95% CrI 0.73 to 1.55). The second study227 included 41 participants who all had an
infected ulcer and was deemed to be at unclear risk of bias and reported a HR of healing of 2.6 (95% CrI
1.17 to 6.10).
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Probability of treatments being best (non-silver dressings)
The treatment associated with the greatest probability of ulcer healing was the hyaluronan fleece dressing
(48%), followed closely by the nano-oligosaccharide technology lipido-colloid dressing (35%) (Table 71).
These results reflect the fairly high relative effect point estimates obtained for these two dressings but also
the wide uncertainty around them. The GRADE and iGRADE assessment in Table 70 highlights that
estimates of the relative effectiveness of these dressings were deemed to be of low quality.
Contributions of direct evidence (non-silver dressings)
Within our network of evidence we were able to assess the contributions of direct evidence for estimates
within the two interlinked evidence loops of the network: basic wound contact versus foam versus
hydrocolloid and basic wound contact versus foam versus alginate. The remaining loop was informed by
data from a single three-arm trial and consequently assessment of consistency was not appropriate.
The varying contributions of the direct estimates (in columns) for each of the five relevant comparisons (in
rows) are presented in Table 72. For example, the mixed-treatment meta-analysis estimate for the alginate vs.
basic wound contact comparison was predominantly informed by indirect data, with the estimate from the
alginate vs. foam comparison contributing most (32.1%) and direct evidence contributing only 9.7% to
the overall estimate. The increased weighting of indirect compared with direct data occurred here because the
effect estimate derived from the study populating the alginate vs. foam comparison294 was more precise than
the estimate derived from the study populating the alginate vs. basic wound contact comparison.287 The
mixed-treatment estimate for alginate versus hydrocolloid was also mainly informed by direct evidence from
other pairwise comparisons: the alginate versus foam and foam versus hydrocolloid comparisons.
Consistency of evidence
The results of the inconsistency assessment over the loops of the network of evidence are presented in
Table 73. The estimated inconsistency factor values and 95% CIs show no evidence of statistical
inconsistency for any of the two loops in the network, that is, as depicted from the 95% CIs, both loops
are compatible with zero inconsistency between direct and indirect evidence.
TABLE 71 Treatment rankings for non-silver treatments in the main mixed-treatment meta-analysis model
(fixed effects): dressings to heal venous leg ulcers
Dressing type
Probability of being the best treatment
choice in terms of healing (%)
Hyaluronan fleece 48
Nano-oligosaccahride technology lipido-colloid 35
Collagen/cellulose 7
Paraffin-impregnated gauze or betadine/saline impregnated gauze 5
Cadexomer iodine 3
Foam 1
Alginate 0
Paraffin gauze dressing 0
Basic wound contact 0
Hydrocolloid 0
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Discussion of mixed-treatment comparison meta-analyses
We used mixed-treatment comparison meta-analysis to comprehensively summarise all trial evidence
regarding the use of dressings to heal (1) foot ulcers in people with diabetes and (2) venous leg ulcers.
We conclude that more expensive ‘advanced’ dressings may offer no advantage in terms of healing than
cheaper, basic dressings. The work also highlights the risk of bias in some studies and how this can impact
on the interpretation of mixed-treatment meta-analyses.
The work also provides a platform from which to consider future research. Given the large number of
dressing options available to clinicians (although a number of dressings have been evaluated here there are
many more for which no RCT data exist), the design of future studies should be driven by those questions
regarded as being of high priority by decision-makers and patients and should be guided by these data.
When we conducted our meta-analysis there was no published method of assessing the quality of
evidence within a network of evidence or mixed-treatment comparison meta-analysis. We developed and
employed a preliminary framework for evidence quality assessment within the framework of mixed-
treatment meta-analysis, based on GRADE.252 We aimed to assess the feasibility of such an approach and
highlight the potential challenges of applying quality assessment to mixed-treatment meta-analysis
evidence. We note, however, that our modified approach has not been validated and is not recognised by
GRADE. It may be that tools other than GRADE would provide a better starting point for assessing the
TABLE 72 Contribution matrix for network evidence loops (dressings for venous leg ulcers): percentage
contribution of each direct estimate to each mixed-treatment meta-analysis estimate
Loop
Direct estimates
ALG vs.
BWC (%)
ALG vs.
foam (%)
BWC vs.
foam (%)
BWC vs.
HYDRO (%)
Foam vs.
HYDRO (%)
Mixed-treatment comparison
ALG vs. BWC 9.7 32.1 5.9 26.2 26.2
ALG vs. foam 7.6 78.6 1.4 6.2 6.2
BWC vs. foam 7.8 7.8 8.6 37.9 37.9
BWC vs. HYDRO 5.1 5.1 5.6 73.4 10.7
Foam vs. HYDRO 6.6 6.6 7.2 13.8 65.8
Indirect estimate
ALG vs. HYDRO 8.2 40.0 3.6 11.8 36.4
ALG, alginate; BWC, basic wound contact; HYDRO, hydrocolloid.
Note
Shaded cells represent the highest contributions for each of these pairwise comparisons.
TABLE 73 Results of the evaluation of statistical inconsistency of the two loops in the network of evidence:
dressings to heal venous leg ulcers
Loop Inconsistency factor 95% CI
BWC vs. foam vs. ALG 0.528 0.0 to 1.80
BWC vs. foam vs. HYDRO 0.438 0.0 to 1.41
ALG, alginate; BWC, basic wound contact; HYDRO, hydrocolloid.
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quality of mixed-treatment meta-analysis evidence. GRADE is primarily concerned with guiding clinical and
policy-level decision-making, which is somewhat different from the challenge of summarising the quality of
evidence within mixed-treatment meta-analysis. At the very least, within our modified approach there are
still several aspects that need addressing, emphasising future challenges in developing such a scale,
for example indirectness as a characteristic of the evidence is not easy to apply to mixed-treatment
meta-analysis (as indirect data are a common feature that should not necessary result in downgrading)
and is perhaps more appropriately termed ‘inconsistency’ in this context. Within the standard GRADE
approach, the term ‘inconsistency’ relates to unexplained heterogeneity. Within iGRADE we considered
unexplained heterogeneity and inconsistency (the mixed-treatment meta-analysis-related meaning)
together in one category. We then added a separate category that assessed the impact of the sensitivity
analysis on the results. Our aim here was to assess the stability of the network and thus its estimates.
Finally, imprecision could perhaps be omitted from this tool as it may be more useful for the reader to use
his or her own judgement regarding the width of CrIs and what they mean. We acknowledge that the
quality assessment of mixed-treatment meta-analysis output is a complex area and further research is
required; however, at the time our work was the only example of quality assessment of mixed-treatment
meta-analysis outputs.196
Within our mixed-treatment comparison meta-analysis of dressings for venous leg ulcers, we implemented
an analysis that allowed us to use available data to assess the impact of silver dressings beyond that of
their non-silver-containing counterparts. From these data we conclude that there is considerable
uncertainty regarding the effect of silver on the healing of venous leg ulcers in people with either infected
or uninfected ulcers at baseline. It was not possible to rule out a true effect in either direction, that is, in
favour of silver or non-silver dressings, and there may be no differential effect. The relative effect estimate
was drawn from two studies involving a total of 255 participants. One study in particular was small
(41 participants) and poorly reported. Ultimately, the scarcity of available data limited the conclusions that
we were able to draw. The methods that have been presented here offer the potential for further work,
notably using IPD from studies when available (although the work described earlier in this chapter suggests
that this is unlikely to be possible currently).
The findings presented result from the analysis of the most comprehensive evidence base available
regarding the effect on healing of dressings to treat diabetic foot ulcers. Although some may argue that
the presence of sparse data should preclude any statistical synthesis of the evidence, we counter that
clinicians cannot postpone treatment selection until high-quality evidence has accumulated. Furthermore,
comprehensive evidence synthesis highlights to researchers and clinicians the state of the current evidence
base and its limitations as well as signposting where future research might focus. A further strength of this
study is the application of an exploratory framework based on GRADE to undertake quality assessment of
mixed-treatment meta-analysis estimates and the presentation of findings in light of this assessment.
We do acknowledge that there are limitations in synthesising sparse data, especially in preventing further
exploration of the potential impact of heterogeneity, for example length of trial follow-up. However, it is
important to note that this is an issue for several evidence synthesis projects in wound care for which data
are sparse and follow-up times vary. In other networks this has been dealt with by assuming a constant
hazard of healing over time, although this assumption is potentially also not valid. In general, the limited
evidence base made a random-effects model difficult to fit; however, we acknowledge that in other
situations this model type may be more appropriate than a fixed-effects approach. We also note that,
besides characterising the potential for bias, it may be possible to adjust the treatment effect estimates for
bias. Further methodological development would be required to inform the application of bias adjustment
to this research and this was beyond the scope of our programme.
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Overall conclusions from workstream 3
We used a range of strategies to identify and prioritise topics for evidence synthesis, including face-to face
contact with local clinicians. The topic of the effectiveness of silver-containing dressings emerged as a
priority in relation to both diabetic foot ulcers and venous leg ulcers. We explored the potential for a new
IPD meta-analysis of the effects of silver-containing wound dressings on venous ulcer healing. We
identified seven eligible RCTs (1102 participants) within which there was a high degree of heterogeneity
in terms of participant eligibility, dressings, comparators, cointerventions, outcomes and duration of
follow-up. Overall, the trial-level data were not suggestive of a difference in healing time with silver
dressings. The heterogeneity of the existing trials led us to conclude that investing in the resources
required for a new IPD meta-analysis would not be worthwhile at this time (because such an analysis
would be unlikely to draw a different conclusion from the aggregate data).
We produced a series of 11 Cochrane reviews (either as updates or new reviews) in areas prioritised by
participating clinicians (five in diabetic foot ulcer treatment, five in venous ulcer treatment and one in
surgical wound treatment). Some treatments may be effective for the management of diabetic foot ulcers
(hydrogel and negative pressure wound therapy) and there is good evidence that compression is effective
for venous leg ulcers and EMLA cream reduces leg ulcer pain during debridement. Beyond these findings
much uncertainty remains because of the scarcity and poor quality of the primary research. The lack of
evidence in relation to some populations, for example people with diabetic foot ulcers, should influence
the future research agenda. Our consultation with clinicians also identified many topics for which the
prevailing uncertainty is a challenge to their daily clinical decision-making and new primary research
is warranted.
One approach to evidence synthesis that arguably delivers the ‘answer’ or result in a more decision-ready
format is mixed-treatment comparison meta-analysis. This approach has the advantage of delivering
ranked probabilities that each treatment is the ‘best’ rather than merely presenting innumerable pairwise
comparisons. We undertook such mixed-treatment comparison meta-analyses of the evidence for different
wound dressings influencing the healing of diabetic foot ulcers and venous leg ulcers. As part of this work
it became obvious that a method of accounting for the quality of the evidence within the evidence
network was required (clearly more complex than accounting for the quality of evidence in a pairwise
comparison). In the absence of any published method at the time, we developed a modification of the
GRADE approach that we called iGRADE.
The mixed-treatment comparison meta-analysis led us to conclude that, for diabetic foot ulcers, matrix
hydrocolloid dressings are associated with a 70% probability of being the best dressing, followed by
hydrogel and foam (both having a 14% probability of being the best). Hydrogel was deemed to have the
highest probability of being the best in one sensitivity analysis but this was when the largest study
evaluating hydrogel was removed from the network. For venous leg ulcers a hyaluronan fleece dressing
had a 50% probability of being the best treatment, followed by a lipido-colloid dressing (35% probability).
It is important to emphasise, however, that when advanced dressings were found to be the likely best
treatments the findings were driven by very uncertain, low-quality data. Although supported by moderate-
quality evidence, the results did not demonstrate a treatment effect (greater healing) associated with
hydrocolloids or alginates relative to basic wound care for either foot ulcers in people with diabetes or
venous leg ulcers.
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Chapter 5 Discussion
Summary of key findings across the programme
Within workstream 1 we derived an estimate of the prevalence of people affected by (and receiving health
care for) a complex wound in the city of Leeds (population 751,487). This prevalence study makes a
valuable contribution to the current literature for several reasons. First, we knew from our own literature
review that there was no accurate contemporary estimate of the prevalence of complex wounds in the UK,
with most previous surveys having focused on individual wound types such as leg ulcers or any kind of
wound (including the non-complex). Many of the surveys were poorly reported and/or flawed. There have
been major developments in wounds research and its implementation since some of the early, higher-
quality studies were conducted. For example, since the early studies of Callam et al.38 and Cornwall et al.41
in the 1980s, leg ulcer care has been revolutionised in the UK and now most venous ulcer patients receive
good first-line treatment (compression therapy). It is quite likely that the point prevalence of open venous
ulcers is therefore lower now than it was in the 1980s. Pressure ulcer prevention has also become a
national priority as part of Commissioning for Quality and Innovation [see www.england.nhs.uk/wp-content/
uploads/2014/02/sc-cquin-guid.pdf (accessed 25 June 2016)] and so one would expect their number to
have reduced.
Second, our survey was unique in its comprehensiveness (we included private hospitals, prisons and
hospices as well as NHS providers). We had a broad focus while maintaining relevance for service providers
so we included people with any kind of complex wound and excluded straightforward wounds such as
surgical incisions that were healing normally. We were particularly focused on gaining good estimates of
the prevalence of complex wounds in people who were current or previous intravenous drug users as this
was perceived as a clinical challenge in Leeds when we began the research and there were no published
estimates at the time. Our finding that 5.64 people per 1000 with a history of current or previous
intravenous drug use have a complex wound (compared with 1.47 per 1000 people in the general
population) is novel. Since we undertook our study there has been a study published reporting the
prevalence and history of skin problems in intravenous drug users.299 This survey purposively sampled
known previous and current injecting drug users, 7% of whom had a current leg ulcer during the survey.
These two prevalence estimates are very different, which is probably explained by the very different
sampling approaches used, but what is clear is that injecting drug users are at a greatly increased risk of
chronic and complex wounds.
The prevalence survey also told us that pressure ulcers were the most frequent wound type (0.31 per
1000 people) and that most people with a complex wound have at least one comorbidity, with 51%
having two or more. The most common comorbidity was CVD (affecting 45%) and 23% had some form
of incontinence. Most people with a complex wound were receiving care from NHS community services
and receiving a median of two consultations per week for their wound, each lasting just under half an
hour on average. The quality of care seemed to be generally high: 81% of people reported as having a
venous leg ulcer were in receipt of compression therapy, 73% of people with at least one pressure ulcer
had a pressure-relieving mattress and nearly 95% of all pressure ulcers had a documented EPUAP ulcer
severity classification in line with NICE guidelines.
We set out with the intention of developing and piloting a complex wounds register and informed this
with a comprehensive review of existing registers of wounds. We were particularly influenced by the
reviews of Drolet and Johnson97 and Raftery et al.,99 who together provided a framework for us to think
about registers. We identified no UK-based current wounds registers but were able to design and
implement one, albeit as a pilot. It was easy to see the potential advantages to patient care and HTA from
such a register, not least because there is a complete absence of usable, routinely collected data on
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community nurses’ work and its associated clinical outcomes. As far as we know this is the first time a
complex wounds register has been implemented in UK community services and there were very real
difficulties associated with this, even on a small scale. For instance, the ethics committee required
individual participant consent to collect health-related quality-of-life data. The very act of seeking consent
for data collection dissuaded participation and our consent rate was only 25%, with a probable selection
bias towards people who were in better overall health. The difficulties of getting a register off the ground
were also compounded by community nurses’ working practices, which do not generally feature mobile IT
(or feature it sporadically). It is difficult or impossible to obtain these data from anyone other than
community nurses because wound care is not documented by GPs or hospitals. The data that we were
able to collect enabled us to glimpse the huge potential value of a high-quality prospective register of
people with complex wounds. Such a register would succeed only if the technology infrastructure
improved in community nursing and the collection of good routine data became possible, and this would
require considerable investment.
Workstream 2 was our conduit to the patient and carer voice, a voice that is heard relatively rarely in
complex wounds research for reasons that are understandable. As far as we are aware this is the first
research conducted that has aimed to understand which outcomes matter to those directly affected
by complex wounds. Consequently, we feel that workstream 2 makes a major contribution to the
international literature on patients’ experiences of living with a complex wound, including for the first time
hearing the voices of people whose wounds are a direct consequence of intravenous drug use. We learned
that some of them are struggling to come to terms with the fact that they may have inflicted irreparable
damage to the veins in their legs such that chronic ulceration may be a permanent feature of their lives.
We also heard from patients with wounds of all types that their most desired outcome is complete healing
and the absence of a wound. Some carers acknowledged that this may be an unrealistic expectation.
The interviews with health-care professionals were in some ways the most fascinating. Here, the tension
was palpable between striving to get wounds completely healed (by trying multiple products in rapid
succession) and helping people to live with a long-term condition. Nowhere is this tension better
exemplified than in this quote from an experienced nurse:
. . . and we don’t have any concept of what the impact of despair has on healing and kind of feeling
that everything that everyone has tried is useless and that they’re in a hopeless situation. We haven’t
really got an understanding of how that affects us metabolically, physiologically but I think that’s
ultimately what we put our patients through a lot of the time.
H12
Our review of complex wounds trials, the nature of their funding and their overall quality also makes a
unique contribution in that for the first time we have profiled the funding of wound treatment research.
It was notable that a large proportion of wounds research did not report a funder (26%), with 41% of
studies having some commercial funding. We have highlighted for the first time that only around 24% of
trials in complex wound treatments have complete healing (the outcome that matters most to patients) as
their primary outcome. We encourage wounds researchers to respond to this finding and endeavour to
capture complete healing as the primary outcome in wounds trials (which will mean extending follow-up
beyond the current median of 2.8 months).
We had not originally intended to undertake a JLA research prioritisation exercise but this seemed an ideal
way of bringing together the goals of greater patient involvement and research prioritisation. We selected
pressure ulcers as the focus for this, the first PSP in complex wounds, because we thought that those with
pressure ulcers would be the most difficult patient group to engage (because of age, overwhelming illness
and social isolation) and we could learn the most from the process. Pressure ulcers were also the most
common type of complex wound in our prevalence survey. It did prove to be enormously challenging (and
ultimately impossible) to ensure that the profile of our JLA participants (in terms of age and comorbidities)
mirrored the profile of the people affected by pressure ulcers in our prevalence survey. Nonetheless, we
captured the patient, carer and health-care professional voice in a way that had not been done before and
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together we developed a list of research priorities that has face validity. A key feature of the uncertainties
generated was the focus on pressure ulcer prevention, with the top five prioritised uncertainties having
prevention as the aim. Our prevalence survey (workstream 1) reported pressure ulceration as the most
prevalent complex wound and in workstream 2 we heard from patients about the huge impact of these
wounds on their lives. Thus, the prevention of pressure ulcers and other wound types is a key area for
future focus.
Finally, workstream 3 focused on evidence synthesis in areas of high priority for the service. We explored
whether or not a meta-analysis of trials of silver dressings for venous leg ulcers, using IPD, would be
feasible and likely to be valuable for decision-making and concluded not because of the heterogeneity of
the existing trials. A review of the existing data at trial level concluded that there was no evidence that
silver dressings were more effective than non-silver dressings for healing venous leg ulcers. Alongside
several Cochrane reviews, covering pairwise comparisons of wound interventions in high-priority topics,
we implemented two major mixed-treatment comparison meta-analyses in areas of high priority for
patients and the health service, namely dressings for leg ulcers and diabetic foot ulcers. These are the first
network meta-analyses of wound dressings and at the time they were conducted there was no published
method for accounting for the quality of the evidence in a network. Consequently, we developed and
implemented one, which we named iGRADE.196 Subsequently, others have published a method that has
increased focus on assessment of the overall network and the treatment rankings as well as assessment of
each comparison.260
Our evidence synthesis work enabled us to conclude that matrix hydrocolloid dressings are associated with
the highest probability (70%) of being the best dressing for diabetic foot ulcers, whereas a hyaluronan
fleece dressing had the highest probability of being the best dressing for venous ulcers (35%); however, in
both cases there was high uncertainty and poor-quality evidence. Looking across the programme we can
see how, collectively, this work highlights limitations in the RCT evidence in wound care. The review of
wound trials in workstream 2 highlighted the limited use of complete healing as an outcome even though
this is most important outcome for patients. We consistently found in workstreams 2 and 3 that the
methodological quality of RCTs is unclear or low in the majority of cases and trials recruit small numbers of
participants and have short durations of follow-up. In workstream 3 we observed how these limitations
impact on evidence synthesis in systematic reviews and meta-analyses. These study limitations mean that
even novel approaches to evidence synthesis cannot overcome the evidence deficits so any effect estimates
have high levels of uncertainty. There are several important clinical questions in complex wound care with
no relevant RCT data. Improvements in trial conduct and reporting is a key priority in wound care. Given
the data collected in the complex wounds register pilot (workstream 2), there would be potential for
routine data to provide valuable intelligence to support the planning and development of RCTs only with
further investment in routine data collection and IT in community nursing (commensurate with that seen in
hospitals and general practices).
Summary of patient and public involvement involvement
In this programme of work, as with all our previous wounds research, we strived for patient involvement to
be integrated and sustained throughout the research; however, this has proved extremely difficult to
achieve because of the age and health of those people affected by complex wounds. We had planned a
patient advisory group for the whole programme but found it difficult to identify participants and
ultimately focused on more targeted exercises, which worked well. Central to this endeavour was the
exploration of which outcomes are important to people with wounds as there had been little if any
exploration of this previously. Second, the JLAPUP engaged patients and carers in a research prioritisation
exercise that was unique in wound care, albeit with rather younger and fitter service users than those
generally at risk of pressure ulceration. We felt that these exercises were largely successful in facilitating
detailed and meaningful patient and public insights and contributions to future research approaches and
agendas, but will continue to explore other strategies for patient involvement in future wounds research.
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Generalisability of the findings
Most of the primary research within this programme was conducted solely in one northern English city,
which may limit the generalisability of the findings. Leeds has a population of 751,000, 20% of its
population live in some of the most deprived areas of the country22 and there are urban, suburban and
rural communities. The population of Leeds is ethnically diverse with approximately 17% of residents from
black and minority ethnic groups.23 Perhaps in the context of this research, what is particularly exceptional
about Leeds is the record of nationally funded wound care research conducted there since the 1990s.
This feature together with long-established, research-led clinical leadership may mean that the standard of
wound care in Leeds will be higher than in many places, although there are no national data with which
to explore this. If it is true then the prevalence of complex wounds in Leeds may be lower than is
typical elsewhere. It is difficult to say whether or not we would have experienced similar challenges in
implementing a comprehensive complex wounds register elsewhere but given the commitment to
high-quality wounds research and care in Leeds it is likely to be at least as difficult elsewhere.
The primary research on patients’, carers’ and professionals’ preferences for wound care outcomes also
reflects the views of people from one city; however, it is difficult to imagine why their views would not be
representative of people elsewhere as there is nothing particularly different about the wounds in Leeds.
It may be that patients’ and carers’ reflections on the care that they receive may be specific to Leeds for
the reasons described above. The research priorities gathered from health-care professionals within
workstream 3 are likely to be shared elsewhere and we checked that they were genuine uncertainties by
comparing them with the international evidence base. Finally, the JLAPUP was a national initiative and the
evidence synthesis work in workstream 3 involved scrutiny of the international literature.
Implications for practice and service delivery
The UK complex wounds population is largely managed by community nursing teams who see a diverse
population of people with complex wounds of different underlying causes. NHS data systems typically
capture community nursing activity in terms of the numbers of patient visits but not detailed reasons for
the visits and, when we began this research, Leeds Community Healthcare NHS Trust had no valid or
reliable data regarding the numbers of people currently receiving wound care, the types of wounds or the
treatments delivered. We now have good estimates of the numbers of people with different wounds and
different comorbidities who need wound care in a large UK city.
Research and service development initiatives that lead to a reduction in the frequency of necessary
consultations while maintaining or improving patient outcomes should be a key target. Furthermore,
this was also a priority expressed by the health professionals in the qualitative interviews in Chapter 3.
The recent research finding that two-layer compression hosiery is as effective as bandages for venous
ulcers but more cost-effective as it reduces the number of nurse consultations is pertinent here; if hosiery
use increases as a result, the NHS will save money without any detriment to patient care or outcomes.118
Although not suitable for everyone with a venous ulcer, in our prevalence survey we found only 33
instances of its use (11% of people with venous ulcers) and therefore there is a great deal of scope for
implementation and positive impacts on patients and services. Those people with leg ulcers as a
consequence of injecting drugs may also benefit from hosiery rather than bandages as they are typically
younger and may have chaotic lifestyles.
The data also underline the importance of cost-effectiveness analysis with robust assessment of costs and
effects in evaluations of new treatments. Too frequently wound treatment evaluations merely report prices
rather than total health-care costs. The survey also indicated that wound management in Leeds is largely in
accord with evidence-based guidelines; however, only one leg ulcer patient was receiving pentoxifylline
(which increases healing). Subsequently, in Leeds, increasing the prescribing of pentoxifylline became a target
for implementation and local prescribing guidance has been developed (stimulated by the survey findings).300
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A surprising finding was the large number of people with non-diabetic foot ulcers (43% of foot ulcers
were not associated with diabetes). Non-diabetic foot ulceration, likely to be caused by arterial disease, is
under-researched and this subpopulation would benefit from closer scrutiny (including careful diagnosis of
the underlying problem and vascular referral when necessary). Another surprising finding for the clinical
staff from the prevalence survey was the significant proportion of people with wound types other than
pressure, leg and foot ulcers; this could not have been known without the survey and allows the Leeds
Community Wound Prevention and Management Service to consider how best to guide staff in delivering
care. The challenge here then is the even poorer evidence base for less-common wounds.
The picture that emerged from the patient interviews is overwhelmingly one of a desperate desire for complete
healing and eradication of the wound. The carers on the other hand seemed rather more circumspect,
expressing beliefs that the wound in question was unlikely to heal. There were sometimes feelings of ‘drifting
along’ without a clear treatment plan and this clearly engendered frustration. Others expressed difficulties in
terms of having honest communication with health-care professionals and/or concerns that the nurses were
really ‘stretched’ by a demanding workload and therefore were not to be pressed too hard. Staff on the other
hand felt that healing was frequently an unrealistic expectation and symptom management was often the
main goal. Senior tissue viability nurses, who are wound specialists, acknowledged that there was no such
thing as the magic dressing to heal many of these complex wounds. What is not clear is the extent to which
honest conversations are happening with patients about prognosis but in questioning this we must also
acknowledge that these conversations are difficult to have, given the absence in the international literature of
good prognostic data. We know that venous ulcers that are < 10 cm2 in area and < 12 months old at the first
consultation have a 29% chance of not healing by 24 weeks.226 This compares with those that are > 10 cm2 in
area and > 12 months old on presentation, which have a 78% chance of not healing. A similar model exists
for diabetic neuropathic foot ulcers.100 We also know that, when wound care centres in the USA were
randomised to receive this prognostic information for individual patients (or not), those patients in centres
receiving it were more likely to heal than those in control centres, despite no advice regarding management
being given.301 Unfortunately, we do not know why this information makes a difference or if particular
management strategies can improve outcomes for patients with a poorer prognosis.
There are also clearly other challenges for health professionals in encouraging patients to change
behaviours, whether concerning treatment adherence (e.g. compression) or healthier lifestyle behaviours
related to diet, smoking and exercise. Very positive messages emerged from the staff interviews: the
pleasure felt when a really tricky dressing procedure produced a good result or when a patient was
referred to the tissue viability service and finally prescribed compression therapy, which resulted in rapid
healing of a leg ulcer, are just two examples.
The messages for the service from these interviews are complex and not straightforward. The treatment
model described in the interviews recalled the ‘specialist healing’ model described by Briggs and
Flemming142 as opposed to a ‘chronic care route’. The treatments used are mainly aimed at healing the
open wound; however, the wound itself is just usually an outward manifestation of an underlying disease.
Health professionals reported frustration with unrealistic expectations from patients about short-term
healing but it may be that referral to tissue viability services itself raises expectations of a speedy resolution.
Tissue viability nurses themselves observed patients’ experiences of cycling hope and despair, and carers
were often frustrated with treatment plans (or an apparent lack of them). Given that most complex
wounds are due to underlying systemic disease there is almost certainly a need for more of a psychological
approach to helping patients live with a long-term condition and a more social model of care.
Finally, there is probably scope to improve communication and ‘intelligence sharing’ in community nursing
and there is clearly an important role for IT in this. The challenges faced when trying to implement
research evidence and high standards of care across community nursing in a large city are easily
underestimated. The responsibility for taking the clinical lead in a topic such as wound care will typically
lie either with nobody or within a specialist clinical team such as a tissue viability or wound care service.
These services often feel under-resourced and ill-equipped to take responsibility for implementing
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high-quality wound care across a city and involving many professions and settings. Many and diverse
staff groups are involved in organising and delivering wound care (e.g. practice nurses, district nurses,
podiatrists, specialist wound care/tissue viability nurses, community matrons, GPs, nursing home staff), all
with sometimes conflicting priorities and different managers and key performance indicators. There is a
great deal of ‘silo working’ within professional groups and within neighbourhoods and communication
between (and within) groups can be poor. Patients and health-care professionals would be better served
by a secure clinical information system that allows the monitoring of patient progress, the ongoing
collection of treatment and outcome data, interprofessional communication and decision support. Our
experience of embedding a wound assessment template in SystmOne was that, although this was quite
straightforward for a patient with one wound at baseline, the system did not lend itself to prospective
monitoring of wound progress combined with clinical decision-making. When patients had multiple
wounds it proved impossible during the register pilot to track each one individually.
Implications for future research
Prioritised uncertainties in the prevention and treatment of pressure ulcers
The JLAPUP prioritised 12 genuine uncertainties that can be taken forward by the research community
(presented in order of decreasing priority):
1. How effective is repositioning in the prevention of pressure ulcers?
2. How effective at preventing pressure ulcers is involving patients, family and lay carers in patient care?
3. Does the education of health and social care staff on prevention lead to a reduction in the incidence
of pressure ulcers and, if so, which are the most effective education programmes (at organisational
and health/social care level)?
4. What is the relative effectiveness of the different types of pressure-relieving beds, mattresses, overlays,
heel protectors and cushions (including cushions for electric and self-propelling wheelchairs) in
preventing pressure ulcers?
5. What impact do different service models have on the incidence of pressure ulcers, including staffing
levels, continuity of care (an ongoing relationship with the same staff members) and the current
organisation of nursing care in hospitals?
6. What are the best service models (and are they sufficiently accessible) to ensure that patients with
pressure ulcers receive the best treatment outcomes (including whether or not getting people with
pressure ulcers and their carers more involved in their own pressure ulcer management improves ulcer
healing and, if so, the most effective models of engagement)?
7. For wheelchair users sitting on a pressure ulcer, how effective is bed rest in promoting pressure
ulcer healing?
8. How effective are wound dressings in the promotion of pressure ulcer healing?
9. Does regular turning of patients in bed promote healing of pressure ulcers?
10. Does improving diet (eating) and hydration (drinking) promote pressure ulcer healing?
11. How effective are surgical operations to close pressure ulcers?
12. How effective are topical skincare products and skincare regimens at preventing pressure ulcers?
Each one of these questions is the result of pooling several or many submitted ‘raw’ uncertainties and they
are not neat PICO questions. We came under some pressure from a research funder to turn these
uncertainties into more focused PICO questions but resisted this as we felt strongly that, after such a
collaborative and productive PSP that excluded academics who were not also active clinicians (as per the
JLA process), it was not our place as academics to now take these uncertainties and turn them into ‘our
kind of’ research questions. We think a more sensitive and appropriate approach would be for the
research community in collaborative teams with patients and clinicians to decide what the top-priority PICO
question is under each of these broad headings. It is then up to these partnerships to persuade research
funders that they have the right question. It may also be the case that further research is required to focus
these questions, which may be epidemiological or modelling work.
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Prioritising and conducting future randomised controlled trials in
wound care
Over the last 20 years there has been a concerted effort to increase the volume and quality of wounds
research, with a great deal of this research being funded by the NIHR.18–20,118,231,267,302 One of the challenges
that researchers encounter, however, is the lack of basic epidemiological and service delivery ‘intelligence’
about wounds and it is this lack of information that stimulated the initiation of this research programme.
For example, when making the case to potential funders for a large RCT of a wound treatment, we need
to know the prevalence, typical treatments and estimates of healing rates. When designing a RCT of a
wound treatment, we need to know typical healing times to plan duration of follow-up. To evaluate
prevention strategies, we need to know typical incidence rates and risk factors. For cost-effectiveness
modelling of treatments we are likely to need to know all of these things plus others including the natural
histories of different wounds and the impacts on health-related quality of life of different wounds.
Generally, and for most common wounds, we have none of this information. The lack of basic information
therefore also contributes to a lack of momentum in wound care research: it is hard to make the case for
new research if we do not know how many people are affected by a condition, what standard care is,
what it costs or what the usual outcomes are. Moreover, our review of wounds research funding in
workstream 2 shows that the evidence base is strongly influenced by the devices industry, which begs the
question, ‘where do patients and clinicians turn for valid evidence for decision-making?’. Whatever RCTs
are conducted it is imperative that the wound healing research community engages with international
standards of research conduct and reporting for future research.169
Synthesising evidence in the two mixed-treatment comparisons highlighted the weak evidence base
available to decision-makers when choosing between different dressing types based on the outcome of
complete healing (which we know is the most important outcome for patients). In the light of the weak
evidence base it is not easy to identify which future research questions should be the highest priority.
It does not necessarily follow that we should prioritise RCTs of matrix hydrocolloid dressings or hyaluronan
fleece dressings because there is a risk that the existing small, poor-quality evaluations will have a
disproportionately large influence on the future research agenda. We argue that the results of the
mixed-treatment comparisons underline a more general point: there are many different dressing types for
venous leg ulcers and diabetic foot ulcers (although a number of dressings have been evaluated here there
are many more for which no RCT data exist) and no current evidence that any one dressing is better than
another. Based on this uncertainty there is a huge number of possible RCTs that could be planned and
prioritising future work in this area is challenging. We had originally planned to undertake decision-analytic
modelling and value of information analysis to inform the prioritisation of the primary research questions in
the dressings field. It was obvious to us, however, that it would be impossible to populate a model without
either harvesting data from the wounds register or eliciting key data from professionals. In the past we
used elicitation to evaluate the value of undertaking future research into the effectiveness of negative
pressure wound therapy for category 3 and 4 pressure ulcers.6,7 In this previous study an absence of data
meant that we had to elicit data on relative healing times of different dressings, treatment trajectories
including probabilities of patients receiving specific treatments and complication rates.6,7 In this programme
of research, unfortunately the wounds register pilot was unable to yield the number of data required for
modelling at the time that it was required.
Asking health professionals and patients to prioritise dressings for evaluation is a possibility. In our work, health
professionals highlighted uncertainty regarding silver-containing dressings, foam dressings and protease-
modulating dressings and, based on current data, there is no evidence that these dressings increase the risk of
healing compared with alternatives. In terms of silver-containing dressings we believe that a next step would
be to combine IPD from the NIHR-funded VULCAN (Venous ULcer Cost-effectiveness of ANtimicrobial
dressings) trial231 alongside the aggregate data in the network, which would allow for more detailed analysis.
As those allocated to the silver-containing dressing group in the VULCAN trial received different types of
dressings (e.g. some people received silver-containing foam dressings and others silver-containing alginate
dressings and so on), using IPD we can start to cautiously examine these subgroups separately and explore
incremental impacts of silver-containing dressings against their non-silver counterparts more fully.
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There is a risk that prioritising research may continue to encourage a focus on single RCTs of two or
maybe three dressing types. Given the inverse relationship between the number of dressing options for
complex wounds and the size of the evidence base regarding their relative effectiveness, we believe that
continued collection and application of large-scale observational data in wound care is extremely
important. This is true for uncertainties regarding dressing treatments, for which in fact it seems potentially
of value to explore a hypothesis that advanced dressings may have little to offer in terms of improved
healing rates for complex wounds that are due to systemic disease (although they may offer benefits for
symptom management).
Although RCTs are key to answering questions about relative treatment effects, real-time naturalistic data
are essential for cost-effectiveness modelling and also help identify which might be the most important
research questions.7 These data could also inform important aspects of trial design, for example by
providing good estimates of potential eligible participants and typical healing rates for different wounds.
Indeed, wound care is an area with a lot of treatment uncertainty and much robust RCT data come from
publicly funded studies [e.g. PRESSURE (Pressure RElieving Support SUrfaces: a Randomised Evaluation)302
and VenUS (Venous leg Ulcer Study) I to IV18–20,118]. However, there is a limit to the number of RCTs that
can be commissioned and huge opportunity costs if suboptimal RCTs are conducted because of a lack of
understanding about the key needs of patients and the NHS. Larger-scale register data collection could be
particularly useful in the timely identification of treatments that are in widespread use and/or are very
costly given the rapid introduction of devices used in wound care to market. The collection of
observational data on wounds, treatments and outcomes offers the potential for estimating the
comparative effects of alternative treatments, if methods such as propensity scoring are used to address
likely confounding. The register pilot and a recent publication303 also suggest that the application of
propensity scoring would have been possible had it been possible to collect more data. We are pursuing
this approach as applied to surgical wounds healing by secondary intention in a separate NIHR programme
grant (‘Surgical wounds healing by secondary intention: characterising and quantifying the problem and
identifying effective treatments’; RP-PG-0609–10171).304
Focus on the development of routine data collection in wound care
The wounds register pilot study highlights the huge challenge associated with collecting high-quality data
about complex wound care and outcomes routinely in community services. Further evolution of IT
infrastructure and of methods to maximise recruitment and follow-up are required as well as refinement
of the scope and quality of data collection, for example the collection of data for multiple wounds,
sometimes of different aetiologies, on the same individual at the same time.
This is arguably an optimal time to think about capturing routinely collected data for research with the
changing state of electronic patient records in the NHS and the increased focus on data linkage as well as
the staff enthusiasm for these changes observed here. However, expanding and developing a wounds
register would require extensive central support. Alternative sources of data on the prognosis and costs of
wound care could also be considered. Such alternatives include more time-limited observational cohort
studies, such as that being run as part of another NIHR programme grant (RP-PG-0609–10171).304
Although moving away from embedding data collection into routine clinical care to more costly,
short-term, research-focused data collection is appealing as a means to an end, it has limitations as a
long-term approach. We also suggest that future exploration regarding the use of GP data collection
systems by practice nurses should take place, given the increased use of these services by ambulatory
patients with wounds in recent years.
The type of data collected in the complex wounds register pilot, once the issues of recruitment rate and
tracking of individual wounds were solved, would be eminently suitable for use in decision-analytical
modelling, especially around the cost-effectiveness of treatments from a NHS perspective.305 Such methods
can inform clinical decision-making and research prioritisation, especially when there is decision
uncertainty. Our previous experience in cost-effectiveness modelling around complex wounds suggests that
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the availability of robust data on even a small number of the fields included in the pilot study, for example
treatments received, healing outcomes and the EQ-5D, would be extremely useful. In previous work we
have had to develop methods to deal with sparse data as well as relying on expert elicitation of data with
which to populate models as there was so little basic UK-relevant complex wounds data available.7
A further area of research relevant to a wounds register is the value of its data for prognostic modelling
and the extension of this into individualised patients care (stratified medicine).306,307 As we have noted,
the generally crude data available to describe wound care populations means that we currently have very
little prognostic information regarding the future likelihood of positive or negative outcomes for most
complex wound types. Such limited insight into the future outcomes for those with specific person- and
wound-level characteristics limits current clinical decision-making and also blinds us to potentially important
research questions. For example, given the current limited data available we have almost no way to explore
whether or not there are treatments that have effect modification for specific subgroups of patients
(currently masked in studies with heterogeneous study populations) and which could be investigated further
in focused RCTs. Importantly, the largest proportion of non-intervention uncertainties raised by patients,
carers and clinicians in the JLAPUP concerned aetiological and prognostic issues (see Chapter 3).
Other research questions emerging from the stand-alone reviews
(without mixed-treatment comparisons)
l The relative cost-effectiveness of negative pressure wound therapy compared with usual care for
treating post-amputation wounds and debrided foot ulcers in people with diabetes.
l The relative cost-effectiveness of 0.5% chlorhexidine compared with povidone iodine in alcohol for
preoperative skin antisepsis in clean surgery.
l The cost-effectiveness of ibuprofen-containing dressings for reducing pain in people with painful
skin ulcers.
Other uncertainties raised by clinicians for which evidence synthesis was not undertaken because of a lack
of primary research were:
l the cost-effectiveness of different dressings for healing after toenail surgery
l obesity as a risk factor for delayed healing in leg ulcers
l the management of underweight patients at risk of pressure ulceration
l post-operative strategies for pilonidal sinus
l the role of EUSOL in wound management
l the topical application of combined steroids and antifungal treatments to the wound bed
l the management of overgranulation
l the management of wounds in patients with dementia
l the prevalence of nutritional risk factors in people with complex wounds.
The legacy of a having a 5-year wounds research programme in
a community health-care trust
The Leeds Community Wound Prevention and Management Service within what is now Leeds Community
Healthcare NHS Trust has been in existence since 1988. Since 1999 the service has been actively engaged in
NIHR-funded wounds research, with the clinical lead being a coinvestigator on several NIHR Health
Technology Assessment programme-funded trials as well as this NIHR programme grant. Partnership in this
programme of research has delivered many benefits that we think are worth drawing attention to as
additional positive consequences of research investment in a community nursing service. One of the
remarkable consequences of this longstanding emphasis on research in Leeds is the involvement of frontline
community nursing staff in research; this was particularly the case for the wounds register pilot study in this
research programme. Clinical staff could see the potential value of it and were keen to see any results.
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The research time funded for the clinical lead enabled her to engage fully in the research and ensure that
it was embedded in the service and that research evidence could be rapidly implemented into patient care.
Research is now part of the culture of the Leeds Community Wound Prevention and Management Service,
with several staff wholly or partly funded on NIHR-funded research projects.
As a consequence of the prevalence survey in workstream 1 (see Chapter 2), the service developed a
strategic action plan for the prevention of pressure ulcers. The survey identified that pressure ulcers were
the most frequent complex wound in Leeds. Recent Department of Health-led safety strategies such as the
NHS Safety Thermometer92 were developed to support a ‘no harm’ culture within the NHS. However, the
data accrued in our prevalence survey highlighted to the trust that pressure ulcers remained a significant
problem and provided robust data to drive the pressure ulcer prevention agenda at both grass roots and
board level. A new local strategy drew directly from the findings of the prevalence survey and received
support from the Leeds Community Healthcare NHS Trust’s Quality Committee whose membership
includes representatives from the trust board. The new pressure ulcer strategy includes a five-point action
plan that addresses training, robust documentation, timely assessment and the implementation and
generation of research evidence to continue to support clinical practice. All of these components are
encapsulated in the local Your Skin: Our Priority campaign, which was developed by the Leeds Community
Wound Prevention and Management Service and is supported by the trust chief nurse and chief executive.
This campaign has recently also been adopted by the University of Leeds student nursing forum.
The prevalence survey also highlighted the number of leg ulcer patients in Leeds. At the start of the
programme grant (2008) there were two community-based leg ulcer clinics serving a population of
> 750,000 people. The prevalence survey results enabled the development of two successful business cases
to increase the number of leg ulcer clinics. There are now seven community leg ulcers clinics across the
city of Leeds, with funding having been awarded by industrial partners as well as the local clinical
commissioning group. These new clinics have the specific aims of bringing care closer to patients’ homes
and reducing the number of inappropriate referrals to specialist hospital services.
The wound assessment template in SystmOne, initiated in the lead-up to the complex wounds register pilot,
continues to be used as a clinical tool. The development of electronic methods of data capture supported by
the programme grant enabled the Wound Prevention and Management Service to become the only service
in the trust and one of very few in the country to use mobile technology and mobile working and to be
completely paper free. The routine data collection facilitated by the wounds register pilot also allowed us to
realise that the assessment and documentation of wounds in the city was often incomplete and that wound
assessments were often being conducted by junior staff. The service responded by developing an extended
wound care skills programme for band 5 nurses. The programme releases community staff nurses from their
clinical teams to spend dedicated time with the specialist wound care nurses, initially for a period of 1 week
and then 1 day per month for an additional 11 months. The nurses work through a tailored training
programme that assesses their skills on entry to the programme and measures what they have learned on
completion. The programme also measures their impact on patient care from a service user perspective via
the Make Yourself Medical Outcome Profile tool [see www.bris.ac.uk/primaryhealthcare/resources/mymop/
(accessed 25 June 2016)]. In addition to supporting best practice locally, these nurses also support the
Wound Prevention and Management Service in research conduct and implementation.
As a direct result of the research prioritisation work undertaken in workstream 2 the Wound Prevention
and Management Service developed its approach to service user engagement, including by enhancing staff
skills in this area. This new approach was exemplified during the worldwide STOP Pressure Ulcer Days in
2012 and 2013. In 2012 the service managed to garner the support of British paralympic basketball player,
Jon Pollock. Jon’s story was a shocking one, both in terms of the care he had received for his pressure
ulcers and the risks he took to compete even when his skin was broken. Jon brought the impact of living
with a pressure ulcer to life and his story led to the service lead developing an application for an URGO
Foundation Award to work alongside the British Paralympic Association. The aim of the application was to
explore the impact of pressure ulceration in sportsmen and women. This application was successful and
the clinical lead received the £20,000 award in November 2013 to conduct this innovative work.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
214
Acknowledgements
The contributions of the following are gratefully acknowledged:
Sally Crowe, who chaired the JLAPUP.
Ms Sue Bennett, Dr Stephen Compton, Dr Rupert Earl, Mr Ed Holloway, Ms Jackie Philip and
Mr Munawar Mecci, steering group members of the JLAPUP.
Richard Allen, who contributed to the review of wound care trials in workstream 2.
Sally Bell-Syer, who contributed to the review of wound care trials in workstream 2 and greatly facilitated
the completion and updating of the Cochrane reviews in workstream 3 in her role as managing editor of
the Cochrane Wounds Group.
Ellen Broderick, who contributed to the review of wound care trials in workstream 2.
Professor Martin Bland, who contributed to the review of wound care trials in workstream 2.
Ruth Foxlee, who undertook literature searching for the evidence synthesis work in workstream 3 and the
review of wound trials in workstream 2.
Dr Robert Hodgson, who contributed to the review of wound care trials and assisted in a ranking system
for the priority-setting meeting in workstream 2.
Dr Marrissa Martyn-St James, who assisted with some of the systematic reviews.
Dorothy McCaughan, who assisted with gathering uncertainties from clinical staff in workstream 3 and
with the priority-setting meeting in workstream 2.
Delia Muir, who assisted with the priority-setting meeting in workstream 2.
Paul Morrin of Leeds Community Healthcare NHS Trust, who was a former cochair of the Programme
Management Board.
Richard Slough, Head of Informatics at Leeds Community Healthcare NHS Trust, who greatly assisted in
workstream 1.
Edward Syal, who was a patient adviser to the JLAPUP.
Contributions of authors
Professor Dame Nicky Cullum (Professor of Nursing) was the chief investigator and led the programme
of research, chaired the Programme Management Group and cochaired the Programme
Management Board.
Hannah Buckley (Statistician) undertook the statistical analysis for workstream 1.
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
215
Dr Jo Dumville (Senior Lecturer) contributed to the design, conduct, analysis and reporting of all three
workstreams, conducted several systematic reviews and contributed to the mixed-treatment comparison
meta-analyses and development of iGRADE.
Jill Hall (Research Fellow) led workstream 1 and was involved in the design, conduct, analysis and
reporting of all aspects of workstream 1. She also contributed to the review of trial quality in
workstream 2.
Karen Lamb (Data Co-ordinator) was involved in the design, conduct and analysis of workstream 1 and
was particularly responsible for NHS liaison. She also contributed to the review of trial quality in
workstream 2.
Dr Mary Madden (Lecturer in Applied Health) led workstream 2, developed the protocol for participative
priority setting and undertook, analysed, interpreted and reported all of the patient, carer and staff
interviews in that workstream.
Richard Morley (Project Support Officer) assisted in the design, analysis, reporting and interpretation
of the JLAPUP in workstream 2.
Dr Susan O’Meara (Senior Research Fellow in Wounds) led the consultation with NHS staff about
evidence synthesis priorities, scoped the review of silver dressings and conducted several reviews in
workstream 3. She also contributed to the James Lind Alliance priority-setting process by checking
uncertainties against existing evidence and contributed to the review of trial quality in workstream 2.
She contributed to the mixed-treatment comparison meta-analyses in workstream 3.
Dr Pedro Saramago Goncalves (Research Fellow) is a health economist and statistician who contributed
to the design, conduct, analysis, interpretation and reporting of the mixed-treatment comparison
meta-analyses in workstream 3.
Dr Marta Soares (Research Fellow) is a health economist and statistician who contributed to the design,
conduct, analysis, interpretation and reporting of the mixed-treatment comparison meta-analyses in
workstream 3 and development of iGRADE.
Nikki Stubbs (Clinical Pathway Lead, Leeds Community Wound Prevention and Management Service) was
the clinical lead for the entire programme of research and contributed to all aspects of each workstream.
Publications
Briggs M, Nelson EA, Martyn-St James M. Topical agents or dressings for pain in venous leg ulcers.
Cochrane Database Syst Rev 2012;11:CD001177.
Dumville JC, Soares MO, O’Meara S, Cullum N. Systematic review and mixed treatment comparison:
dressings to heal diabetic foot ulcers. Diabetologia 2012;55:1902–10.
Madden M. Alienating evidence based medicine vs. innovative medical device marketing: a report on the
evidence debate at a wounds conference. Soc Sci Med 2012;74:2046–52.
O’Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. Cochrane Database Syst
Rev 2012;11:CD000265.
Dumville J, Deshpande S, O’Meara S, Speak K. Foam dressings for healing diabetic foot ulcers. Cochrane
Database Syst Rev 2013;6:CD009111.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
Dumville J, Deshpande S, O’Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers.
Cochrane Database Syst Rev 2013;8:CD009099.
Dumville J, Hinchliffe R, Cullum N, Game F, Akesson N, Sweeting M. Negative pressure wound therapy for
treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev 2013;10:CD010318.
Dumville JC, McFarlane E, Edwards P, Lipp A, Holmes A. Preoperative skin antiseptics for preventing
surgical wound infections after clean surgery. Cochrane Database Syst Rev 2013;3:CD003949.
Dumville J, O’Meara S, Deshpande S, Speak K. Alginate dressings for healing diabetic foot ulcers. Cochrane
Database Syst Rev 2013;6:CD009110.
Dumville J, O’Meara S, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers.
Cochrane Database Syst Rev 2013;7:CD009101.
Lockyer S, Hodgson R, Dumville JC, Cullum N. ‘Spin’ in wound care research: the reporting and
interpretation of randomized controlled trials with statistically non-significant primary outcome results or
unspecified primary outcomes. Trials 2013;14:371.
O’Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St James M, Richardson R. Antibiotics and
antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2013;12:CD003557.
O’Meara S, Martyn-St James M. Alginate dressings for venous leg ulcers. Cochrane Database Syst Rev
2013;4:CD010182.
O’Meara S, Martyn-St James M. Foam dressings for venous leg ulcers. Cochrane Database Syst Rev
2013;5:CD009907.
Hodgson R, Allen R, Broderick E, Bland JM, Dumville JC, Ashby R, et al. Funding source and the quality of
reports of chronic wounds trials: 2004 to 2011. Trials 2014;15:19.
Data sharing statement
Data relating to the systematic reviews reported in Chapters 2–4 are contained either in this report or in
the relevant Cochrane review (referenced). Please contact the corresponding author for access to
other data.
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
217

References
1. Posnett J, Franks PJ. The burden of chronic wounds in the UK. Nurs Times 2008;104:44–5.
2. Kaltenthaler E, Whitfield MD, Walters SJ, Akehurst RL, Paisley S. UK, USA and Canada: how do
their pressure ulcer prevalence and incidence data compare? J Wound Care 2001;10:530–5.
http://dx.doi.org/10.12968/jowc.2001.10.1.26039
3. Moffatt CJ, Franks PJ, Doherty DC, Martin R, Blewett R, Ross F. Prevalence of leg ulceration in a
London population. QJM 2004;97:431–7. http://dx.doi.org/10.1093/qjmed/hch075
4. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg
1998;176(Suppl. 1):5–10. http://dx.doi.org/10.1016/S0002-9610(98)00181-0
5. Hunt DL. Diabetes: foot ulcers and amputations. BMJ Clin Evid 2011;2011:0602.
6. Soares MO, Bojke L, Dumville J, Iglesias C, Cullum N, Claxton K. Methods to elicit experts’ beliefs
over uncertain quantities: application to a cost-effectiveness transition model of negative pressure
wound therapy for severe pressure ulceration. Stat Med 2011;30:2363–80. http://dx.doi.org/
10.1002/sim.4288
7. Soares MO, Dumville JC, Ashby RL, Iglesias CP, Bojke L, Adderley U, et al. Methods to assess
cost-effectiveness and value of further research when data are sparse: negative-pressure wound
therapy for severe pressure ulcers. Med Decis Making 2012;33:415–36. http://dx.doi.org/
10.1177/0272989X12451058
8. Health and Social Care Information Centre. Prescription Cost Analysis, England (2012).
URL: www.hscic.gov.uk/searchcatalogue?productid=11412&topics=0%2fPrescribing&
sort=Relevance&size=10&page=3#top (accessed December 2013).
9. Essex HN, Clark M, Sims J, Warriner A, Cullum N. Health-related quality of life in hospital inpatients
with pressure ulceration: assessment using generic health-related quality of life measures. Wound
Repair Regen 2009;17:797–805. http://dx.doi.org/10.1111/j.1524-475X.2009.00544.x
10. Jull A, Parag V, Walker N, Rodgers A. Responsiveness of generic and disease-specific health-related
quality of life instruments to venous ulcer healing. Wound Repair Regen 2010;18:26–30. http://dx.
doi.org/10.1111/j.1524-475X.2009.00556.x
11. Iglesias CP, Birks Y, Nelson EA, Scanlon E, Cullum NA. Quality of life of people with venous leg
ulcers: a comparison of the discriminative and responsive characteristics of two generic and a
disease specific instruments. Qual Life Res 2005;14:1705–18. http://dx.doi.org/10.1007/
s11136-005-2751-9
12. De Meneses LC, Blanes L, Francescato Veiga D, Carvalho Gomes H, Masako Ferreira L.
Health-related quality of life and self-esteem in patients with diabetic foot ulcers: results of
a cross-sectional comparative study. Ostomy Wound Manage 2011;57:36–43.
13. National Institute for Health and Care Excellence, Royal College of Nursing. Pressure Ulcers:
the Management of Pressure Ulcers in Primary and Secondary Care. NICE guidelines CG29.
September 2005. URL: www.nice.org.uk/guidance/cg179 (accessed June 2013).
14. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines.
BMJ 2001;323:334–6. http://dx.doi.org/10.1136/bmj.323.7308.334
15. Scottish Intercollegiate Guidelines Network. SIGN Guideline 120: Management of Chronic Venous
Leg Ulcers. August 2010. URL: www.sign.ac.uk/guidelines/fulltext/120/contents.html (accessed
March 2012).
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
219
16. National Institute for Health and Care Excellence. Type 2 Diabetes Foot Problems: Prevention and
Management of Foot Problems. NICE guidelines CG10. January 2004. URL: publications.nice.org.uk/
type-2-diabetes-foot-problems-cg10/full-guideline (accessed September 2012).
17. National Institute for Health Research. Research. URL: www.nihr.ac.uk/research/Pages/default.aspx
(accessed December 2013).
18. Iglesias C, Nelson EA, Cullum NA, Torgerson DJ. VenUS I: a randomised controlled trial of two
types of bandage for treating venous leg ulcers. Health Technol Assess 2004;8(29). http://dx.doi.
org/10.3310/hta8290
19. Dumville JC, Worthy G, Soares MO, Bland JM, Cullum N, Dowson C, et al. VenUS II: a
randomised controlled trial of larval therapy in the management of leg ulcers. Health Technol
Assess 2009;13(55). http://dx.doi.org/10.3310/hta13550
20. Watson JM, Kang’ombe AR, Soares MO, Chuang L-H, Worthy G, Bland JM, et al. VenUS III: a
randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers.
Health Technol Assess 2011;15(13). http://dx.doi.org/10.3310/hta15130
21. Ashby RL, Dumville JC, Soares MO, McGinnis E, Stubbs N, Torgerson DJ, et al. A pilot randomised
controlled trial of negative pressure wound therapy to treat grade III/IV pressure ulcers
(ISRCTN69032034). Trials 2012;13:119. http://dx.doi.org/10.1186/1745-6215-13-119
22. Office for National Statistics. 2011 Census for England and Wales. 2011. URL: www.ons.gov.uk/
ons/guide-method/census/2011/index.html (accessed November 2013).
23. Leeds City Council. State of the City 2012. URL: www.westyorkshireobservatory.org/resource/
view?resourceId=2661 (accessed 9 December 2013).
24. Porta MS. International Epidemiological Association. A Dictionary of Epidemiology. Oxford: Oxford
University Press; 2008.
25. Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, et al. Development quality
criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic
diseases: pilot study of new checklists. J Clin Epidemiol 2011;64:637–57. http://dx.doi.org/
10.1016/j.jclinepi.2010.08.006
26. Gupta N, Gupta SK, Shukla VK, Singh SP. An Indian community-based epidemiological study of
wounds. J Wound Care 2004;13:323–5. http://dx.doi.org/10.12968/jowc.2004.13.8.26657
27. Lindholm C, Bergsten A, Berglund E. Chronic wounds and nursing care. J Wound Care
1999;8:5–10. http://dx.doi.org/10.12968/jowc.1999.8.1.25828
28. McDermott-Scales L, Cowman S, Gethin G. Prevalence of wounds in a community care setting in
Ireland. J Wound Care 2009;18:405–17. http://dx.doi.org/10.12968/jowc.2009.18.10.44602
29. Pieper B, Templin TN, Dobal M, Jacox A. Wound prevalence, types, and treatments in home care.
Adv Wound Care 1999;12:117–26.
30. Rodrigues I, Mégie M-F. Prevalence of chronic wounds in Quebec home care: an exploratory
study. Ostomy Wound Manage 2006;52:46–8, 50, 52–7.
31. Srinivasaiah N, Dugdall H, Barrett S, Drew PJ. A point prevalence survey of wounds in north-east
England. J Wound Care 2007;16:413–16, 418–19. http://dx.doi.org/10.12968/jowc.2007.16.
10.27910
32. Vowden KR, Vowden P. A survey of wound care provision within one English health care district.
J Tissue Viability 2009;18:2–6. http://dx.doi.org/10.1016/j.jtv.2008.11.003
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
220
33. Vowden KR, Vowden P. The prevalence, management, equipment provision and outcome for
patients with pressure ulceration identified in a wound care survey within one English health care
district. J Tissue Viability 2009;18:20–6. http://dx.doi.org/10.1016/j.jtv.2008.11.001
34. Vowden KR, Vowden P. The prevalence, management and outcome for patients with lower limb
ulceration identified in a wound care survey within one English health care district. J Tissue
Viability 2009;18:13–19. http://dx.doi.org/10.1016/j.jtv.2008.11.002
35. Vowden K, Vowden P, Posnett J. The resource costs of wound care in Bradford and Airedale
primary care trust in the UK. J Wound Care 2009;18:93–94, 96–98, 100 passim. http://dx.doi.org/
10.12968/jowc.2009.18.3.39814
36. Baker SR, Stacey MC, Jopp-McKay AG, Hoskin SE, Thompson PJ. Epidemiology of chronic venous
ulcers. Br J Surg 1991;78:864–7. http://dx.doi.org/10.1002/bjs.1800780729
37. Baker SR, Stacey MC. Epidemiology of chronic leg ulcers in Australia. Aust N Z J Surg
1994;64:258–61. http://dx.doi.org/10.1111/j.1445-2197.1994.tb02196.x
38. Callam MJ, Ruckley CV, Harper DR, Dale JJ. Chronic ulceration of the leg: extent of the problem
and provision of care. Br Med J Clin Res Ed 1985;290:1855–6. http://dx.doi.org/10.1136/bmj.290.
6485.1855
39. Clarke-Moloney M, Keane N, Kavanagh E. An exploration of current leg ulcer management
practices in an Irish community setting. J Wound Care 2006;15:407–10. http://dx.doi.org/
10.12968/jowc.2006.15.9.26963
40. Clarke-Moloney M, Keane N, Kavanagh E. Changes in leg ulcer management practice following
training in an Irish community setting. J Wound Care 2008;17:116, 118–21. http://dx.doi.org/
10.12968/jowc.2008.17.3.28669
41. Cornwall JV, Doré CJ, Lewis JD. Leg ulcers: epidemiology and aetiology. Br J Surg 1986;73:693–6.
http://dx.doi.org/10.1002/bjs.1800730905
42. Forssgren A, Fransson I, Nelzén O. Leg ulcer point prevalence can be decreased by broad-scale
intervention: a follow-up cross-sectional study of a defined geographical population. Acta Derm
Venereol 2008;88:252–6.
43. Franks PJ, Morton N, Campbell A, Moffatt CJ. Leg ulceration and ethnicity: a study in west
London. Public Health 1997;111:327–9. http://dx.doi.org/10.1016/s0033-3506(97)00063-2
44. Freak L, Simon D, Kinsella A, McCollum C, Walsh J, Lane C. Leg ulcer care: an audit of
cost-effectiveness. Health Trends 1995;27:133–6.
45. Johnson M. The prevalence of leg ulcers in older people: implications for community nursing.
Public Health Nurs 1995;12:269–75. http://dx.doi.org/10.1111/j.1525-1446.1995.tb00147.x
46. Lees TA, Lambert D. Prevalence of lower limb ulceration in an urban health district. Br J Surg
1992;79:1032–4. http://dx.doi.org/10.1002/bjs.1800791015
47. Marklund B, Sülau T, Lindholm C. Prevalence of non-healed and healed chronic leg ulcers in an
elderly rural population. Scand J Prim Health Care 2000;18:58–60. http://dx.doi.org/10.1080/
02813430050202587
48. O’Brien JF, Grace PA, Perry IJ, Burke PE. Prevalence and aetiology of leg ulcers in Ireland. Ir J Med
Sci 2000;169:110–12. http://dx.doi.org/10.1007/BF03166911
49. Pina E, Furtado K, Franks PJ, Moffatt CJ. Leg ulceration in Portugal: prevalence and clinical history.
Eur J Vasc Endovasc Surg 2005;29:549–53. http://dx.doi.org/10.1016/j.ejvs.2005.01.026
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
221
50. Walker NK, Vandal AC, Holden JK, Rodgers A, Birchall N, Norton R, et al. Does capture–recapture
analysis provide more reliable estimates of the incidence and prevalence of leg ulcers in the
community? Aust N Z J Public Health 2002;26:451–5. http://dx.doi.org/10.1111/j.1467-842X.
2002.tb00346.x
51. Walker N, Rodgers A, Birchall N, Norton R, MacMahon S. The occurrence of leg ulcers in
Auckland: results of a population-based study. N Z Med J 2002;115:159–62.
52. Jull A, Walker N, Hackett M, Jones M, Rodgers A, Birchall N, et al. Leg ulceration and perceived
health: a population based case–control study. Age Ageing 2004;33:236–41. http://dx.doi.org/
10.1093/ageing/afh087
53. Andersson E, Hansson C, Swanbeck G. Leg and foot ulcer prevalence and investigation of the
peripheral arterial and venous circulation in a randomised elderly population. An epidemiological
survey and clinical investigation. Acta Derm Venereol 1993;73:57–61.
54. Andersson E, Hansson C, Swanbeck G. Leg and foot ulcers. An epidemiological survey.
Acta Derm Venereol 1984;64:227–32.
55. Dale JJ, Callam MJ, Ruckley CV, Harper DR, Berrey PN. Chronic ulcers of the leg: a study of
prevalence in a Scottish community. Health Bull (Edinb) 1983;41:310–14.
56. Ebbeskog B, Lindholm C, Ohman S. Leg and foot ulcer patients. Epidemiology and nursing care in
an urban population in south Stockholm, Sweden. Scand J Prim Health Care 1996;14:238–43.
http://dx.doi.org/10.3109/02813439608997091
57. Harrison MB, Graham ID, Friedberg E, Lorimer K, Vandevelde-Coke S. Regional planning study.
Assessing the population with leg and foot ulcers. Can Nurse 2001;97:18–23.
58. Lorimer KR, Harrison MB, Graham ID, Friedberg E, Davies B. Assessing venous ulcer population
characteristics and practices in a home care community. Ostomy Wound Manage 2003;49:32–4,
38–40, 42–3.
59. Lindholm C, Bjellerup M, Christensen OB, Zederfeldt B. A demographic survey of leg and foot
ulcer patients in a defined population. Acta Derm Venereol 1992;72:227–30.
60. Nelzén O, Bergqvist D, Lindhagen A, Hallböök T. Chronic leg ulcers: an underestimated problem
in primary health care among elderly patients. J Epidemiol Community Health 1991;45:184–7.
http://dx.doi.org/10.1136/jech.45.3.184
61. Nelzén O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and
appearance in a population study. Br J Surg 1994;81:182–7. http://dx.doi.org/10.1002/
bjs.1800810206
62. Nelzén O, Bergqvist D, Lindhagen A. The prevalence of chronic lower-limb ulceration has been
underestimated: results of a validated population questionnaire. Br J Surg 1996;83:255–8.
http://dx.doi.org/10.1002/bjs.1800830235
63. Öien RF, Håkansson A, Ovhed I, Hansen BU. Wound management for 287 patients with chronic
leg ulcers demands 12 full-time nurses. Leg ulcer epidemiology and care in a well-defined
population in southern Sweden. Scand J Prim Health Care 2000;18:220–5. http://dx.doi.org/
10.1080/028134300448788
64. Wong I, Lee D, Thompson D. Lower limb ulcerations in older people in Hong Kong. J Clin Nurs
2005;14:118–19. http://dx.doi.org/10.1111/j.1365-2702.2004.00947.x
65. Abbott CA, Garrow AP, Carrington AL, Morris J, Van Ross ER, Boulton AJ, et al. Foot ulcer risk is
lower in South-Asian and African-Caribbean compared with European diabetic patients in the UK:
the North-West diabetes foot care study. Diabetes Care 2005;28:1869–75. http://dx.doi.org/
10.2337/diacare.28.8.1869
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
222
66. Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and
potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes
clinic-based study. Ann Saudi Med 2007;27:25–31. http://dx.doi.org/10.4103/0256-4947.51536
67. Kumar S, Ashe HA, Parnell LN, Fernando DJ, Tsigos C, Young RJ, et al. The prevalence of foot
ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med J Br
Diabet Assoc 1994;11:480–4. http://dx.doi.org/10.1111/j.1464-5491.1994.tb00310.x
68. Reid KS, Martin BD, Duerksen F, Nicolle LE, Garrett M, Simonsen JN, et al. Diabetic foot
complications in a northern Canadian Aboriginal community. Foot Ankle Int 2006;27:1065–73.
69. De Sonnaville JJ, Colly LP, Wijkel D, Heine RJ. The prevalence and determinants of foot ulceration in
type II diabetic patients in a primary health care setting. Diabetes Res Clin Pract 1997;35:149–56.
http://dx.doi.org/10.1016/S0168-8227(97)01380-6
70. Tseng C-H. Prevalence and risk factors of diabetic foot problems in Taiwan: a cross-sectional
survey of non-type 1 diabetic patients from a nationally representative sample. Diabetes Care
2003;26:3351. http://dx.doi.org/10.2337/diacare.26.12.3351
71. Bristow I. Foot ulceration in a non-diabetic population: a cross-sectional audit of staff in one
health district. J Wound Care 2008;17:445–8. http://dx.doi.org/10.12968/jowc.2008.17.10.31309
72. Firth J, Hale C, Helliwell P, Hill J, Nelson EA. The prevalence of foot ulceration in patients with
rheumatoid arthritis. Arthritis Rheum 2008;59:200–5. http://dx.doi.org/10.1002/art.23335
73. Barbenel JC, Jordan MM, Nicol SM, Clark MO. Incidence of pressure-sores in the Greater Glasgow
Health Board area. Lancet 1977;2:548–50. http://dx.doi.org/10.1016/S0140-6736(77)90676-6
74. Barbenel JC, Jordon MM, Nicol SM. Major pressure of sores. Health Soc Serv J 1980;90:1344–5.
75. Bergquist S, Frantz R. Pressure ulcers in community-based older adults receiving home health
care. Prevalence, incidence, and associated risk factors. Adv Wound Care 1999;12:339–51.
76. Hallett A. Managing pressure sores in the community. J Wound Care 1996;5:105–7.
77. Inman C, Firth JR. Pressure sore prevalence in the community. Prof Nurse 1998;13:515–20.
78. Meehan M, O’Hara L, Morrison YM. Report on the prevalence of skin ulcers in a home health
agency population. Adv Wound Care 1999;12:459–67.
79. Raghavan P, Raza WA, Ahmed YS, Chamberlain MA. Prevalence of pressure sores in a community
sample of spinal injury patients. Clin Rehabil 2003;17:879–84. http://dx.doi.org/10.1191/
0269215503cr692oa
80. Torrance C, Maylor M. Pressure sore survey: part one. J Wound Care 1999;8:27–30.
http://dx.doi.org/10.12968/jowc.1999.8.1.25829
81. Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle
1981;2:64–122.
82. Torrance C. Pressure Sores: Aetiology, Treatment and Prevention. London: Groom Helm; 1983.
83. European Pressure Ulcer Advisory Panel and National Pressure Ulcer Advisory Panel. Prevention
and Treatment of Pressure Ulcers: Clinical Practice Guidelines. Washington, DC: National Pressure
Ulcer Advisory Panel; 2009.
84. Shea JD. Pressure ulcer classification and management. Clin Orthop 1975;112:89–100.
http://dx.doi.org/10.1097/00003086-197510000-00012
85. Waterlow J. Pressure Ulcer Prevention Manual. Taunton: Waterlow; 2005.
86. Norton D, McLaren R, Exton-Smith AN. An Investigation of Geriatric Nursing Problems in Hospital.
New York, NY: Churchill Livingstone; 1962.
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
223
87. Bergstrom N, Braden BJ, Laguzza A, Holman V. The Braden scale for predicting pressure sore risk.
Nurs Res 1987;36:205–10. http://dx.doi.org/10.1097/00006199-198707000-00002
88. Williams C. A comparative study of pressure sore prevention scores. J Tissue Viability
1992;2:64–6. http://dx.doi.org/10.1016/S0965-206X(14)80165-4
89. Moffatt CJ, Franks PJ, Doherty DC, Smithdale R, Steptoe A. Psychological factors in leg ulceration:
a case–control study. Br J Dermatol 2009;161:750–6. http://dx.doi.org/10.1111/j.1365-2133.
2009.09211.x
90. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods
for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of
results from the Medical Outcomes Study. Med Care 1995;33(Suppl. 4):AS264–79.
91. Posnett J, Gottrup F, Lundgren H, Saal G. The resource impact of wounds on health-care providers
in Europe. J Wound Care 2009;18:154–61. http://dx.doi.org/10.12968/jowc.2009.18.4.41607
92. NHS. Delivering the NHS Safety Thermometer CQUIN 2013/14. A New Mindset in Patient Safety
Improvement. 2012. URL: harmfreecare.org/wp-content/uploads/2012/06/NHS-ST-CQUIN-2012.pdf
(accessed 17 May 2016).
93. Royal College of Nursing. Clinical Practice Guideline. The Nursing Management of Patients with
Venous Leg Ulcers. Recommendations. London: RCH Publishing; 2006. URL: www.rcn.org.uk/
__data/assets/pdf_file/0006/115926/000989.pdf (accessed September 2012).
94. Scottish Intercollegiate Guidelines Network. SIGN Guideline 120: Management of Chronic Venous
Leg Ulcers: Summary of Recommendations. URL: www.sign.ac.uk/guidelines/fulltext/120/
recommendations.html (accessed December 2013).
95. Braden BJ, Maklebust J, Maklebust J. Preventing pressure ulcers with the Braden scale: an update
on this easy-to-use tool that assesses a patient’s risk. Am J Nurs 2005;105:70–2. http://dx.doi.org/
10.1097/00000446-200506000-00031
96. Waterlow J. A risk assessment card. Nurs Times 1985;81:24–7.
97. Drolet BC, Johnson KB. Categorizing the world of registries. J Biomed Inform 2008;41:1009–20.
http://dx.doi.org/10.1016/j.jbi.2008.01.009
98. Newton J, Garner S. Disease Registers in England. Oxford: Institute of Health Sciences, University of
Oxford; 2002. URL: www.sepho.org.uk/download/Public/5445/1/disease_registers_in_england.pdf
(accessed 3 June 2016).
99. Raftery J, Roderick P, Stevens A. Potential use of routine databases in health technology
assessment. Health Technol Assess 2005;9(20). http://dx.doi.org/10.3310/hta9200
100. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: predicting which
ones will not heal. Am J Med 2003;115:627–31. http://dx.doi.org/10.1016/j.amjmed.2003.06.006
101. Kantor J, Margolis DJ. The accuracy of using a wound care specialty clinic database to study
diabetic neuropathic foot ulcers. Wound Repair Regen 2000;8:169–73. http://dx.doi.org/10.1046/
j.1524-475x.2000.00169.x
102. Golinko MS, Margolis DJ, Tal A, Hoffstad O, Boulton AJM, Brem H. Preliminary development of a
diabetic foot ulcer database from a wound electronic medical record: a tool to decrease limb
amputations. Wound Repair Regen 2009;17:657–65. http://dx.doi.org/10.1111/j.1524-475X.
2009.00527.x
103. Coerper S, Wicke C, Pfeffer F, Köveker G, Becker H-D. Documentation of 7051 chronic wounds
using a new computerized system within a network of wound care centers. Arch Surg
2004;139:251–8. http://dx.doi.org/10.1001/archsurg.139.3.251
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
224
104. Taylor RJ, Taylor AD, Marcuson RW. A computerised leg ulcer database with facilities for
reporting and auditing. J Wound Care 1999;8:34–8. http://dx.doi.org/10.12968/jowc.1999.8.
1.25832
105. Öien RF. RUT – a winning concept for both patients and the health care sector. Eur Wound
Manage Assoc 2009;2:41–4.
106. Öien RF. The Register RUT Can Help in Wound Care. Helsinki: European Wound Management
Association; 2009.
107. European-Hospital: RUT – A National Quality Register for Ulcer Treatment. URL: www.european-
hospital.com/en/article/6136-RUT_-.html (accessed 26 December 2013).
108. Lundstrom M. Literature Review on Quality Registries. URL: www.eurequo.org/downloads/
EUREQUO.pdf (accessed 26 December 2013).
109. Department of Health. White Paper. Saving Lives: Our Healthier Nation. London: The Stationery
Office; 1999. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/
265576/4386.pdf (accessed 22 June 2016).
110. Department of Health. The Power of Information: Putting All of Us in Control of the Health and
Care Information We Need. London: Department of Health; May 2012. URL: http://webarchive.
nationalarchives.gov.uk/20130802094648/https://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/134336/dh_134205.pdf.pdf (accessed 22 June 2016).
111. Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998.
112. Great Britain. Human Rights Act 1998. London: The Stationery Office; 1998.
113. Great Britain. NHS Act 2006. London: The Stationery Office; 2006.
114. Hodgson R, Allen R, Broderick E, Bland J, Dumville J, Ashby R, et al. Funding source and the
quality of reports of chronic wounds trials: 2004 to 2011. Trials 2014;15:19. http://dx.doi.org/
10.1186/1745-6215-15-19
115. The EuroQoL Group. EuroQoL – a new facility for the measurement of health-related quality of
life. Health Policy 1990;16:199–208. http://dx.doi.org/10.1016/0168-8510(90)90421-9
116. Kind P. The EuroQol Instrument: An Index of Health-Related Quality of Life. In Spilker B, editor.
Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. New York, NY:
Lippincott-Raven; 1996. pp. 191–202.
117. Dolan P, Gudex C, Kind P. A Social Tariff for EuroQol: Results From a UK General Population
Survey. York: University of York, Centre for Health Economics; 1995.
118. Ashby RL, Gabe R, Ali S, Adderley U, Bland JM, Cullum NA, et al. Clinical and cost-effectiveness
of compression hosiery versus compression bandages in treatment of venous leg ulcers
(Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial. Lancet 2014;383:871–9.
http://dx.doi.org/10.1016/S0140-6736(13)62368-5
119. Petherick ES, Cullum NA, Pickett KE. Investigation of the effect of deprivation on the burden
and management of venous leg ulcers: a cohort study using the THIN database. PLOS ONE
2013;8:e58948. http://dx.doi.org/10.1371/journal.pone.0058948
120. Department of Health. Equity and Excellence: Liberating the NHS. London: Department of Health;
2010. URL: www.gov.uk/government/publications/liberating-the-nhs-white-paper (accessed
3 January 2014).
121. Department of Health. The NHS Outcomes Framework 2012–13. London: Her Majesty’s Stationery
Office; 2011. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/213711/
dh_131723.pdf (accessed 17 May 2016).
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
225
122. Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the
clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises.
Arthritis Rheum 2008;59:952–60. http://dx.doi.org/10.1002/art.23826
123. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative
to improve outcome measurement in rheumatology. Trials 2007;8:38. http://dx.doi.org/10.1186/
1745-6215-8-38
124. Cullum N, Nelson EA, Flemming K, Sheldon T. Systematic reviews of wound care management:
(5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and
electromagnetic therapy. Health Technol Assess 2001;5(9). http://dx.doi.org/10.3310/hta5090
125. Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers.
J Invest Dermatol 2002;119:1420–5. http://dx.doi.org/10.1046/j.1523-1747.2002.19629.x
126. Cardinal M, Eisenbud DE, Phillips T, Harding K. Early healing rates and wound area measurements
are reliable predictors of later complete wound closure. Wound Repair Regen 2008;16:19–22.
http://dx.doi.org/10.1111/j.1524-475X.2007.00328.x
127. Edsberg L, Wyffels J, Daniel S. Longitudinal study of stage III and stage IV pressure ulcer area and
perimeter as healing parameters to predict wound closure. Ostomy Wound Manage 2011;57:50–62.
128. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? J Am Med
Assoc 1999;282:790–5. http://dx.doi.org/10.1001/jama.282.8.790
129. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. BMJ 2011;343:d7995.
http://dx.doi.org/10.1136/bmj.d7995
130. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research
consumer. Lancet 2000;355:2037–40. http://dx.doi.org/10.1016/S0140-6736(00)02351-5
131. Griffiths KM, Jorm AF, Christensen H, Medway J, Dear KBG. Research priorities in mental health,
part 2: an evaluation of the current research effort against stakeholders’ priorities. Aust N Z J
Psychiatry 2002;36:327–39. http://dx.doi.org/10.1046/j.1440-1614.2001.01024.x
132. Chalmers I, Essali A, Rezk E, Crowe S. Is academia meeting the needs of non-academic users of
the results of research? Lancet 2012;380:S43. http://dx.doi.org/10.1016/S0140-6736(13)60219-6
133. NHS Direct. Patient Safety – 10 for 2010: Pressure Ulcers. URL: www.nrls.npsa.nhs.uk/resources/
collections/10-for-2010/pressure-ulcers/ (accessed 6 January 2014).
134. Gottrup F, Apelqvist J, Price P, European Wound Management Association Patient Outcome
Group. Outcomes in controlled and comparative studies on non-healing wounds:
recommendations to improve the quality of evidence in wound management. J Wound Care
2010;19:237–68. http://dx.doi.org/10.12968/jowc.2010.19.6.48471
135. McIsaac C. Managing wound care outcomes. Ostomy Wound Manage 2005;51:54–56, 58,
59 passim.
136. European Wound Management Association. Patient Outcome Group. URL: ewma.org/?id=243
(accessed 3 January 2014).
137. Spilsbury K, Nelson A, Cullum N, Iglesias C, Nixon J, Mason S. Pressure ulcers and their treatment
and effects on quality of life: hospital inpatient perspectives. J Adv Nurs 2007;57:494–504.
http://dx.doi.org/10.1111/j.1365-2648.2006.04140.x
138. Guest G, MacQueen KM, Namey EE. Applied Thematic Analysis. Thousand Oaks, CA: Sage; 2011.
139. Glaser BG, Strauss AL. The Discovery of Grounded Theory: Strategies for Qualitative Research.
Chicago, IL: Aldine Publishing Company; 1967.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
226
140. Kuzel A. Sampling in Qualitative Inquiry. In Crabtree B, Miller W, editors. Doing Qualitative
Research. Newbury Park, CA: Sage; 1992. pp. 31–44.
141. Charmaz K. Studying the Experience of Chronic Illness Through Grounded Theory. In Scambler G,
Scambler S, eds. New Directions in the Sociology of Chronic and Disabling Conditions: Assaults
on the Lifeworld. Basingstoke: Palgrave Macmillan; 2010. pp. 8–36. http://dx.doi.org/10.1057/
9780230297432_2
142. Briggs M, Flemming K. Living with leg ulceration: a synthesis of qualitative research. J Adv Nurs
2007;59:319–28. http://dx.doi.org/10.1111/j.1365-2648.2007.04348.x
143. Corbin J, Strauss A. Accompaniments of Chronic Illness: Changes in Body, Self, Biography and
Biographical Time. In Roth JA, Conrad P, editors. The Experience and Management of Chronic
Illness. Greenwich, CT: JAI Press Limited; 1987. pp. 249–81.
144. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity
and implications for health care, research, and medical education: a cross-sectional study.
Lancet 2012;380:37–43. http://dx.doi.org/10.1016/S0140-6736(12)60240-2
145. Bower P, Hann M, Rick J, Rowe K, Burt J, Roland M, et al. Multimorbidity and delivery of care for
long-term conditions in the English National Health Service: baseline data from a cohort study.
J Health Serv Res Policy 2013;18:29–37. http://dx.doi.org/10.1177/1355819613492148
146. Great Britain. Health and Social Care Act 2012. London: The Stationery Office; 2012.
147. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between
large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982–9.
http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00010
148. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in
treatment effect estimates in controlled trials with different interventions and outcomes: meta-
epidemiological study. BMJ 2008;336:601–5. http://dx.doi.org/10.1136/bmj.39465.451748.AD
149. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome
reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
http://dx.doi.org/10.1136/bmj.c365
150. Singh JA, Murphy S, Bhandari M. Trial sample size, but not trial quality, is associated with positive
study outcome. J Clin Epidemiol 2010;63:154–62. http://dx.doi.org/10.1016/j.jclinepi.2009.05.007
151. Chan A-W, Altman DG. Epidemiology and reporting of randomised trials published in PubMed
journals. Lancet 2005;365:1159–62. http://dx.doi.org/10.1016/S0140-6736(05)71879-1
152. Hui D, Arthur J, Dalal S, Bruera E. Quality of the supportive and palliative oncology literature:
a focused analysis on randomized controlled trials. Support Care Cancer 2012;20:1779–85.
http://dx.doi.org/10.1007/s00520-011-1275-9
153. Strippoli GFM, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled
trials in nephrology. J Am Soc Nephrol 2004;15:411–19. http://dx.doi.org/10.1097/01.ASN.
0000100125.21491.46
154. Danilla S, Wasiak J, Searle S, Arriagada C, Pedreros C, Cleland H, et al. Methodological quality
of randomised controlled trials in burns care. A systematic review. Burns 2009;35:956–61.
http://dx.doi.org/10.1016/j.burns.2009.04.031
155. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial
interests and study outcome in randomized controlled drug trials. Fam Pract 2001;18:565–8.
http://dx.doi.org/10.1093/fampra/18.6.565
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
227
156. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome.
Cochrane Database Syst Rev 2012;12:MR000033. http://dx.doi.org/10.1002/14651858.
mr000033.pub2
157. Ioannidis JP. Effect of the statistical significance of results on the time to completion and
publication of randomized efficacy trials. J Am Med Assoc 1998;279:281–6. http://dx.doi.org/
10.1001/jama.279.4.281
158. Mandelkern M. Manufacturer support and outcome. J Clin Psychiatry 1999;60:122–3.
http://dx.doi.org/10.4088/JCP.v60n0210a
159. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty
principle and industry-sponsored research. Lancet 2000;356:635–8. http://dx.doi.org/10.1016/
S0140-6736(00)02605-2
160. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern
Med 1996;124:485–9. http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00004
161. Jones R, Younie S, Macallister A, Thornton J. A comparison of the scientific quality of publicly
and privately funded randomized controlled drug trials. J Eval Clin Pract 2010;16:1322–5.
http://dx.doi.org/10.1111/j.1365-2753.2009.01335.x
162. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
http://dx.doi.org/10.1136/bmj.d5928
163. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.
The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org (accessed 15 July 2013).
164. Lockyer S, Hodgson R, Dumville JC, Cullum N. ‘Spin’ in wound care research: the reporting and
interpretation of randomized controlled trials with statistically non-significant primary outcome
results or unspecified primary outcomes. Trials 2013;14:371. http://dx.doi.org/10.1186/
1745-6215-14-371
165. O’Meara SM, Bland JM, Dumville JC, Cullum NA. A systematic review of the performance of
instruments designed to measure the dimensions of pressure ulcers. Wound Repair Regen
2012;20:263–76. http://dx.doi.org/10.1111/j.1524-475X.2012.00783.x
166. Berger VW. Does the Prentice criterion validate surrogate endpoints? Stat Med 2004;23:1571–8.
http://dx.doi.org/10.1002/sim.1780
167. Devereaux PJ, Choi PT-L, El-Dika S, Bhandari M, Montori VM, Schünemann HJ, et al.
An observational study found that authors of randomized controlled trials frequently use
concealment of randomization and blinding, despite the failure to report these methods.
J Clin Epidemiol 2004;57:1232–6. http://dx.doi.org/10.1016/j.jclinepi.2004.03.017
168. Hopewell S, Dutton S, Yu L-M, Chan A-W, Altman DG. The quality of reports of randomised trials
in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010;340:c723.
http://dx.doi.org/10.1136/bmj.c723
169. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010
explanation and elaboration: updated guidelines for reporting parallel group randomised trials.
Int J Surg 2012;10:28–55. http://dx.doi.org/10.1016/j.ijsu.2011.10.001
170. Broerse JEW, Zweekhorst MBM, van Rensen AJML, de Haan MJM. Involving burn survivors in
agenda setting on burn research: an added value? Burns 2010;36:217–31. http://dx.doi.org/
10.1016/j.burns.2009.04.004
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
228
171. Brett J, Staniszewska S, Mockford C, Seers K, Herron-Marx S, Bayliss H. The PIRICOM Study: A
Systematic Review of the Conceptualisation, Measurement, Impact and Outcomes of Patients and
Public Involvement in Health and Social Care Research. University of Warwick; 2010. URL: www.
researchgate.net/publication/235643775_The_PIRICOM_Study_A_systematic_review_of_the_
conceptualisation_measurement_impact_and_outcomes_of_patient_and_public_involvement_in_
health_and_social_care_research._UKCRC_report/file/d912f5123c609ea276.pdf (accessed
3 January 2014).
172. Viergever RF, Olifson S, Ghaffar A, Terry RF. A checklist for health research priority setting: nine
common themes of good practice. Health Res Policy Syst 2010;8:1–9.
173. Cowan K, Oliver S. The James Lind Alliance Guidebook. URL: www.jlaguidebook.org/
pdfguidebook/guidebook.pdf (accessed 3 January 2014).
174. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve
searching PubMed for clinical questions. BMC Med Inform Decis Mak 2007;7:16. http://dx.doi.org/
10.1186/1472-6947-7-16
175. Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health
care research and how to do it. J Health Econ 2007;26:171–89. http://dx.doi.org/10.1016/
j.jhealeco.2006.04.002
176. Moore DC, Hanratty B. Out of sight, out of mind? A review of data available on the health of
care home residents in longitudinal and nationally representative cross-sectional studies in the UK
and Ireland. Age Ageing 2013;42:798–803. http://dx.doi.org/10.1093/ageing/aft125
177. Madden M, Morley R. Exploring the challenge of health research priority setting in partnership:
reflections on the methodology used by the James Lind Alliance Pressure Ulcer Priority Setting
Partnership. Res Involve Engage 2016;2:12. http://dx.doi.org/10.1186/s40900-016-0026-y
178. Madden M. Providing patient centred pressure ulcer care. Nurs Pract 2015;85:3.
179. Ford S. List of 12 Priorities for Pressure Ulcer Study Identified by UK Researchers. Nursing
Times.net, 8 May 2013.
180. McInnes E, Jammali-Blasi A, Bell-Syer SE, Dumville JC, Cullum N. Support surfaces for pressure
ulcer prevention. Cochrane Database Syst Rev 2011;4:CD001735. http://dx.doi.org/10.1002/
14651858.cd001735.pub4
181. National Institute for Health and Care Excellence. Pressure Ulcers: Prevention and Management.
URL: www.nice.org.uk/guidance/CG179/chapter/introduction (accessed 27 June 2014).
182. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some
lessons from recent UK experience. PharmacoEconomics 2006;24:1055–68. http://dx.doi.org/
10.2165/00019053-200624110-00003
183. Centre for Reviews and Dissemination. Systematic Reviews. CRD’s Guidance for Undertaking
Reviews in Health Care. York: Centre for Reviews and Dissemination, University of York; 2009.
URL: www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm (accessed 19 July 2013).
184. O’Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. Cochrane
Database Syst Rev 2012;11:CD000265. http://dx.doi.org/10.1002/14651858.cd000265.pub3
185. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews
using individual patient data. Eval Health Prof 2002;25:76–97. http://dx.doi.org/10.1177/
0163278702025001006
186. Simmonds MC, Higgins JPT, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of
individual patient data from randomized trials: a review of methods used in practice. Clin Trials
2005;2:209–17. http://dx.doi.org/10.1191/1740774505cn087oa
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
229
187. O’Meara S, Tierney J, Cullum N, Bland JM, Franks PJ, Mole T, et al. Four layer bandage compared
with short stretch bandage for venous leg ulcers: systematic review and meta-analysis of
randomised controlled trials with data from individual patients. BMJ 2009;338:1054–7.
http://dx.doi.org/10.1136/bmj.b1344
188. Kent DJ. Effects of a just-in-time educational intervention placed on wound dressing packages:
a multicenter randomized controlled trial. J Wound Ostomy Continence Nurs 2010;37:609–14.
http://dx.doi.org/10.1097/WON.0b013e3181f1826b
189. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons.
Stat Med 2004;23:3105–24. http://dx.doi.org/10.1002/sim.1875
190. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison
meta-analysis. Stat Med 2010;29:932–44. http://dx.doi.org/10.1002/sim.3767
191. Li T, Puhan MA, Vedula SS, Singh S, Dickersin K, Ad Hoc Network Meta-analysis Methods
Meeting Working Group. Network meta-analysis highly attractive but more methodological
research is needed. BMC Med 2011;9:79. http://dx.doi.org/10.1186/1741-7015-9-79
192. Dumville J, Deshpande S, O’Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot
ulcers. Cochrane Database Syst Rev 2013;8:CD009099. http://dx.doi.org/10.1002/14651858.
cd009099.pub3
193. Dumville J, O’Meara S, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers.
Cochrane Database Syst Rev 2013;7:CD009101. http://dx.doi.org/10.1002/14651858.
cd009101.pub3
194. Dumville J, O’Meara S, Deshpande S, Speak K. Alginate dressings for healing diabetic foot ulcers.
Cochrane Database Syst Rev 2013;6:CD009110. http://dx.doi.org/10.1002/14651858.
cd009110.pub3
195. Dumville J, Deshpande S, O’Meara S, Speak K. Foam dressings for healing diabetic foot ulcers.
Cochrane Database Syst Rev 2013;6:CD009111. http://dx.doi.org/10.1002/14651858.
cd009111.pub3
196. Dumville JC, Soares MO, O’Meara S, Cullum N. Systematic review and mixed treatment comparison:
dressings to heal diabetic foot ulcers. Diabetologia 2012;55:1902–10. http://dx.doi.org/10.1007/
s00125-012-2558-5
197. O’Meara S, Martyn-St James M. Foam dressings for venous leg ulcers. Cochrane Database Syst
Rev 2013;5:CD009907. http://dx.doi.org/10.1002/14651858.cd009907.pub2
198. O’Meara S, Martyn-St James M. Alginate dressings for venous leg ulcers. Cochrane Database Syst
Rev 2013;4:CD010182. http://dx.doi.org/10.1002/14651858.cd010182.pub2
199. O’Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St James M, Richardson R. Antibiotics
and antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2013;12:CD003557.
http://dx.doi.org/10.1002/14651858.cd003557.pub4
200. Langer G, Fink A. Nutritional interventions for preventing and treating pressure ulcers. Cochrane
Database Syst Rev 2014;6:CD003216. http://dx.doi.org/10.1002/14651858.cd003216.pub2
201. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead.
Lancet 2009;374:1196–208. http://dx.doi.org/10.1016/S0140-6736(09)61460-4
202. Noël B. Surgical treatment of ingrown toenail without matricectomy. Dermatol Surg
2008;34:79–83. http://dx.doi.org/10.1097/00042728-200801000-00013
203. McIntosh CD, Thomson CE. Honey dressing versus paraffin tulle gras following toenail surgery.
J Wound Care 2006;15:133–6. http://dx.doi.org/10.12968/jowc.2006.15.3.26877
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
230
204. Collins CE, Kershaw J, Brockington S. Effect of nutritional supplements on wound healing in
home-nursed elderly: a randomized trial. Nutr Burbank Los Angel Cty Calif 2005;21:147–55.
http://dx.doi.org/10.1016/j.nut.2004.10.006
205. Thomas DR. Improving outcome of pressure ulcers with nutritional interventions: a review of
the evidence. Nutr Burbank Los Angel Cty Calif 2001;17:121–5. http://dx.doi.org/10.1016/
S0899-9007(00)00514-1
206. Augustin M, Brocatti LK, Rustenbach SJ, Schäfer I, Herberger K. Cost-of-illness of leg ulcers in the
community. Int Wound J 2014;11:283–92. http://dx.doi.org/10.1111/j.1742-481X.2012.01089.x
207. Graham ID, Harrison MB, Nelson EA, Lorimer K, Fisher A. Prevalence of lower-limb ulceration: a
systematic review of prevalence studies. Adv Skin Wound Care 2003;16:305–16. http://dx.doi.org/
10.1097/00129334-200311000-00013
208. Herber OR, Schnepp W, Rieger MA. A systematic review on the impact of leg ulceration on
patients’ quality of life. Health Qual Life Outcomes 2007;5:44. http://dx.doi.org/10.1186/
1477-7525-5-44
209. Nelzén O. Prevalence of venous leg ulcer: the importance of the data collection method.
Phlebolymphology 2008;15:143–50.
210. Trengove NJ, Stacey MC, McGechie DF, Mata S. Qualitative bacteriology and leg ulcer healing.
J Wound Care 1996;5:277–80.
211. Davies CE, Hill KE, Newcombe RG, Stephens P, Wilson MJ, Harding KG, et al. A prospective study
of the microbiology of chronic venous leg ulcers to reevaluate the clinical predictive value of tissue
biopsies and swabs. Wound Repair Regen 2007;15:17–22. http://dx.doi.org/10.1111/j.1524-475X.
2006.00180.x
212. Gardner SE, Frantz RA, Doebbeling BN. The validity of the clinical signs and symptoms used to
identify localized chronic wound infection. Wound Repair Regen 2001;9:178–86. http://dx.doi.org/
10.1046/j.1524-475x.2001.00178.x
213. Cutting KF, White R. Defined and refined: criteria for identifying wound infection revisited.
Br J Community Nurs 2004;9:S6–15. http://dx.doi.org/10.12968/bjcn.2004.9.Sup1.12495
214. White R. An historical overview of the use of silver in wound management. Br J Community Nurs
2001;6:3–8. http://dx.doi.org/10.12968/bjcn.2001.6.Sup1.12619
215. NHS National Prescribing Centre. Evidence-based prescribing of advanced wound dressings for
chronic wounds in primary care. MeReC Bull 2010;21:1–7.
216. Chambers H, Dumville JC, Cullum N. Silver treatments for leg ulcers: a systematic review. Wound
Repair Regen 2007;15:165–73. http://dx.doi.org/10.1111/j.1524-475X.2007.00201.x
217. Lo S-F, Chang C-J, Hu W-Y, Hayter M, Chang Y-T. The effectiveness of silver-releasing dressings
in the management of non-healing chronic wounds: a meta-analysis. J Clin Nurs 2009;18:716–28.
http://dx.doi.org/10.1111/j.1365-2702.2008.02534.x
218. Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected
wounds. Cochrane Database Syst Rev 2007;1:CD005486. http://dx.doi.org/10.1002/14651858.
cd005486.pub2
219. Higgins J, Altman D, Sterne J on behalf of the Cochrane Statistical Methods Group and the
Cochrane Bias Methods Group. Assessing Risk of Bias in Included Studies. In Higgins JPT, Green S,
editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane
Collaboration; 2011. URL: www.cochrane-handbook.org (accessed 15 July 2013).
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
231
220. Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation
concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol
2007;36:847–57. http://dx.doi.org/10.1093/ije/dym087
221. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456–8. http://dx.doi.org/
10.1001/jama.1995.03530180050029
222. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of
methodological quality associated with estimates of treatment effects in controlled trials. JAMA
1995;273:408–12. http://dx.doi.org/10.1001/jama.1995.03520290060030
223. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol
2005;34:79–87. http://dx.doi.org/10.1093/ije/dyh300
224. Deeks J, Higgins J, Altman D on behalf of the Cochrane Statistical Methods Group. Analysing
Data and Undertaking Meta-Analyses. In Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. URL:
www.cochrane-handbook.org (accessed 15 July 2013).
225. Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limb compression
bandages? Am J Med 2000;109:15–19. http://dx.doi.org/10.1016/S0002-9343(00)00379-X
226. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. The accuracy of venous leg ulcer prognostic
models in a wound care system. Wound Repair Regen 2004;12:163–8. http://dx.doi.org/10.1111/
j.1067-1927.2004.012207.x
227. Dimakakos E, Katsenis K, Kalemikerakis J, Arkadopoulos N, Mylonas S, Arapoglou V, et al.
Infected venous leg ulcers: management with silver-releasing foam dressing. Wounds Compend
Clin Res Pract 2009;21:4–8.
228. Jørgensen B, Price P, Andersen KE, Gottrup F, Bech-Thomsen N, Scanlon E, et al. The silver-releasing
foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers:
a randomised, controlled trial. Int Wound J 2005;2:64–73. http://dx.doi.org/10.1111/
j.1742-4801.2005.00084.x
229. Lazareth I, Meaume S, Sigal-Grinberg M, Combemale P, Le Guyadec T, Zagnoli A, et al. The role
of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs
suggesting heavy bacterial colonization: results of a randomized controlled study. Wounds
Compend Clin Res Pract 2008;20:158–66.
230. Meaume S, Vallet D, Morere MN, Téot L. Evaluation of a silver-releasing hydroalginate dressing in
chronic wounds with signs of local infection. J Wound Care 2005;14:411–19. http://dx.doi.org/
10.12968/jowc.2005.14.9.26835
231. Michaels JA, Campbell B, King B, Palfreyman SJ, Shackley P, Stevenson M. Randomized controlled
trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers
(VULCAN trial). Br J Surg 2009;96:1147–56. http://dx.doi.org/10.1002/bjs.6786
232. Münter KC, Beele H, Russell L, Crespi A, Gröchenig E, Basse P, et al. Effect of a sustained
silver-releasing dressing on ulcers with delayed healing: the CONTOP study. J Wound Care
2006;15:199–206. http://dx.doi.org/10.12968/jowc.2006.15.5.26909
233. Wunderlich U, Orfanos CE. [Treatment of venous ulcera cruris with dry wound dressings. Phase
overlapping use of silver impregnated activated charcoal xerodressing.] Hautarzt Z Für Dermatol
Venerol Verwandte Geb 1991;42:446–50.
234. Kingsley A. A proactive approach to wound infection. Nurs Stand 2001;15:50–4, 56, 58.
http://dx.doi.org/10.7748/ns2001.04.15.30.50.c3012
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
232
235. Australian Wound Management Association Inc. Position Document of the Australian Wound
Management Association: Bacterial Impact on Wound Healing: From Contamination to Infection.
West Leederville, WA: Cambridge Media; 2011. URL: www.awma.com.au (accessed June 2016).
236. White RJ, Cutting KF. Critical colonization – the concept under scrutiny. Ostomy Wound
Manage 2006;52:50–6.
237. European Wound Management Association. Identifying Criteria for Wound Infection: EWMA
Position Document. London: EWMA; 2005. URL: www.woundsinternational.com/clinical-
guidelines/identifying-criteria-for-wound-infection (accessed 17 May 2016).
238. Joint Formulary Committee. British National Formulary. 65th ed. London: BMJ Group and
Pharmaceutical Press; 2013.
239. Leaper D, Drake R. Should one size fit all? An overview and critique of the VULCAN study on
silver dressings. Int Wound J 2011;8:1–4. http://dx.doi.org/10.1111/j.1742-481X.2010.00766.x
240. Ghersi D, Berlin J, Akie L on behalf of the Cochrane Prospective Meta-analysis Methods Group.
Prospective Meta-Analysis. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic
Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. URL: www.cochrane-
handbook.org (accessed 15 July 2013).
241. The PPP Investigators. Design, rational, and baseline characteristics of the Prospective Pravastatin
Pooling (PPP) project – a combined analysis of three large-scale randomized trials: Long-term
Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE),
and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995;76:899–905.
http://dx.doi.org/10.1016/S0002-9149(99)80259-8
242. Marty M, Coombes R, Peckitt C, Perez Lopez F, Tres A, Morvan F, et al. Prospective meta-analysis
of randomised trials of cyclophosphamide, methotrexate and fluorouracil (CMF) vs. fluorouracil,
epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer. J Clin Oncol
2004;22:592.
243. Steinbeck KS, Baur LA, Morris AM, Ghersi D. A proposed protocol for the development of a
register of trials of weight management of childhood overweight and obesity. Int J Obes (Lond)
2006;30:2–5. http://dx.doi.org/10.1038/sj.ijo.0803169
244. Dumville J, Hinchliffe R, Cullum N, Game F, Akesson N, Sweeting M. Negative pressure wound
therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev
2013;10:CD010318. http://dx.doi.org/10.1002/14651858.cd010318
245. Briggs M, Nelson EA, Martyn-St James M. Topical agents or dressings for pain in venous leg
ulcers. Cochrane Database Syst Rev 2012;11:CD001177. http://dx.doi.org/10.1002/14651858.
cd001177.pub3
246. Dumville JC, McFarlane E, Edwards P, Lipp A, Holmes A. Preoperative skin antiseptics for
preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev
2013;3:CD003949. http://dx.doi.org/10.1002/14651858.cd003949.pub3
247. Lefebvre C, Manheimer E, Glanville J on behalf of the Cochrane Information Retrieval Methods
Group. Searching for Studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic
Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. URL: www.cochrane-
handbook.org (accessed 15 July 2013).
248. Scottish Intercollegiate Guidelines Network. Search Filters. 2011. URL: www.sign.ac.uk/
methodology/filters.html#random (accessed 3 June 2016).
249. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med 1998;17:2815–34. http://dx.doi.org/10.1002/
(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
233
250. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines:
13. Preparing summary of findings tables and evidence profiles – continuous outcomes. J Clin
Epidemiol 2013;66:173–83. http://dx.doi.org/10.1016/j.jclinepi.2012.08.001
251. Schünemann H, Oxman A, Vist G, Higgins J, Deeks J, Glasziou P, et al. Interpreting Results and
Drawing Conclusions. In Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org
(accessed 15 July 2013).
252. Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction –
GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.
http://dx.doi.org/10.1016/j.jclinepi.2010.04.026
253. Joint Formulary Committee. British National Formulary. 60th edn. London: BMJ Group and
Pharmaceutical Press; 2010.
254. Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers.
Cochrane Database Syst Rev 2014;5:CD001103. http://dx.doi.org/10.1002/14651858.
cd001103.pub3
255. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-
analysis: many names, many benefits, many concerns for the next generation evidence synthesis
tool. Res Synth Methods 2012;3:80–97. http://dx.doi.org/10.1002/jrsm.1037
256. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat
Assoc 2006;101:447–59. http://dx.doi.org/10.1198/016214505000001302
257. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D’Amico R, et al. Indirect comparisons
of competing interventions. Health Technol Assess 2005;9(26). http://dx.doi.org/10.3310/hta9260
258. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting
results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol
2011;64:163–71. http://dx.doi.org/10.1016/j.jclinepi.2010.03.016
259. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment
comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683–91.
http://dx.doi.org/10.1016/S0895-4356(97)00049-8
260. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of
evidence from a network meta-analysis. PLOS ONE 2014;9:e99682. http://dx.doi.org/10.1371/
journal.pone.0099682
261. Ahroni JH, Boyko EJ, Pecoraro RE. Diabetic foot ulcer healing: extrinsic vs. intrinsic factors.
Wounds 1993;5:245–55.
262. Baker NR, Creevy J, Baker NR. A Randomised Comparative Pilot Study to Evaluate Allevyn
Hydrocellular Dressings and Sorbsan Calcium Alginate Dressings in the Treatment of Diabetic Foot
Ulcers. In Harding KG, editor. Proceedings of the 3rd European Conference on Advances in
Wound Management. London: Macmillan; 1994. pp. 170.
263. Blackman JD, Senseng D, Quinn L, Mazzone T. Clinical evaluation of a semipermeable polymeric
membrane dressing for the treatment of chronic diabetic foot ulcers. Diabetes Care
1994;17:322–5. http://dx.doi.org/10.2337/diacare.17.4.322
264. Clever HU, Dreyer M. Comparing Two Wound Dressings for the Treatment of Neuropathic
Diabetic Foot Ulcers. In Cherry GW, ed. 5th European Conference on Advances in Wound
Management Proceedings. London: Macmillan Magazines Ltd; 1996. pp. 201–3.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
234
265. Donaghue VM, Chrzan JS, Rosenblum BI, Giurini JM, Habershaw GM, Veves A. Evaluation of a
collagen-alginate wound dressing in the management of diabetic foot ulcers. Adv Wound Care
1998;11:114–19.
266. Foster AVM, Greenhill MT, Edmonds ME. Comparing two dressings in the treatment of diabetic
foot ulcers. J Wound Care 1995;3:224–8.
267. Jeffcoate WJ, Price PE, Phillips CJ, Game FL, Mudge E, Davies S, et al. Randomised controlled trial
of the use of three dressing preparations in the management of chronic ulceration of the foot in
diabetes. Health Technol Assess 2009;13(54). http://dx.doi.org/10.3310/hta13540
268. Jensen JL, Seeley J, Gillin B. Diabetic foot ulcerations. A controlled, randomized comparison of
two moist wound healing protocols: Carrasyn Hydrogel Wound dressing and wet-to-moist saline
gauze. Adv Wound Care 1998;11:1–4.
269. Jude EB, Apelqvist J, Spraul M, Martini J, Silver Dressing Study Group. Prospective randomized
controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in
non-ischaemic diabetic foot ulcers. Diabet Med 2007;24:280–8. http://dx.doi.org/10.1111/
j.1464-5491.2007.02079.x
270. Mazzone T, Blackman JD. Evaluation of a new loaded foam membrane on the healing rate of
diabetic foot ulcers. Wound Repair Regen 1993;1:88.
271. Piaggesi A, Baccetti F, Rizzo L, Romanelli M, Navalesi R, Benzi L. Sodium carboxyl-methyl-cellulose
dressings in the management of deep ulcerations of diabetic foot. Diabet Med 2001;18:320–4.
http://dx.doi.org/10.1046/j.1464-5491.2001.00466.x
272. Roberts GH, Hammad LH, Baker N, Haggan G, Sandemann DD, Mani R. Hydrocellular against
non-adherent dressings to treat diabetic foot ulcers – a randomised controlled study. Wound
Repair Regen 2001;9:393.
273. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized
regenerated cellulose dressing) vs. standard treatment in the management of diabetic foot ulcers.
Arch Surg 2002;137:822–7. http://dx.doi.org/10.1001/archsurg.137.7.822
274. Vandeputte J, Gryson L. Diabetic foot infection controlled by immuno-modulating hydrogel
containing 65% glycerine. Presentation of a clinical trial. J Wound Care 1996;5:50–3.
275. D’Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethyl cellulose aqueous-based gel vs.
becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds
1998;10:69–75.
276. Soares MO, Dumville JC, Ades AE, Welton NJ. Treatment comparisons for decision making:
facing the problems of sparse and few data. R Stat Soc Ser A Stat Soc 2014;177:259–79.
http://dx.doi.org/10.1111/rssa.12010
277. Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses.
BMC Med Res Methodol 2013;13:35. http://dx.doi.org/10.1186/1471-2288-13-35
278. Chaimani A, Vasiliadis HS, Pandis N, Schmid CH, Welton NJ, Salanti G. Effects of study precision
and risk of bias in networks of interventions: a network meta-epidemiological study. Int J
Epidemiol 2013;42:1120–31. http://dx.doi.org/10.1093/ije/dyt074
279. Jull A, Walker N, Parag V, Molan P, Rodgers A, Honey as Adjuvant Leg Ulcer Therapy trial
collaborators. Randomized clinical trial of honey-impregnated dressings for venous leg ulcers.
Br J Surg 2008;95:175–82. http://dx.doi.org/10.1002/bjs.6059
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
235
280. Harding K, Gottrup F, Jawien´ A, Mikosin´ski J, Twardowska-Saucha K, Kaczmarek S, et al. A
prospective, multi-centre, randomised, open label, parallel, comparative study to evaluate effects of
AQUACEL® Ag and Urgotul® Silver dressing on healing of chronic venous leg ulcers. Int Wound J
2012;9:285–94. http://dx.doi.org/10.1111/j.1742-481X.2011.00881.x
281. Wild T, Eberlein T, Andriessen A. Wound cleansing efficacy of two cellulose-based dressings.
Wounds UK 2010;3:14–21.
282. Backhouse CM, Blair SD, Savage AP, Walton J, McCollum CN. Controlled trial of occlusive
dressings in healing chronic venous ulcers. Br J Surg 1987;74:626–7. http://dx.doi.org/10.1002/
bjs.1800740732
283. Blair SD, Backhouse CM, Wright DDI, Riddle E, McCollum CN. Do dressings influence the healing
of chronic venous ulcers? Phlebology 1988;3:129–34.
284. Nelson EA, Prescott RJ, Harper DR, Gibson B, Brown D, Ruckley CV. A factorial, randomized trial
of pentoxifylline or placebo, four-layer or single-layer compression, and knitted viscose or
hydrocolloid dressings for venous ulcers. J Vasc Surg 2007;45:134–41. http://dx.doi.org/10.1016/
j.jvs.2006.09.043
285. Moffatt CJ, Franks PJ, Oldroyd MI, Greenhalgh RM. Randomized trial of an occlusive dressing in
the treatment of chronic non-healing leg ulcers. Phlebology 1992;7:105–7.
286. Callam MJ, Harper DR, Dale JJ, Brown D, Gibson B, Prescott RJ, et al. Lothian and Forth Valley Leg
Ulcer Healing Trial, part 2: knitted viscose dressing versus a hydrocellular dressing in the treatment
of chronic leg ulceration. Phlebology 1992;7:142–5.
287. Moffatt CJ, Oldroyd M, Franks PJ. Assessing a calcium alginate dressing for venous ulcers of the
leg. J Wound Care 1992;4:22–4.
288. Bowszyc J, Bowszyc-Dmochowska M, Kazmierowski M, Ben-Amer HM, Garbowska T, Harding E.
Comparison of two dressings in the treatment of venous leg ulcers. J Wound Care 1995;4:106–10.
289. Charles H, Callicot C, Mathurin D, Ballard K, Hart J. Randomised, comparative study of three
primary dressings for the treatment of venous ulcers. Br J Community Nurs 2002;7:48–54.
http://dx.doi.org/10.12968/bjcn.2002.7.Sup1.12965
290. Thomas S, Banks V, Bale S, Fear-Price M, Hagelstein S, Harding KG, et al. A comparison of two
dressings in the management of chronic wounds. J Wound Care 1997;6:383–6.
291. Vanscheidt W, Sibbald RG, Eager CA. Comparing a foam composite to a hydrocellular foam
dressing in the management of venous leg ulcers: a controlled clinical study. Ostomy Wound
Manage 2004;50:42–55.
292. Zuccarelli F. [A comparative study of the hydrocellular dressing Allevyn and the hydrocolloid
dressing Duoderm in the local treatment of leg ulcers.] Phlébologie 1992;45:529–33.
293. Arnold TE, Stanley JC, Fellows EP, Moncada GA, Allen R, Hutchinson JJ, et al. Prospective,
multicenter study of managing lower extremity venous ulcers. Ann Vasc Surg 1994;8:356–62.
http://dx.doi.org/10.1007/BF02132997
294. Mulder G, Jensen J, Seeley S. Use of hydrocellular dressing versus a calcium alginate in the
treatment of venous leg ulcers. Wound Repair Regen 1995;3:361.
295. Vin F, Teot L, Meaume S. The healing properties of Promogran in venous leg ulcers. J Wound
Care 2002;11:335–41. http://dx.doi.org/10.12968/jowc.2002.11.9.26438
296. Taddeucci P, Pianigiani E, Colletta V, Torasso F, Andreassi L, Andreassi A. An evaluation of
Hyalofill-F plus compression bandaging in the treatment of chronic venous ulcers. J Wound Care
2004;13:202–4. http://dx.doi.org/10.12968/jowc.2004.13.5.26613
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
236
297. Schmutz J-L, Meaume S, Fays S, Ourabah Z, Guillot B, Thirion V, et al. Evaluation of the nano-
oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results
of a randomised, controlled trial. Int Wound J 2008;5:172–82. http://dx.doi.org/10.1111/
j.1742-481X.2008.00453.x
298. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers
compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study
Group. Int J Dermatol 1998;37:390–6. http://dx.doi.org/10.1046/j.1365-4362.1998.00415.x
299. Coull AF, Atherton I, Taylor A, Watterson AE. Prevalence of skin problems and leg ulceration in a
sample of young injecting drug users. Harm Reduct J 2014;11:22. http://dx.doi.org/10.1186/
1477-7517-11-22
300. Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane
Database Syst Rev 2012;12:CD001733. http://dx.doi.org/10.1002/14651858.cd001733.pub3
301. Kurd SK, Hoffstad OJ, Bilker WB, Margolis DJ. Evaluation of the use of prognostic information for
the care of individuals with venous leg ulcers or diabetic neuropathic foot ulcers. Wound Repair
Regen 2009;17:318–25. http://dx.doi.org/10.1111/j.1524-475X.2009.00487.x
302. Nixon J, Cranny G, Iglesias C, Nelson EA, Hawkins K, Phillips A, et al. Randomised, controlled trial
of alternating pressure mattresses compared with alternating pressure overlays for the prevention
of pressure ulcers: PRESSURE (pressure relieving support surfaces) trial. BMJ 2006;332:1413–15.
http://dx.doi.org/10.1136/bmj.38849.478299.7C
303. Margolis DJ, Gupta J, Hoffstad O, Papdopoulos M, Glick HA, Thom SR, et al. Lack of effectiveness
of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of
amputation: a cohort study. Diabetes Care 2013;36:1961–6. http://dx.doi.org/10.2337/dc12-2160
304. National Institute for Health Research. Surgical Wounds Healing by Secondary Intention:
Characterising and Quantifying the Problem and Identifying Effective Treatments.
URL: www.nihr.ac.uk/funding/funded-research/funded-research.htm?postid=2194
(accessed 4 August 2016).
305. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for
good practice in decision-analytic modelling in health technology assessment. Health Technol
Assess 2004;8(36). http://dx.doi.org/10.3310/hta8360
306. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. Prognosis research strategy
(PROGRESS) 1: a framework for researching clinical outcomes. BMJ 2013;346:e5595.
http://dx.doi.org/10.1136/bmj.e5595
307. Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis
Research Strategy (PROGRESS) 3: prognostic model research. PLOS Med 2013;10:e1001381.
http://dx.doi.org/10.1371/journal.pmed.1001381
308. Podiatry Rheumatic Care Association. Standards of Care for People with Musculoskeletal Foot Health
Problems. 2008. URL: www.prcassoc.org.uk/standards-project (accessed 21 November 2013).
309. Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev
2010;1:CD003556. http://dx.doi.org/10.1002/14651858.cd003556.pub2
310. Nelson EA, O’Meara S, Craig D, Iglesias C, Golder S, Dalton J, et al. A series of systematic reviews
to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health
Technol Assess 2006;10(12). http://dx.doi.org/10.3310/hta10120
311. Foley GB, Allen J. Wound healing after toenail avulsion. A comparison of Kaltostat and Melolin as
postoperative dressings. Foot 1994;4:88–91. http://dx.doi.org/10.1016/0958-2592(94)90035-3
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
237
312. Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have
osteomyelitis of the lower extremity? JAMA 2008;299:806–13. http://dx.doi.org/10.1001/
jama.299.7.806
313. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests
for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis 2008;47:519–27.
http://dx.doi.org/10.1086/590011
314. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan L, et al. Foot infections in
diabetic patients. Decision and cost-effectiveness analyses. JAMA 1995;273:712–20. http://dx.doi.
org/10.1001/jama.1995.03520330042035
315. Kapoor A, Page S, Lavalley M, Gale DR, Felson DT. Magnetic resonance imaging for diagnosing
foot osteomyelitis: a meta-analysis. Arch Intern Med 2007;167:125–32. http://dx.doi.org/10.1001/
archinte.167.2.125
316. Morrison WB, Schweitzer ME, Wapner KL, Hecht PJ, Gannon FH, Behm WR. Osteomyelitis in feet
of diabetics: clinical accuracy, surgical utility, and cost-effectiveness of MR imaging. Radiology
1995;196:557–64. http://dx.doi.org/10.1148/radiology.196.2.7617877
317. Medical Services Advisory Committee. LeukoScan. For Use in Diagnostic Imaging of the Long
Bones and Feet in Patients with Suspected Osteomyelitis, Including those with Diabetic Foot
Ulcers. Canberra, ACT: MSAC; 2003.
318. Pakos EE, Koumoullis HD, Koumoulis HD, Fotopoulos AD, Ioannidis JPA. Osteomyelitis:
antigranulocyte scintigraphy with 99mTC radiolabeled monoclonal antibodies for diagnosis –
meta-analysis. Radiology 2007;245:732–41. http://dx.doi.org/10.1148/radiol.2452061877
319. Termaat MF, Raijmakers PGHM, Scholten HJ, Bakker FC, Patka P, Haarman HJTM. The accuracy of
diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-
analysis. J Bone Joint Surg Am 2005;87:2464–71. http://dx.doi.org/10.2106/JBJS.D.02691
320. Wrobel JS, Connolly JE. Making the diagnosis of osteomyelitis. The role of prevalence. J Am
Podiatr Med Assoc 1998;88:337–43. http://dx.doi.org/10.7547/87507315-88-7-337
321. Carter MJ, Tingley-Kelley K, Warriner RA. Silver treatments and silver-impregnated dressings for
the healing of leg wounds and ulcers: a systematic review and meta-analysis. J Am Acad
Dermatol 2010;63:668–79. http://dx.doi.org/10.1016/j.jaad.2009.09.007
322. Gilsdorf P, Patterson R, Fisher S. Thirty-minute continuous sitting force measurements with
different support surfaces in the spinal cord injured and able-bodied. J Rehabil Res Dev
1991;28:33–8. http://dx.doi.org/10.1682/JRRD.1991.10.0033
323. Al-Khamis A, McCallum I, King PM, Bruce J. Healing by primary versus secondary intention after
surgical treatment for pilonidal sinus. Cochrane Database Syst Rev 2010;1:CD006213. http://dx.
doi.org/10.1002/14651858.cd006213.pub3
324. Bergin S, Ross L, Thomas S, Royle P, Waugh N. Protease modulating dressings for treatment
diabetic foot ulcers (protocol). Cochrane Database Syst Rev 2005;3:CD005361.
325. Lázaro-Martínez JL, García-Morales E, Beneit-Montesinos JV, Martínez-de-Jesús FR,
Aragón-Sánchez FJ. [Randomized comparative trial of a collagen/oxidized regenerated cellulose
dressing in the treatment of neuropathic diabetic foot ulcers.] Cir Esp 2007;82:27–31.
http://dx.doi.org/10.1016/S0009-739X(07)71657-3
326. Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G, et al. Synergistic
action of protease-modulating matrix and autologous growth factors in healing of diabetic foot
ulcers. A prospective randomized trial. J Diabetes Complications 2007;21:387–91. http://dx.doi.org/
10.1016/j.jdiacomp.2007.03.006
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
238
327. Dunford C. Hypergranulation tissue. J Wound Care 1999;8:506–7. http://dx.doi.org/10.12968/
jowc.1999.8.10.26222
328. Hampton S. Understanding overgranulation in tissue viability practice. Br J Community Nurs
2007;12:S24–30. http://dx.doi.org/10.12968/bjcn.2007.12.Sup4.43000
329. Nelson L. Wound care. Points of friction. Nurs Times 1999;95:72, 75.
330. Young T. Common problems in wound care: overgranulation. Br J Nurs 1995;4:169–70.
http://dx.doi.org/10.12968/bjon.1995.4.3.169
331. Dovison R, Keenan AM. Wound healing and infection in nail matrix phenolization wounds. Does
topical medication make a difference? J Am Podiatr Med Assoc 2001;91:230–3. http://dx.doi.org/
10.7547/87507315-91-5-230
332. Harris A, Rolstad BS. Hypergranulation tissue: a nontraumatic method of management. Ostomy
Wound Manage 1994;40:20–2, 24, 26–30.
333. Hofman D, Moore K, Cooper R, Eagle M, Cooper S. Use of topical corticosteroids on chronic leg
ulcers. J Wound Care 2007;16:227–30. http://dx.doi.org/10.12968/jowc.2007.16.5.27047
334. Wang SQ, Goldberg LH. Pulsed dye laser for the treatment of hypergranulation tissue with
chronic ulcer in postsurgical defects. J Drugs Dermatol 2007;6:1191–4.
335. Russell L. The importance of patients’ nutritional status in wound healing. Br J Nurs 2001;10:S42,
S44–49. http://dx.doi.org/10.12968/bjon.2001.10.sup1.5336
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
239

Appendix 1 Prevalence survey proforma
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          Section 3 completed up to four times where the patient had multiple wounds 
 
 
 
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
247

Appendix 2 Prevalence of complex wounds by
age and sex: prevalence survey data
Pressure ulcer
Venous leg ulcer
Traumatic wound
Other surgical wound
Other
Non-diabetic foot ulcer
Arterial/venous leg ulcer
Diabetic foot ulcer
Dehisced surgical wound
Arterial leg ulcer
Abscess
Fungating carcinoma
Pilonidal sinus
Burn
0.00 0.05 0.10 0.15
0.39
0.23
0.33
0.25
0.15
0.07
0.13
0.15
0.13
0.09
0.12
0.07
0.11
0.09
0.08
0.17
0.08
0.06
0.05
0.05
0.05
0.04
0.03
0.01
0.02
0.05
0.02
0.02
0.20
Point prevalence per 1000
0.25 0.30 0.35 0.40 0.45
Female
Male
Mean age associated with individual wound types
Wound type Age (years), mean (SD)
Arterial/venous leg ulcer 79.65 (11.32)
Arterial leg ulcer 79.11 (13.79)
Non-diabetic foot ulcer 78.89 (13.32)
Fungating carcinoma 75.00 (17.69)
Pressure ulcer 74.79 (14.51)
Traumatic wounds 73.58 (22.10)
Diabetic foot ulcer 70.68 (14.40)
Venous leg ulcer 70.61 (17.10)
Other wounds 70.48 (19.62)
Dehisced surgical wounds 59.96 (17.72)
Burns 58.07 (22.98)
Pilondial sinus 37.48 (20.33)
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Appendix 3 Medical data registries of chronic
diseases: review protocol
Background
One component of the NIHR programme grant is to assess the utility, feasibility and sustainability of a
chronic wounds registry. We are not aware of any UK registries of chronic wound care; however,
information from registries of other chronic diseases may prove insightful in the development of such a
wounds registry and how data collection can be sustained and may provide insight into how the data
generated from a registry can be used.
Objective
The objective is to identify, appraise and summarise reports of chronic disease registries.
Aims
Specific aims are:
1. to identify chronic diseases (and countries) in which a registry has been utilised
2. to identify the methods of data collection used
3. to summarise the uses of registry data
4. to describe how the registry (and data collection related to it) integrates with other data collection
systems in the organisation
5. to examine the configuration of registries across multiple specialty teams or across health-care
interfaces, for example primary and secondary care.
Methods
A scoping review/information gathering exercise will be undertaken.
Inclusion criteria
Any paper reporting a chronic disease registry will be included.
A chronic disease will be defined as a long-lasting or recurrent condition. Registries relating to surgical
procedures will be excluded.
A medical registry will be defined as a database that meets the six characteristics that defined a medical
database registry compiled by Drolet and Johnson:97
1. Mergeable data. Data stored in a format that allows a user/researcher to create a single aggregate and
searchable data set for research and patient care purposes.
2. Data set standardised. The same data are collected for all patients/records in a registry.
3. Rules for data collection. A set of characteristics are defined prior to the collection of data. These data
are collected in a systematic and prospective manner.
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4. Observations associated over time. Database is designed so that each patient is identified in the registry
as a single continuous record for storage of longitudinal data.
5. Knowledge of outcomes. Follow-up must be obtained to assess outcomes or manage patient care.
6. Inclusion principle. The characteristic that is common to all patients in a disease register, that is, disease.
General discussion articles about the design and implementation of disease registries will also be included
for background information but data will not be extracted.
Search methods
Using OvidSP an electronic search on MEDLINE will be undertaken using the following search strategy:
1. exp Chronic Disease/ (182,090)
2. (chronic adj (illness$or disease$)).tw. (25,675)
3. 1 or 2 (199,178)
4. exp Registries/ (35,210)
5. (registr$or register$1).tw. (77,603)
6. 4 or 5 (92,049)
7. 6 and 3 (1409)
Relevant information will also be gathered from other sources (known to the authors) who are experienced
in the development and implementation of disease registries. We will also conduct a bibliographic search
of the Drolet and Johnson publication.97
Screening stage 1
All study titles and abstract (when available) will be reviewed. Full papers will be obtained when the title
and/or abstracts suggests:
(a) a review of a medical registries
(b) a study in which a medical data registry relating to a chronic condition is discussed or explicitly used as
a source of data.
This process will be carried out by two reviewers. Any disagreement will be taken to a third,
senior reviewer.
Screening stage 2
Full articles will then be screened against the criteria of Drolet and Johnson97 and classed as medical data
registries or not. When a paper provides very limited information, that is, a registry is mentioned only
briefly as a source of data and does not provide enough data to make a decision using this criterion, we
will follow the methods of Drolet and Johnson97 and search for further information on MEDLINE and the
internet. We will also contact authors. When no further useful information can be obtained the study will
be excluded for further data extraction. Again, all phases will be conducted by two reviewers.
Data collection
Medical registries will be extracted into a database according to predefined criteria. Studies describing the
same registries will be grouped and extracted together so that each registry has one extraction record.
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When possible, extracted data will include:
l general information:
¢ country
¢ location
¢ type of condition
¢ duration of registry
l data collection:
¢ methods of data collection
¢ summary of data collected
¢ details of how registry data collection relates to data collection systems in the organisation, that is,
routinely collected data
¢ information on IT systems and storage of data
¢ methods of data quality assurance
¢ details of how data from multiple sources (i.e. health-care interfaces) is collected and collated
l data use:
¢ detail any outputs using registry data.
Analysis
Descriptive variables will be presented and a critical narrative report will be undertaken.
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Appendix 4 Wound assessment form
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Appendix 5 James Lind Alliance Pressure Ulcer
Partnership voting sheet
 
 
 
The James Lind Alliance Pressure Ulcer Priority Setting Partnership needs your help 
to decide two shortlists of the most important questions about preventing and treating 
pressure ulcers.   
We are drawing up a shortlist of 15 questions about preventing pressure ulcers and a 
second one of 15 questions about treating pressure ulcers that matter most to patients, 
carers and health professionals.  Research has not yet provided a reliable answer to 
any of these questions. 
Earlier this year we asked patients, carers and healthcare professionals where they 
would like to see further research or where they thought there was uncertainty about 
the best medical and nursing care.  More recently we asked people to rate the most 
frequently submitted questions according to how important they feel the questions 
are. 
We now have two lists that are displayed where there is agreement between patients, 
carers and health professionals.  We are now asking you to choose, from the questions 
listed in this voting paper, THREE prevention questions and THREE treatment 
questions to make up the shortlists of 15. 
Your vote will be confidential but we do ask you to let us know whether you are a 
patient, carer or health professional. 
Please read the questions carefully and put an X in the boxes next to your choices.  
Then return your voting paper to the JLAPUP stand. 
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Thank you. 
November 2012 
 
 
 
First please tell us about yourself.   
X all that apply. 
I am a patient  
I am a carer  
I am a health professional  
 
 
                                PREVENTION QUESTIONS 
CHOOSE THREE ONLY FROM THE QUESTIONS BELOW  
Health Professional Questions 
Staffing levels  
Do staffing levels have an impact on the incidence of pressure ulcers? 
Bed rest  
For wheelchair users, how effective are periods of bed rest in 
preventing pressure ulcers? 
Clinical leadership  
How effective is clinical leadership in preventing pressure ulcers in the 
NHS and independent sectors? 
Incontinence management (spinal injury)  
For those with spinal injury, to what extent is pressure ulceration 
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prevented by good management of urinary and faecal incontinence? 
Use of Healthcare Assistants  
How effective is it for Healthcare Assistants to assess pressure ulcer 
risk? 
Wound care champion  
How effective in preventing pressure ulcers is having a wound care 
champion [particular staff, managers or personal carers responsible 
for the prevention of pressure ulcers]? 
Static flow mattresses over time 
How effective are static flow mattresses over time? 
Public awareness campaigns  
Are public awareness campaigns effective at preventing pressure 
ulcers? 
 
Patients’ Questions 
Pressure mapping for wheelchair users  
For wheelchair users at risk of developing pressure ulcers, what is the 
most effective method of pressure mapping to assess pressure areas at 
risk to prevent the development of pressure ulcers? 
 
Specialist shoe and boot design  
For people at risk of heel pressure ulcers, how effective are specialist 
boot and shoe design and fitting at preventing pressure ulcers? 
 
Massage  
Is massaging pressure areas effective in the prevention of pressure 
ulcers? 
 
Organisation of nursing care in hospitals  
For people in hospital at risk of developing pressure ulcers, is the 
current organisation of nursing care effective as best practice in the 
prevention of pressure ulcers? 
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Carers’ Questions 
Continuity of care 
How does continuity of care impact on the prevention of pressure 
ulcers? 
 
 
Cushions vs. bed rest 
For people sitting on a pressure ulcer are pressure relieving cushions 
an effective alternative to bed rest? 
 
 
TREATMENT QUESTIONS 
CHOOSE THREE ONLY FROM THE QUESTIONS BELOW 
Health Professional Questions 
Ulcer grading systems  
How effective are pressure ulcer grading systems in determining the 
amount of skin damage and does the use of such scales improve 
ulcer healing? 
 
 
 
 
Patients’ Questions 
Staff training  
Is staff training effective in improving pressure ulcer healing? 
 
 
Best means of personal hygiene  
What is the most effective way of keeping clean to aid pressure 
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ulcer healing? 
Wet/dry wound healing  
Is it more effective to keep pressure ulcers dry and exposed to the 
air or moist and dressed to aid pressure ulcer healing? 
 
 
Carers’ Questions 
Bed-making 
Does the way a bed is made or the type of bedding have an impact 
on ulcer healing? 
 
Multiple sclerosis posture  
For people with multiple sclerosis and pressure ulcers is posture 
important in relation to healing? 
 
‘Bed coaching’- support and passive exercise  
For people who are bed bound as a result of pressure ulcers, does 
support and ‘bed coaching' aid recovery from pressure ulcers? 
 
 ‘Supporting frame’ vs air bed  
In patients who have pressure ulcers, would a ‘supporting frame’ be 
a more effective means of relieving pressure than an air bed? 
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Appendix 6 James Lind Alliance Pressure Ulcer
Partnership pre-workshop questionnaire
 
 
   
 
 
 
 
JLAPUP Final Priority Setting 
Workshop  
 
28th March 2013, Shine, Leeds  
 
 
 
Pre-workshop exercise  
 
 
 
 
 
Please complete this and bring it along with you to the final 
workshop meeting.   
NIHR Wounds Research for 
Patient Benefit Programme 
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James Lind Alliance Pressure Ulcer Partnership 
PRE-WORKSHOP RANKING FORM 
Please choose your top 10 from the questions listed below and rank them from
with 1 being the most important.   
Bring this form with you to the workshop as we will be discussing your individu
at the beginning of the priority setting process.   
Thank you. 
The thumbs up rankings are to let you know how important patients, carers and health professionals have
questions so far.  Please consider the full list in your choice. 
 
Raised and ranked as very important by patients, carers and health professionals 
 
Raised and ranked as important by patients, carers and health professionals 
 
Raised by two groups and ranked as important (but lower) OR raised by one group but prioritised as important b
in the integration phase. 
 ID Rank 
your top 
10 here 
 
How patients, 
carers and 
health 
professionals 
have rated 
this so far 
Question 
A   
 
 
1st among 
How effective is repositioning in the prevention of 
pressure ulcers?  
 
Particular questions were raised about three affected 
groups: those in bed, those seated and those with 
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health 
professionals 
for prevention 
contracted limbs. Key areas of uncertainty for those in 
bed were the most effective means of turning yourself, 
being turned (or having your position changed) by 
others and whether the impact  on health and well-being 
of sleep disruption was taken into account. For those 
seated, the key area of uncertainty was the most 
effective means of repositioning yourself or being 
repositioned (by others) in a chair. 
B   
 
 
1st among 
carers for 
prevention 
What is the relative effectiveness of the different types 
of pressure relieving beds, mattresses, overlays and 
cushions (including cushions for electric and self-
propelling wheelchairs) in preventing pressure ulcers? 
 
There were uncertainties about whether devices were 
meeting the needs of the full range of patients at risk 
and how devices in use compared with conventional and 
other specialist surfaces.  The needs of three affected 
groups were raised in particular: those who share a 
mattress with a partner, people with multiple sclerosis 
and those with contracted limbs. 
C   
 
 
1st among 
patients for 
prevention 
How effective at preventing pressure ulcers is involving 
patients, family and lay carers in patient care?  
  
 
 
This question includes uncertainties about the best 
means of informing, educating and motivating people.  
 
 
D   
 
Does improved diet (eating) and hydration (drinking) 
promote the prevention of pressure ulcers?  
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There were particular uncertainties about the 
effectiveness of high protein diet, micronutrients and the 
effects of weight loss and gain. Also particular effects 
for people with multiple sclerosis, spina bifida or spinal 
cord injury. 
 
E   
 
 
1st among 
health 
professionals 
for treatment 
 
Does improving diet (eating) and hydration (drinking) 
promote pressure ulcer healing? 
 
 
 
 
 
 
F   
 
 
1st among 
carers for 
treatment 
Do pressure relieving support surfaces, particularly 
mattresses help heal pressure ulcers? 
 
 
There were specific uncertainties about the design of 
devices used in the treatment of the frail and elderly and 
those with multiple sclerosis. 
 
G   
 
Does regular turning of patients in bed promote 
healing of pressure ulcers? 
 
 
There were particular uncertainties about how often it is 
best to turn people, the most effective means of 
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
272
repositioning for people who require a carer to help 
them move, and whether a “prompt of routine” tool 
which reminds people to reposition themselves would 
be helpful for people with limited memory as well as 
limited mobility. 
 
 
H   
 
What are the best service models (and are they 
sufficiently accessible) to ensure that patients with 
pressure ulcers receive the best treatment outcomes? 
 
There were particular questions about whether 
awareness of and access to tissue viability nurses 
improved outcomes and whether people with specialist 
conditions (e.g. spinal cord injury) received the best 
pressure ulcer treatment at specialist centres compared 
to generalist services. 
 
I   
 
 
 
J   
 
 
1st among 
patients for 
treatment 
How effective are surgical operations to close pressure 
ulcers? 
 
This included uncertainty about the most appropriate 
surgical referral for people with MS and ulcers that 
won’t heal. 
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K   
 
For wheelchair users sitting on a pressure ulcer, how 
effective is bed rest in promoting pressure ulcer 
healing? 
 
There were concerns about whether bed rest was 
detrimental to mental health, whether it was safe for 
those with Multiple Sclerosis who have been advised to 
keep moving, how its effectiveness compared with 
sitting on a pressure relieving cushion and whether 
sitting for a small time (for example to eat a meal) was 
likely to substantially increase pressure ulcer healing 
time.  
L   
 
Does (surgical and non-surgical) debridement promote 
healing in patients with pressure ulcers, and if so, what 
is the most effective debridement strategy? 
 
M   
 
N   
  
 
O   
 
How effective are heel protectors in preventing pressure 
ulcers? 
 
P   How effective are topical skin care products and skin care regimes at preventing pressure ulcers?  
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 There were particular uncertainties about the application 
of barrier creams or sprays (Sudocrem and Cavilon), 
methylated spirits and moisturisers; also whether the use 
of skin care regimes diminishes the likelihood of 
pressure ulcer occurrence. For example, for patients 
confined to bed, whether treating with washing, surgical 
spirit and/or talcum powder at all pressure areas would 
prevent the occurrence of pressure ulcers. 
   
Q   
Patients and 
carers 
For people with limited mobility, does exercise 
coaching help in the prevention of pressure ulcers (for 
example, community physiotherapy interventions)? 
 
 R   
Patients and 
Health Profs 
Is using a pressure ulcer risk rating scale/tool better 
than clinical judgement in preventing pressure ulcers 
and is there a best scale? 
 
 S   
Patients and 
Health Profs 
What impact do different service models have on the 
incidence of pressure ulcers?  
 
There were particular uncertainties about whether, for 
people with Multiple Sclerosis or Spinal Cord Injury, 
working with specialist clinicians was more effective for 
prevention than working with generalists. Also whether 
access to a specialist wound prevention service 
improved pressure ulcer prevention. 
 
 T   
Carers and 
Health Profs
How effective are incontinence devices in the 
prevention of pressure ulcers? 
There was a particular uncertainty about whether 
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cheaper incontinence pads caused more irritation 
compared to expensive pads. 
 
U   
Health Profs 
and Mixed 
Do staffing levels have an impact on the incidence of 
pressure ulcers?  
 V   
Patients and  
Mixed 
For people in hospital, is the current organisation of 
nursing care effective as best practice in the prevention 
of pressure ulcers?  
W   
Carers and 
Mixed 
How does continuity of care (an on-going relationship 
with same staff members) impact on the prevention of 
pressure ulcers?  
X   
Carers and 
Health Profs 
Does getting people with pressure ulcers and their carers 
more involved in their own pressure ulcer management 
improve ulcer healing and if so, what are the most 
effective models of engagement?  
 
There were particular uncertainties about the most 
effective way for family carers to be involved and the 
effectiveness of education strategies aimed at lay carers 
to ensure understanding and concordance  to 
recommendations from health care professionals (like 
turning regimes, diet and fluids).  
Y   
Patients and 
Carers 
How does continuity of care (an on-going relationship 
with same staff members) impact on treatment of 
pressure ulcers 
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Z   
Patients and 
Carers 
For people with pressure ulcers which analgesics (pain 
relief) are effective and safe for the treatment of 
pressure-ulcer related pain? 
 
There was a particular uncertainty about pressure ulcer 
pain relief for people with Multiple Sclerosis. 
AA   
Patients and 
Carers 
What is the value of topical agents in promoting 
pressure ulcer healing? 
 
There were particular uncertainties about honey-based 
treatments and the application of sugar. 
 
AB 
 
 
Patients and 
Carers 
How effective is negative pressure wound therapy as a 
treatment for pressure ulcers? 
AC   
Patients and 
Mixed 
Is staff training effective in improving pressure ulcer 
healing?  
 
AD   
Health Profs 
and Mixed 
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Appendix 7 Collation and scoping of research
ideas for workstream 3
Research questions relating to foot ulcers and other
foot conditions
Research question (origin) Relevant literature and comments Actions taken
What is the best package of care for
people with non-diabetic foot ulcers?
(Podiatry team)
A document outlining standards of care
for people with musculoskeletal and
rheumatological foot health problems
was identified.308 This includes
recommendations for the care of
patients with inflammatory arthritis,
osteoarthritis, back pain, metabolic
bone disease and connective tissue
disease. There are also sections
covering the multidisciplinary team and
suggestions for improving access to
services, good practice examples and
implementation materials including
audit and educational resources
The podiatry team found this
document useful for confirming
standards of care for people with
musculoskeletal foot disease and did
not need to implement any changes
to practice in relation to that patient
group. The best strategy for managing
non-diabetic patients with foot
ischaemia, particularly those at risk of
ulceration or amputation, remains
uncertain
What is the impact of the time lag
involved in obtaining the dressing,
antibiotic or other treatment that the
podiatrist feels is clinically indicated?
(e.g. a time lag may ensue between
identification of potential clinical
infection and dispensing of
antimicrobial dressings or systemic
antibiotics if the podiatrist needs to
refer the patient to the GP for
prescription) (Podiatry team)
No literature was identified on different
prescribing policies in relation to foot
ulcers. This is a service delivery
organisational issue rather than
prescribing
None, as outside the remit of the
programme grant
What is the relationship between
debridement and healing in all types
of foot ulcers? (Podiatry team)
One good-quality, up-to-date
systematic review in diabetic foot ulcers
was identified.309 Six RCTs were
included (four evaluating hydrogel, one
surgical debridement and one larval
therapy). Conclusion: there is evidence
to suggest that hydrogel increases the
healing rate compared with gauze
dressing/standard care and larval
therapy resulted in a significantly
greater reduction in wound area than
hydrogel. More research is needed to
evaluate the relative effects of all
available debridement methods
(including sharp debridement) and the
effects of debridement per se.
Frequency of the procedure was not
addressed in any of the primary studies.
No relevant references were found for
non-diabetic foot ulceration
The podiatry team found this
document useful for confirming good
practice (i.e. use of hydrogel) in
patients with diabetic foot ulcers
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Research question (origin) Relevant literature and comments Actions taken
What is the effectiveness of silver
dressing vs. povidone iodine dressing
for treating diabetic foot ulcers?
(Podiatry team)
At the time of scoping, there was no
existing systematic review on dressings
for diabetic foot ulcers but between 10
and 20 clinical trials of various dressing
types were identified
Comparison of different dressing
types for treating diabetic foot ulcers
was selected as a priority topic for
systematic review and network
meta-analysis
What are the best strategies for
detecting and treating infection in
diabetic foot ulcers? (Podiatry team)
Previous systematic reviews of
diagnostic and treatment strategies
could not draw firm conclusions.310 An
ongoing primary study is evaluating
methods of diagnosing infection in
diabetic foot ulcers [see www.nets.nihr.
ac.uk/projects/hta/097501 (accessed
3 June 2016)]
Information was relayed to the
Cochrane Wounds Group; this has
helped to progress a review of
systemic antibiotics, which now has a
published protocol. Antimicrobial
dressings were included in the
systematic review and network meta-
analysis of different dressing types for
treating diabetic foot ulcers
What is the cost-effectiveness of
different dressings for healing after
nail surgery (silver, povidone iodine,
non-adherent)? (Podiatry team)
No systematic reviews were identified.
Two relevant RCTs were identified:
honey dressing vs. paraffin tulle gras203
and alginate vs. non-adherent dry
dressing.311 No economic evaluations
were identified
Not selected for systematic review
within the programme grant because
of the small number of RCTs available
What is the best way to diagnose
osteomyelitis in patients with diabetic
foot ulcers? (Podiatry team)
Several systematic reviews, meta-
analyses and economic evaluations
were identified312–320
This topic was undertaken as a MSc
dissertation. A range of diagnostic tests
was evaluated including probing to
bone, erythrocyte sedimentation rate,
plain radiographs, magnetic resonance
imaging, bone scan and leucocyte scan.
Overall, measures of diagnostic
performance suggested that probing to
bone and magnetic resonance imaging
were the tests best able to discriminate
between presence and absence of
osteomyelitis
What is the acceptability of different
dressings for those with foot ulcers
who self-care? (Podiatry team)
No relevant literature identified None, as not considered a high
priority for the programme grant
What is the significance of locus of
control issues regarding the patient’s
view of his or her own adherence with
foot ulcer treatment? [e.g. ‘It doesn’t
matter what I do, you (i.e. the
podiatrist) have to make it heal’]
(Podiatry team)
No relevant literature identified None, as not considered a high
priority for the programme grant
MSc, Master of Science.
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Research questions relating to leg ulcers
Research question (origin) Relevant literature and comments Actions taken
What is the effectiveness and cost-
effectiveness of breathable foam film
dressings (e.g. Allevyn) compared
with absorbent dressings used with
leg ulcers? (Nursing team)
A systematic review of dressings for
venous leg ulcers compared foam
dressings with low-adherent dressings
(three RCTs), alginate dressings (one RCT)
and silicone dressings (one RCT) and did
not detect any differences between foam
and other types of dressing254
New systematic review undertaken
focusing on foam dressings in
venous leg ulcers. All dressing types
were included in the systematic
review and network meta-analysis of
dressings for venous leg ulcers
What is the effectiveness of silver-
impregnated dressings when used
with venous leg ulcers? (Nursing
team)
Four relevant systematic reviews were
identified.216–218,321 Most findings indicated
no evidence to support the use of silver-
impregnated dressings in venous leg
ulcers
A scoping review of silver dressings
used with venous leg ulcers was
undertaken to explore the feasibility
of IPD meta-analysis. There was no
evidence to support the use of silver
dressings except for some short-term
(at 4 weeks) intermediate outcomes
of healing (e.g. change in ulcer area)
How does obesity affect healing of
leg ulcers? (Nursing team)
A search for prognostic studies
investigating obesity as a predictor for
delayed healing did not identify anything
relevant to leg ulcers
None, because of lack of primary
material
Research questions relating to pressure ulcers
Research question (origin) Relevant literature and comments Actions taken
What is the best management of
underweight patients deemed to be at
risk of pressure ulceration in relation to
support surfaces? (Nursing team)
No literature identified that specifically
targets this patient group
None, because of lack of primary
material
What are the best ways to measure
shear force in wheelchair users in
relation to preventing and treating
pressure ulcers? (Launch event
participants)
One evaluation of measurement methods
was identified322
None – shear force is a surrogate
outcome measure and evaluation of
different measurement instruments
would require methods comparison
evaluations. This topic was outside of
the scope of this programme grant
Research questions relating to surgical wounds
Research question (origin) Relevant literature and comments Actions taken
What is the effectiveness of topical
negative pressure compared with
conventional dressings such as
hydrocolloid or alginates when
treating dehisced abdominal
wounds? (Nursing team)
No relevant literature identified None – this is covered by a separate
programme grant (see www.york.ac.
uk/healthsciences/swhsi/)
How does obesity affect healing of
dehisced abdominal wounds?
(Nursing team)
A search for prognostic studies
investigating obesity as a predictor for
delayed healing did not identify anything
relevant to abdominal wounds
None, because of lack of primary
material
What are the best strategies for
post-operative care of pilonidal
sinus? Is it better to pack or not to
pack? (Launch event participants)
Cochrane review of healing by primary vs.
secondary intention after surgery suggested
that both methods have pros and cons
(26 RCTs).323 No new RCTs identified
None, because no new primary
material
DOI: 10.3310/pgfar04130 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 13
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cullum et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
281
Research questions relating to all wound types
Research question (origin) Relevant literature and comments Actions taken
What role should EUSOL have in
wound management? (Nursing team)
Findings from an existing systematic
review indicated that there are no RCTs
evaluating EUSOL in venous leg ulcers.199
No relevant RCTs were identified in
other types of complex wounds
None, because of absence of primary
material
Is direct application of steroids and
antifungal preparations to the wound
bed effective? (Nursing team)
No systematic reviews or RCTs identified None, because of lack of primary
material
What is the role of protease-
modulating matrix dressings (e.g.
Promogran) in wound management?
(Nursing team)
A Cochrane review protocol324 and two
clinical trials were identified.325,326 All
three studies focus on diabetic foot
ulceration
Protease-modulating dressings were
included in both network meta-
analyses: dressings for diabetic foot
ulcers and dressings for venous leg
ulcers
What is known about overgranulation
(also known as hypergranulation)?
This is a general question that includes
natural history, prevalence, cause,
relationship with other diseases (e.g.
malignancy), types of wound most
likely to be affected and best methods
of management (Nursing team)
A small number of non-informative
literature was identified including
non-systematic topic overviews.327–330
One RCT of nail matrix ablation
described hypergranulation as an
adverse effect of hydrogel.331 Otherwise,
individual case reports and uncontrolled
case series were identified332–334
None, because of lack of informative
literature
What is the best way to manage
wounds in mental health patients who
have dementia? (Launch event
participants)
No relevant literature identified None, because no primary material
How many of those with complex/
chronic wounds also have nutritional
risks? Nutritional risks include poor
hydration, undernutrition, evidence of
10% unintentional weight loss, poorly
controlled diabetes, artificial feeding
and obesity. (Community dietitian)
No relevant literature identified except
for older, non-systematic topic overviews
concluding that nutritional status is likely
to be important for healing pressure
ulcers205,335
The wounds prevalence survey
collected data on recent weight loss
or gain (workstream 1). No further
consideration of systematic review
because of lack of suitable primary
material
Do complex wounds have an impact
on patients’ ability to shop, prepare,
cook or eat all their meals and drink
all their drinks throughout the day
and hence their overall food and fluid
intake, resultant nutritional status and
quality of life? (Community dietitian)
No literature identified on whether or
not complex wounds impact specifically
on patients’ nutritional activities
The impact of complex wounds on
quality of life is addressed through
the qualitative interviews undertaken
as part of workstream 2
Which nutrition interventions aid
wound healing? Can data from a
wound register tell us about the
effectiveness of nutritional
interventions? (Community dietitian)
A Cochrane review concluded that there
was no clear evidence that adding an
oral nutritional supplement to standard
diet reduced the incidence of pressure
ulceration compared with standard diet
alone.200 There were no firm conclusions
for the treatment of existing pressure
ulcers. The search was carried out in
2002 and the yield from CENTRAL
suggested at least five additional recent
trials that could be included
The wounds register captured data
enabling evaluation of treatment
effectiveness, but not specifically in
relation to nutritional interventions.
A previous review has undergone a
substantive update and at the time
of writing is in the final stages of
editorial review. A new review on
nutritional interventions for venous
leg ulcers is in progress at the time
of writing
Could food fortification using dried
milk powder promote wound healing?
(Community dietitian)
No relevant references found None because of lack of primary
material. Possible candidate topic for
future research commissioning
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Appendix 8 Search string used for MEDLINE:
silver dressings for venous leg ulcers
1. exp Leg Ulcer/
2. (varicose ulcer$or venous ulcer$or leg ulcer$or stasis ulcer$or (lower extremit$adj ulcer$) or crural ulcer
$or ulcus cruris).ti,ab.
3. exp Silver/
4. silver.ti,ab.
5. 1 or 2
6. 3 or 4
7. 5 and 6
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Appendix 9 Data extraction tables: silver
dressings for venous leg ulcers
Study, methods and
funding Participants Interventions Outcomes
Dimakakos 2009;227
Greece; RCT
No information about
methods of randomisation,
allocation concealment or
blinding; healing data
analysed by intention to
treat
Funder not stated
42 patients with venous
leg ulcers (confirmed by
Doppler) randomised. All
ulcers were infected at
baseline. Baseline wound
size and duration reported
but no mention of primary/
recurrent ulceration
Group 1: silver foam
dressing (Contreet®,
Coloplast) (n= 21; group 2:
non-adhesive foam dressing
(Biatain®, Coloplast) (n= 21)
All patients received short-
stretch bandage. Dressings
were changed twice weekly.
Some patients received
antibiotics. Treatment
duration was 9 weeks
Complete healing at 5 weeks:
group 1: 8/21 (38%);
group 2: 4/21 (19%)
Complete healing at 9 weeks:
group 1: 17/21 (81%);
group 2: 10/21 (48%)
Healing also shown at 3, 4, 6,
7 and 8 weeks in a table
Data on bacterial load were
reported
Other outcomes: pain,
exudation, adverse events
No withdrawals for healing
data
Jørgensen 2005;228 Canada
Denmark, Germany, Italy,
The Netherlands, UK, USA;
RCT
Computer-generated block
randomisation used;
allocation concealment not
described; outcome
assessment non-blind;
safety analysis was by
intention to treat and
efficacy analysis was per
protocol
Funded by Coloplast A/S,
Humlebaek, Denmark
129 patients with
moderately or highly
exuding venous or mixed
venous/arterial leg ulcers
were randomised.
Minimum ulcer area was
2 cm2. Ulcers were ‘critically
colonised’ at baseline
(definition provided) but
not clinically infected (this
was an exclusion criterion).
Baseline wound size and
duration reported but no
information about primary/
recurrent ulceration
Group 1: silver-release foam
dressing (Contreet) (n= 65);
group 2: polyurethane foam
dressing (Allevyn; S&N)
(n= 64)
Compression therapy
described as ‘mandatory’
according to clinical practice
of study centres
(modification of compression
for those with mixed disease
not described). Some
patients received topical
steroids to peri-ulcer skin.
Dressings and bandages
were changed weekly.
Treatment duration was
4 weeks
Complete healing at 4 weeks
(per protocol): group 1: 5/52
(10%); group 2: 5/57 (9%)
Time to healing not reported
Assessment of infection not
reported (patients requiring
systemic antibiotics were
excluded from the per-
protocol analysis)
Other outcomes: absolute
and relative change in ulcer
area; odour; exudate; quality
of life; dressing performance;
adverse events
Withdrawals: 20 in total
(16%)
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Study, methods and
funding Participants Interventions Outcomes
Lazareth 2008;229 France;
RCT
Block randomisation was
used; allocation
concealment by sealed
envelopes; outcome
assessment not blind but
assessments retrospectively
checked by blinded
investigators; analysis was
by intention to treat;
population defined as
randomised patients with
at least one follow-up
assessment for wound size
Funded by URGO
Laboratories, France
102 patients with venous
leg ulcers (ABPI > 0.8) of
duration < 24 months and
surface area 5–40 cm2 were
randomised. In addition,
leg ulcers had to have at
least three of five clinical
signs of ‘high bacterial
load’ (pain, erythema,
oedema, odour,
exudation). At baseline, all
patients had clinical signs
of high bacterial load but
clinical infection and
current/recent antibiotic
use were exclusion criteria.
Baseline wound size,
duration and ulcer status
(primary or recurrent) were
reported
Group 1: silver dressing
(non-adhesive, non-occlusive
dressing – proprietary name
not stated) (n= 52); group 2:
dressing as above but not
containing silver (n= 50)
All patients received
compression (details not
given). Dressings and
bandages were changed
every other day or less
frequently. Treatment
duration for randomised
comparison was 4 weeks
(all patients received the
non-silver dressing between
weeks 4 and 8)
Dichotomous healing data
not reported, nor time to
healing
Main outcome was
mean± SD (median) change
in ulcer area at 4 weeks
(cm2): group 1: –6.5± 13.4
(4.2); group 2: –1.3± 9.0
(1.1) (p= 0.023)
Other outcomes: healing
rate (cm2/day); probability of
achieving 40% area
reduction; local signs of
heavy bacterial colonisation;
adverse events
Withdrawals at 8 weeks:
group 1: 8/52 (15%);
group 2: 20/50 (40%)
Meaume 2005;230 France;
RCT
Randomisation stratified
according to wound type;
allocation concealment not
mentioned; outcome
assessment not blind;
analysis by intention to
treat
Funded by Johnson &
Johnson Wound
Management
101 patients with venous
leg ulcers and pressure
ulcers were randomised
(99 patients analysed).
Wounds were colonised
but not clinically infected at
baseline; recent systemic
antibiotic use was an
exclusion criterion. Baseline
wound area, duration and
whether primary or
recurrent ulcers were
reported
Group 1: silver-releasing
hydroalginate dressing
(Silvercel®, Systagenix)
(n= 51; 38 with leg ulcers
and 13 with pressure ulcers);
group 2: non-silver calcium
alginate dressing
(Algosteril®, Smith &
Nephew) (n= 48; 33 with
leg ulcers and 15 with
pressure ulcers)
All venous leg ulcer patients
received compression.
Dressings were changed
every few days. Treatment
duration was 4 weeks
Dichotomous healing data
not reported, nor time to
healing
Main outcome was
mean± SD change in ulcer
area (cm2) – results for leg
ulcers only: group 1:
–9.5± 17.9; group 2:
–6.0± 11.7 (p= 0.117)
Other outcomes: percentage
change in ulcer area; healing
rate (cm2/day); use of
systemic antibiotics during
the trial; number of wounds
developing clinical infection;
adverse events
Withdrawals: group 1: 10/51
(20%); group 2: 9/48 (19%)
Michaels 2009;231 UK;
pragmatic RCT
Computer-generated block
randomisation with
stratification according to
ulcer size and treatment
centre; allocation
concealment not described;
methods of outcome
assessment not reported
(but unlikely to be blind);
analysis was by intention to
treat
Funded by UK NIHR Health
Technology Assessment
programme
213 patients with venous
leg ulcers (ABPI ≥ 0.8,
wound duration > 6 weeks,
maximum wound diameter
< 1 cm) were randomised.
Recent use of antibiotics
was an exclusion criterion.
Baseline ulcer size/duration
and primary/recurrent
ulceration were reported
Group 1: silver-releasing
dressing according to
clinicians’ choice [most
commonly Urgotul SSD
(Urgo), Acticoat 7 (S&N),
Aquacel Ag (S&N) or
Contreet foam] (n= 107);
group 2: non-adherent, non-
antimicrobial dressing from
any manufacturer according
to clinicians’ choice (most
patients received low-
adherence knitted viscose
dressings) (n= 106)
Complete healing at
12 weeks (n= 208 analysed):
group 1: 62/104 (59.6%);
group 2: 59/104 (56.7%)
(p= 0.673)
Complete healing at
6 months (n= 203 analysed):
group 1: 87/102 (85.3%);
group 2: 78/101 (77.2%)
(p= 0.141)
Complete healing at
12 months (n= 193
analysed): group 1: 95/99
(96.0%); group 2: 90/94
(95.7%) (p= 0.940)
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Study, methods and
funding Participants Interventions Outcomes
All patients received
multilayer compression
(choice of bandage
according to local practice).
Dressings/bandages were
changed weekly or more
often if required. Treatment
duration was 12 weeks.
After 12 weeks the
randomised treatment could
be changed or stopped,
according to the clinicians’
judgement
Median days to healing:
group 1: 67 (95% CI 54 to
80); group 2: 58 (95% CI
43 to 73) (p= 0.408) (Cox
proportional hazards model)
Other outcomes: ulcer
recurrence at 6 and
12 months (no difference
between groups); adverse
events; quality of life (EQ-5D
and SF-36); costs; resource
use; cost-effectiveness
Münter 2006;232 Germany,
UK, Denmark, Italy,
Switzerland, Belgium,
Slovenia, Brazil, Canada;
pragmatic RCT
Computer-generated block
randomisation; sealed
envelopes; outcome
assessment not blind;
analysis by intention to
treat (last observation
carried forward)
Funded by Coloplast A/S,
Humlebaek, Denmark
619 patients with various
chronic wounds were
randomised (burns, donor
sites, surgical, leg ulcers,
pressure ulcers, diabetic
foot ulcers). Clinical
infection of the wound was
not an exclusion criterion.
Baseline wound area and
duration were reported but
primary/recurrent ulceration
not mentioned
Group 1: sustained silver-
releasing foam dressing
(Contreet Foam) (n= 326
overall; 218 with venous/
mixed leg ulcers); group 2:
local best practice (included
various alternative dressings
including silver) (n= 293
overall; 197 with venous/
mixed leg ulcers)
Compression given to leg
ulcer patients in line with
local practice. Dressings and
bandages changed at least
weekly. Treatment duration
was 4 weeks
No report of dichotomous
healing or time to healing
Median % reduction in ulcer
area for all leg ulcers
(n= 415 analysed): group 1:
45.5%; group 2: 28.8%
(p= 0.0001); for venous leg
ulcers (a subset of the above
– n= 297 analysed): group 1:
46.2%; group 2: 26.9%
(p= 0.0001)
Other outcomes: % slough;
wound progress; peri-ulcer
skin/maceration; exudate;
ease of dressing use; odour;
pain; time spent on dressing
change; mean wear time of
dressing; quality of life
Withdrawals not described
Wunderlich 1991;233
Germany; RCT
Methods of randomisation
and allocation concealment
not stated; outcome
assessment not blind;
analysis not by intention to
treat
Funder not stated
40 patients with venous
leg ulcers were
randomised. No mention of
ulcer infection status at
baseline. Baseline ulcer
area and duration were
reported; no mention of
primary/recurrent ulceration
Group 1: silver-impregnated
charcoal dressing (Actisorb
Plus; J&J) used for all stages
of wound healing (n= 20);
group 2: various topical
agents used; if wound in
granulation phase, mineral
oil or povidone iodine/sea
salt paste was used, whereas
if in epithelialisation phase,
paraffin-impregnated gauze
or oil and water emulsion
was used (n= 20)
All patients received
debridement initially and
throughout the trial as
required. No mention of
compression. Treatment
duration was 6 weeks
Complete healing at
6 weeks: group 1: 6/19
(32%); group 2: 2/19 (11%).
Between-group difference
reported as not significant
Other outcomes: mean ulcer
size at 6 weeks; percentage
reduction in ulcer area at 2,
4 and 6 weeks
Withdrawals: one patient
per group
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Appendix 10 Dressings for foot ulcers in people
with diabetes: search strategy
We searched CENTRAL using the following exploded medical subject heading (MeSH) headingsand keywords:
#1 MeSH descriptor Occlusive Dressings explode all trees
#2 MeSH descriptor Biological Dressings explode all trees
#3 MeSH descriptor Alginates explode all trees
#4 MeSH descriptor Hydrogels explode all trees
#5 MeSH descriptor Silver explode all trees
#6 MeSH descriptor Honey explode all trees
#7 (dressing* or alginate* or hydrogel* or ‘foam’ or ‘bead’ or ‘film’ or ‘films’ or tulle or gauze or
non-adherent or ‘non adherent’ or silver or honey or matrix):ti,ab,kw
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 MeSH descriptor Foot Ulcer explode all trees
#10 MeSH descriptor Diabetic Foot explode all trees
#11 diabet* NEAR/3 ulcer*:ti,ab,kw
#12 diabet* NEAR/3 (foot or feet):ti,ab,kw
#13 diabet* NEAR/3 wound*:ti,ab,kw
#14 (#9 OR #10 OR #11 OR #12 OR #13)
#15 (#8 AND #14)
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Appendix 11 Quality assessment of mixed-
treatment comparison estimates using iGRADE:
comparison with the GRADE tool
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Appendix 12 Dressings for foot ulcers in people
with diabetes: PRISMA flow chart
Unique citations retrieved and
screened for potential inclusion
(n = 346)
Full reports screened for inclusion
(n = 103)
• The study was not randomised, n = 11
• No homogeneous dressing group was 
   evaluated, n = 19
• Another intervention, not a dressing, 
   differed between study groups, n = 30
• A relevant outcome was not reported or 
   not reported for diabetic foot ulcers, n = 11
• Other, n = 17
Studies included
(n = 15)
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Appendix 13 Dressings for venous leg ulcers:
search strategy
We searched CENTRAL using the following exploded MeSH headings and keywords:
#1 MeSH descriptor: [Leg Ulcer] explode all trees
#2 (varicose next ulcer*) or (venous next ulcer*) or (leg next ulcer*) or (stasis next ulcer*) or ((lower next
extremit*) near/2 ulcer*) or (crural next ulcer*) or ‘ulcus cruris’:ti,ab,kw
#3 #1 or #2
#4 MeSH descriptor: [Bandages, Hydrocolloid] explode all trees
#5 MeSH descriptor: [Hydrogels] explode all trees
#6 MeSH descriptor: [Alginates] explode all trees
#7 (dressing* or hydrocolloid* or alginate* or hydrogel* or ‘foam’ or ‘bead’ or ‘film’ or ‘films’ or tulle or
gauze or non-adherent or ‘non adherent’):ti,ab,kw
#8 MeSH descriptor: [Cellulose, Oxidised] explode all trees
#9 ((protease adj modulat*) or promogran):ti,ab,kw
#10 MeSH descriptor: [Silver Sulfadiazine] explode all trees
#11 silver*:ti,ab,kw
#12 MeSH descriptor: [Honey] explode all trees
#13 honey:ti,ab,kw
#14 #4 or #5 or #6 or #7 or #10 or #11 or #12 or #13
#15 #3 and #14
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Appendix 14 Dressings for venous leg ulcers:
PRISMA flow chart
Unique citations retrieved and
screened for potential inclusion
(n = 609)
Full reports screened for inclusion
(n = 91)
• The study was not of the correct design, n = 58
• Study did not have appropriate outcome
   measure for inclusion in the review, n = 2
• Study did not use standardised 
   compression, n = 9
• Study fitted inclusion criteria but was not
   able to be included in network, n = 3
Studies included in network
(n = 19)
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Appendix 15 Alternative mixed-treatment
meta-analysis models explored
The table shows the results from six synthesis models, divided into three sets. The first set (models A1and A2) models the proportion of patients healed, thus ignoring the time component. The second set
(models B1 and B2) considers the time component of the outcome but ignores the fact that an underlying
silver effect may exist. The last set of results (models C1 and C2) takes into account the time component
and considers the estimation of the incremental effect of silver. For each set of results, models 1 and 2
relate to the fixed-effects and random-effects approaches, respectively. All models use the same data and
assume the same likelihood and, thus, the DIC is comparable across models.
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The results show that the models represent the data equally well (the DICs are not different by > 5 units).
We therefore pursued modelling approach C, in which follow-up time is taken into account and an effect
of silver explored.
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